Original Article
Comparison of Four Chemotherapy Regimens for Advanced Non–Small-Cell Lung Cancer
N Engl J Med 2002; 346:92-98January 10, 2002
- Abstract
Background
We conducted a randomized study to determine whether any of three chemotherapy regimens was superior to cisplatin and paclitaxel in patients with advanced non–small-cell lung cancer.
Methods
A total of 1207 patients with advanced non–small-cell lung cancer were randomly assigned to a reference regimen of cisplatin and paclitaxel or to one of three experimental regimens: cisplatin and gemcitabine, cisplatin and docetaxel, or carboplatin and paclitaxel.
Results
The response rate for all 1155 eligible patients was 19 percent, with a median survival of 7.9 months (95 percent confidence interval, 7.3 to 8.5), a 1-year survival rate of 33 percent (95 percent confidence interval, 30 to 36 percent), and a 2-year survival rate of 11 percent (95 percent confidence interval, 8 to 12 percent). The response rate and survival did not differ significantly between patients assigned to receive cisplatin and paclitaxel and those assigned to receive any of the three experimental regimens. Treatment with cisplatin and gemcitabine was associated with a significantly longer time to the progression of disease than was treatment with cisplatin and paclitaxel but was more likely to cause grade 3, 4, or 5 renal toxicity (in 9 percent of patients, vs. 3 percent of those treated with cisplatin plus paclitaxel). Patients with a performance status of 2 had a significantly lower rate of survival than did those with a performance status of 0 or 1.
Conclusions
None of four chemotherapy regimens offered a significant advantage over the others in the treatment of advanced non–small-cell lung cancer.
Media in This Article
Figure 2
Kaplan–Meier Estimates of Overall Survival (Panel A) and the Time to Progression of Disease (Panel B) in the Study Patients, According to the Assigned Treatment.Figure 1
Stratification and Randomly Assigned Treatment Regimens.Article Activity
- Article
Approximately one third of all cancer-related deaths are due to lung cancer, which accounts for more deaths each year than breast, prostate, and colon cancer combined. The median survival of patients with untreated metastatic non–small-cell lung cancer is only four to five months, with a survival rate at one year of only 10 percent.1
Chemotherapy for advanced non–small-cell lung cancer is often considered ineffective or excessively toxic. However, meta-analyses have demonstrated that, as compared with supportive care, chemotherapy results in a small improvement in survival in patients with advanced non–small-cell lung cancer.2-4 In addition, randomized studies comparing chemotherapy with the “best supportive care” have shown that chemotherapy reduces symptoms and improves the quality of life.5
Over the past decade, a number of new agents have become available for the treatment of metastatic non–small-cell lung cancer, including the taxanes, gemcitabine, and vinorelbine. The combination of one or more of these agents with a platinum compound has resulted in high response rates and prolonged survival at one year in phase 2 studies.6-10 However, there have been few comparisons of these newer chemotherapy regimens, which are now used frequently, with each other.
The Eastern Cooperative Oncology Group (ECOG) conducted a randomized clinical trial to compare the efficacy of three commonly used regimens with that of a reference regimen of cisplatin and paclitaxel.11 The primary objective of this study was to compare overall survival in patients treated with cisplatin and gemcitabine, cisplatin and docetaxel, carboplatin and paclitaxel, or cisplatin and paclitaxel.
Methods
Patients with non–small-cell lung cancer that was classified as stage IIIB (with malignant pleural or pericardial effusion), stage IV, or recurrent disease were randomly assigned to one of four treatment groups (Figure 1Figure 1
Stratification and Randomly Assigned Treatment Regimens.). The first group received the reference treatment: 135 mg of paclitaxel per square meter of body-surface area, administered over a 24-hour period on day 1, followed by 75 mg of cisplatin per square meter on day 2. The cycle was repeated every three weeks. In the second group, gemcitabine, at a dose of 1000 mg per square meter, was administered on days 1, 8, and 15, and cisplatin, at a dose of 100 mg per square meter, was administered on day 1 of a four-week cycle. Patients in the third group received 75 mg of docetaxel per square meter and 75 mg of cisplatin per square meter on day 1 of a three-week cycle. Those in the fourth group were treated with 225 mg of paclitaxel per square meter, given over a three-hour period on day 1, followed on the same day by carboplatin at a dose calculated to produce an area under the concentration–time curve of 6.0 mg per milliliter per minute, in a three-week cycle. Patients were stratified according to ECOG performance status (0 or 1 vs. 2, with higher scores indicating greater impairment), weight loss in the previous six months (<5 percent vs. ≥5 percent), the stage of disease (IIIB vs. IV or recurrent disease), and the presence or absence of brain metastases.Eligibility Criteria
Patients who had received prior chemotherapy were ineligible for the study. The criteria for eligibility included confirmed disease, measurable or nonmeasurable; an age of at least 18 years; and adequate hematologic function (as indicated by a white-cell count of at least 4000 per cubic millimeter and a platelet count of at least 100,000 per cubic millimeter), hepatic function (as indicated by a bilirubin level that did not exceed 1.5 mg per deciliter [25.6 μmol per liter]), and renal function (as indicated by a creatinine level that did not exceed 1.5 mg per deciliter [132.6 μmol per liter]). Prior radiation therapy at symptomatic sites was permitted provided that the indicator sites (the sites that were followed to determine whether there was a response) had not been irradiated and that the radiation therapy had been completed before chemotherapy was initiated. Patients with stable brain metastases were eligible. All patients gave informed consent.
Standard ECOG response criteria were used. Briefly, a complete response was defined as the absence of disease at all known sites for at least four weeks. A partial response was defined as a 50 percent reduction in the sum of the perpendicular diameters of all measurable lesions, lasting at least four weeks. Progressive disease was defined as either a 25 percent increase in the area of any one lesion over the prior measurement or the development of one or more new lesions. Survival was calculated from the date of enrollment to the date of death or the date when the patient was last known to be alive. The time to the progression of disease was calculated from the date of enrollment to the date of progression or death; data for patients who were alive and relapse-free were censored as of the date of the last known follow-up visit.
The protocol was approved by the institutional review board at each participating center. All patients gave written informed consent.
Statistical Analysis
Survival from the date of enrollment was the main end point. The primary analysis specified by the protocol was a comparison of each of the survival distributions for the three experimental-treatment groups with that for the control reference-treatment group, with the use of a two-sided log-rank test.12 To control for type I error (i.e., to control for multiple comparisons), a nominal two-sided P value of 0.016 was used for each comparison. The study was designed to have 80 percent power to detect a 33 percent increase in median survival in the experimental-treatment groups — that is, a median survival of 12 months, since the reference regimen had resulted in a median survival of 9 months in a previous study.11 Full power to detect a 33 percent improvement in survival would have required a total of approximately 1070 deaths in the four groups, or 535 per pairwise comparison. On the basis of accrual and eligibility rates in previous ECOG trials, we estimated that we would need to enroll 300 patients per treatment group over a 30-month period.
Interim analyses for the study were monitored by the ECOG Data Monitoring Committee. The design specified two interim analyses and one final analysis of the survival data, with the use of an O'Brien–Fleming boundary,13 when 33 percent, 67 percent, and 100 percent of the anticipated number of deaths had occurred.
All reported P values are two-sided and were adjusted for interim analyses according to the O'Brien–Fleming method. All time-to-event distributions were estimated by the Kaplan–Meier method.14 All reported time-to-event comparisons were made with the use of the log-rank test. Categorical data, such as data on treatment, responses, and toxic effects, were compared among treatment groups with the use of Fisher's exact test.15
Results
A total of 1207 patients were enrolled in the study between October 1996 and May 1999. The median follow-up period was 8.0 months. As of May 1, 2001, 1074 patients had died. Of the 1207 patients who were enrolled, 52 (4.3 percent) were subsequently found to be ineligible (Table 1Table 1
Characteristics of the Patients.).The clinical characteristics of the patients in the four groups were similar (Table 1). The median age was 63 years. Almost two thirds of the patients were men. Sixty-four percent of patients had a performance-status score of 1, and 13 percent had brain metastases. About two thirds of the patients had a weight loss of less than 5 percent in the previous six months. Most (87 percent) had stage IV or recurrent disease.
The median survival for all 1207 patients was 8.0 months; the survival rate at 1 year was 34 percent, and the rate at 2 years was 12 percent (Table 2Table 2
Outcome for All Treatment Groups Combined.). Analyses that compared the total group of 1207 patients with the group of 1155 eligible patients showed no significant differences in response rates, survival, or the time to the progression of disease.The overall response rate for the 1155 eligible patients was 19 percent (Table 3Table 3
Outcome According to Treatment Group.). In the group of patients who received cisplatin and paclitaxel, the median survival was 7.8 months, and the 1-year and 2-year survival rates were 31 percent and 10 percent, respectively (Table 3 and Figure 2AFigure 2Kaplan–Meier Estimates of Overall Survival (Panel A) and the Time to Progression of Disease (Panel B) in the Study Patients, According to the Assigned Treatment.). There were no significant differences in the response rate or survival among the three experimental-treatment groups. The median survival was 8.1 months among the patients who received cisplatin and gemcitabine, 7.4 months among those who received cisplatin and docetaxel, and 8.1 months among those who received carboplatin and paclitaxel (Table 3). The survival rate for those three groups was 36 percent, 31 percent, and 34 percent, respectively, at one year and 13 percent, 11 percent, and 11 percent, respectively, at two years.The median time to the progression of disease was 3.4 months in the cisplatin-plus-paclitaxel group, as compared with 4.2 months in the cisplatin-plus-gemcitabine group (P=0.001 by the two-sided log-rank test) (Table 3). The median time to progression in the other two experimental-treatment groups did not differ significantly from that in the cisplatin-plus-paclitaxel group (Figure 2B). Since the protocol specified that patients should be assessed for disease progression after every two cycles of treatment, patients who received cisplatin and docetaxel or carboplatin and paclitaxel, regimens that were administered in 21-day cycles, might have been found to have radiographic evidence of progression earlier than patients who received cisplatin and gemcitabine, which was administered in a 28-day cycle. However, that was not the case (data not shown).
According to the original trial design, patients with an ECOG performance status of 2, as well as those with a performance status of 0 or 1, were eligible for enrollment. However, in October 1997, after 66 patients with a performance status of 2 had been enrolled, the study design was amended to include only patients with a performance status of 0 or 1 because of the high rate of serious adverse events in the patients with a performance status of 2.16 The median survival among patients with a performance status of 0 was 10.8 months, as compared with 7.1 months for patients with a performance status of 1 and 3.9 months for those with a performance status of 2 (P<0.001 by the log-rank test for both comparisons) (Table 2).
Table 4Table 4
Toxic Effects. shows toxic complications in the four groups. These complications were the types usually associated with combination chemotherapy. They were similar in the four groups, with several exceptions, as noted in the table.Fifty-three percent of the patients who received carboplatin and paclitaxel were withdrawn from the study because of progressive disease, as compared with 44 percent of the patients who received cisplatin and paclitaxel (P<0.001). Twenty-seven percent of the patients who received cisplatin and gemcitabine were withdrawn because of complications of therapy, as compared with 15 percent of the patients who received cisplatin and paclitaxel (P<0.001 by Fisher's exact test).
Discussion
Cisplatin-based chemotherapy for metastatic non–small-cell lung cancer results in a small but statistically significant improvement in survival, as compared with supportive care alone.2-4 Whereas older chemotherapy regimens (e.g., mitomycin, ifosfamide, and cisplatin) resulted in survival rates of 10 to 15 percent at one year, second-generation regimens (e.g., cisplatin and etoposide) have typically resulted in survival rates of 20 to 25 percent at one year.1,5,17-20 Our trial showed that third-generation regimens result in survival rates of 33 percent at one year and 11 percent at two years among patients with good performance status.
We sought to determine whether any of three newer third-generation chemotherapy regimens was superior to the first of these third-generation regimens, cisplatin plus paclitaxel, with respect to survival. There were no significant differences in survival between patients who received one of the three experimental regimens and those who received cisplatin and paclitaxel. Although the time to the progression of disease was longer in the group of patients who received cisplatin plus gemcitabine than in the other groups, this result was at the expense of greater renal toxicity. Given the lack of a survival benefit with this regimen and its greater toxicity, the clinical relevance of the increase in the time to disease progression is questionable.
Toxicity is particularly problematic in patients with a poor performance status. Patients with a performance status of 2 were excluded from our study after the early results suggested that such patients were likely to be more susceptible to adverse events, including death within 30 days from any cause, than were patients with a performance status of 0 or 1. Since the role of chemotherapy in the treatment of advanced non–small-cell lung cancer is supportive and palliative at best, the routine use of platinum-based combination chemotherapy in patients with a poor performance status cannot be recommended.
Although we did not obtain data on second-line chemotherapy in this study, it is possible that some of our patients crossed over to another therapy when the disease progressed. The effect of such a crossover on the results of this trial is unknown. We also did not compare the cost effectiveness of the four regimens, which is of potential importance, given the differences in the costs of the various drugs and in the costs associated with their administration.21 Finally, the quality of life was not assessed in this study. Although reductions in toxicity are often assumed to improve the quality of life, in a recent Southwest Oncology Group study comparing cisplatin and vinorelbine with carboplatin and paclitaxel, there were no differences in the quality of life between the two treatment groups, despite significantly lower rates of toxic effects in the group of patients who received carboplatin and paclitaxel.21
We conclude that third-generation chemotherapy regimens in patients with non–small-cell lung cancer who have a good performance status can moderately improve survival at one and two years. No significant difference in survival was observed among four commonly used regimens, although the regimen of carboplatin and paclitaxel had a lower rate of toxic effects than the other regimens. On the basis of these results, ECOG has chosen carboplatin and paclitaxel as its reference regimen for future studies.
Supported by a grant (CA-23318) from the National Institutes of Health. Dr. Schiller also received support from the William S. Middleton Veterans Affairs Hospital. Drs. Schiller, Belani, Langer, Sandler, and Johnson have received research support from Eli Lilly, Bristol-Myers, and Aventis and have served as consultants to Eli Lilly and Bristol-Myers. Drs. Schiller, Belani, Langer, and Sandler have served as consultants to Aventis. Dr. Langer is a member of speakers' bureaus for Eli Lilly, Bristol-Myers, and Aventis.
Source Information
From the University of Wisconsin Hospital and Clinics, Madison (J.H.S.); the Dana–Farber Cancer Institute, Boston (D.H., J.Z.); the University of Pittsburgh Cancer Institute, Pittsburgh (C.P.B.); the Fox Chase Cancer Center, Philadelphia (C.L.); Indiana University, Indianapolis (A.S.); the Duluth Clinic, Duluth, Minn. (J.K.); and Vanderbilt University, Nashville (D.H.J.).
- References
References
1
Rapp E ,Pater JL ,Willan A , et al. Chemotherapy can prolong survival in patients with advanced non-small-cell lung cancer -- report of a Canadian multicenter randomized trial. J Clin Oncol 1988;6:633-641
Web of Science | Medline2
Marino P ,Pampallona S ,Preatoni A ,Cantoni A ,Invernizzi F . Chemotherapy vs. supportive care in advanced non-small-cell lung cancer: results of a meta-analysis of the literature. Chest 1994;106:861-865
CrossRef | Web of Science | Medline3
Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. BMJ 1995;311:899-909
CrossRef | Web of Science4
Grilli R ,Oxman AD ,Julian JA . Chemotherapy for advanced non-small-cell lung cancer: how much benefit is enough? J Clin Oncol 1993;11:1866-1872
Web of Science | Medline5
Cullen M ,Billingham J ,Woodraffe C , et al. Mitomycin, ifosfamide, and cisplatin in unresectable non-small-cell lung cancer: effects on survival and quality of life. J Clin Oncol 1999;17:3188-3194
Web of Science | Medline6
Sandler AB ,Ansari R ,McClean J ,Fisher W ,Dorr A ,Einhorn LH . A Hoosier Oncology Group phase II study of gemcitabine plus cisplatin in non-small cell lung cancer (NSCLC). Prog Proc Am Soc Clin Oncol 1995;14:357-357 abstract.7
Abratt RP ,Bezwoda WR ,Goedhals L ,Hacking DJ . A phase 2 study of gemcitabine with cisplatin in patients with non-small cell lung cancer. Prog Proc Am Soc Clin Oncol 1995;14:375-375 abstract.8
Crino L ,Scagliotti G ,Marangolo M , et al. Cisplatin-gemcitabine combination in non-small cell lung cancer (NSCLC): a phase II study. Prog Proc Am Soc Clin Oncol 1995;14:352-352 abstract.9
Langer CJ ,Leighton JC ,Comis RL , et al. Paclitaxel and carboplatin in combination in the treatment of advanced non-small-cell lung cancer: a phase II toxicity, response, and survival analysis. J Clin Oncol 1995;13:1860-1870
Web of Science | Medline10
Le Chevalier T ,Belli L ,Monnier A , et al. Phase II study of docetaxel (Taxotere) and cisplatin in advanced non small cell lung cancer (NSCLC): an interim analysis. Prog Proc Am Soc Clin Oncol 1995;14:350-350 abstract.11
Bonomi P ,Kim K ,Fairclough D , et al. Comparison of survival and quality of life in advanced non-small-cell lung cancer patients treated with two dose levels of paclitaxel combined with cisplatin versus etoposide with cisplatin: results of an Eastern Cooperative Oncology Group trial. J Clin Oncol 2000;18:623-631
Web of Science | Medline12
Mantel N . Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 1966;50:163-170
Medline13
O'Brien PC ,Fleming TR . A multiple testing procedure for clinical trials. Biometrics 1979;35:549-556
CrossRef | Web of Science | Medline14
Kaplan EL ,Meier P . Nonparametric estimation of incomplete observations. J Am Stat Assoc 1958;53:457-481
CrossRef | Web of Science15
Cox DR, Snell EJ. Analysis of binary data. 2nd ed. London: Chapman & Hall, 1989.
16
Johnson DH ,Zhu J ,Schiller J , et al. E1594 -- a randomized phase III trial in metastatic non-small cell lung cancer (NSCLC) -- outcome of PS 2 patients (Pts): an Eastern Cooperative Oncology Group Trial (ECOG). Prog Proc Am Soc Clin Oncol 1999;18:461a-461a abstract.17
Gandara DR ,Crowley J ,Livingston RB , et al. Evaluation of cisplatin intensity in metastatic non-small-cell lung cancer: a phase III study of the Southwest Oncology Group. J Clin Oncol 1993;11:873-878
Web of Science | Medline18
Ruckdeschel JC ,Finkelstein DM ,Ettinger DS , et al. A randomized trial of the four most active regimens for metastatic non-small-cell lung cancer. J Clin Oncol 1986;4:14-22
Web of Science | Medline19
Klastersky J ,Sculier JP ,Bureau G , et al. Cisplatin versus cisplatin plus etoposide in the treatment of advanced non-small-cell lung cancer. J Clin Oncol 1989;7:1087-1092
Web of Science | Medline20
Bonomi PD ,Finkelstein DM ,Ruckdeschel JC , et al. Combination chemotherapy versus single agents followed by combination chemotherapy in stage IV non-small-cell lung cancer: a study of the Eastern Cooperative Oncology Group. J Clin Oncol 1989;7:1602-1613
Web of Science | Medline21
Ramsey SD ,Moinpour CM ,Lovato LC ,Grevstad PK ,Kelly K ,Presant C . An economic analysis of Southwest Oncology Group Trial S9509: cisplatin/vinorelbine vs. carboplatin/paclitaxel for advanced nonsmall cell lung cancer. Prog Proc Am Soc Clin Oncol 2000;19:489a-489a abstract.
- Citing Articles (1151)
Citing Articles
1
Charu Aggarwal, Corey J. Langer. (2012) Older age, poor performance status and major comorbidities. Current Opinion in Oncology 24:2, 130-136
CrossRef2
Rathi N. Pillai, Suresh S. Ramalingam. (2012) The Biology and Clinical Features of Non–small Cell Lung Cancers with EML4-ALK Translocation. Current Oncology Reports
CrossRef3
Alexandre Chan, Terence Rong De Ng, Kevin Yi-Lwern Yap. (2012) Clinically–relevant anticancer-antidepressant drug interactions. Expert Opinion on Drug Metabolism & Toxicology 8:2, 173-199
CrossRef4
V. Ludovini, F. Bianconi, L. Pistola, V. Minotti, R. Chiari, R. Colella, G. Bellezza, F. R. Tofanetti, A. Siggillino, E. Baldelli, A. Flacco, D. Giuffrida, A. Sidoni, L. Crinò. (2012) Optimization of patient selection for EGFR-TKIs in advanced non-small cell lung cancer by combined analysis of KRAS, PIK3CA, MET, and non-sensitizing EGFR mutations. Cancer Chemotherapy and Pharmacology
CrossRef5
M. Falk, C. Hallas, M. Tiemann. (2012) Molekularpathologische Grundlagen für die Therapie des NSCLC. best practice onkologie 7:1, 4-11
CrossRef6
Takashi Kobayashi, Tomonobu Koizumi, Toshihide Agatsuma, Masanori Yasuo, Kenji Tsushima, Keishi Kubo, Seiichiro Eda, Hiroshi Kuraishi, Shigeru Koyama, Tsutomu Hachiya, Nariaki Ohura. (2012) A phase II trial of erlotinib in patients with EGFR wild-type advanced non-small-cell lung cancer. Cancer Chemotherapy and Pharmacology
CrossRef7
Wei-Xiang Qi, Li-Na Tang, Ai-Na He, Zan Shen, Yang Yao. (2012) Effectiveness and safety of pemetrexed-based doublet versus pemetrexed alone as second-line treatment for advanced non-small-cell lung cancer: a systematic review and meta-analysis. Journal of Cancer Research and Clinical Oncology
CrossRef8
C Boni, M Tiseo, L Boni, E Baldini, F Recchia, C Barone, F Grossi, D Germano, E Matano, G Marini, R Labianca, F Di Costanzo, A Bagnulo, C Pennucci, C Caroti, M Mencoboni, F Zanelli, T Prochilo, M A Cafferata, A Ardizzoni. (2012) Triplets versus doublets, with or without cisplatin, in the first-line treatment of stage IIIB–IV non-small cell lung cancer (NSCLC) patients: a multicenter randomised factorial trial (FAST). British Journal of Cancer
CrossRef9
David A. Proia, Jim Sang, Suqin He, Donald L. Smith, Manuel Sequeira, Chaohua Zhang, Yuan Liu, Shuxia Ye, Dan Zhou, Ronald K. Blackman, Kevin P. Foley, Keizo Koya, Yumiko Wada. (2012) Synergistic activity of the Hsp90 inhibitor ganetespib with taxanes in non-small cell lung cancer models. Investigational New Drugs
CrossRef10
M. Knopf, M. Reck. (2012) Erstlinientherapie beim fortgeschrittenen nichtkleinzelligen Lungenkarzinom. Der Pneumologe
CrossRef11
Luis Corrales-Rodriguez, Normand Blais. (2012) Lung cancer associated venous thromboembolic disease: A comprehensive review. Lung Cancer 75:1, 1-8
CrossRef12
Janessa Laskin, Lucio Crinò, Enriqueta Felip, Fabio Franke, Vera Gorbunova, Harry Groen, Guo-liang Jiang, Martin Reck, Claus-Peter Schneider. (2012) Safety and Efficacy of First-Line Bevacizumab Plus Chemotherapy in Elderly Patients with Advanced or Recurrent Nonsquamous Non-small Cell Lung Cancer. Journal of Thoracic Oncology 7:1, 203-211
CrossRef13
Haihua Yuan, Zhong-Zheng Zhu, Yachao Lu, Feng Liu, Wenying Zhang, Gang Huang, Guanshan Zhu, Bin Jiang. (2012) A Modified Extraction Method of Circulating Free DNA for Epidermal Growth Factor Receptor Mutation Analysis. Yonsei Medical Journal 53:1, 132
CrossRef14
Guanghui Gao, Haiqing Chu, Lan Zhao, Tao Gui, Qinghua Xu, Jianping Shi. (2012) A meta-analysis of paclitaxel-based chemotherapies administered once every week compared with once every 3 weeks first-line treatment of advanced non-small-cell lung cancer. Lung Cancer
CrossRef15
H.A. Wakelee, S.E. Dahlberg, J.R. Brahmer, J.H. Schiller, M.C. Perry, C.J. Langer, A.B. Sandler, C.P. Belani, D.H. Johnson. (2012) Differential effect of age on survival in advanced NSCLC in women versus men: Analysis of recent Eastern Cooperative Oncology Group (ECOG) studies, with and without bevacizumab. Lung Cancer
CrossRef16
Johan Vansteenkiste, Rodryg Ramlau, Joachim von Pawel, Belen San Antonio, Corinna Eschbach, Aleksandra Szczesna, Liam Kennedy, Carla Visseren-Grul, Nadia Chouaki, Martin Reck. (2012) A Phase II Randomized Study of Cisplatin-Pemetrexed plus either Enzastaurin or Placebo in Chemonaive Patients with Advanced Non-Small Cell Lung Cancer. Oncology 82:1, 25-29
CrossRef17
D. Gómez Herrero, A. Albert Marí, M. Merino Sanjuán, M.L. Boquera Ferrer, N. Víctor Jiménez Torres. (2012) Toxicity Profile and Adherence to the Pharmacotherapeutic Regimen of Gemcitabine–carboplatin in Non-small Cell Lung Cancer. Farmacia Hospitalaria (English Edition)
CrossRef18
Roman Thomas, Jürgen Wolf. (2012) Personalized Therapy of Lung Cancer. Onkologie 35:s1, 14-19
CrossRef19
Seiji Niho, Hideo Kunitoh, Hiroshi Nokihara, Takeshi Horai, Yukito Ichinose, Toyoaki Hida, Nobuyuki Yamamoto, Masaaki Kawahara, Tetsu Shinkai, Kazuhiko Nakagawa, Kaoru Matsui, Shunichi Negoro, Akira Yokoyama, Shinzoh Kudoh, Katsuyuki Kiura, Kiyoshi Mori, Hiroaki Okamoto, Hiroshi Sakai, Koji Takeda, Soichiro Yokota, Nagahiro Saijo, Masahiro Fukuoka. (2012) Randomized phase II study of first-line carboplatin-paclitaxel with or without bevacizumab in Japanese patients with advanced non-squamous non-small-cell lung cancer. Lung Cancer
CrossRef20
Boyka Markova, Patricia S. Hähnel, Stefan Kasper, Stephan Herbertz, Martin Schuler, Frank Breitenbuecher. (2011) Pharmacologic inhibition of mTOR antagonizes the cytotoxic activity of pemetrexed in non-small cell lung cancer. Journal of Cancer Research and Clinical Oncology
CrossRef21
L. Decoster, I. Wauters, J. F. Vansteenkiste. (2011) Vaccination therapy for non-small-cell lung cancer: review of agents in phase III development. Annals of Oncology
CrossRef22
M. Wada, M. Yamamoto, S. Ryuge, Y. Nagashima, N. Hayashi, S. Maki, S. Otani, K. Katono, A. Takakura, T. Yanaihara, S. Igawa, M. Yokoba, H. Mitsufuji, M. Kubota, M. Katagiri, N. Masuda. (2011) Phase II study of S-1 monotherapy in patients with previously treated, advanced non-small-cell lung cancer. Cancer Chemotherapy and Pharmacology
CrossRef23
Laura Bonanno, Adolfo Favaretto, Massimo Rugge, Miquel Taron, Rafael Rosell. (2011) Role of Genotyping in Non-Small Cell Lung Cancer Treatment. Drugs 71:17, 2231-2246
CrossRef24
Xu-ming Ji, Bing Ouyang, Heng Liu, Guo-wei Liu, Zhi-chun Wu, Hua-yun Yu, Chun-yan Wang, Zhong-xia Wang, Wen-ping Wang. (2011) In Vitro and In Vivo inhibitory effect of the combination of Wenxia Changfu Formula (
) with cisplatin in non-small cell lung cancer. Chinese Journal of Integrative Medicine 17:12, 908-916
CrossRef25
Meiling Zhao, Haihong Yang, Jun liu, Yubao Guan, Mingchong Mo, Enyun Lin, Jianxing He. (2011) Effects of gemcitabine and cisplatin chemotherapy in advanced non-small cell lung cancer patients with RRM1 low protein expression. The Chinese-German Journal of Clinical Oncology 10:12, 687-691
CrossRef26
Takeshi Hanagiri, Masaru Takenaka, Soich Oka, Yoshiki Shigematsu, Yoshika Nagata, Hidehiko Shimokawa, Hidetaka Uramoto, Fumihiro Tanaka. (2011) Results of a Surgical Resection for Patients With Stage IV Non–Small-Cell Lung Cancer. Clinical Lung Cancer
CrossRef27
Mathilda L. Bongers, Veerle M.H. Coupé, Elise P. Jansma, Egbert F. Smit, Carin A. Uyl-de Groot. (2011) Cost Effectiveness of Treatment with New Agents in Advanced Non-Small-Cell Lung Cancer. PharmacoEconomics1
CrossRef28
Thanyanan Reungwetwattana, Saravut J. Weroha, Julian R. Molina. (2011) Oncogenic Pathways, Molecularly Targeted Therapies, and Highlighted Clinical Trials in Non-Small-Cell Lung Cancer (NSCLC). Clinical Lung Cancer
CrossRef29
Fang Wang, Gui-fang Guo, Hui-juan Qiu, Xu-xian Chen, Pi-li Hu, Fei-fei Zhou, Wen-zhuo He, Bei Zhang, Liang-ping Xia. (2011) Pemetrexed monotherapy and pemetrexed plus platinum combination therapy as non-first-line treatments for advanced non-small cell lung cancer. Clinical Oncology and Cancer Research 8:4, 235-241
CrossRef30
Liang Li, Daniel J. Schaid, Brooke L. Fridley, Krishna R. Kalari, Gregory D. Jenkins, Ryan P. Abo, Anthony Batzler, Irene Moon, Linda Pelleymounter, Bruce W. Eckloff, Eric D. Wieben, Zhifu Sun, Ping Yang, Liewei Wang. (2011) Gemcitabine metabolic pathway genetic polymorphisms and response in patients with non-small cell lung cancer. Pharmacogenetics and Genomics1
CrossRef31
Gury Doshi, Guru Sonpavde, Cora N Sternberg. (2011) Clinical and pharmacokinetic evaluation of satraplatin. Expert Opinion on Drug Metabolism & Toxicology1-9
CrossRef32
Yasumitsu Moriya, Nijiro Nohata, Takashi Kinoshita, Muradil Mutallip, Tatsuro Okamoto, Shigetoshi Yoshida, Makoto Suzuki, Ichiro Yoshino, Naohiko Seki. (2011) Tumor suppressive microRNA-133a regulates novel molecular networks in lung squamous cell carcinoma. Journal of Human Genetics
CrossRef33
L. V. Sequist, R. S. Heist, A. T. Shaw, P. Fidias, R. Rosovsky, J. S. Temel, I. T. Lennes, S. Digumarthy, B. A. Waltman, E. Bast, S. Tammireddy, L. Morrissey, A. Muzikansky, S. B. Goldberg, J. Gainor, C. L. Channick, J. C. Wain, H. Gaissert, D. M. Donahue, A. Muniappan, C. Wright, H. Willers, D. J. Mathisen, N. C. Choi, J. Baselga, T. J. Lynch, L. W. Ellisen, M. Mino-Kenudson, M. Lanuti, D. R. Borger, A. J. Iafrate, J. A. Engelman, D. Dias-Santagata. (2011) Implementing multiplexed genotyping of non-small-cell lung cancers into routine clinical practice. Annals of Oncology
CrossRef34
Jordi Rodon, Charlotte D. Jacobs, Quincy Chu, Eric K. Rowinsky, Arturo Lopez-Anaya, Chris H. Takimoto, Heather A. Wakelee. (2011) A phase I pharmacokinetic study of bexarotene with paclitaxel and carboplatin in patients with advanced non-small cell lung cancer (NSCLC). Cancer Chemotherapy and Pharmacology
CrossRef35
Young Hak Kim, Michiaki Mishima. (2011) Maintenance chemotherapy for non-small-cell lung cancer. Cancer Treatment Reviews 37:7, 505-510
CrossRef36
Nathan A. Pennell. (2011) Integration of EGFR Inhibitors and Conventional Chemotherapy in the Treatment of Non–Small-cell Lung Cancer. Clinical Lung Cancer 12:6, 350-359
CrossRef37
Akshay Sudhindra, Roberto Ochoa, Edgardo S. Santos. (2011) Biomarkers, Prediction, and Prognosis in Non–Small-Cell Lung Cancer: A Platform for Personalized Treatment. Clinical Lung Cancer 12:6, 360-368
CrossRef38
Joaquim Bosch-Barrera, Nuria Quer, Joan Brunet. (2011) Costs and Ethical Issues Related to First-Line Treatment of Metastatic Non–Small-Cell Lung Cancer: Considerations From a Public Healthcare System Perspective. Clinical Lung Cancer 12:6, 335-340
CrossRef39
Yukito Ichinose, Takashi Seto, Tomonari Sasaki, Takeharu Yamanaka, Isamu Okamoto, Koji Takeda, Masahiro Tanaka, Nobuyuki Katakami, Toshiyuki Sawa, Shinzoh Kudoh, Hideo Saka, Yasumasa Nishimura, Kazuhiko Nakagawa, Masahiro Fukuoka. (2011) S-1 Plus Cisplatin with Concurrent Radiotherapy for Locally Advanced Non-small Cell Lung Cancer. Journal of Thoracic Oncology1
CrossRef40
Ezra E.W. Cohen, Janakiraman Subramanian, Feng Gao, Livia Szeto, Mark Kozloff, Leonardo Faoro, Theodore Karrison, Ravi Salgia, Ramaswamy Govindan, Everett E. Vokes. (2011) Targeted and Cytotoxic Therapy in Coordinated Sequence (TACTICS): Erlotinib, Bevacizumab, and Standard Chemotherapy for Non–Small-Cell Lung Cancer, A Phase II Trial. Clinical Lung Cancer
CrossRef41
Joseph Treat, Giorgio V. Scagliotti, Guangbin Peng, Matthew J. Monberg, Coleman K. Obasaju, Mark A. Socinski. (2011) Comparison of pemetrexed plus cisplatin with other first-line doublets in advanced non-small cell lung cancer (NSCLC): A combined analysis of three phase 3 trials. Lung Cancer
CrossRef42
Peter Mazzone, Tarek Mekhail. (2011) Current and emerging medical treatments for non–small cell lung cancer: A primer for pulmonologists. Respiratory Medicine
CrossRef43
Ji-Young Hong, Hwa-Jin Chung, Hye-Jung Lee, Hyen Joo Park, Sang Kook Lee. (2011) Growth Inhibition of Human Lung Cancer Cells via Down-regulation of Epidermal Growth Factor Receptor Signaling by Yuanhuadine, a Daphnane Diterpene from Daphne genkwa. Journal of Natural Products 74:10, 2102-2108
CrossRef44
Anna E. Maciag, Rahul S. Nandurdikar, Sam Y. Hong, Harinath Chakrapani, Bhalchandra Diwan, Nicole L. Morris, Paul J. Shami, Yih-Horng Shiao, Lucy M. Anderson, Larry K. Keefer, Joseph E. Saavedra. (2011) Activation of the c-Jun N-terminal Kinase/Activating Transcription Factor 3 (ATF3) Pathway Characterizes Effective Arylated Diazeniumdiolate-Based Nitric Oxide-Releasing Anticancer Prodrugs. Journal of Medicinal Chemistry111028141144008
CrossRef45
Cabot, Richard C.Harris, Nancy Lee, Shepard, Jo-Anne O., Rosenberg, Eric S., Cort, Alice M., Ebeling, Sally H.Peters, Christine C., Lanuti, Michael, Sequist, Lecia V., Sharma, Amita, Mino-Kenudson, Mari, . (2011) Case 31-2011. New England Journal of Medicine 365:15, 1426-1435
Full Text46
George R. Blumenschein. (2011) Developmental antiangiogenic agents for the treatment of Non-Small Cell Lung Cancer (NSCLC). Investigational New Drugs
CrossRef47
J. Clarey, S. C. Kao, S. J. Clarke, J. Vardy. (2011) The eligibility of advanced non-small-cell lung cancer patients for targeted therapy clinical trials. Annals of Oncology
CrossRef48
Mark J.C. Nuijten, Rick Aultman, Javier de Castro Carpeño, Alain Vergnenègre, Christos Chouaid, Stefan Walzer, Uwe Siebert. (2011) An indirect comparison of the efficacy of bevacizumab plus carboplatin and paclitaxel versus pemetrexed with cisplatin in patients with advanced or recurrent non-squamous adenocarcinoma non-small cell lung cancer. Current Medical Research and Opinion1-9
CrossRef49
Dan Zhang, Nobuaki Ochi, Nagio Takigawa, Yasushi Tanimoto, Yanyan Chen, Eiki Ichihara, Katsuyuki Hotta, Masahiro Tabata, Mitsune Tanimoto, Katsuyuki Kiura. (2011) Establishment of pemetrexed-resistant non-small cell lung cancer cell lines. Cancer Letters 309:2, 228-235
CrossRef50
Tobias Engel Ayer Botrel, Otávio Clark, Luciana Clark, Luciano Paladini, Enéas Faleiros, Bruna Pegoretti. (2011) Efficacy of bevacizumab (Bev) plus chemotherapy (CT) compared to CT alone in previously untreated locally advanced or metastatic non-small cell lung cancer (NSCLC): Systematic review and meta-analysis. Lung Cancer 74:1, 89-97
CrossRef51
Collin Blakely, Thierry Jahan. (2011) Emerging antiangiogenic therapies for non-small-cell lung cancer. Expert Review of Anticancer Therapy 11:10, 1607-1618
CrossRef52
Elena Galvani, Godefridus J Peters, Elisa Giovannetti. (2011) Thymidylate synthase inhibitors for non-small cell lung cancer. Expert Opinion on Investigational Drugs 20:10, 1343-1356
CrossRef53
Antonio Passaro, Enrico Cortesi, Filippo de Marinis. (2011) Second-line treatment of non-small-cell lung cancer: chemotherapy or tyrosine kinase inhibitors?. Expert Review of Anticancer Therapy 11:10, 1587-1597
CrossRef54
Mengying Yao, Weihong Zhang, Qingxian Zhang, Lihua Xing, Aiguo Xu, Qiuhong Liu, Bing Cui. (2011) Overexpression of MUC1 Enhances Proangiogenic Activity of Non-Small-Cell Lung Cancer Cells Through Activation of Akt and Extracellular Signal-regulated Kinase Pathways. Lung
CrossRef55
Gian Kayser, Wulf Sienel, Britta Kubitz, Dominik Mattern, Elmar Stickeler, Bernward Passlick, Martin Werner, Axel zur Hausen. (2011) Poor outcome in primary non-small cell lung cancers is predicted by transketolase TKTL1 expression. Pathology1
CrossRef56
F. Wang, L.D. Wang, B. Li, Z.X. Sheng. (2011) Gefitinib Compared with Systemic Chemotherapy as First-line Treatment for Chemotherapy-naive Patients with Advanced Non-small Cell Lung Cancer: A Meta-analysis of Randomised Controlled Trials. Clinical Oncology
CrossRef57
Klazien Matter-Walstra, Markus Joerger, Ursula Kühnel, Thomas Szucs, Bernhard Pestalozzi, Matthias Schwenkglenks. (2011) Cost-Effectiveness of Maintenance Pemetrexed in Patients with Advanced Nonsquamous-Cell Lung Cancer from the Perspective of the Swiss Health Care System. Value in Health
CrossRef58
Athanasios G. Pallis, Vassilis Georgoulias. (2011) Is there a standard regimen for first-line treatment of advanced/metastatic Non-Small-Cell Lung Cancer? What has meta-analyses contributed to today's standard of care. Lung Cancer
CrossRef59
Li Guo, Shu-Ping Bai, Ling Zhao, Xiao-Hong Wang. (2011) Astragalus polysaccharide injection integrated with vinorelbine and cisplatin for patients with advanced non-small cell lung cancer: effects on quality of life and survival. Medical Oncology
CrossRef60
Shengchu Zhang, Yihu Zheng, Panpan Yu, Fuxiang Yu, Qiyu Zhang, Yinxiang Lv, Xiaoxi Xie, Yunxiao Gao. (2011) The combined treatment of CT-guided percutaneous 125I seed implantation and chemotherapy for non-small-cell lung cancer. Journal of Cancer Research and Clinical Oncology
CrossRef61
Min-Chul Cho, Chang-Min Choi, Sollip Kim, Seongsoo Jang, Sejin Jang, Chan-Jeoung Park, Hyun-Sook Chi, Michael J. Peyton, Woochang Lee, Sail Chun, Sang-We Kim, Won-Ki Min. (2011) Direct sequencing in cytological specimens as a useful strategy for detecting EGFR mutations in non-small cell lung cancer patients. Clinical Chemistry and Laboratory Medicine---
CrossRef62
Raffaele Califano, Richard Griffiths, Paul Lorigan, Linda Ashcroft, Paul Taylor, Paul Burt, Lip Lee, Abbas Chittalia, Margaret Harris, Corinne Faivre-Finn, Nick Thatcher, Fiona Blackhall. (2011) Randomised phase II trial of 4 dose levels of single agent docetaxel in performance status (PS) 2 patients with advanced non-small cell lung cancer (NSCLC): DOC PS2 trial. Manchester lung cancer group. Lung Cancer 73:3, 338-344
CrossRef63
Ana Custodio, Javier de Castro. (2011) Strategies for maintenance therapy in advanced non-small cell lung cancer: Current status, unanswered questions and future directions. Critical Reviews in Oncology/Hematology
CrossRef64
Charles Butts, Andrew Maksymiuk, Glenwood Goss, Denis Soulières, Ernie Marshall, Yvon Cormier, Peter M. Ellis, Allan Price, Ravinder Sawhney, Frank Beier, Martin Falk, Nevin Murray. (2011) Updated survival analysis in patients with stage IIIB or IV non-small-cell lung cancer receiving BLP25 liposome vaccine (L-BLP25): phase IIB randomized, multicenter, open-label trial. Journal of Cancer Research and Clinical Oncology 137:9, 1337-1342
CrossRef65
Chanida Vinayanuwattikun, Virote Sriuranpong, Suebpong Tanasanvimon, Poonchavist Chantranuwat, Apiwat Mutirangura. (2011) Epithelial-Specific Methylation Marker. Journal of Thoracic Oncology1
CrossRef66
Corey J. Langer. (2011) Clinical Evidence on the Undertreatment of Older and Poor Performance Patients Who Have Advanced Non-Small-Cell Lung Cancer: Is There a Role for Targeted Therapy in These Cohorts?. Clinical Lung Cancer 12:5, 272-279
CrossRef67
R.A. Hubner, R. Goldstein, S. Mitchell, A. Jones, S. Ashley, M.E.R. O’Brien, S. Popat. (2011) Influence of co-morbidity on renal function assessment by Cockcroft–Gault calculation in lung cancer and mesothelioma patients receiving platinum-based chemotherapy. Lung Cancer 73:3, 356-360
CrossRef68
Rodrigo Dienstmann, Enriqueta Felip. (2011) Necitumumab in the treatment of advanced non-small cell lung cancer: translation from preclinical to clinical development. Expert Opinion on Biological Therapy 11:9, 1223-1231
CrossRef69
Jen-Chung Ko, Min-Shao Tsai, Shao-Hsing Weng, Ya-Hsun Kuo, Yu-Fan Chiu, Yun-Wei Lin. (2011) Curcumin enhances the mitomycin C-induced cytotoxicity via downregulation of MKK1/2–ERK1/2-mediated Rad51 expression in non-small cell lung cancer cells. Toxicology and Applied Pharmacology 255:3, 327-338
CrossRef70
M. Pérol. (2011) Traitement d’induction et de maintenance des CBNPC au stade métastatique. Revue des Maladies Respiratoires Actualités 3:4, 365-371
CrossRef71
Alexander I. Spira, Nicholas O. Iannotti, Michael A. Savin, Marcus Neubauer, Nashat Y. Gabrail, Ronald H. Yanagihara, Edith A. Zang, Patricia E. Cole, Dale Shuster, Asha Das. (2011) A Phase II Study of Eribulin Mesylate (E7389) in Patients With Advanced, Previously Treated Non–Small-Cell Lung Cancer. Clinical Lung Cancer
CrossRef72
Tony S. K. Mok. (2011) Personalized medicine in lung cancer: what we need to know. Nature Reviews Clinical Oncology 8:11, 661-668
CrossRef73
Tomonori Hirashima, Hidekazu Suzuki, Masashi Kobayashi, Youko Kondoh, Yoshie Tokuoka, Yuka Matsuura, Motohiro Tamiya, Naoko Morishita, Shinji Sasada, Norio Okamoto, Kohei Akazawa, Ichiro Kawase. (2011) Long-term chemotherapy may prolong survival in advanced non-small-cell lung cancer among responders to first-line chemotherapy. Medical Oncology
CrossRef74
Rachel A. Murphy, Marina Mourtzakis, Quincy S. C. Chu, Vickie E. Baracos, Tony Reiman, Vera C. Mazurak. (2011) Supplementation with fish oil increases first-line chemotherapy efficacy in patients with advanced nonsmall cell lung cancer. Cancer 117:16, 3774-3780
CrossRef75
Tiago B de Castria, Edina MK da Silva, Aecio FT Gois, Rachel Riera, Tiago B de Castria. 2011. Cisplatin versus carboplatin in association with third-generation drugs for advanced non-small cell lung cancer. .
CrossRef76
Xiao-Hang Zhang, Cheng Li, Chen-Fei Dai, Bao-Sen Zhou. (2011) Epidermal growth factor receptor mutations and their correlation with epidermal growth factor receptor-tyrosine kinase inhibitor therapy and association with the characteristics of patients with non-small-cell lung cancer: A meta-analysis. Thoracic Cancer 2:3, 101-108
CrossRef77
Yuhchyau Chen, Kishan J. Pandya, Ollivier Hyrien, Peter C. Keng, Therese Smudzin, Joy Anderson, Raman Qazi, Brian Smith, Thomas J. Watson, Richard H. Feins, David W. Johnstone. (2011) Preclinical and Pilot Clinical Studies of Docetaxel Chemoradiation for Stage III Non–Small-Cell Lung Cancer. International Journal of Radiation Oncology*Biology*Physics 80:5, 1358-1364
CrossRef78
Caicun Zhou, Yi-Long Wu, Gongyan Chen, Jifeng Feng, Xiao-Qing Liu, Changli Wang, Shucai Zhang, Jie Wang, Songwen Zhou, Shengxiang Ren, Shun Lu, Li Zhang, Chengping Hu, Chunhong Hu, Yi Luo, Lei Chen, Ming Ye, Jianan Huang, Xiuyi Zhi, Yiping Zhang, Qingyu Xiu, Jun Ma, Li Zhang, Changxuan You. (2011) Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. The Lancet Oncology 12:8, 735-742
CrossRef79
Ian Paul, Kienan I Savage, Jaine K Blayney, Elisabeth Lamers, Kathy Gately, Keith Kerr, Michael Sheaff, Kenneth Arthur, Derek J Richard, Peter W Hamilton, Jacqueline A James, Kenneth J O'Byrne, D Paul Harkin, Jennifer E Quinn, Dean A Fennell. (2011) PARP inhibition induces BAX/BAK-independent synthetic lethality of BRCA1-deficient non-small cell lung cancer. The Journal of Pathology 224:4, 564-574
CrossRef80
Hironori Satoh, Akira Inoue, Kunihiko Kobayashi, Makoto Maemondo, Satoshi Oizumi, Hiroshi Isobe, Akihiko Gemma, Yasuo Saijo, Hirohisa Yoshizawa, Koichi Hagiwara, Toshihiro Nukiwa. (2011) Low-Dose Gefitinib Treatment for Patients with Advanced Non-small Cell Lung Cancer Harboring Sensitive Epidermal Growth Factor Receptor Mutations. Journal of Thoracic Oncology 6:8, 1413-1417
CrossRef81
Shinichiro Motohashi, Yoshitaka Okamoto, Ichiro Yoshino, Toshinori Nakayama. (2011) Anti-tumor immune responses induced by iNKT cell-based immunotherapy for lung cancer and head and neck cancer. Clinical Immunology 140:2, 167-176
CrossRef82
Isabelle Ray-Coquard, Axel Le Cesne. (2011) A role for maintenance therapy in managing sarcoma. Cancer Treatment Reviews
CrossRef83
Peter M. Ellis, Normand Blais, Dennis Soulieres, Diana N. Ionescu, Meenakshi Kashyap, Geoff Liu, Barb Melosky, Tony Reiman, Phillippe Romeo, Frances A. Shepherd, Ming-Sound Tsao, Natasha B. Leighl. (2011) A Systematic Review and Canadian Consensus Recommendations on the Use of Biomarkers in the Treatment of Non-small Cell Lung Cancer. Journal of Thoracic Oncology 6:8, 1379-1391
CrossRef84
B. Glimelius, M. Lahn. (2011) Window-of-opportunity trials to evaluate clinical activity of new molecular entities in oncology. Annals of Oncology 22:8, 1717-1725
CrossRef85
Xin-xing Zhang, Mei-juan Huang, You-ling Gong, Lin Zhou, Yong-mei Liu, Jiang Zhu. (2011) A retrospective study of pemetrexed combined with oxaliplatin as the second-line treatment for advanced non-small cell lung cancer: comparable toxicity, better outcome*. Thoracic Cancerno-no
CrossRef86
Domenico Galetta, Salvatore Pisconti, Saverio Cinieri, Giovanni Luigi Pappagallo, Vittorio Gebbia, Nicola Borsellino, Evaristo Maiello, Antonio Rinaldi, Michele Montrone, Pietro Rizzo, Nicola Marzano, Nicola Sasso, Antonio Febbraro, Giuseppe Colucci. (2011) Induction Pemetrexed and Cisplatin Followed by Maintenance Pemetrexed Versus Carboplatin Plus Paclitaxel Plus Bevacizumab Followed by Maintenance Bevacizumab: A Quality of Life–Oriented Randomized Phase III Study in Patients With Advanced Non-Squamous Non–Small-Cell Lung Cancer (ERACLE). Clinical Lung Cancer
CrossRef87
Tsung-Ying Yang, Gee-Chen Chang, Kun-Chieh Chen, Hsiao-Wen Hung, Kuo-Hsuan Hsu, Gwo-Tarng Sheu, Shih-Lan Hsu. (2011) Sustained activation of ERK and Cdk2/cyclin-A signaling pathway by pemetrexed leading to S-phase arrest and apoptosis in human non-small cell lung cancer A549 cells. European Journal of Pharmacology 663:1-3, 17-26
CrossRef88
Maria Spiliotaki, Haris Markomanolaki, Marilena Mela, Dimitris Mavroudis, Vassilis Georgoulias, Sofia Agelaki. (2011) Targeting the insulin-like growth factor I receptor inhibits proliferation and VEGF production of non-small cell lung cancer cells and enhances paclitaxel-mediated anti-tumor effect. Lung Cancer 73:2, 158-165
CrossRef89
Alan Sandler, Charles Graham, Maria Baggstrom, Roy Herbst, Christopher Zergebel, Kaku Saito, Dennie Jones. (2011) An Open-Label, Multicenter, Three-Stage, Phase II Study of S-1 in Combination with Cisplatin as First-Line Therapy for Patients with Advanced Non-small Cell Lung Cancer. Journal of Thoracic Oncology 6:8, 1400-1406
CrossRef90
David Planchard. (2011) Bevacizumab in non-small-cell lung cancer: a review. Expert Review of Anticancer Therapy 11:8, 1163-1179
CrossRef91
Jeong-Seon Ryu, Eun-Soon Shin, Hae-Seong Nam, Hyeon-Gyu Yi, Jae-Hwa Cho, Chul-Soo Kim, Hyun-Jung Kim, Jong-Eun Lee. (2011) Differential Effect of Polymorphisms of CMPK1 and RRM1 on Survival in Advanced Non-small Cell Lung Cancer Patients Treated with Gemcitabine or Taxane/Cisplatinum. Journal of Thoracic Oncology 6:8, 1320-1329
CrossRef92
F. Tanaka, H. Wada, Y. Fukui, M. Fukushima. (2011) Thymidylate synthase (TS) gene expression in primary lung cancer patients: a large-scale study in Japanese population. Annals of Oncology 22:8, 1791-1797
CrossRef93
S. Matsuura, N. Inui, Y. Ozawa, Y. Nakamura, M. Toyoshima, K. Yasuda, T. Yamada, T. Shirai, H. Suganuma, K. Yokomura, T. Suda, K. Chida. (2011) Phase II Study of Erlotinib as Third-line Monotherapy in Patients with Advanced Non-small-cell Lung Cancer without Epidermal Growth Factor Receptor Mutations. Japanese Journal of Clinical Oncology 41:8, 959-963
CrossRef94
Paul Zarogoulidis, Ellada Eleftheriadou, Iordanis Sapardanis, Vasiliki Zarogoulidou, Helliel Lithoxopoulou, Theodoros Kontakiotis, Nikolaos Karamanos, George Zachariadis, Maria Mabroudi, Athanasios Zisimopoulos, Kostantinos Zarogoulidis. (2011) Feasibility and effectiveness of inhaled carboplatin in NSCLC patients. Investigational New Drugs
CrossRef95
J. Chmielecki, J. Foo, G. R. Oxnard, K. Hutchinson, K. Ohashi, R. Somwar, L. Wang, K. R. Amato, M. Arcila, M. L. Sos, N. D. Socci, A. Viale, E. de Stanchina, M. S. Ginsberg, R. K. Thomas, M. G. Kris, A. Inoue, M. Ladanyi, V. A. Miller, F. Michor, W. Pao. (2011) Optimization of Dosing for EGFR-Mutant Non-Small Cell Lung Cancer with Evolutionary Cancer Modeling. Science Translational Medicine 3:90, 90ra59-90ra59
CrossRef96
V.M. Garrisi, I. Bongarzone, A. Mangia, M. Cremona, M. De Bortoli, E. Vaghi, D. Galetta, U. Pastorino, M. Quaranta, I. Abbate, A. Paradiso. (2011) Characterization of a serum protein pattern from NSCLC patients treated with Gefitinib. Clinical Biochemistry 44:10-11, 936-940
CrossRef97
M. Lin, D. J. Stewart, M. R. Spitz, M. A. T. Hildebrandt, C. Lu, J. Lin, J. Gu, M. Huang, S. M. Lippman, X. Wu. (2011) Genetic variations in the transforming growth factor-beta pathway as predictors of survival in advanced non-small cell lung cancer. Carcinogenesis 32:7, 1050-1056
CrossRef98
E. Felip, C. Gridelli, P. Baas, R. Rosell, R. Stahel, . (2011) Metastatic non-small-cell lung cancer: consensus on pathology and molecular tests, first-line, second-line, and third-line therapy: 1st ESMO Consensus Conference in Lung Cancer; Lugano 2010. Annals of Oncology 22:7, 1507-1519
CrossRef99
Vera Hirsh. (2011) Afatinib (BIBW 2992) development in non-small-cell lung cancer. Future Oncology 7:7, 817-825
CrossRef100
Shannon Otsuka, Alexander C. Klimowicz, Karen Kopciuk, Stephanie K. Petrillo, Mie Konno, Desiree Hao, Huong Muzik, Erin Stolte, William Boland, Don Morris, Anthony M. Magliocco, D. Gwyn Bebb. (2011) CXCR4 Overexpression Is Associated with Poor Outcome in Females Diagnosed with Stage IV Non-small Cell Lung Cancer. Journal of Thoracic Oncology 6:7, 1169-1178
CrossRef101
Mohit K. Verma, Yasuhiro Miki, Hironobu Sasano. (2011) Aromatase in human lung carcinoma. Steroids 76:8, 759-764
CrossRef102
Masayuki Takeda, Isamu Okamoto, Naoko Hirabayashi, Mami Kitano, Kazuhiko Nakagawa. (2011) Thymidylate synthase and dihydropyrimidine dehydrogenase expression levels are associated with response to S-1 plus carboplatin in advanced non-small cell lung cancer. Lung Cancer 73:1, 103-109
CrossRef103
Filippo de Marinis, Antonio Rossi, Massimo Di Maio, Serena Ricciardi, Cesare Gridelli. (2011) Treatment of advanced non-small-cell lung cancer: Italian Association of Thoracic Oncology (AIOT) clinical practice guidelines. Lung Cancer 73:1, 1-10
CrossRef104
Vega Iranzo, Rafael Sirera, Roy M. Bremnes, Ana Blasco, Eloísa Jantus-Lewintre, Miquel Tarón, Alfonso Berrocal, Sara Blasco, Cristina Caballero, Nieves del Pozo, Rafael Rosell, Carlos Camps. (2011) Chemotherapy-Induced Neutropenia Does Not Correlate With DNA Repair Gene Polymorphisms and Treatment Efficacy in Advanced Non–Small-Cell Lung Cancer Patients. Clinical Lung Cancer 12:4, 224-230
CrossRef105
Helen H.W. Chen, Jiang-Jou Yan, Wen-Chung Chen, Macus Tien Kuo, Yu-Hsuan Lai, Wu-Wei Lai, Hsiao-Sheng Liu, Wu-Chou Su. (2011) Predictive and prognostic value of human copper transporter 1 (hCtr1) in patients with stage III non-small-cell lung cancer receiving first-line platinum-based doublet chemotherapy. Lung Cancer
CrossRef106
Runbo Zhong, Jiajun Teng, Baohui Han, Hua Zhong. (2011) Dendritic cells combining with cytokine-induced killer cells synergize chemotherapy in patients with late-stage non-small cell lung cancer. Cancer Immunology, Immunotherapy
CrossRef107
Mariacarmela Santarpia, Giuseppe Altavilla, Maria F Salazar, Ignacio Magri, Giuseppe Pettineo, Sara Benecchi, Rafael Rosell. (2011) Tyrosine kinase inhibitors for non-small-cell lung cancer: finding patients who will be responsive. Expert Review of Respiratory Medicine 5:3, 413-424
CrossRef108
Radj Gervais, John D. Hainsworth, Normand Blais, Benjamin Besse, Janessa Laskin, John T. Hamm, Allan Lipton, Kathy S. Albain, Gregory A. Masters, Ronald B. Natale, Paulina Selaru, Sindy T. Kim, Richard C. Chao, Ray D. Page. (2011) Phase II study of sunitinib as maintenance therapy in patients with locally advanced or metastatic non-small cell lung cancer. Lung Cancer
CrossRef109
Baohui Han, Qingyu Xiu, Huimin Wang, Jie Shen, Aiqin Gu, Yi Luo, Chunxue Bai, Shuliang Guo, Wenchao Liu, Zhixiang Zhuang, Yang Zhang, Yizhuo Zhao, Liyan Jiang, Jianying Zhou, Xianqiao Jin. (2011) A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy of Paclitaxel-Carboplatin Alone or with Endostar for Advanced Non-small Cell Lung Cancer. Journal of Thoracic Oncology 6:6, 1104-1109
CrossRef110
B. Besse, G. Zalcman. (2011) Quelle séquence de traitement chez les patients EGFR mutés ?. Revue de Pneumologie Clinique 67, S24-S29
CrossRef111
Alain Makinson, Jean-Charles Tenon, Sabrina Eymard-Duvernay, Jean-Louis Pujol, Clotilde Allavena, Lise Cuzin, Isabelle Poizot-Martin, Xavier de la Tribonnière, André Cabié, Pascal Pugliese, Jacques Reynes, Vincent Le Moing. (2011) Human Immunodeficiency Virus Infection and Non-small Cell Lung Cancer. Journal of Thoracic Oncology 6:6, 1022-1029
CrossRef112
Shang-Gin Wu, Chih-Hsin Yang, Chong-Jen Yu, Jih-Hsiang Lee, Ya-Chieh Hsu, Yih-Leong Chang, Jin-Yuan Shih, Pan-Chyr Yang. (2011) Good response to pemetrexed in patients of lung adenocarcinoma with epidermal growth factor receptor (EGFR) mutations. Lung Cancer 72:3, 333-339
CrossRef113
M. Früh. (2011) The search for improved systemic therapy of non-small cell lung cancer—What are today's options?. Lung Cancer 72:3, 265-270
CrossRef114
V KimCurran, C Zhou, G Schmid-Bindert, Ren Shengxiang, S Zhou, L Zhang, J Zhang. (2011) Lack of correlation between ERCC1 (C8092A) Single Nucleotide Polymorphism and efficacy/toxicity of platinum based chemotherapy in Chinese patients with advanced Non-Small Cell Lung Cancer. Advances in Medical Sciences 56:1, 30-38
CrossRef115
Yaping Xu, Shenglin Ma, Yongling Ji, Xiaojiang Sun, Hao Jiang, Jianxiang Chen, Xianghui Du, Yuanda Zheng, Guoqin Qiu. (2011) Concomitant chemoradiotherapy using pemetrexed and carboplatin for unresectable stage III non-small cell lung cancer (NSCLC): Preliminary results of a phase II study. Lung Cancer 72:3, 327-332
CrossRef116
Ross A. Soo, Marie Loh, Tony S. Mok, Sai-Hong I. Ou, Byoung-Chul Cho, Wee-Lee Yeo, Dan G. Tenen, Richie Soong. (2011) Ethnic Differences in Survival Outcome in Patients with Advanced Stage Non-small Cell Lung Cancer. Journal of Thoracic Oncology 6:6, 1030-1038
CrossRef117
Antoinette Wozniak. (2011) Challenges in the current antiangiogenic treatment paradigm for patients with non-small cell lung cancer. Critical Reviews in Oncology/Hematology
CrossRef118
Sarah R Goodyear, Hossein Borghaei. (2011) Lung cancer vaccines: a review of three ongoing trials. Clinical Investigation 1:6, 849-858
CrossRef119
Vega Iranzo, Rafael Sirera, Alfredo Carrato, Andrea Cabrera, Eloísa Jantus, Ricardo Guijarro, Elena Sanmartín, Ana Blasco, Mireia Gil, Lorenzo Gómez-Aldaraví, José Luis González-Larriba, Bertomeu Massuti, Amalia Velasco, Mariano Provencio, Rafael Rosell, Carlos Camps. (2011) Phase II clinical trial with gemcitabine and paclitaxel sequential monotherapy as first-line treatment for advanced non-small-cell lung cancer (SLCG 01-04). Clinical and Translational Oncology 13:6, 411-418
CrossRef120
Yuh-Min Chen, Jacqueline Whang-Peng, Chien-Ming Chen. (2011) First-line Systemic Therapy for Metastatic Non-small-cell Lung Cancer – A Review. Journal of Experimental & Clinical Medicine 3:3, 116-120
CrossRef121
Yoshiki Ishii, Sakae Fujimoto, Kazumi Okazaki, Masaaki Miyoshi, Tomoe Furihata, Isano Hase, Hidenori Takizawa, Yasuko Kikkawa, Issei Yamada, Takeshi Fukuda. (2011) Fractionated administration of carboplatin/paclitaxel reduces neurotoxicity in patients with advanced non-small cell lung cancer. Anti-Cancer Drugs1
CrossRef122
Kanwal Pratap Singh Raghav, George R Blumenschein. (2011) Motesanib and advanced NSCLC: experiences and expectations. Expert Opinion on Investigational Drugs 20:6, 859-869
CrossRef123
John Wen-Cheng CHANG, Sumitra THONGPRASERT, Elaine WRIGHT, Kenneth TSANG, Heung Tae KIM, Myung-Ju AHN, Joo-Hang KIM, Jin Hyoung KANG, Sang-We KIM, Stefan WALZER. (2011) An indirect comparison of bevacizumab plus cisplatin-gemcitabine and cisplatin plus pemetrexed treatment for patients with advanced first-line non-squamous non-small cell lung cancer in East Asia. Asia-Pacific Journal of Clinical Oncology 7, 13-21
CrossRef124
Sandra Gottschling, Anna Jauch, Ruprecht Kuner, Esther Herpel, Karin Mueller-Decker, Philipp A. Schnabel, Elizabeth C. Xu, Thomas Muley, Holger Sültmann, Christian Bender, Martin Granzow, Thomas Efferth, Hans Hoffmann, Hendrik Dienemann, Felix J.F. Herth, Michael Meister. (2011) Establishment and comparative characterization of novel squamous cell non-small cell lung cancer cell lines and their corresponding tumor tissue. Lung Cancer
CrossRef125
Seung Tae Kim, Ji Eun Uhm, Jeeyun Lee, Jong-mu Sun, Insuk Sohn, Seon Woo Kim, Sin-Ho Jung, Yeon Hee Park, Jin Seok Ahn, Keunchil Park, Myung-Ju Ahn. (2011) Randomized phase II study of gefitinib versus erlotinib in patients with advanced non-small cell lung cancer who failed previous chemotherapy. Lung Cancer
CrossRef126
X. Wu, Y. Ye, R. Rosell, C. I. Amos, D. J. Stewart, M. A. T. Hildebrandt, J. A. Roth, J. D. Minna, J. Gu, J. Lin, S. C. Buch, T. Nukui, J. L. Ramirez Serrano, M. Taron, A. Cassidy, C. Lu, J. Y. Chang, S. M. Lippman, W. K. Hong, M. R. Spitz, M. Romkes, P. Yang. (2011) Genome-Wide Association Study of Survival in Non-Small Cell Lung Cancer Patients Receiving Platinum-Based Chemotherapy. JNCI Journal of the National Cancer Institute 103:10, 817-825
CrossRef127
K Takezawa, I Okamoto, W Okamoto, M Takeda, K Sakai, S Tsukioka, K Kuwata, H Yamaguchi, K Nishio, K Nakagawa. (2011) Thymidylate synthase as a determinant of pemetrexed sensitivity in non-small cell lung cancer. British Journal of Cancer 104:10, 1594-1601
CrossRef128
Niels Reinmuth, Michael Thomas. (2011) An approach to personalized medicine: the BATTLE trial. Clinical Investigation 1:5, 699-705
CrossRef129
Mark J. McKeage. (2011) Clinical Trials of Vascular Disrupting Agents in Advanced Non–Small-Cell Lung Cancer. Clinical Lung Cancer 12:3, 143-147
CrossRef130
Haihong Yang, Wei Wang, Yalei Zhang, Jin Zhao, Enyun Lin, Jing Gao, Jianxing He. (2011) The Role of NF-E2-Related Factor 2 in Predicting Chemoresistance and Prognosis in Advanced Non–Small-Cell Lung Cancer. Clinical Lung Cancer 12:3, 166-171
CrossRef131
Cesare Gridelli, Andrea Ardizzoni, Sandro Barni, Lucio Crinò, Alberto Caprioli, Elena Piazza, Vito Lorusso, Santi Barbera, Nicoletta Zilembo, Vittorio Gebbia, Vincenzo Adamo, Riccardo Pela, Maurizio Marangolo, Raffaella Morena, Gianfranco Filippelli, Calogero Buscarino, Oscar Alabiso, Paolo Maione, Paola Venturino, Filippo De Marinis. (2011) Medical treatment choices for patients affected by advanced NSCLC in routine clinical practice: Results from the Italian observational “SUN” (Survey on the lUng cancer maNagement) study. Lung Cancer
CrossRef132
Herbert H. Loong, Jia Wei, Tony S. Mok. (2011) Ethnic variation in response to EGFR inhibitors. Drug Discovery Today: Therapeutic Strategies
CrossRef133
T. Zander, M. Hallek. (2011) Thyrosinkinaseinhibitoren in der Onkologie. Der Internist 52:5, 595-600
CrossRef134
D. Gómez Herrero, A. Albert Marí, M. Merino Sanjuán, M.L. Boquera Ferrer, N. Víctor Jiménez Torres. (2011) Perfil de toxicidad y adherencia del esquema farmacoterapéutico gemcitabina-carboplatino en cáncer de pulmón no microcítico. Farmacia Hospitalaria
CrossRef135
Ana Custodio, Míriam Méndez, Mariano Provencio. (2011) Targeted therapies for advanced non-small-cell lung cancer: Current status and future implications. Cancer Treatment Reviews
CrossRef136
Chien-Chih Chiu, Po-Len Liu, Kuang-Jing Huang, Hui-Min Wang, Kuo-Feng Chang, Chon-Kit Chou, Fang-Rong Chang, Inn-Wen Chong, Kang Fang, Jia-Shing Chen, Hsueh-Wei Chang, Yang-Chang Wu. (2011) Goniothalamin Inhibits Growth of Human Lung Cancer Cells through DNA Damage, Apoptosis, and Reduced Migration Ability. Journal of Agricultural and Food Chemistry 59:8, 4288-4293
CrossRef137
Susanna V. Ulahannan, Julie R. Brahmer. (2011) Antiangiogenic Agents in Combination with Chemotherapy in Patients with Advanced Non-Small Cell Lung Cancer. Cancer Investigation 29:4, 325-337
CrossRef138
C. Manegold, N. van Zandwijk, A. Szczesna, P. Zatloukal, J. S. K. Au, M. Blasinska-Morawiec, P. Serwatowski, M. Krzakowski, J. Jassem, E. H. Tan, R. J. Benner, A. Ingrosso, S. J. Meech, D. Readett, N. Thatcher. (2011) A phase III randomized study of gemcitabine and cisplatin with or without PF-3512676 (TLR9 agonist) as first-line treatment of advanced non-small-cell lung cancer. Annals of Oncology
CrossRef139
S. I. Rothschild, O. Gautschi. (2011) Maintenance therapy for patients with advanced non-small cell lung cancer: Who to treat and how to treat?. memo - Magazine of European Medical Oncology 4:1, 19-22
CrossRef140
Anjaiah Srirangam, Monica Milani, Ranjana Mitra, Zhijun Guo, Mariangellys Rodriguez, Hitesh Kathuria, Seiji Fukuda, Anthony Rizzardi, Stephen Schmechel, David G. Skalnik, Louis M. Pelus, David A. Potter. (2011) The Human Immunodeficiency Virus Protease Inhibitor Ritonavir Inhibits Lung Cancer Cells, in Part, by Inhibition of Survivin. Journal of Thoracic Oncology 6:4, 661-670
CrossRef141
Keita Kudo, Fumiyoshi Ohyanagi, Atushi Horiike, Eisaku Miyauchi, Noriko Yanagitani, Rira Hoshi, Yukitoshi Satoh, Noriko Motoi, Wakako Hamanaka, Yuichi Ishikawa, Mingyon Mun, Yukinori Sakao, Sakae Okumura, Ken Nakagawa, Takeshi Horai, Makoto Nishio. (2011) Clinicopathological findings of non-small-cell lung cancer with high serum progastrin-releasing peptide concentrations. Lung Cancer
CrossRef142
Fernanda Salazar, Miguel Angel Molina, Maria Sanchez-Ronco, Teresa Moran, Jose Luis Ramirez, Jose Miguel Sanchez, Rolf Stahel, Pilar Garrido, Manuel Cobo, Dolores Isla, Jordi Bertran-Alamillo, Bartomeu Massuti, Felipe Cardenal, Christian Manegold, Pilar Lianes, Jose Manuel Trigo, Jose Javier Sanchez, Miquel Taron, Rafael Rosell. (2011) First-line therapy and methylation status of CHFR in serum influence outcome to chemotherapy versus EGFR tyrosine kinase inhibitors as second-line therapy in stage IV non-small-cell lung cancer patients. Lung Cancer 72:1, 84-91
CrossRef143
Ari VanderWalde, Sumanta Kumar Pal, Karen L. Reckamp. (2011) Management of non-small-cell lung cancer in the older adult. Maturitas 68:4, 311-321
CrossRef144
P. A. Kosmidis, G. Fountzilas, A. G. Eleftheraki, H. P. Kalofonos, G. Pentheroudakis, D. Skarlos, M. A. Dimopoulos, D. Bafaloukos, D. Pectasides, E. Samantas, J. Boukovinas, S. Lambaki, N. Katirtzoglou, C. Bakogiannis, K. N. Syrigos. (2011) Paclitaxel and gemcitabine versus paclitaxel and vinorelbine in patients with advanced non-small-cell lung cancer. A phase III study of the Hellenic Cooperative Oncology Group (HeCOG). Annals of Oncology 22:4, 827-834
CrossRef145
Sanghui Park, Seung Yeon Ha, Hyun Yee Cho, Dong Hae Chung, Na Rae Kim, Junshik Hong, Eun Kyung Cho. (2011) Prognostic implications of hypoxia-inducible factor-1α in epidermal growth factor receptor-negative non-small cell lung cancer. Lung Cancer 72:1, 100-107
CrossRef146
D. Galetta, V. Gebbia, N. Silvestris, F. Ferraù, F. Carrozza, S. Cigolari, P. Russo, F. Calista, V. Adamo, G. Colucci. (2011) Cisplatin, fotemustine and whole-brain radiotherapy in non-small cell lung cancer patients with asymptomatic brain metastases: A multicenter phase II study of the Gruppo Oncologico Italia Meridionale (GOIM 2603). Lung Cancer 72:1, 59-63
CrossRef147
Liang Cheng, Shaobo Zhang, Riley Alexander, Yongxue Yao, Gregory T MacLennan, Chong-xian Pan, Jiaoti Huang, Mingsheng Wang, Rodolfo Montironi, Antonio Lopez-Beltran. (2011) The landscape of EGFR pathways and personalized management of non-small-cell lung cancer. Future Oncology 7:4, 519-541
CrossRef148
U. Nappa, O. Lindqvist, B. H. Rasmussen, B. Axelsson. (2011) Palliative chemotherapy during the last month of life. Annals of Oncology
CrossRef149
Jun Sakakibara-Konishi, Satoshi Oizumi, Ichiro Kinoshita, Naofumi Shinagawa, Junko Kikuchi, Mototsugu Kato, Tetsuya Inoue, Norio Katoh, Rikiya Onimaru, Hiroki Shirato. (2011) Phase I study of concurrent real-time tumor-tracking thoracic radiation therapy with paclitaxel and carboplatin in locally advanced non-small cell lung cancer. Lung Cancer
CrossRef150
Cataldo, Vince D., Gibbons, Don L., Pérez-Soler, Román, Quintás-Cardama, Alfonso, . (2011) Treatment of Non–Small-Cell Lung Cancer with Erlotinib or Gefitinib. New England Journal of Medicine 364:10, 947-955
Full Text151
Y. Naito, K. Kubota, H. Ohmatsu, K. Goto, S. Niho, K. Yoh, Y. Ohe. (2011) Phase II study of nedaplatin and docetaxel in patients with advanced squamous cell carcinoma of the lung. Annals of Oncology
CrossRef152
Oscar Arrieta, Cynthia Villarreal-Garza, Digna Pachuca, Rosa M. Michel Ortega, Luis Martinez-Barrera, Diana Flores-Estrada, Alma Astorga. (2011) High response of second-line chemotherapy with pemetrexed or gemcitabine combined with carboplatin in patients with non-small-cell lung cancer experiencing progression following 6 months after concluding platinum-based chemotherapy. Medical Oncology 28:1, 300-306
CrossRef153
Jenny Andrews, Paul Yeh, William Pao, Leora Horn. (2011) Molecular Predictors of Response to Chemotherapy in Non-Small Cell Lung Cancer. The Cancer Journal 17:2, 104-113
CrossRef154
Peng Chen, Long Wang, Bing Liu, Hai-Zhong Zhang, Hong-Chen Liu, Zui Zou. (2011) EGFR-targeted therapies combined with chemotherapy for treating advanced non-small-cell lung cancer: a meta-analysis. European Journal of Clinical Pharmacology 67:3, 235-243
CrossRef155
Suresh S. Ramalingam, Taofeek K. Owonikoko, Fadlo R. Khuri. (2011) Lung cancer: New biological insights and recent therapeutic advances. CA: A Cancer Journal for Clinicians 61:2, 91-112
CrossRef156
Noriyuki Masuda, Shunichi Negoro, Frederick Hausheer, Kazuhiko Nakagawa, Kaoru Matsui, Shinzoh Kudoh, Koji Takeda, Nobuyuki Yamamoto, Naruo Yoshimura, Yasuo Ohashi, Masahiro Fukuoka. (2011) Phase I and pharmacologic study of BNP7787, a novel chemoprotector in patients with advanced non-small cell lung cancer. Cancer Chemotherapy and Pharmacology 67:3, 533-542
CrossRef157
George Dranitsaris, Ilse Truter, Martie S. Lubbe, Eitan Amir, William Evans. (2011) Advances in Cancer Therapeutics and Patient Access to New Drugs. PharmacoEconomics 29:3, 213-224
CrossRef158
Hua Cheng, She-Juan An, Xu-Chao Zhang, Song Dong, Yi-Fang Zhang, Zhi-Hong Chen, Hua-Jun Chen, Ai-Lin Guo, Qiu-xiong Lin, Yi-Long Wu. (2011) In vitro sequence-dependent synergism between paclitaxel and gefitinib in human lung cancer cell lines. Cancer Chemotherapy and Pharmacology 67:3, 637-646
CrossRef159
Yongfa Zheng, Wei Ge, Ling Zhang, Zhenyu Zhao, Fangfang Jie. (2011) Clinical observation of pemetrexed on advanced non-small-cell lung cancer. The Chinese-German Journal of Clinical Oncology 10:3, 140-143
CrossRef160
Gabriella Farina, Flavia Longo, Olga Martelli, Ida Pavese, Andrea Mancuso, Luca Moscetti, Roberto Labianca, Alessandro Bertolini, Enrico Cortesi, Antonio Farris, Daniele Fagnani, Maria Cristina Locatelli, Giuseppe Valmadre, Antonio Ardizzoia, Maurizio Tomirotti, Eliana Rulli, Marina Chiara Garassino, Alberto Scanni. (2011) Rationale for Treatment and Study Design of TAILOR: A Randomized Phase III Trial of Second-line Erlotinib Versus Docetaxel in the Treatment of Patients Affected by Advanced Non–Small-Cell Lung Cancer With the Absence of Epidermal Growth Factor Receptor Mutations. Clinical Lung Cancer 12:2, 138-141
CrossRef161
A.- M. C. Dingemans, A. J. de Langen, V. van den Boogaart, J. T. Marcus, W. H. Backes, H. T. G. M. Scholtens, H. van Tinteren, O. S. Hoekstra, J. Pruim, B. Brans, F. B. Thunnissen, E. F. Smit, H. J. M. Groen. (2011) First-line erlotinib and bevacizumab in patients with locally advanced and/or metastatic non-small-cell lung cancer: a phase II study including molecular imaging. Annals of Oncology 22:3, 559-566
CrossRef162
Satoshi Yoda, Kenzo Soejima, Hiroyuki Yasuda, Katsuhiko Naoki, Ichiro Kawada, Hideo Watanabe, Ichiro Nakachi, Ryosuke Satomi, Sohei Nakayama, Sinnosuke Ikemura, Hideki Terai, Takashi Sato, Maiko Morosawa, Koichiro Asano. (2011) A phase I study of S-1 and irinotecan combination therapy in previously treated advanced non-small cell lung cancer patients. Cancer Chemotherapy and Pharmacology 67:3, 717-722
CrossRef163
Sacha I Rothschild, Oliver Gautschi, Primo N Lara, Philip C Mack, David R Gandara. (2011) Biomarkers of DNA repair and related pathways: significance in non-small cell lung cancer. Current Opinion in Oncology 23:2, 150-157
CrossRef164
Cheng-liang Yang, Shun-shou Liu, Ye-gang Ma, Yong-yu Liu, Yi-xue Xue, Bo Huang. (2011) The influence of intraoperative pleural perfusion with matrine–cisplatin or cisplatin on stromal cell-derived factor-1 in non-small cell lung cancer patients with subclinical pleural metastasis. Medical Oncology
CrossRef165
David J. Stewart, Carmen Behrens, Jack Roth, Ignacio I. Wistuba. (2011) Exponential decay nonlinear regression analysis of patient survival curves: Preliminary assessment in non-small cell lung cancer. Lung Cancer 71:2, 217-223
CrossRef166
Ki-Hwan Eum, Michael Lee. (2011) Crosstalk between autophagy and apoptosis in the regulation of paclitaxel-induced cell death in v-Ha-ras-transformed fibroblasts. Molecular and Cellular Biochemistry 348:1-2, 61-68
CrossRef167
Akihiro Tamiya, Tateaki Naito, Akira Ono, Eriko Ayabe, Asuka Tsuya, Yukiko Nakamura, Kyoichi Kaira, Haruyasu Murakami, Toshiaki Takahashi, Masahiro Endo, Nobuyuki Yamamoto. (2011) Evaluation of the efficacy and safety of chemotherapy for patients with wet stage IIIB/IV non-small-cell lung cancer aged 80 years old or more. Lung Cancer 71:2, 173-177
CrossRef168
Renaud Descourt, Alain Vergnenegre, Fabrice Barlesi, Herve Lena, Pierre Fournel, Lionel Falchero, Henri Berard, Jose Hureaux, Herve Le Caer, Jean Michel Chavaillon, Laurence Geriniere, Isabelle Monnet, Stéphane Chouabe, Gilles Robinet. (2011) Oral Vinorelbine and Cisplatin with Concurrent Radiotherapy After Induction Chemotherapy with Cisplatin and Docetaxel for Patients with Locally Advanced Non-small Cell Lung Cancer. Journal of Thoracic Oncology 6:2, 351-357
CrossRef169
Chao H. Huang, Stephen K. Williamson, Peter J. Van Veldhuizen, Chung-Tsen Hsueh, Ace Allen, Ossama Tawfik, Jo Wick, Holly Smith, Adelina M. Uypeckcuat, Matthew Mayo, Karen Kelly. (2011) Potential Role of Platelet-Derived Growth Factor Receptor Inhibition Using Imatinib in Combination with Docetaxel in the Treatment of Recurrent Non-small Cell Lung Cancer. Journal of Thoracic Oncology 6:2, 372-377
CrossRef170
William Pao, Nicolas Girard. (2011) New driver mutations in non-small-cell lung cancer. The Lancet Oncology 12:2, 175-180
CrossRef171
Hiroshi Saito, Kazuhiko Nakagawa, Koji Takeda, Yasuo Iwamoto, Masahiko Ando, Masao Maeda, Nobuyuki Katakami, Takashi Nakano, Takayasu Kurata, Masahiro Fukuoka. (2011) Randomized Phase II Study of Carboplatin-Paclitaxel or Gemcitabine-Vinorelbine in Patients With Advanced Nonsmall Cell Lung Cancer and a Performance Status of 2. American Journal of Clinical Oncology1
CrossRef172
C Papadaki, E Tsaroucha, L Kaklamanis, E Lagoudaki, M Trypaki, K Tryfonidis, D Mavroudis, E Stathopoulos, V Georgoulias, J Souglakos. (2011) Correlation of BRCA1, TXR1 and TSP1 mRNA expression with treatment outcome to docetaxel-based first-line chemotherapy in patients with advanced/metastatic non-small-cell lung cancer. British Journal of Cancer 104:2, 316-323
CrossRef173
Xin Zhao, Kai Mei, Xiaohong Cai, Jing Chen, Jingrui Yu, Chengya Zhou, Qiu Li. (2011) A randomized phase II study of recombinant human endostatin plus gemcitabine/cisplatin compared with gemcitabine/cisplatin alone as first-line therapy in advanced non-small-cell lung cancer. Investigational New Drugs
CrossRef174
Alex Soltermann, Sandra Kilgus-Hawelski, Silvia Behnke, Martina Storz, Holger Moch, Beata Bode. (2011) Automated ERCC1 immunochemistry on hybrid cytology/tissue microarray of malignant effusions: evaluation of antibodies 8F1 and D-10. Journal of Clinical Bioinformatics 1:1, 25
CrossRef175
Shiro Tanaka, Yuichi Sakamori, Miyuki Niimi, Megumi Hazama, Young H Kim, Kazuhiro Yanagihara. (2011) Design paper: A phase II study of Bevacizumab and Erlotinib in patients with non-Squamous non-small cell lung cancer that is refractory or relapsed after 1-2 previous Treatment (BEST). Trials 12:1, 120
CrossRef176
Sharon Lai-Fung Chan, Raymond Wai-Yin Sun, Mei-Yuk Choi, Yibo Zeng, Lam Shek, Stephen Sin-Yin Chui, Chi-Ming Che. (2011) An anti-cancer trinuclear ruthenium(iii) complex with 2-thiosalicylate ligands attenuates Wnt-β-catenin signaling. Chemical Science 2:9, 1788
CrossRef177
Daniel J Lebovic, Alberto Chiappori, Jhanelle Gray. (2011) Maintenance therapies in advanced non-small-cell lung cancer. Therapy 8:1, 33-41
CrossRef178
Myung Hee Chang, Hee Kyung Ahn, Jeeyun Lee, Chan-Kwon Jung, Yoon-La Choi, Yeon Hee Park, Jin Seok Ahn, Keunchil Park, Myung-Ju Ahn. (2011) Clinical impact of amphiregulin expression in patients with epidermal growth factor receptor (EGFR) wild-type nonsmall cell lung cancer treated with EGFR-tyrosine kinase inhibitors. Cancer 117:1, 143-151
CrossRef179
Han Jo Kim, Kyoung Ha Kim, Jina Yun, Se Hyung Kim, Hyun Jung Kim, Sang-Cheol Lee, Sang Byung Bae, Chan Kyu Kim, Nam Su Lee, Kyu Taek Lee, Do-Jin Kim, Seong-Kyu Park, Jong-Ho Won, Dae Sik Hong, Hee Sook Park. (2011) Phase II Clinical Trial of Genexol® (Paclitaxel) and Carboplatin for Patients with Advanced Non-small Cell Lung Cancer. Cancer Research and Treatment 43:1, 19
CrossRef180
Fumihiro Oshita, Takeshi Honda, Shuji Murakami, Tetsuro Kondo, Haruhiro Saito, Kazumasa Noda, Kouzo Yamada. (2011) Comparison of Nedaplatin and Irinotecan for Patients with Squamous and Nonsquamous Cell Carcinoma of the Lung. Journal of Thoracic Oncology 6:1, 128-131
CrossRef181
Julie R. Brahmer, Suzanne E. Dahlberg, Robert J. Gray, Joan H. Schiller, Michael C. Perry, Alan Sandler, David H. Johnson. (2011) Sex Differences in Outcome with Bevacizumab Therapy. Journal of Thoracic Oncology 6:1, 103-108
CrossRef182
Davide Tassinari, Sergio Sartori, Maximilian Papi, Fabrizio Drudi, Cinzia Castellani, Federica Carloni, Paola Tombesi, Luigi Lazzari-Agli. (2011) Bevacizumab in the Treatment of Advanced, Non-Squamous Non-Small Cell Lung Cancer: An Evidence-Based Approach. Oncology 80:5-6, 350-358
CrossRef183
Salah Abbasi, Ahmed Badheeb. (2011) Prognostic Factors in Advanced Non-Small-Cell Lung Cancer Patients: Patient Characteristics and Type of Chemotherapy. Lung Cancer International 2011, 1-4
CrossRef184
Yoshio Okano, Hiroyuki Hino, Mitsuteru Yoshida, Nobuo Hatakeyama, Tsutomu Shinohara, Fumitaka Ogushi. (2011) Safety of Adjuvant Chemotherapy with Carboplatin and Weekly Paclitaxel for Pathological Stage IB-IIIB Non-small Cell Lung Cancer. Haigan 51:3, 165-170
CrossRef185
Yuan Chen, Tiantian Cui, Linlin Yang, Masoud Mireskandari, Thomas Knoesel, Qing Zhang, Manuela Pacyna-Gengelbach, Iver Petersen. (2011) The Diagnostic Value of Cytokeratin 5/6, 14, 17, and 18 Expression in Human Non-Small Cell Lung Cancer. Oncology 80:5-6, 333-340
CrossRef186
Fu-Tsai Chung, Kang-Yun Lee, Yueh-Fu Fang, Meng-Heng Shieh, Shu-Min Lin, Chih-Teng Yu, Yun-Lun Lo, Ting-Yu Lin, Chih-Hsi Kuo, Po-Hao Feng, Yung-Lun Ni, Han-Pin Kuo. (2011) Low-Dose Weekly Docetaxel Is as Tolerable as Pemetrexed in Previously Treated Advanced Non-Small-Cell Lung Cancer. Chemotherapy 57:2, 147-155
CrossRef187
Kwok-Chi LAM, Tony S. MOK. (2011) Targeted therapy: An evolving world of lung cancer. Respirology 16:1, 13-21
CrossRef188
Wen-Xiu Ni, Wai-Lun Man, Myra Ting-Wai Cheung, Raymond Wai-Yin Sun, Yuan-Lan Shu, Yun-Wah Lam, Chi-Ming Che, Tai-Chu Lau. (2011) Osmium(vi) complexes as a new class of potential anti-cancer agents. Chemical Communications 47:7, 2140
CrossRef189
Fumihiko Hirai, Kaname Nosaki, Taro Ohba, Takuro Kometani, Masafumi Yamaguchi, Motoharu Hamatake, Takashi Seto, Kenji Sugio, Yukito Ichinose. (2011) A Retrospective Study of Feasibility of Third-line or Higher Chemotherapy Using Pemetrexed in Non-squamous, Non-small Cell Lung Cancer Patients. Haigan 51:4, 227-232
CrossRef190
Kenji Akie, Satoshi Oizumi, Shigeaki Ogura, Naofumi Shinagawa, Eiki Kikuchi, Shinichi Fukumoto, Masao Harada, Ichiro Kinoshita, Tetsuya Kojima, Toshiyuki Harada, Yuka Fujita, Yoshinobu Ohsaki, Hirotoshi Dosaka-Akita, Hiroshi Isobe, Masaharu Nishimura. (2011) Phase II Study of Irinotecan plus S-1 Combination for Previously Untreated Advanced Non-Small Cell Lung Cancer: Hokkaido Lung Cancer Clinical Study Group Trial (HOT) 0601. Oncology 81:2, 84-90
CrossRef191
Renhua Guo, Xiaofen Chen, Tongshan Wang, Zhiyuan Zhang, Jin Sun, Yongqian Shu. (2011) Subsequent chemotherapy reverses acquired tyrosine kinase inhibitor resistance and restores response to tyrosine kinase inhibitor in advanced non-small-cell lung cancer. BMC Cancer 11:1, 90
CrossRef192
Federico Longo, Alejandro Riquelme, Mercedes Rodríguez, María E. Olmedo, Pilar Garrido. (2011) Long-Term Survival in a Smoking Caucasian Male Patient Treated with Gefitinib for Spinal Cord Compression Secondary to Lung Cancer. Onkologie 34:6, 326-328
CrossRef193
Yohei Imamura, Koichi Azuma, Seiji Kurata, Satoshi Hattori, Tetsuro Sasada, Takashi Kinoshita, Masaki Okamoto, Tomotaka Kawayama, Hayato Kaida, Masatoshi Ishibashi, Hisamichi Aizawa. (2011) Prognostic value of SUVmax measurements obtained by FDG-PET in patients with non-small cell lung cancer receiving chemotherapy. Lung Cancer 71:1, 49-54
CrossRef194
Hisatsugu Goto, Masaki Hanibuchi, Satoshi Sakaguchi, Takanori Kanematsu, Soji Kakiuchi, Hideki Tomimoto, Masahiko Azuma, Toshifumi Tezuka, Hiroya Tada, Yukiyo Miki, Toshimi Nakamura, Saburo Sone, Yasuhiko Nishioka. (2011) Investigation of the outpatient chemotherapy for lung cancer patients in Tokushima University Hospital. The Journal of Medical Investigation 58:3,4, 219-226
CrossRef195
Max Dahele, Suresh Senan. (2011) The Role of Stereotactic Ablative Radiotherapy for Early-Stage and Oligometastatic Non-small Cell Lung Cancer: Evidence for Changing Paradigms. Cancer Research and Treatment 43:2, 75
CrossRef196
Ben-Xu Tan, Wen-Xiu Yao, Jun Ge, Xing-Chen Peng, Xiao-Bo Du, Ru Zhang, Bin Yao, Ke Xie, Long-Hao Li, Hang Dong, Feng Gao, Feng Zhao, Jian-Mei Hou, Jing-Mei Su, Ji-Yan Liu. (2011) Prognostic influence of metformin as first-line chemotherapy for advanced nonsmall cell lung cancer in patients with type 2 diabetes. Cancern/a-n/a
CrossRef197
Dong-Wan Kim, Se-Hoon Lee, Jong Seok Lee, Myung Ah Lee, Jin Hyoung Kang, Si Young Kim, Sang Won Shin, Hoon-Kyo Kim, Dae Seog Heo. (2011) A multicenter phase II study to evaluate the efficacy and safety of gefitinib as first-line treatment for Korean patients with advanced pulmonary adenocarcinoma harboring EGFR mutations. Lung Cancer 71:1, 65-69
CrossRef198
Hee Joung Kim, Wan Seop Kim, Kyeong-Cheol Shin, Gwan Ho Lee, Mi-Jin Kim, Jeong Eun Lee, Kyu Sang Song, Sun Young Kim, Kye Young Lee. (2011) Comparative Analysis of Peptide Nucleic Acid (PNA)-Mediated Real-Time PCR Clamping and DNA Direct Sequencing for EGFR Mutation Detection. Tuberculosis and Respiratory Diseases 70:1, 21
CrossRef199
Seong Ha Cheon, Kyung Seok Kim, Sehyun Kim, Hyun Sik Jung, Won Cheol Choi, Wan Kyu Eo. (2011) Efficacy and Safety of <i>Rhus verniciflua</i> Stokes Extracts in Patients with Previously Treated Advanced Non-Small Cell Lung Cancer. Forschende Komplementärmedizin / Research in Complementary Medicine 18:2, 2-2
CrossRef200
Hua C. Gong, Sean Wang, Gary Mayer, Guoan Chen, Glen Leesman, Sharat Singh, David G. Beer. (2011) Signatures of Drug Sensitivity in Nonsmall Cell Lung Cancer. International Journal of Proteomics 2011, 1-13
CrossRef201
Elizabeth M. Blanchard, James Moon, Paul J. Hesketh, Karen Kelly, Antoinette J. Wozniak, John Crowley, David Gandara. (2011) Comparison of Platinum-Based Chemotherapy in Patients Older and Younger than 70 Years. Journal of Thoracic Oncology 6:1, 115-120
CrossRef202
Wen-Chien Fan, Chong-Jen Yu, Chun-Ming Tsai, Ming-Shyan Huang, Chun-Liang Lai, Te-Chun Hsia, Yin-Jing Tien, Shiang-Fen Huang, Chieh-Hung Wu, Kun-Ta Chou, Yu-Chin Lee, Reury-Perng Perng, Yuh-Min Chen. (2011) Different Efficacies of Erlotinib and Gefitinib in Taiwanese Patients with Advanced Non-small Cell Lung Cancer. Journal of Thoracic Oncology 6:1, 148-155
CrossRef203
George R. Simon, Michael J. Schell, Mubeena Begum, Jongphil Kim, Alberto Chiappori, Eric Haura, Scott Antonia, Gerold Bepler. (2011) Preliminary indication of survival benefit from ERCC1 and RRM1-tailored chemotherapy in patients with advanced nonsmall cell lung cancer: Evidence from an individual patient analysis. Cancern/a-n/a
CrossRef204
Yoichi Nakamura, Hiroshi Soda, Mikio Oka, Akitoshi Kinoshita, Minoru Fukuda, Masaaki Fukuda, Hiroshi Takatani, Seiji Nagashima, Yoshifumi Soejima, Takashi Kasai, Katsumi Nakatomi, Noriyuki Masuda, Kazuhiro Tsukamoto, Shigeru Kohno. (2011) Randomized Phase II Trial of Irinotecan with Paclitaxel or Gemcitabine for Non-small Cell Lung Cancer. Journal of Thoracic Oncology 6:1, 121-127
CrossRef205
Tsung-Ying Yang, Gee-Chen Chang, Kun-Chieh Chen, Hsiao-Wen Hung, Kuo-Hsuan Hsu, Chi-Hao Wu, Gwo-Tarng Sheu, Shih-Lan Hsu. (2011) Pemetrexed induces both intrinsic and extrinsic apoptosis through ataxia telangiectasia mutated/p53-dependent and -independent signaling pathways. Molecular Carcinogenesisn/a-n/a
CrossRef206
T. Sugiyama, T. Hirose, M. Nakashima, K. Ishida, Y. Oki, Y. Murata, S. Kusumoto, T. Shirai, T. Yamaoka, K. Okuda, T. Ohnishi, T. Ohmori, M. Adachi. (2011) Evaluation of the Efficacy and Safety of the Combination of Gemcitabine and Nedaplatin for Elderly Patients with Advanced Non-Small-Cell Lung Cancer. Oncology 81:3-4, 273-280
CrossRef207
Suchita Pakkala, Zhengjia Chen, David Rimland, Taofeek K. Owonikoko, Clifford Gunthel, Johann R. Brandes, Nabil R. Saba, Dong M. Shin, Walter J. Curran, Fadlo R. Khuri, Suresh S. Ramalingam. (2011) Human immunodeficiency virus-associated lung cancer in the era of highly active antiretroviral therapy. Cancern/a-n/a
CrossRef208
Dal Yong Kim, Dae Ho Lee, Sun-Joo Jang, Sang-We Kim, Cheolwon Suh, Jung Shin Lee. (2011) Phase II Study of S-1 Plus Either Irinotecan or Docetaxel for Non-small Cell Lung Cancer Patients Treated with More Than Three Lines of Treatment. Cancer Research and Treatment 43:4, 212
CrossRef209
Sang Hoon Chun, Ji Eun Lee, Mi Hee Park, Jin-Hyoung Kang, Young Kyoon Kim, Young-Pil Wang, Jae Kil Park, Hoon-Kyo Kim. (2011) Gemcitabine Plus Platinum Combination Chemotherapy for Elderly Patients with Advanced Non-small Cell Lung Cancer: A Retrospective Analysis. Cancer Research and Treatment 43:4, 217
CrossRef210
Seol-Bong Yoo, Hyojin Kim, Xianhua Xu, Ping-Li Sun, Yan Jin, Jin Ho Paik, Sanghoon Jheon, Choon-Taek Lee, Jin-Haeng Chung. (2011) Clinicopathologic Implications of ALK Gene Copy Number Gain in Non-small Cell Lung Cancer. Journal of Lung Cancer 10:2, 87
CrossRef211
Guanghui Gao, Shengxiang Ren, Aiwu Li, Jianfang Xu, Qinghua Xu, Chunxia Su, Jian Guo, Qinfang Deng, Caicun Zhou. (2011) Epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) therapy is effective as first-line treatment of advanced non-small-cell lung cancer with mutated EGFR: a meta-analysis from 6 phase III randomized controlled trials. International Journal of Cancern/a-n/a
CrossRef212
S Cicėnas, J Kurtinaitis, G Smailytė. (2010) Outcome and treatment strategy in female lung cancer: a single institution experience. Advances in Medical Sciences 55:2, 273-280
CrossRef213
Joseph Treat, Martin J. Edelman, Chandra P. Belani, Mark A. Socinski, Matthew J. Monberg, Ruqin Chen, Coleman K. Obasaju. (2010) A retrospective analysis of outcomes across histological subgroups in a three-arm phase III trial of gemcitabine in combination with carboplatin or paclitaxel versus paclitaxel plus carboplatin for advanced non-small cell lung cancer. Lung Cancer 70:3, 340-346
CrossRef214
Rafael Rosell, Alain Vergnenegre, Baorui Liu, Manuel Cobo, Bartomeu Massuti, Jia Wei, Miguel Angel Molina, Carlota Costa, Cristina Queralt, Miquel Taron. (2010) Biomarkers in lung oncology. Pulmonary Pharmacology & Therapeutics 23:6, 508-514
CrossRef215
, Noriyasu Usami, Kohei Yokoi, Yoshinori Hasegawa, Hiroyuki Taniguchi, Joe Shindo, Masashi Yamamoto, Ryujiro Suzuki, Kazuyoshi Imaizumi, Masashi Kondo, Kaoru Shimokata. (2010) Phase II study of carboplatin and gemcitabine as adjuvant chemotherapy in patients with completely resected non-small cell lung cancer: a report from the Central Japan Lung Study Group, CJLSG 0503 trial. International Journal of Clinical Oncology 15:6, 583-587
CrossRef216
Meera Nanjundan, Lauren Averett Byers, Mark S. Carey, Doris R. Siwak, Maria Gabriela Raso, Lixia Diao, Jing Wang, Kevin R. Coombes, Jack A. Roth, Gordon B. Mills, Ignacio I. Wistuba, John D. Minna, John V. Heymach. (2010) Proteomic Profiling Identifies Pathways Dysregulated in Non-small Cell Lung Cancer and an Inverse Association of AMPK and Adhesion Pathways with Recurrence. Journal of Thoracic Oncology 5:12, 1894-1904
CrossRef217
Eleni G. Iliopoulou, Panteleimon Kountourakis, Michalis V. Karamouzis, Dimitrios Doufexis, Alexandros Ardavanis, Constantin N. Baxevanis, Gerasimos Rigatos, Michael Papamichail, Sonia A. Perez. (2010) A phase I trial of adoptive transfer of allogeneic natural killer cells in patients with advanced non-small cell lung cancer. Cancer Immunology, Immunotherapy 59:12, 1781-1789
CrossRef218
Tatsuya Katayama, Keitaro Matsuo, Takayuki Kosaka, Taijiro Sueda, Yasushi Yatabe, Tetsuya Mitsudomi. (2010) Effect of gefitinib on the survival of patients with recurrence of lung adenocarcinoma after surgery: A retrospective case-matching cohort study. Surgical Oncology 19:4, e144-e149
CrossRef219
Mark A. Socinski, Robert N. Raju, Thomas Stinchcombe, Darren M. Kocs, Linda S. Couch, David Barrera, Steven R. Rousey, Janak K. Choksi, Robert Jotte, Debra A. Patt, Phillip O. Periman, Howard R. Schlossberg, Charles H. Weissman, Yunfei Wang, Lina Asmar, Sharon Pritchard, Jane Bromund, Guangbin Peng, Joseph Treat, Coleman K. Obasaju. (2010) Randomized, Phase II Trial of Pemetrexed and Carboplatin with or without Enzastaurin versus Docetaxel and Carboplatin as First-Line Treatment of Patients with Stage IIIB/IV Non-small Cell Lung Cancer. Journal of Thoracic Oncology 5:12, 1963-1969
CrossRef220
Yiqing Qu, Yie Yang, Baoyi Liu, Wei Xiao. (2010) Comparative proteomic profiling identified sorcin being associated with gemcitabine resistance in non-small cell lung cancer. Medical Oncology 27:4, 1303-1308
CrossRef221
Joel W Neal. (2010) The SATURN trial: the value of maintenance erlotinib in patients with non-small-cell lung cancer. Future Oncology 6:12, 1827-1832
CrossRef222
Jean-François Morère, Jeanne-Marie Bréchot, Virginie Westeel, Valerie Gounant, Bernard Lebeau, Fabien Vaylet, Fabrice Barlési, Thierry Urban, Pierre-Jean Souquet, Didier Debieuvre, Laurence Baudrin, Gérard Zalcman, Franck Morin, Bernard Milleron, Denis Moro-Sibilot. (2010) Randomized phase II trial of gefitinib or gemcitabine or docetaxel chemotherapy in patients with advanced non-small-cell lung cancer and a performance status of 2 or 3 (IFCT-0301 study). Lung Cancer 70:3, 301-307
CrossRef223
Tatsuya Nagano, Masahiro Yasunaga, Koichi Goto, Hirotsugu Kenmotsu, Yoshikatsu Koga, Jun-ichiro Kuroda, Yoshihiro Nishimura, Takashi Sugino, Yutaka Nishiwaki, Yasuhiro Matsumura. (2010) Synergistic antitumor activity of the SN-38-incorporating polymeric micelles NK012 with S-1 in a mouse model of non-small cell lung cancer. International Journal of Cancer 127:11, 2699-2706
CrossRef224
David R. Gandara, Peter Grimminger, Philip C. Mack, Primo N. Lara, Tianhong Li, Peter V. Danenberg, Kathleen D. Danenberg. (2010) Association of Epidermal Growth Factor Receptor Activating Mutations with Low ERCC1 Gene Expression in Non-small Cell Lung Cancer. Journal of Thoracic Oncology 5:12, 1933-1938
CrossRef225
Tokujiro Yano, Akira Haro, Tsukihisa Yoshida, Yosuke Morodomi, Kensaku Ito, Yasunori Shikada, Fumihiro Shoji, Riichiroh Maruyama, Yoshihiko Maehara. (2010) Prognostic impact of local treatment against postoperative oligometastases in non-small cell lung cancer. Journal of Surgical Oncology 102:7, 852-855
CrossRef226
M. Iqbal Choudhary, Shabbir Hussain, Sammar Yousuf, Ahsana Dar, Mudassar, Atta-ur-Rahman. (2010) Chlorinated and diepoxy withanolides from Withania somnifera and their cytotoxic effects against human lung cancer cell line. Phytochemistry 71:17-18, 2205-2209
CrossRef227
Zhengbo Song, Yongfeng Yu, Zhiwei Chen, Shun Lu. (2010) Third-line therapy for advanced non-small-cell lung cancer patients: feasible drugs for feasible patients. Medical Oncology
CrossRef228
Elaine T. Lam, Jessie L.- S. Au, Gregory A. Otterson, M. Guillaume Wientjes, Ling Chen, Tong Shen, Yong Wei, Xiaobai Li, Tanios Bekaii-Saab, Anthony J. Murgo, Rhonda R. Jensen, Michael Grever, Miguel A. Villalona-Calero. (2010) Phase I trial of non-cytotoxic suramin as a modulator of docetaxel and gemcitabine therapy in previously treated patients with non-small cell lung cancer. Cancer Chemotherapy and Pharmacology 66:6, 1019-1029
CrossRef229
Shengxiang Ren, Songwen Zhou, Ling Zhang, Jianfang Xu, Meijun Lv, Jie Zhang, Caicun Zhou, Jie Zhang. (2010) High-Level mRNA of Excision Repair Cross-Complementation Group 1 Gene Is Associated With Poor Outcome of Platinum-Based Doublet Chemotherapy of Advanced Nonsmall Cell Lung Cancer Patients. Cancer Investigation 28:10, 1078-1083
CrossRef230
Ryan J. Summers, Bahig M. Shehata, John C. Bleacher, Christina Stockwell, Louis Rapkin. (2010) Mucinous adenocarcinoma of the lung in association with congenital pulmonary airway malformation. Journal of Pediatric Surgery 45:11, 2256-2259
CrossRef231
Rosana Crespo, Margarita G. de Bravo, Pedro A. Colinas, Rodolfo D. Bravo. (2010) In vitro antitumor activity of N-glycosyl sulfonamides. Bioorganic & Medicinal Chemistry Letters 20:22, 6469-6471
CrossRef232
G. P. Stathopoulos, D. Antoniou, J. Dimitroulis, P. Michalopoulou, A. Bastas, K. Marosis, J. Stathopoulos, A. Provata, P. Yiamboudakis, D. Veldekis, N. Lolis, N. Georgatou, M. Toubis, C. Pappas, G. Tsoukalas. (2010) Liposomal cisplatin combined with paclitaxel versus cisplatin and paclitaxel in non-small-cell lung cancer: a randomized phase III multicenter trial. Annals of Oncology 21:11, 2227-2232
CrossRef233
A. F. Eichler, K. T. Kahle, D. L. Wang, V. A. Joshi, H. Willers, J. A. Engelman, T. J. Lynch, L. V. Sequist. (2010) EGFR mutation status and survival after diagnosis of brain metastasis in nonsmall cell lung cancer. Neuro-Oncology 12:11, 1193-1199
CrossRef234
Benjamin Levy, Alexander Drilon, KarLeung Siu, Michael Grossbard. (2010) Extended-Duration Therapy in Advanced Non–Small-Cell Lung Cancer: Promise and Pitfalls. Clinical Lung Cancer 11:6, 383-390
CrossRef235
Kun Chen, Qiang Lin, Chunlin Chang, Yannan Zhao, Yue’e Liu, Na Wang, Huiling Su, Yuehua Huang. (2010) A clinical comparative study of GP and TP 1st-line chemotherapies for advanced non-small cell lung cancer. The Chinese-German Journal of Clinical Oncology 9:11, 621-624
CrossRef236
Martin Reck, Norbert Frickhofen, Susana Cedres, Ulrich Gatzemeier, David Heigener, Heinz-Georg Fuhr, Aron Thall, Silvana Lanzalone, Patricia Stephenson, Ana Ruiz-Garcia, Richard Chao, Enriqueta Felip. (2010) Sunitinib in combination with gemcitabine plus cisplatin for advanced non-small cell lung cancer: A phase I dose-escalation study. Lung Cancer 70:2, 180-187
CrossRef237
E. Stoelben, R.M. Huber, R.-P. Müller, J. Wolf. (2010) Multimodale Therapie des Lungenkarzinoms. Der Internist 51:11, 1348-1357
CrossRef238
William Pao, Juliann Chmielecki. (2010) Rational, biologically based treatment of EGFR-mutant non-small-cell lung cancer. Nature Reviews Cancer 10:11, 760-774
CrossRef239
Kohsuke Okita, Shinichiro Motohashi, Ryo Shinnakasu, Kaoru Nagato, Kazuki Yamasaki, Yasunori Sato, Hiroshi Kitamura, Atsushi Hijikata, Masakatsu Yamashita, Kanako Shimizu, Shin-ichiro Fujii, Osamu Ohara, Masaru Taniguchi, Isao Sakaida, Toshinori Nakayama. (2010) A set of genes associated with the interferon-γ response of lung cancer patients undergoing α-galactosylceramide-pulsed dendritic cell therapy. Cancer Science 101:11, 2333-2340
CrossRef240
Heather R. Sanders, Maher Albitar. (2010) Somatic mutations of signaling genes in non-small-cell lung cancer. Cancer Genetics and Cytogenetics 203:1, 7-15
CrossRef241
Jae Jin Lee, Chi Hoon Maeng, Seon Kyung Baek, Gou Young Kim, Jee-Hong Yoo, Cheon Woong Choi, Yee Hyung Kim, Young-Tae Kwak, Dae-Hyun Kim, Young Kyung Lee, Jung Bo Kim, Si-Young Kim. (2010) The immunohistochemical overexpression of ribonucleotide reductase regulatory subunit M1 (RRM1) protein is a predictor of shorter survival to gemcitabine-based chemotherapy in advanced non-small cell lung cancer (NSCLC). Lung Cancer 70:2, 205-210
CrossRef242
Christelle Clément-Duchêne, Yelena Krupitskaya, Kristen Ganjoo, Philip Lavori, Alex McMillan, Atul Kumar, Gary Zhao, Sukhmani Padda, Lisa Zhou, Melanie San Pedro-Salcedo, A. Dimitrios Colevas, Heather A. Wakelee. (2010) A Phase II First-Line Study of Gemcitabine, Carboplatin, and Bevacizumab in Advanced Stage Nonsquamous Non-small Cell Lung Cancer. Journal of Thoracic Oncology 5:11, 1821-1825
CrossRef243
Hiroaki Kuroda, Satsuki Mochizuki, Masayuki Shimoda, Miyuki Chijiiwa, Kazunori Kamiya, Yotaro Izumi, Masazumi Watanabe, Hirohisa Horinouchi, Masahumi Kawamura, Koichi Kobayashi, Yasunori Okada. (2010) ADAM28 is a serological and histochemical marker for non-small-cell lung cancers. International Journal of Cancer 127:8, 1844-1856
CrossRef244
Moyez Jiwa, Eric Maujean, Katrina Spilsbury, Tim Threlfal. (2010) The trajectory of lung cancer patients in Western Australia—A data linkage study: Still a grim tale. Lung Cancer 70:1, 22-27
CrossRef245
Tony S Mok, Qing Zhou, Linda Leung, Herbert H Loong. (2010) Personalized medicine for non-small-cell lung cancer. Expert Review of Anticancer Therapy 10:10, 1601-1611
CrossRef246
Jung Hye Kwon, Jung Han Kim, Jung-Ae Lee, Hyun Chun Shin, Hyo Jung Kim, Hun Ho Song, Joo Young Jung, Ho Young Kim, Dae Ro Choi, Hyeong Su Kim, Young-iee Park, Dae Young Zang. (2010) Phase II study with fractionated schedule of docetaxel and cisplatin in patients with advanced non-small cell lung cancer. Cancer Chemotherapy and Pharmacology 66:5, 889-897
CrossRef247
Drew W. Rasco, Jingsheng Yan, Yang Xie, Jonathan E. Dowell, David E. Gerber. (2010) Looking Beyond Surveillance, Epidemiology, and End Results. Journal of Thoracic Oncology 5:10, 1529-1535
CrossRef248
Wan-yin Wu, Xiao-bing Yang, Hong Deng, Shun-qin Long, Liang-sheng Sun, Wen-feng He, Yu-shu Zhou, Gui-ya Liao, Sai-man Chan, Shi-pu Shan. (2010) Treatment of advanced non-small cell lung cancer with extracorporeal high frequency thermotherapy combined with Chinese medicine. Chinese Journal of Integrative Medicine 16:5, 406-410
CrossRef249
Chenguang Li, Yihua Sun, Yunjian Pan, Qifeng Wang, Shu Yang, Haiquan Chen. (2010) Gemcitabine Plus Paclitaxel Versus Carboplatin Plus Either Gemcitabine or Paclitaxel in Advanced Non-small-cell Lung Cancer: A Literature-based Meta-analysis. Lung 188:5, 359-364
CrossRef250
E. Felip, S. Cedres, E. Checa, P. Martinez. (2010) How to integrate current knowledge in selecting patients for first line in NSCLC?. Annals of Oncology 21:Supplement 7, vii230-vii233
CrossRef251
Fan Li, Xinchen Sun, Ning Sun, Shukui Qin, Hongyan Cheng, Jifeng Feng, Baoan Chen, Lu Cheng, Zuhong Lu, Jiazhong Ji, Yingfeng Zhou. (2010) Association Between Polymorphisms of ERCC1 and XPD and Clinical Response to Platinum-Based Chemotherapy in Advanced Non–Small Cell Lung Cancer. American Journal of Clinical Oncology 33:5, 489-494
CrossRef252
Silvia Novello, Francisco Luis Pimentel, Jean-Yves Douillard, Mary OʼBrien, Joachim von Pawel, John Eckardt, Astra M. Liepa, Lorinda Simms, Carla Visseren-Grul, Luis Paz-Ares. (2010) Safety and Resource Utilization by Non-small Cell Lung Cancer Histology. Journal of Thoracic Oncology 5:10, 1602-1608
CrossRef253
Sri Navaratnam, Erich V. Kliewer, Jim Butler, Alain A. Demers, Grace Musto, Ketan Badiani. (2010) Population-based patterns and cost of management of metastatic non-small cell lung cancer after completion of chemotherapy until death. Lung Cancer 70:1, 110-115
CrossRef254
H. Francis, B. Solomon. (2010) The current status of targeted therapy for non-small cell lung cancer. Internal Medicine Journal 40:9, 611-618
CrossRef255
Guo Jian, Zhou Songwen, Zhang Ling, Deng Qinfang, Zhang Jie, Tang Liang, Zhou Caicun. (2010) Prediction of epidermal growth factor receptor mutations in the plasma/pleural effusion to efficacy of gefitinib treatment in advanced non-small cell lung cancer. Journal of Cancer Research and Clinical Oncology 136:9, 1341-1347
CrossRef256
N. Saijo, M. Fukuoka, S. Thongprasert, Y. Ichinose, T. Mitsudomi, T. S. K. Mok, Y. Ohe, K. Park, Y.-L. Wu. (2010) Lung Cancer Working Group Report. Japanese Journal of Clinical Oncology 40:Supplement 1, i7-i12
CrossRef257
Fengsheng Chen, Xi Luo, Jinbiao Zhang, Yang Lu, Rongcheng Luo. (2010) Elevated serum levels of TPS and CYFRA 21-1 predict poor prognosis in advanced non-small-cell lung cancer patients treated with gefitinib. Medical Oncology 27:3, 950-957
CrossRef258
Ralph G. Zinner, Scott B. Saxman, Guangbin Peng, Matthew J. Monberg, Waldo I. Ortuzar. (2010) Treatment Rationale and Study Design for a Randomized Trial of Pemetrexed/Carboplatin Followed by Maintenance Pemetrexed Versus Paclitaxel/Carboplatin/Bevacizumab Followed by Maintenance Bevacizumab in Patients With Advanced Non–Small-Cell Lung Cancer of Nonsquamous Histology. Clinical Lung Cancer 11:5, 352-357
CrossRef259
John H. Heinzerling, Hak Choy, Randall S. Hughes, Ramaswamy Govindan, Jeffrey D. Bradley, Lee S. Schwartzberg, Guangbin Peng, Joseph Treat, Taylor Tran, Coleman Obasaju. (2010) Toxicity and Response of Pemetrexed Plus Carboplatin or Cisplatin with Concurrent Chest Radiation Therapy for Patients with Locally Advanced Non-small Cell Lung Cancer. Journal of Thoracic Oncology 5:9, 1391-1396
CrossRef260
Sara Caponi, Enrico Vasile, Laura Ginocchi, Carmelo Tibaldi, Francesca Borghi, Armida D'Incecco, Maurizio Lucchesi, Chiara Caparello, Michele Andreuccetti, Alfredo Falcone. (2010) Second-line Treatment for Non–Small-Cell Lung Cancer: One Size Does Not Fit All. Clinical Lung Cancer 11:5, 320-327
CrossRef261
Sanja Stanisic, Helge G. Bischoff, David F. Heigener, Alain Vergnenègre, Javier de Castro Carpeño, Christos Chouaid, Stefan Walzer, Elvira Mueller, Elvira Schmidt. (2010) Societal cost savings through bevacizumab-based treatment in non-small cell lung cancer (NSCLC). Lung Cancer 69, S24-S30
CrossRef262
Helge G. Bischoff, David F. Heigener, Stefan Walzer, Mark Nuijten. (2010) Costs of bevacizumab and pemetrexed for advanced non-squamous NSCLC in Italy and Germany. Lung Cancer 69, S18-S23
CrossRef263
Elvira Mueller. (2010) Editorial: Comparative efficacy and cost associated with new agents in the treatment of non-small cell lung cancer (NSCLC). Lung Cancer 69, S1-S3
CrossRef264
Sandra C Tomaszek, Marianne Huebner, Dennis A Wigle. (2010) Prospects for molecular staging of non-small-cell lung cancer from genomic alterations. Expert Review of Respiratory Medicine 4:4, 499-508
CrossRef265
Mark Nuijten, David F. Heigener, Helge G. Bischoff, Christos Chouaid, Alain Vergnenègre, Javier de Castro Carpeño, Rick Aultman, Stefan Walzer, Uwe Siebert. (2010) Effectiveness of bevacizumab- and pemetrexed-cisplatin treatment for patients with advanced non-squamous non-small cell lung cancer. Lung Cancer 69, S4-S10
CrossRef266
Kathryn E. Reinicke, Mary J. Kuffel, Matthew P. Goetz, Matthew M. Ames. (2010) Synergistic interactions between aminoflavone, paclitaxel and camptothecin in human breast cancer cells. Cancer Chemotherapy and Pharmacology 66:3, 575-583
CrossRef267
Lian Jiang, Dao-yuan Wang, Zhi-hua Zhu, Liang-fa Tang, Xin-heng Hou, Hong-da Zhao, Zheng Xie, Dan-feng Wang. (2010) Phase II study of carboplatin combined with weekly docetaxel in patients with advanced non-small cell lung cancer. Cancer Chemotherapy and Pharmacology 66:3, 449-453
CrossRef268
Tania Fleitas, Vicenta Martínez-Sales, José Gómez-Codina, María Martín, Gaspar Reynés. (2010) Circulating endothelial and endothelial progenitor cells in non-small-cell lung cancer. Clinical and Translational Oncology 12:8, 521-525
CrossRef269
Giovanni Giuliani, Francesco Grossi, Filippo de Marinis, Stefan Walzer. (2010) Cost-effectiveness analysis of bevacizumab versus pemetrexed for advanced non-squamous NSCLC in Italy. Lung Cancer 69, S11-S17
CrossRef270
Jing Zhu, Lixia Ma, Ying Cheng. (2010) ATP-bioluminescence assay indicates the treatment of recurrent non-small cell lung cancer combined with malignant pleural effusion. The Chinese-German Journal of Clinical Oncology 9:8, 441-443
CrossRef271
Yuji Ueda, Hisakazu Yamagishi, Daisuke Ichikawa, Kazuma Okamoto, Eigo Otsuji, Jun Morii, Kinya Koizumi, Naoki Kakihara, Masataka Shimotsuma, Tetsuro Yamashita, Fumihiro Taniguchi, Hideki Aragane, Hiroshi Nishi, Yoshiki Itokawa, Satoshi Morita, Junichi Sakamoto. (2010) Multicenter phase II study of weekly paclitaxel plus S-1 combination chemotherapy in patients with advanced gastric cancer. Gastric Cancer 13:3, 149-154
CrossRef272
Jie Luo, Shiang J. Leaw, Ying Xu, Di Zheng. (2010) Comparison of cisplatin- and carboplatin-based third-generation chemotherapy in 1,014 Chinese patients with advanced non-small-cell lung cancer. Medical Oncology
CrossRef273
Yoshitsugu Horio, Hirotaka Osada, Junichi Shimizu, Shizu Ogawa, Toyoaki Hida, Yoshitaka Sekido. (2010) Relationship of mRNA expressions of RanBP2 and topoisomerase II isoforms to cytotoxicity of amrubicin in human lung cancer cell lines. Cancer Chemotherapy and Pharmacology 66:2, 237-243
CrossRef274
Noriyuki Masuda, Kaoru Matsui, Shunichi Negoro, Koji Takeda, Shinzoh Kudoh, Kazuhiko Nakagawa, Akihira Mukaiyama, Hiroaki Arase, Pascal Yoshida, Toshiyuki Ijima, Minoru Takada, Masahiro Fukuoka. (2010) Phase I and Pharmacologic Study of Weekly Bolus Topotecan for Advanced Non–Small-Cell Lung Cancer. Clinical Lung Cancer 11:4, 271-279
CrossRef275
Aristea Kalikaki, Anastasios Koutsopoulos, Dora Hatzidaki, Maria Trypaki, Emmanouel Kontopodis, Efstathios Stathopoulos, Dimitris Mavroudis, Vassilis Georgoulias, Alexandra Voutsina. (2010) Clinical outcome of patients with non-small cell lung cancer receiving front-line chemotherapy according to EGFR and K-RAS mutation status. Lung Cancer 69:1, 110-115
CrossRef276
Ariel Lopez-Chavez, Giuseppe Giaccone. (2010) Targeted therapies: Importance of patient selection for EGFR TKIs in lung cancer. Nature Reviews Clinical Oncology 7:7, 360-362
CrossRef277
Filip Janku, David J. Stewart, Razelle Kurzrock. (2010) Targeted therapy in non-small-cell lung cancer—is it becoming a reality?. Nature Reviews Clinical Oncology 7:7, 401-414
CrossRef278
Robert C. Doebele, Ana B. Oton, Nir Peled, D. Ross Camidge, Paul A. Bunn. (2010) New strategies to overcome limitations of reversible EGFR tyrosine kinase inhibitor therapy in non-small cell lung cancer. Lung Cancer 69:1, 1-12
CrossRef279
Takaaki Sasaki, Scott J. Rodig, Lucian R. Chirieac, Pasi A. Jänne. (2010) The biology and treatment of EML4-ALK non-small cell lung cancer. European Journal of Cancer 46:10, 1773-1780
CrossRef280
Maemondo, Makoto, Inoue, Akira, Kobayashi, Kunihiko, Sugawara, Shunichi, Oizumi, Satoshi, Isobe, Hiroshi, Gemma, Akihiko, Harada, Masao, Yoshizawa, Hirohisa, Kinoshita, Ichiro, Fujita, Yuka, Okinaga, Shoji, Hirano, Haruto, Yoshimori, Kozo, Harada, Toshiyuki, Ogura, Takashi, Ando, Masahiro, Miyazawa, Hitoshi, Tanaka, Tomoaki, Saijo, Yasuo, Hagiwara, Koichi, Morita, Satoshi, Nukiwa, Toshihiro, . (2010) Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR. New England Journal of Medicine 362:25, 2380-2388
Full Text281
Seung Tae Kim, Jeeyun Lee, Jeong-hoon Kim, Young-Woong Won, Jong-Mu Sun, Jina Yun, Yeon Hee Park, Jin Seok Ahn, Keunchil Park, Myung-Ju Ahn. (2010) Comparison of gefitinib versus erlotinib in patients with nonsmall cell lung cancer who failed previous chemotherapy. Cancer 116:12, 3025-3033
CrossRef282
Helge G. Bischoff, Ben van den Borne, Francisco L. Pimentel, Jorge Arellano, Frank Langer, Monika I. Leschinger, Nicholas Thatcher. (2010) Observation of the treatment and outcomes of patients receiving chemotherapy for advanced NSCLC in Europe (ACTION study). Current Medical Research and Opinion 26:6, 1461-1470
CrossRef283
Jan Gerard Maring, Floris M. Wachters, Monique Slijfer, J. Marina Maurer, H. Marike Boezen, Donald R. A. Uges, Elisabeth G. E. Vries, Harry J. M. Groen. (2010) Pharmacokinetics of gemcitabine in non-small-cell lung cancer patients: impact of the 79A>C cytidine deaminase polymorphism. European Journal of Clinical Pharmacology 66:6, 611-617
CrossRef284
Elizabeth M. Blanchard, Konstantinos Arnaoutakis, Paul J. Hesketh. (2010) Lung Cancer in Octogenarians. Journal of Thoracic Oncology 5:6, 909-916
CrossRef285
Lucia Nogova, Matthias Scheffler, Christian Mattonet, Thomas Zander, Jürgen Wolf. (2010) Systemische Therapie des nichtkleinzelligen Bronchialkarzinoms. Onkopipeline 3:2, 113-117
CrossRef286
Xin Wang, Jun Zhao, Lu Yang, Li Mao, Tongtong An, Hua Bai, Shuhang Wang, Xuyi Liu, Guoshuang Feng, Jie Wang. (2010) Positive expression of ERCC1 predicts a poorer platinum-based treatment outcome in Chinese patients with advanced non-small-cell lung cancer. Medical Oncology 27:2, 484-490
CrossRef287
Mark A. Socinski, Georgiy M. Manikhas, Daniil L. Stroyakovsky, Anatoly N. Makhson, Sergey V. Cheporov, Sergei V. Orlov, Petr K. Yablonsky, Paul H. Bhar, Jose Iglesias. (2010) A Dose Finding Study of Weekly and Every-3-Week nab-Paclitaxel Followed by Carboplatin as First-Line Therapy in Patients with Advanced Non-small Cell Lung Cancer. Journal of Thoracic Oncology 5:6, 852-861
CrossRef288
Cesare Gridelli, Andrea Ardizzoni, Jean-Yves Douillard, Nasser Hanna, Christian Manegold, Francesco Perrone, Robert Pirker, Rafael Rosell, Frances A. Shepherd, Luigi De Petris, Massimo Di Maio, Filippo de Marinis. (2010) Recent issues in first-line treatment of advanced non-small-cell lung cancer: Results of an International Expert Panel Meeting of the Italian Association of Thoracic Oncology. Lung Cancer 68:3, 319-331
CrossRef289
Masahiko Higashiyama, Kazuyuki Oda, Jiro Okami, Jun Maeda, Ken Kodama, Fumio Imamura, Kazuhiko Minamikawa, Toshikazu Takano, Hisayuki Kobayashi. (2010) Prediction of chemotherapeutic effect on postoperative recurrence by in vitro anticancer drug sensitivity testing in non-small cell lung cancer patients. Lung Cancer 68:3, 472-477
CrossRef290
Yuichi Takiguchi, Yuji Tada, Akihiko Gemma, Shoji Kudoh, Mitsunori Hino, Kozo Yoshimori, Akinobu Yoshimura, Keiichi Nagao, Hisanobu Niitani. (2010) Phase I/II study of docetaxel and S-1, an oral fluorinated pyrimidine, for untreated advanced non-small cell lung cancer. Lung Cancer 68:3, 409-414
CrossRef291
Enric Carcereny, Jose Luis Ramirez, Maria Sanchez-Ronco, Dolores Isla, Manuel Cobo, Teresa Moran, Itziar de Aguirre, Tatsuro Okamoto, Jia Wei, Mariano Provencio, Guillermo Lopez-Vivanco, Carlos Camps, Manuel Domine, Vicente Alberola, Jose Miguel Sanchez, Bartomeu Massuti, Pedro Mendez, Miquel Taron, Rafael Rosell. (2010) Blood-based CHRNA3 single nucleotide polymorphism and outcome in advanced non-small-cell lung cancer patients. Lung Cancer 68:3, 491-497
CrossRef292
F Toffalorio, E Giovannetti, T De Pas, D Radice, G Pelosi, M Manzotti, D Minocci, L Spaggiari, G Spitaleri, C Noberasco, C Catania, S Boselli, R Danesi, F de Braud. (2010) Expression of gemcitabine- and cisplatin-related genes in non-small-cell lung cancer. The Pharmacogenomics Journal 10:3, 180-190
CrossRef293
A. Camerini, C. Valsuani, F. Mazzoni, O. Siclari, C. Puccetti, S. Donati, M. Rondini, G. Tartarelli, P. Puccinelli, F. Di Costanzo, D. Amoroso. (2010) Phase II trial of single-agent oral vinorelbine in elderly (>=70 years) patients with advanced non-small-cell lung cancer and poor performance status. Annals of Oncology 21:6, 1290-1295
CrossRef294
Mariano Provencio, Ramón de Las Peñas, Carlos Camps, Angel Artal, Bartomeu Massuti, Manuel Cobo, Francisco Javier Pérez, Antonio Sánchez, Rafael Rosell. (2010) Cisplatin plus vinorelbine as first-line treatment for advanced non-small-cell lung cancer: Is a hemogram on day 8 essential?. Lung Cancer 68:3, 415-419
CrossRef295
Qian-Ze Dong, Yue Zhao, Yang Liu, Yang Wang, Peng-Xin Zhang, Gui-Yang Jiang, Xin-Jun Dong, Quan-Ze Cui, En-Hua Wang. (2010) Overexpression of SCC-S2 correlates with lymph node metastasis and poor prognosis in patients with non-small-cell lung cancer. Cancer Science 101:6, 1562-1569
CrossRef296
David R. Spigel, John D. Hainsworth, John H. Barton, Jeffrey F. Patton, John D. Zubkus, Lisa Simons, Paula Griner, Howard A. Burris, F. Anthony Greco. (2010) Phase II Study of Biweekly Pemetrexed and Gemcitabine in Patients with Previously Untreated Advanced Non-small Cell Lung Cancer. Journal of Thoracic Oncology 5:6, 841-845
CrossRef297
Mario Scartozzi, Paola Mazzanti, Riccardo Giampieri, Rossana Berardi, Eva Galizia, Stefano Gasparini, Lina Zuccatosta, Stefano Cascinu. (2010) Clinical predictive factors for advanced non-small cell lung cancer (NSCLC) patients receiving third-line therapy: Selecting the unselectable?. Lung Cancer 68:3, 433-437
CrossRef298
Mark A. Socinski. (2010) The Emerging Role of Biomarkers in Advanced Non–Small-Cell Lung Cancer. Clinical Lung Cancer 11:3, 149-159
CrossRef299
Masafumi Yamaguchi, Sadanori Takeo, Ryuichi Suemitsu, Hironori Matsuzawa. (2010) Feasibility study for biweekly administration of cisplatin plus gemcitabine as adjuvant-chemotherapy for completely resected non-small cell lung cancer. Cancer Chemotherapy and Pharmacology 66:1, 107-112
CrossRef300
Alessandra Bearz, Isabella Garassino, Marcello Tiseo, Orazio Caffo, Hector Soto-Parra, Massimo Boccalon, Renato Talamini, Armando Santoro, Marco Bartolotti, Viviana Murgia, Massimiliano Berretta, Umberto Tirelli. (2010) Activity of Pemetrexed on brain metastases from Non-Small Cell Lung Cancer. Lung Cancer 68:2, 264-268
CrossRef301
Kyoichi Kaira, Noriaki Sunaga, Noriko Yanagitani, Hisao Imai, Mitsuyoshi Utsugi, Yasuki Iwasaki, Kimihiro Shimizu, Hironobu Iijima, Hiroaki Tsurumaki, Yoshio Tomizawa, Takeshi Hisada, Tamotsu Ishizuka, Ryusei Saito, Masatomo Mori. (2010) Phase 2 study of S-1 plus carboplatin in patients with advanced non-small cell lung cancer. Lung Cancer 68:2, 253-257
CrossRef302
Josephine Cashman, Juliet Wright, Alistair Ring. (2010) The treatment of co-morbidities in older patients with metastatic cancer. Supportive Care in Cancer 18:5, 651-655
CrossRef303
Yang Wang, Qianze Dong, Qingfu Zhang, Zixuan Li, Enhua Wang, Xueshan Qiu. (2010) Overexpression of yes-associated protein contributes to progression and poor prognosis of non-small-cell lung cancer. Cancer Science 101:5, 1279-1285
CrossRef304
Matthew K. Wong, Alvis I. Lo, Bing Lam, W. K. Lam, Mary S. Ip, James C. Ho. (2010) Erlotinib as salvage treatment after failure to first-line gefitinib in non-small cell lung cancer. Cancer Chemotherapy and Pharmacology 65:6, 1023-1028
CrossRef305
Chiharu Tanai, Nobuyuki Yamamoto, Yuichiro Ohe, Toshiaki Takahashi, Hideo Kunitoh, Haruyasu Murakami, Noboru Yamamoto, Yukiko Nakamura, Hiroshi Nokihara, Takehito Shukuya, John R. Baldwin, Minori Koshiji, Tomohide Tamura. (2010) A Phase I Study of Enzastaurin Combined with Pemetrexed in Advanced Non-small Cell Lung Cancer. Journal of Thoracic Oncology1
CrossRef306
Coleman K. Obasaju, Rafat H. Ansari, Mark A. Socinski, Ruqin Chen, Matthew J. Monberg, Robert B. Catalano, Donna M. Marinucci, Darla K. Liles, Maria-Jose Ribeiro, Robert L. Comis, Joseph Treat. (2010) A Comparison of White and African American Outcomes from a Three-Arm, Randomized, Phase III Multicenter Trial of Advanced or Metastatic Non-small Cell Lung Cancer. Journal of Thoracic Oncology1
CrossRef307
Binu Malhotra, Tracey Evans, Jared Weiss, Beth Eaby, Susan Stonehouse-Lee, Victoria Sherry, Corey J. Langer. (2010) Carboplatin/Pemetrexed/Bevacizumab in the Treatment of Patients With Advanced Non–Small-Cell Lung Cancer: A Single-Institution Experience. Clinical Lung Cancer 11:3, 192-197
CrossRef308
Anne Kirstine Hundahl Møller, Karen Damgaard Pedersen, Anita Gothelf, Gedske Daugaard. (2010) Paclitaxel, cisplatin and gemcitabine in treatment of carcinomas of unknown primary site, a phase II study. Acta Oncologica 49:4, 423-430
CrossRef309
Mark J. McKeage, Bruce C. Baguley. (2010) Disrupting established tumor blood vessels. Cancer 116:8, 1859-1871
CrossRef310
Anna L. Blobaum, Lawrence J. Marnett. 2010. NSAID Action and the Foundations for Cardiovascular Toxicity. , 257-285.
CrossRef311
Pasquale Comella, Vincenzo E. Chiuri, Giuseppe De Cataldis, Gianfranco Filippelli, Luigi Maiorino, Giacomo Vessia, Riccardo Cioffi, Sergio Mancarella, Carlo Putzu, Ettore Greco, Laura Palmeri, Raffaele Costanzo, Antonio Avallone, Luca Franco. (2010) Gemcitabine combined with either pemetrexed or paclitaxel in the treatment of advanced non-small cell lung cancer. Lung Cancer 68:1, 94-98
CrossRef312
Siow Ming LEE, Paul BAAS, Heather WAKELEE. (2010) Anti-angiogenesis drugs in lung cancer. Respirology 15:3, 387-392
CrossRef313
Xiaoyu Xu, Glenn D. Prestwich. (2010) Inhibition of tumor growth and angiogenesis by a lysophosphatidic acid antagonist in an engineered three-dimensional lung cancer xenograft model. Cancer 116:7, 1739-1750
CrossRef314
T. Kawaguchi, M. Sho, T. Tojo, I. Yamato, T. Nomi, K. Hotta, K. Hamada, Y. Suzaki, S. Sugiura, K. Kushibe, Y. Nakajima, S. Taniguchi. (2010) Clinical Significance of Prostate Stem Cell Antigen Expression in Non-small Cell Lung Cancer. Japanese Journal of Clinical Oncology 40:4, 319-326
CrossRef315
Michel Velez, Astrid Belalcazar, Gelenis Domingo, Marcelo Blaya, Luis E Raez, Edgardo S Santos. (2010) Accelerated second-line or maintenance chemotherapy versus treatment at disease progression in NSCLC. Expert Review of Anticancer Therapy 10:4, 549-557
CrossRef316
Akira Ono, Tateaki Naito, Haruyasu Murakami, Toshiaki Takahashi, Yukiko Nakamura, Asuka Tsuya, Kyoichi Kaira, Satoshi Igawa, Takehiro Shukuya, Akihiro Tamiya, Rieko Kaira, Masahiro Endo, Nobuyuki Yamamoto. (2010) Evaluation of S-1 as third- or further-line chemotherapy in advanced non-small-cell lung cancer. International Journal of Clinical Oncology 15:2, 161-165
CrossRef317
Tianhong Li, Liawaty Ho, Bilal Piperdi, Tarek Elrafei, Fernando J. Camacho, James R. Rigas, Roman Perez-Soler, Rasim Gucalp. (2010) Phase II study of the proteasome inhibitor bortezomib (PS-341, Velcade®) in chemotherapy-naïve patients with advanced stage non-small cell lung cancer (NSCLC). Lung Cancer 68:1, 89-93
CrossRef318
T. Sakakibara, A. Inoue, S. Sugawara, M. Maemondo, T. Ishida, K. Usui, T. Abe, M. Kanbe, H. Watanabe, Y. Saijo, T. Nukiwa. (2010) Randomized phase II trial of weekly paclitaxel combined with carboplatin versus standard paclitaxel combined with carboplatin for elderly patients with advanced non-small-cell lung cancer. Annals of Oncology 21:4, 795-799
CrossRef319
Kang-Seo Park, Hyun-Kyoung Kim, Jung-Hwa Lee, Yong-Bock Choi, Seong-Yeol Park, Sei-Hoon Yang, Soo-Youl Kim, Kyeong-Man Hong. (2010) Transglutaminase 2 as a cisplatin resistance marker in non-small cell lung cancer. Journal of Cancer Research and Clinical Oncology 136:4, 493-502
CrossRef320
Kun Yang, You-Juan Wang, Xue-Rong Chen, Hai-Ning Chen. (2010) Effectiveness and Safety of Bevacizumab for Unresectable Non-Small-Cell Lung Cancer. Clinical Drug Investigation 30:4, 229-241
CrossRef321
Marc C Chamberlain. (2010) Anticancer therapies and CNS relapse: overcoming blood–brain and blood–cerebrospinal fluid barrier impermeability. Expert Review of Neurotherapeutics 10:4, 547-561
CrossRef322
Paul Wheatley-Price, Christine Massey, Tony Panzarella, Frances A. Shepherd, Joseph Mikhael. (2010) Resident preparedness in discussing prognosis in patients with advanced lung cancer. Supportive Care in Cancer 18:4, 491-497
CrossRef323
Kimihide Yoshida, Yasushi Yatabe, Jangchul Park, Shizu Ogawa, Ji Young Park, Junichi Shimizu, Yoshitsugu Horio, Keitaro Matsuo, Tetsuya Mitsudomi, Toyoaki Hida. (2010) Clinical outcomes of advanced non-small cell lung cancer patients screened for epidermal growth factor receptor gene mutations. Journal of Cancer Research and Clinical Oncology 136:4, 527-535
CrossRef324
Ping CHEN, Jian LI, Li-Ping GE, Chun-Hua DAI, Xiao-Qin LI. (2010) Prognostic value of survivin, X-linked inhibitor of apoptosis protein and second mitochondria-derived activator of caspases expression in advanced non-small-cell lung cancer patients. Respirology 15:3, 501-509
CrossRef325
Tong SU, Li-jun ZHAO, Wen-jun CHANG, Guo-ping WANG, Yong-chao HE, Qin-ying SUN, Hong-wei ZHANG, Qiang LI, Guang-wen CAO. (2010) Relationship of ERCC1,XPD,and BRCA1 polymorphisms with efficacy of platinum-based chemotherapy for patients with advanced non-small cell lung cancer. Academic Journal of Second Military Medical University 30:2, 117-122
CrossRef326
Raymond Wai-Yin Sun, Carrie Ka-Lei Li, Dik-Lung Ma, Jessie Jing Yan, Chun-Nam Lok, Chung-Hang Leung, Nianyong Zhu, Chi-Ming Che. (2010) Stable Anticancer Gold(III)-Porphyrin Complexes: Effects of Porphyrin Structure. Chemistry - A European Journal 16:10, 3097-3113
CrossRef327
Youngil Koh, Bogun Jang, Sae-Won Han, Tae-Min Kim, Do-Youn Oh, Se-Hoon Lee, Chang Hyun Kang, Dong-Wan Kim, Seock-Ah Im, Doo Hyun Chung, Young Tae Kim, Tae-You Kim, Young-Whan Kim, Joo Hyun Kim, Dae Seog Heo, Yung-Jue Bang. (2010) Expression of Class III Beta-Tubulin Correlates with Unfavorable Survival Outcome in Patients with Resected Non-small Cell Lung Cancer. Journal of Thoracic Oncology 5:3, 320-325
CrossRef328
Wolfram C.M. Dempke, Tamas Suto, Martin Reck. (2010) Targeted therapies for non-small cell lung cancer. Lung Cancer 67:3, 257-274
CrossRef329
Meina Wu, Jun Zhao, Sonya Wei Song, Minglei Zhuo, Xin Wang, Hua Bai, Shuhang Wang, Lu Yang, Tongtong An, Yan Zhang, Jianchun Duan, Yuyan Wang, Qingzhi Guo, Xuyi Liu, Ninghong Liu, Jie Wang. (2010) EGFR mutations are associated with prognosis but not with the response to front-line chemotherapy in the Chinese patients with advanced non-small cell lung cancer. Lung Cancer 67:3, 343-347
CrossRef330
Liangping Xia, Yuming Rong, Guifang Guo, Huijuan Qiu, Feifei Zhou, Fang Wang. (2010) Efficacy of cetuximab combination with chemotherapy in non-small cell lung cancer first-line setting: the summary based on publications. The Chinese-German Journal of Clinical Oncology 9:3, 137-141
CrossRef331
Linda E. Coate, Frances A. Shepherd. (2010) Maintenance Therapy in Advanced Non-small Cell Lung Cancer. Journal of Thoracic Oncology1
CrossRef332
Jacqueline Neuhaus, Brian Angus, Justyna D Kowalska, Alberto La Rosa, Jim Sampson, Deborah Wentworth, Amanda Mocroft. (2010) Risk of all-cause mortality associated with nonfatal AIDS and serious non-AIDS events among adults infected with HIV. AIDS 24:5, 697-706
CrossRef333
Jared Weiss, Beth Eaby, James Stevenson, John Kucharczuk, Joel Cooper, Larry Kaiser, Joseph Shrager, Ramesh Rengan, Corey Langer, Tracey Evans. (2010) Adjuvant Cisplatin and Docetaxel for Non-small Cell Lung Cancer. Journal of Thoracic Oncology1
CrossRef334
Young Hak Kim, Kiyotaka Yoh, Seiji Niho, Koichi Goto, Hironobu Ohmatsu, Kaoru Kubota, Yutaka Nishiwaki. (2010) Trends in chemotherapy for elderly patients with advanced non-small-cell lung cancer. Respiratory Medicine 104:3, 434-439
CrossRef335
Lu Yang, Zhi-jie Wang, Tong-tong An, Hua Bai, Jun Zhao, Jian-chun Duan, Ping-ping Li, Mei-na Wu, Hong Sun, Li Liang, Jie Wang. (2010) A phase II trial of gefitinib as maintenance therapy after first-line chemotherapy for advanced non-small cell lung cancer in China. Chinese Journal of Cancer Research 22:1, 1-9
CrossRef336
Cesare Gridelli, Antonio Rossi, Filippo de Marinis. (2010) Pattern of care for advanced non-small cell lung cancer in the era of histology-based treatment: A survey of the Italian Association of Thoracic Oncology (AIOT). Lung Cancer 67:3, 339-342
CrossRef337
Luca Toschi, Federico Cappuzzo. (2010) Impact of biomarkers on non-small cell lung cancer treatment. Targeted Oncology 5:1, 5-17
CrossRef338
Philip D. Bonomi. (2010) Implications of key trials in advanced nonsmall cell lung cancer. Cancer 116:5, 1155-1164
CrossRef339
J. A. Treat, R. Gonin, M. A. Socinski, M. J. Edelman, R. B. Catalano, D. M. Marinucci, R. Ansari, H. H. Gillenwater, K. M. Rowland, R. L. Comis, C. K. Obasaju, C. P. Belani, . (2010) A randomized, phase III multicenter trial of gemcitabine in combination with carboplatin or paclitaxel versus paclitaxel plus carboplatin in patients with advanced or metastatic non-small-cell lung cancer. Annals of Oncology 21:3, 540-547
CrossRef340
Kishan J. Pandya, Ajeet Gajra, Ghulam M. Warsi, Eliza Argonza-Aviles, Solveig G. Ericson, Antoinette J. Wozniak. (2010) Multicenter, randomized, phase 2 study of zoledronic acid in combination with docetaxel and carboplatin in patients with unresectable stage IIIB or stage IV non-small cell lung cancer. Lung Cancer 67:3, 330-338
CrossRef341
M. Zemanova, L. Petruzelka, A. Pazdro, D. Kralova, M. Smejkal, G. Pazdrova, H. Honova. (2010) Prospective non-randomized study of preoperative concurrent platinum plus 5-fluorouracil-based chemoradiotherapy with or without paclitaxel in esophageal cancer patients: long-term follow-up. Diseases of the Esophagus 23:2, 160-167
CrossRef342
Anne M. Traynor, Ju-Whei Lee, Gerald K. Bayer, John M. Tate, Sachdev P. Thomas, Miroslaw Mazurczak, David L. Graham, Jill M. Kolesar, Joan H. Schiller. (2010) A phase II trial of Triapine® (NSC# 663249) and gemcitabine as second line treatment of advanced non-small cell lung cancer: Eastern Cooperative Oncology Group Study 1503. Investigational New Drugs 28:1, 91-97
CrossRef343
Satoshi Igawa, Haruyasu Murakami, Toshiaki Takahashi, Yukiko Nakamura, Asuka Tsuya, Tateaki Naito, Kyoichi Kaira, Akira Ono, Takehito Shukuya, Akihiro Tamiya, Masahiro Endo, Nobuyuki Yamamoto. (2010) Efficacy of chemotherapy with carboplatin and paclitaxel for unresectable thymic carcinoma. Lung Cancer 67:2, 194-197
CrossRef344
Yang Yang, Yu Bai, Gang Xie, Na Zhang, Yong-Ping Ma, Li-Juan Chen, Yu Jiang, Xia Zhao, Yu-Quan Wei, Hong-Xin Deng. (2010) Efficient Inhibition of Non-Small-Cell Lung Cancer Xenograft by Systemic Delivery of Plasmid-Encoding Short-Hairpin RNA Targeting VEGF. Cancer Biotherapy & Radiopharmaceuticals 25:1, 65-73
CrossRef345
Ning Sun, Xinchen Sun, Baoan Chen, Hongyan Cheng, Jifeng Feng, Lu Cheng, Zuhong Lu. (2010) MRP2 and GSTP1 polymorphisms and chemotherapy response in advanced non-small cell lung cancer. Cancer Chemotherapy and Pharmacology 65:3, 437-446
CrossRef346
Tetsuya Mitsudomi, Satoshi Morita, Yasushi Yatabe, Shunichi Negoro, Isamu Okamoto, Junji Tsurutani, Takashi Seto, Miyako Satouchi, Hirohito Tada, Tomonori Hirashima, Kazuhiro Asami, Nobuyuki Katakami, Minoru Takada, Hiroshige Yoshioka, Kazuhiko Shibata, Shinzoh Kudoh, Eiji Shimizu, Hiroshi Saito, Shinichi Toyooka, Kazuhiko Nakagawa, Masahiro Fukuoka. (2010) Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. The Lancet Oncology 11:2, 121-128
CrossRef347
Jing-Hua Ren, Wen-Shan He, Li Nong, Qing-Yao Zhu, Kai Hu, Rui-Guang Zhang, Li-Li Huang, Fang Zhu, Gang Wu. (2010) Acquired Cisplatin Resistance in Human Lung Adenocarcinoma Cells Is Associated with Enhanced Autophagy. Cancer Biotherapy & Radiopharmaceuticals 25:1, 75-80
CrossRef348
T. Mitsudomi. (2010) Advances in Target Therapy for Lung Cancer. Japanese Journal of Clinical Oncology 40:2, 101-106
CrossRef349
Yun-Chung Cheung, John Wen-Cheng Chang, Jia-Juan Hsieh, Gigin Lin, Ying-Huang Tsai. (2010) Adequacy and complications of computed tomography-guided core needle biopsy on non-small cell lung cancers for epidermal growth factor receptor mutations demonstration: 18-gauge or 20-gauge biopsy needle. Lung Cancer 67:2, 166-169
CrossRef350
John Goffin, Christina Lacchetti, Peter M. Ellis, Yee C. Ung, William K. Evans. (2010) First-Line Systemic Chemotherapy in the Treatment of Advanced Non-small Cell Lung Cancer. Journal of Thoracic Oncology 5:2, 260-274
CrossRef351
Ahad A. Sadiq, Manish R. Patel, Blake A. Jacobson, Marco Escobedo, Keith Ellis, Lisa M. Oppegard, Hiroshi Hiasa, Robert A. Kratzke. (2010) Anti-proliferative effects of simocyclinone D8 (SD8), a novel catalytic inhibitor of topoisomerase II. Investigational New Drugs 28:1, 20-25
CrossRef352
Scott A. Laurie, Lillian L. Siu, Eric Winquist, Andrew Maksymiuk, Erica L. Harnett, Wendy Walsh, Dongsheng Tu, Wendy R. Parulekar. (2010) A phase 2 study of platinum and gemcitabine in patients with advanced salivary gland cancer. Cancer 116:2, 362-368
CrossRef353
William N. William, Merrill S. Kies, Frank V. Fossella, Diane D. Liu, Gregory Gladish, Warner H. Tse, J. Jack Lee, Waun K. Hong, Scott M. Lippman, Edward S. Kim. (2010) Phase 2 study of carboplatin, docetaxel, and bevacizumab as frontline treatment for advanced nonsmall-cell lung cancer. CancerNA-NA
CrossRef354
Brigette BY Ma, Edwin P Hui, Tony SK Mok. (2010) Population-based differences in treatment outcome following anticancer drug therapies. The Lancet Oncology 11:1, 75-84
CrossRef355
Luis E. Raez, Svetlana Kobina, Edgardo S. Santos. (2010) Oxaliplatin in First-line Therapy for Advanced Non–Small-Cell Lung Cancer. Clinical Lung Cancer 11:1, 18-24
CrossRef356
Francisco Robert, Karen Harper, Judie Ackerman, Sunil Gupta. (2010) A phase I study of larotaxel (XRP9881) administered in combination with carboplatin in chemotherapy-naïve patients with stage IIIB or stage IV non-small cell lung cancer. Cancer Chemotherapy and Pharmacology 65:2, 227-234
CrossRef357
Takanori Kanematsu, Masaki Hanibuchi, Hideki Tomimoto, Shoji Sakiyakma, Koichiro Kenzaki, Kazuya Kondo, Hiroyasu Bando, Takashi Haku, Kazuo Yoneda, Toshiyuki Hirose, Yuko Toyoda, Hisatsugu Goto, Satoshi Sakaguchi, Katsuhiro Kinoshita, Momoyo Azuma, Soji Kakiuchi, Jun Kishi, Masahiko Azuma, Hiroya Tada, Masayuki Sumitomo, Yasuhiko Nishioka, Seiji Yano, Saburo Sone. (2010) Epidemiological and clinical features of lung cancer patients from 1999 to 2009 in Tokushima Prefecture of Japan. The Journal of Medical Investigation 57:3,4, 326-333
CrossRef358
Laura R. Triano, Hari Deshpande, Scott N. Gettinger. (2010) Management of Patients with Advanced Non-Small Cell Lung Cancer. Drugs 70:2, 167-179
CrossRef359
Masahiro Yamasaki, Nobuyuki Ohashi, Toshiki Kajihara, Tomoko Nitta, Akiko Mito, Hirokazu Awaya, Yasuhiko Ikegami, Ken-ichi Arita. (2010) A Retrospective Study of Chemotherapy with Carboplatin and Weekly Paclitaxel for Advanced Non-small Cell Lung Cancer. Haigan 50:1, 1-6
CrossRef360
Fereidoun Abtin, Robert D. Suh. 2010. Radiofrequency Ablation of Lung Tumors. , 266-274.
CrossRef361
Nagato Sato, Junkichi Koinuma, Tomoo Ito, Eiju Tsuchiya, Satoshi Kondo, Yusuke Nakamura, Yataro Daigo. (2010) Activation of an oncogenic TBC1D7 (TBC1 domain family, member 7) protein in pulmonary carcinogenesis. Genes, Chromosomes and CancerNA-NA
CrossRef362
Liewei Wang. (2010) Pharmacogenomics: a systems approach. Wiley Interdisciplinary Reviews: Systems Biology and Medicine 2:1, 3-22
CrossRef363
Luis Paz-Ares, Denis Soulières, Ivan Melezínek, Joachim Moecks, Lorenz Keil, Tony Mok, Rafael Rosell, Barbara Klughammer. (2010) Clinical outcomes in non-small-cell lung cancer patients with EGFR mutations: pooled analysis. Journal of Cellular and Molecular Medicine 14:1-2, 51-69
CrossRef364
Kazuhiko Yamada, Masao Nakao, Chikara Fukuyama, Hiroshi Nokihara, Noboru Yamamoto, Ikuo Sekine, Hideo Kunitoh, Yuichiro Ohe, Emiko Ohki, Junichi Hashimoto, Tomohide Tamura. (2010) Phase I study of TLR9 agonist PF-3512676 in combination with carboplatin and paclitaxel in patients with advanced non-small-cell lung cancer. Cancer Science 101:1, 188-195
CrossRef365
Karen M. Clements, Gerson Peltz, Douglas E. Faries, Kathleen Lang, Joshua Nyambose, Craig C. Earle, Katherine P. Sugarman, Douglas C. A. Taylor, David Thompson, Martin D. Marciniak. (2010) Does Type of Tumor Histology Impact Survival among Patients with Stage IIIB/IV Non-Small Cell Lung Cancer Treated with First-Line Doublet Chemotherapy?. Chemotherapy Research and Practice 2010, 1-8
CrossRef366
F. Meriggi, A. Zaniboni. (2010) Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors for Elderly Patients with Advanced Non-Small Cell Lung Cancer. Current Gerontology and Geriatrics Research 2010, 1-8
CrossRef367
Junshik Hong, Sun Young Kyung, Sang Pyo Lee, Jeong Woong Park, Sung Hwan Jung, Jae-Ik Lee, Se Hoon Park, Sun Jin Sym, Jinny Park, Eun Kyung Cho, Dong Bok Shin, Jae Hoon Lee. (2010) Pemetrexed versus Gefitinib versus Erlotinib in Previously Treated Patients with Non-Small Cell Lung Cancer. The Korean Journal of Internal Medicine 25:3, 294
CrossRef368
Toshio NISHIKAWA, Takayuki NINOMIYA, Toshiya FUJIWARA, Kazuhiko KATAOKA, Motoki MATSUURA. (2010) A CASE OF LUNG CANCER AFTER CHEMOTHERAPY OF HILAR AND MEDIASTINUM LYMPHNODE CANCER OF UNKNOWN ORIGIN. Nihon Rinsho Geka Gakkai Zasshi (Journal of Japan Surgical Association) 71:8, 2000-2004
CrossRef369
A.P. GREYSTOKE, D.I. JODRELL, M. CHEUNG, I. RIVANS, M.J. MACKEAN. (2010) How many cisplatin administration protocols does your department use?. European Journal of Cancer Care 19:1, 80-90
CrossRef370
Daniel Morgensztern, Saiama Waqar, Janakiraman Subramanian, Feng Gao, Ramaswamy Govindan. (2009) Improving Survival for Stage IV Non-small Cell Lung Cancer. Journal of Thoracic Oncology 4:12, 1524-1529
CrossRef371
Nicolas Girard, Pascale Jacoulet, Marie Gainet, Rami Elleuch, Didier Pernet, Alain Depierre, Jean-Charles Dalphin, Virginie Westeel. (2009) Third-Line Chemotherapy in Advanced Non-small Cell Lung Cancer: Identifying the Candidates for Routine Practice. Journal of Thoracic Oncology 4:12, 1544-1549
CrossRef372
Noboru Yamamoto, Tomohide Tamura, Takayasu Kurata, Nobuyuki Yamamoto, Ikuo Sekine, Hideo Kunitoh, Yuichiro Ohe, Nagahiro Saijo. (2009) A dose-finding and pharmacokinetic study of nedaplatin in elderly patients with advanced non-small cell lung cancer. Cancer Chemotherapy and Pharmacology 65:1, 79-88
CrossRef373
A. Hiramatsu, Y. Iwasaki, Y. Koyama, N. Tamiya, S. Hosogi, M. Nakanishi, Y. Kohno, M. Ueda, T. Arimoto, Y. Marunaka. (2009) Phase II Trial of Weekly Gemcitabine and Split-dose Cisplatin for Advanced Non-small-cell Lung Cancer. Japanese Journal of Clinical Oncology 39:12, 779-783
CrossRef374
Jian-chun Duan, Lu Yang, Jie Wang, Jun Zhao, Mei-na Wu, Tong-tong An. (2009) Cetuximab combination with chemotherapy in advanced non-small cell lung cancer. Chinese Journal of Cancer Research 21:4, 265-271
CrossRef375
David Planchard, Yohann Loriot, Aicha Goubar, Fréderic Commo, Jean-Charles Soria. (2009) Differential Expression of Biomarkers in Men and Women. Seminars in Oncology 36:6, 553-565
CrossRef376
Craig Reynolds, David Barrera, Robert Jotte, Alexander I. Spira, Charles Weissman, Kristi A. Boehm, Sharon Pritchard, Lina Asmar. (2009) Phase II Trial of Nanoparticle Albumin-Bound Paclitaxel, Carboplatin, and Bevacizumab in First-line Patients with Advanced Nonsquamous Non-small Cell Lung Cancer. Journal of Thoracic Oncology 4:12, 1537-1543
CrossRef377
, P. Manchon Walsh, Rafael Aguiló, María Alejo, M. Mar Arnaiz, Julio Astudillo, Remei Blanco, Emili Canalís, Felip Cardenal, Víctor Curull, Enriqueta Felip, Rafael Fuentes, Ángel Gayete, Ana M. Giménez, Josep Jové, Carmen Lainez, Josep Lloreta, Ramón Marrades, José Ignacio Martínez, Xesca Martínez, M. Ángeles Montero, Cinta Pallarès, Ramón Palmero, Josep Ramírez, Nuria Rodríguez, Antoni Rosell, Josep Saumench, Nuria Viñolas, Ángel Olazábal. (2009) Lung Cancer OncoGuia. Clinical and Translational Oncology 11:12, 805-824
CrossRef378
Kaoru Kubota, Seiji Niho, Sotaro Enatsu, Yoshihiro Nambu, Yutaka Nishiwaki, Nagahiro Saijo, Masahiro Fukuoka. (2009) Efficacy Differences of Pemetrexed by Histology in Pretreated Patients with Stage IIIB/IV Non-small Cell Lung Cancer. Journal of Thoracic Oncology 4:12, 1530-1536
CrossRef379
Girish S. Kulkarni, Shabbir M. H. Alibhai, Antonio Finelli, Neil E. Fleshner, Michael A. S. Jewett, Steven R. Lopushinsky, Ahmed M. Bayoumi. (2009) Cost-effectiveness analysis of immediate radical cystectomy versus intravesical Bacillus Calmette-Guerin therapy for high-risk, high-grade (T1G3) bladder cancer. Cancer 115:23, 5450-5459
CrossRef380
Byoung Yong SHIM, Chi Hong KIM, Myeong Im AHN, Sung Whan KIM, Deog Gon CHO, Kyo Do CHO, Jinyoung YOO, Hoon-Kyo KIM. (2009) HER2 and tau expression as potential markers for response and survival to first line taxane plus cisplatin therapy in non-small cell lung cancer. Asia-Pacific Journal of Clinical Oncology 5:4, 232-241
CrossRef381
Danielle Shafer, Kathy Albain. (2009) Lung Cancer Outcomes in Women. Seminars in Oncology 36:6, 532-541
CrossRef382
Seema Harichand-Herdt, Suresh S. Ramalingam. (2009) Gender-Associated Differences in Lung Cancer: Clinical Characteristics and Treatment Outcomes in Women. Seminars in Oncology 36:6, 572-580
CrossRef383
Jun-Ho Ahn, Ki-Hwan Eum, Michael Lee. (2009) The enhancement of Raf-1 kinase activity by knockdown of Spry2 is associated with high sensitivity to paclitaxel in v-Ha-ras-transformed NIH 3T3 fibroblasts. Molecular and Cellular Biochemistry 332:1-2, 189-197
CrossRef384
Tony S. K. Mok, Suresh S. Ramalingam. (2009) Maintenance therapy in nonsmall-cell lung cancer. Cancer 115:22, 5143-5154
CrossRef385
A. R. Jazieh, R. Komrokji, A. Gupta, S. Patil, D. Flora, M. Knapp, M. Issa, N. Abdel Karim. (2009) Phase II Trial of Thalidomide, Irinotecan and Gemcitabine in Chemonaive Patients with Advanced Non-Small Cell Lung Cancer. Cancer Investigation 27:9, 932-936
CrossRef386
Robert Klein, Catherine Muehlenbein, Astra M. Liepa, Steve Babineaux, Ron Wielage, Lee Schwartzberg. (2009) Cost-Effectiveness of Pemetrexed Plus Cisplatin as First-Line Therapy for Advanced Nonsquamous Non-small Cell Lung Cancer. Journal of Thoracic Oncology 4:11, 1404-1414
CrossRef387
Ross A Soo, Benjamin O Anderson, Byoung Chul Cho, Chih-Hsin Yang, Meilin Liao, Wan-Teck Lim, Peter Goldstraw, Tony S Mok. (2009) First-line systemic treatment of advanced stage non-small-cell lung cancer in Asia: consensus statement from the Asian Oncology Summit 2009. The Lancet Oncology 10:11, 1102-1110
CrossRef388
A FATHI, J BRAHMER. (2009) Chemotherapy for Advanced Stage Non-Small Cell Lung Cancer. Seminars in Thoracic and Cardiovascular Surgery 20:3, 210-216
CrossRef389
Jian Li, Zhen-Nan Li, Yong-Jie Du, Xiao-Qin Li, Qian-Lei Bao, Ping Chen. (2009) Expression of <i>MRP1, BCRP, LRP,</i> and <i>ERCC1</i> in Advanced Non–Small-Cell Lung Cancer: Correlation With Response to Chemotherapy and Survival. Clinical Lung Cancer 10:6, 414-421
CrossRef390
Panagiota Vrouchou, Prashanth Kandaswamy, Elisabeth George, David Barnett. (2009) Pemetrexed approved for the first-line treatment of non-small-cell lung cancer: summary of the NICE appraisal. The Lancet Oncology 10:11, 1031-1032
CrossRef391
Antonio Rossi, Serena Ricciardi, Paolo Maione, Filippo de Marinis, Cesare Gridelli. (2009) Pemetrexed in the treatment of advanced non-squamous lung cancer. Lung Cancer 66:2, 141-149
CrossRef392
Lecia V. Sequist, Panos M. Fidias, Jennifer S. Temel, Tatjana Kolevska, Michael S. Rabin, Ralph V. Boccia, Howard A. Burris, Robert J. Belt, Mark S. Huberman, Ostap Melnyk, Glenn M. Mills, Craig W. Englund, David C. Caldwell, James G. Keck, Lisa Meng, Marsha Jones, Gail L. Brown, Martin J. Edelman, Thomas J. Lynch. (2009) Phase 1-2a Multicenter Dose-Ranging Study of Canfosfamide in Combination with Carboplatin and Paclitaxel as First-Line Therapy for Patients with Advanced Non-small Cell Lung Cancer. Journal of Thoracic Oncology 4:11, 1389-1396
CrossRef393
Fariba Némati, Rui Bras-Gonçalves, Jean-Jacques Fontaine, Gonzague de Pinieux, Patricia De Cremoux, Alain Chapelier, Catherine Daniel, Pierre Laurent-Puig, Alain Livartowski, Jean-Gabriel Judde, Vincent Bordier, Marie-France Poupon, Didier Decaudin. (2009) Preclinical assessment of cisplatin-based therapy versus docetaxel-based therapy on a panel of human non-small-cell lung cancer xenografts. Anti-Cancer Drugs 20:10, 932-940
CrossRef394
Yoshitaka Totani, Yuji Saito, Masamichi Hayashi, Toshihiko Tada, Yasuo Kohashi, Yuki Mieno, Atsushi Kato, Hiromi Imizu, Yukiko Yoneda, Tami Hoshino, Yasuhiro Uchiyama, Yasuo Takeuchi, Mitsushi Okazawa, Hiroki Sakakibara. (2009) A phase II study of S-1 monotherapy as second-line treatment for advanced non-small cell lung cancer. Cancer Chemotherapy and Pharmacology 64:6, 1181-1185
CrossRef395
Benjamin Goldsmith, Jamie Cesaretti, Juan P. Wisnivesky. (2009) Radiotherapy planning complexity and survival after treatment of advanced stage lung cancer in the elderly. Cancer 115:20, 4865-4873
CrossRef396
Takuya Fukazawa, Yutaka Maeda, Junji Matsuoka, Noriaki Tanaka, Hirotoshi Tanaka, Mary L. Durbin, Yoshio Naomoto. (2009) Drug-regulatable cancer cell death induced by BID under control of the tissue-specific, lung cancer-targeted TTS promoter system. International Journal of Cancer 125:8, 1975-1984
CrossRef397
Nick Pavlakis, Gavin Marx, Shane White, Christopher W Lee, Mustafa Khasraw, Nick Pavlakis. 2009. Anti-angiogenic therapy for lung cancer. .
CrossRef398
Jianxing He, Weiqiang Ying, Haihong Yang, Xin Xu, Wenlong Shao, Yubao Guan, Mei Jiang, Yizhuang Wu, Baoliang Zhong, Daoyuan Wang, Steven Tucker, Nanshan Zhong. (2009) Gemcitabine plus cisplatin chemotherapy with concurrent para-toluenesulfonamide local injection therapy for peripherally advanced nonsmall cell lung cancer larger than 3 cm in the greatest dimension. Anti-Cancer Drugs 20:9, 838-844
CrossRef399
Tudor Ciuleanu, Thomas Brodowicz, Christoph Zielinski, Joo Hang Kim, Maciej Krzakowski, Eckart Laack, Yi-Long Wu, Isabel Bover, Stephen Begbie, Valentina Tzekova, Branka Cucevic, Jose Rodrigues Pereira, Sung Hyun Yang, Jayaprakash Madhavan, Katherine P Sugarman, Patrick Peterson, William J John, Kurt Krejcy, Chandra P Belani. (2009) Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study. The Lancet 374:9699, 1432-1440
CrossRef400
Fei Ma, Tong Sun, Yuankai Shi, Dianke Yu, Wen Tan, Ming Yang, Chen Wu, Datong Chu, Yan Sun, Binghe Xu, Dongxin Lin. (2009) Polymorphisms of EGFR predict clinical outcome in advanced non-small-cell lung cancer patients treated with Gefitinib. Lung Cancer 66:1, 114-119
CrossRef401
Thomas A. d’Amato, Brian L. Pettiford, Mathew J. Schuchert, Ricardo Parker, William A. Ricketts, James D. Luketich, Rodney J. Landreneau. (2009) Survival Among Patients with Platinum Resistant, Locally Advanced Non-Small Cell Lung Cancer Treated with Platinum-Based Systemic Therapy. Annals of Surgical Oncology 16:10, 2848-2855
CrossRef402
Michaela J Higgins, David S Ettinger. (2009) Chemotherapy for lung cancer: the state of the art in 2009. Expert Review of Anticancer Therapy 9:10, 1365-1378
CrossRef403
Fausto Petrelli, Mara Ghilardi, Marco Cremonesi, Mary Cabiddu, Sandro Barni. (2009) Is there a role for maintenance therapy in non-small-cell lung cancer? An emerging issue. Expert Review of Anticancer Therapy 9:10, 1455-1465
CrossRef404
Myung Hee Chang, Kyoung Ha Kim, Hyun Jung Jun, Hyo Song Kim, Seong Yoon Yi, Ji Eun Uhm, Min Jae Park, Do Hyoung Lim, Sang Hoon Ji, In Gyu Hwang, Jeeyun Lee, Yeon Hee Park, Jin Seok Ahn, Myung-ju Ahn, Keunchil Park. (2009) Irinotecan and oxaliplatin combination as the first-line treatment for patients with advanced non-small cell lung cancer. Cancer Chemotherapy and Pharmacology 64:5, 917-924
CrossRef405
Stefan Wilop, Sabine Hobe, Martina Crysandt, Albert Esser, Rainhardt Osieka, Edgar Jost. (2009) Impact of angiotensin I converting enzyme inhibitors and angiotensin II type 1 receptor blockers on survival in patients with advanced non-small-cell lung cancer undergoing first-line platinum-based chemotherapy. Journal of Cancer Research and Clinical Oncology 135:10, 1429-1435
CrossRef406
Mok, Tony S., Wu, Yi-Long, Thongprasert, Sumitra, Yang, Chih-Hsin, Chu, Da-Tong, Saijo, Nagahiro, Sunpaweravong, Patrapim, Han, Baohui, Margono, Benjamin, Ichinose, Yukito, Nishiwaki, Yutaka, Ohe, Yuichiro, Yang, Jin-Ji, Chewaskulyong, Busyamas, Jiang, Haiyi, Duffield, Emma L., Watkins, Claire L., Armour, Alison A., Fukuoka, Masahiro, . (2009) Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma. New England Journal of Medicine 361:10, 947-957
Full Text407
Rosell, Rafael, Moran, Teresa, Queralt, Cristina, Porta, Rut, Cardenal, Felipe, Camps, Carlos, Majem, Margarita, Lopez-Vivanco, Guillermo, Isla, Dolores, Provencio, Mariano, Insa, Amelia, Massuti, Bartomeu, Gonzalez-Larriba, Jose Luis, Paz-Ares, Luis, Bover, Isabel, Garcia-Campelo, Rosario, Moreno, Miguel Angel, Catot, Silvia, Rolfo, Christian, Reguart, Noemi, Palmero, Ramon, Sánchez, José Miguel, Bastus, Roman, Mayo, Clara, Bertran-Alamillo, Jordi, Molina, Miguel Angel, Sanchez, Jose Javier, Taron, Miquel, . (2009) Screening for Epidermal Growth Factor Receptor Mutations in Lung Cancer. New England Journal of Medicine 361:10, 958-967
Full Text408
Panos Fidias, Nathan A. Pennell, Anthony L. Boral, Geoffrey I. Shapiro, Arthur T. Skarin, Joseph P. Eder, T Jesse Kwoh, Richard S. Geary, Bruce E. Johnson, Thomas J. Lynch, Jeffrey G. Supko. (2009) Phase I Study of the c-raf-1 Antisense Oligonucleotide ISIS 5132 in Combination with Carboplatin and Paclitaxel in Patients with Previously Untreated, Advanced Non-small Cell Lung Cancer. Journal of Thoracic Oncology 4:9, 1156-1162
CrossRef409
Matjaz Zwitter, Viljem Kovac, Uros Smrdel, Martina Vrankar, Vesna Zadnik. (2009) Gemcitabine in Brief versus Prolonged Low-Dose Infusion, both Combined with Cisplatin, for Advanced Non-small Cell Lung Cancer. Journal of Thoracic Oncology 4:9, 1148-1155
CrossRef410
Giorgio V. Scagliotti, Keunchil Park, Shekar Patil, Janusz Rolski, Tuncay Goksel, Renato Martins, Steven J.M. Gans, Carla Visseren-Grul, Patrick Peterson. (2009) Survival without toxicity for cisplatin plus pemetrexed versus cisplatin plus gemcitabine in chemonaïve patients with advanced non-small cell lung cancer: A risk-benefit analysis of a large phase III study. European Journal of Cancer 45:13, 2298-2303
CrossRef411
Hyun Woo Lee, Yong-Won Choi, Jae Ho Han, Jang Hee Kim, Jae Ho Jung, Seong Hyun Jeong, Seok Yun Kang, Jin-Hyuk Choi, Young Taek Oh, Kwang Joo Park, Sung Chul Hwang, Seung Soo Sheen. (2009) Expression of excision repair cross-complementation group 1 protein predicts poor outcome in advanced non-small cell lung cancer patients treated with platinum-based doublet chemotherapy. Lung Cancer 65:3, 377-382
CrossRef412
Ji Eun Uhm, Byeong-Bae Park, Myung-Ju Ahn, Jeeyun Lee, Jin Seok Ahn, Sang We Kim, Heung-Tae Kim, Jong Seog Lee, Jin Hyung Kang, Jae Yong Cho, Hong Suk Song, Se Hoon Park, Chang Hak Sohn, Sang Won Shin, Jin Hyuck Choi, Keunchil Park. (2009) Erlotinib Monotherapy for Stage IIIB/IV Non-small Cell Lung Cancer. Journal of Thoracic Oncology 4:9, 1136-1143
CrossRef413
K. Naoki, H. Kunikane, T. Fujii, S. Tsujimura, N. Hida, H. Okamoto, K. Watanabe. (2009) Dose-escalating and Pharmacokinetic Study of a Weekly Combination of Paclitaxel and Carboplatin for Inoperable Non-small Cell Lung Cancer: JCOG 9910-DI. Japanese Journal of Clinical Oncology 39:9, 569-575
CrossRef414
Y. H. Kim, K. Kubota, K. Goto, K. Yoh, S. Niho, H. Ohmatsu, N. Saijo, Y. Nishiwaki. (2009) A Phase I Study of Gemcitabine and Carboplatin in Patients with Advanced Non-small Cell Lung Cancer and a Performance Status of 2. Japanese Journal of Clinical Oncology 39:9, 576-581
CrossRef415
Wangjian Zhong, Richard Hansen, Bing Li, Yihua Cai, Carolina Salvador, Grace D. Moore, Jun Yan. (2009) Effect of Yeast-derived β-glucan in Conjunction With Bevacizumab for the Treatment of Human Lung Adenocarcinoma in Subcutaneous and Orthotopic Xenograft Models. Journal of Immunotherapy 32:7, 703-712
CrossRef416
Kosei Yasumoto, Takeshi Hanagiri, Mitsuhiro Takenoyama. (2009) Lung cancer-associated tumor antigens and the present status of immunotherapy against non-small-cell lung cancer. General Thoracic and Cardiovascular Surgery 57:9, 449-457
CrossRef417
Daniel Binder, Matthias Hackenthal, Lutz Graseck, Hans Schweisfurth, Christoph Schäper, Matthias Krüll, Bettina Temmesfeld-Wollbrück, Norbert Suttorp, Thomas Beinert, Klaus-Peter Hellriegel. (2009) A Phase II Study of Weekly Docetaxel-Cisplatin As First-Line Treatment for Advanced Non-small Cell Lung Cancer. Journal of Thoracic Oncology 4:9, 1144-1147
CrossRef418
Andrea Treszl, Andrew V. Schally, Stephan Seitz, Luca Szalontay, Ferenc G. Rick, Karoly Szepeshazi, Gabor Halmos. (2009) Inhibition of human non-small cell lung cancers with a targeted cytotoxic somatostatin analog, AN-162. Peptides 30:9, 1643-1650
CrossRef419
Xiaoyu Xu, Guanghui Yang, Honglu Zhang, Glenn D. Prestwich. (2009) Evaluating dual activity LPA receptor pan-antagonist/autotaxin inhibitors as anti-cancer agents in vivo using engineered human tumors. Prostaglandins & Other Lipid Mediators 89:3-4, 140-146
CrossRef420
Yingwei Qi, Steven E. Schild, Sumithra J. Mandrekar, Angelina D. Tan, James E. Krook, Kendrith M. Rowland, Yolanda I. Garces, Gamini S. Soori, Alex A. Adjei, Jeff A. Sloan. (2009) Pretreatment Quality of Life Is an Independent Prognostic Factor for Overall Survival in Patients with Advanced Stage Non-small Cell Lung Cancer. Journal of Thoracic Oncology 4:9, 1075-1082
CrossRef421
Howard West, Rogerio Lilenbaum, David Harpole, Antoinette Wozniak, Lecia Sequist. (2009) Molecular Analysis-Based Treatment Strategies for the Management of Non-small Cell Lung Cancer. Journal of Thoracic Oncology 4:Supplement 2, S1029-S1039
CrossRef422
James C. Ho, David C. Lam, Matthew K. Wong, Bing Lam, Mary S. Ip, Wah K. Lam. (2009) Capecitabine as Salvage Treatment for Lymphoepithelioma-Like Carcinoma of Lung. Journal of Thoracic Oncology 4:9, 1174-1177
CrossRef423
César Mendiola, M. Ángeles Vaz. (2009) Is capecitabine a new choice of treatment for lung adenocarcinoma? A case report involving partial response in second line of treatment and hypothesis of the biological basis. Clinical and Translational Oncology 11:8, 554-557
CrossRef424
Xinchen Sun, Fan Li, Ning Sun, Qin Shukui, Chen Baoan, Feng Jifeng, Cheng Lu, Lu Zuhong, Cheng Hongyan, Cao YuanDong, Ji Jiazhong, Zhou Yingfeng. (2009) Polymorphisms in XRCC1 and XPG and response to platinum-based chemotherapy in advanced non-small cell lung cancer patients. Lung Cancer 65:2, 230-236
CrossRef425
Jared Weiss, Corey Langer. (2009) NSCLC in the Elderly—The Legacy of Therapeutic Neglect. Current Treatment Options in Oncology 10:3-4, 180-194
CrossRef426
Riccardo Soffietti, Wallace Akerley, Randy L. Jensen, Joachim Bischoff, Anne Constanze Regierer. (2009) The Role of Intra-cerebrospinal Fluid Treatment and Prophylaxis in Patients With Solid Tumors. Seminars in Oncology 36, S55-S68
CrossRef427
Kenji Tamura, Isamu Okamoto, Tomohiro Ozaki, Tatsuhiko Kashii, Koji Takeda, Masashi Kobayashi, Kaoru Matsui, Takashi Shibata, Takayasu Kurata, Kazuhiko Nakagawa, Masahiro Fukuoka. (2009) Phase I/II study of S-1 plus carboplatin in patients with advanced non-small cell lung cancer. European Journal of Cancer 45:12, 2132-2137
CrossRef428
H A Burris. (2009) Shortcomings of current therapies for non-small-cell lung cancer: unmet medical needs. Oncogene 28, S4-S13
CrossRef429
Mark J. McKeage, Martin Reck, Michael B. Jameson, Mark A. Rosenthal, David Gibbs, Paul N. Mainwaring, Lutz Freitag, Richard Sullivan, Joachim Von Pawel. (2009) Phase II study of ASA404 (vadimezan, 5,6-dimethylxanthenone-4-acetic acid/DMXAA) 1800mg/m2 combined with carboplatin and paclitaxel in previously untreated advanced non-small cell lung cancer. Lung Cancer 65:2, 192-197
CrossRef430
Brian Z Ring, Robert S Seitz, Rodney A Beck, William J Shasteen, Alex Soltermann, Stefanie Arbogast, Francisco Robert, Marshall T Schreeder, Douglas T Ross. (2009) A novel five-antibody immunohistochemical test for subclassification of lung carcinoma. Modern Pathology 22:8, 1032-1043
CrossRef431
William N. William, Fadlo R. Khuri, Frank V. Fossella, Bonnie S. Glisson, Ralph G. Zinner, J Jack Lee, Roy S. Herbst, Scott M. Lippman, Edward S. Kim. (2009) Phase II Study of Vinorelbine and Docetaxel in the Treatment of Advanced Non–Small-Cell Lung Cancer as Frontline and Second-Line Therapy. American Journal of Clinical Oncology1
CrossRef432
Aubrey Jolly Graham, Anil Potti. (2009) Translating genomics into clinical practice: Applications in lung cancer. Current Oncology Reports 11:4, 263-268
CrossRef433
Jing Li, Yan Li, Zhi-qiang Feng, Xiao-guang Chen. (2009) Anti-tumor activity of a novel EGFR tyrosine kinase inhibitor against human NSCLC in vitro and in vivo. Cancer Letters 279:2, 213-220
CrossRef434
Yun Oh, Sarah Taylor, Benjamin Nebiyou Bekele, J. Matthew Debnam, Pamela K. Allen, Dima Suki, Raymond Sawaya, Ritsuko Komaki, David J. Stewart, Daniel D. Karp. (2009) Number of metastatic sites is a strong predictor of survival in patients with nonsmall cell lung cancer with or without brain metastases. Cancer 115:13, 2930-2938
CrossRef435
Gyeong-Won Lee, Myung-Hee Kang, Hoon-Gu Kim, Jung Hun Kang, Seok Hyun Kim, Yu Ji Cho, Yi Yeong Jeong, Ho-Cheol Kim, Jong Duk Lee, Young Sil Hwang, Hye Jung Kim, Jong-Seok Lee. (2009) Fixed-dose rate infusion of gemcitabine and weekly cisplatin in elderly or poor performance status patients with unresectable non-small cell lung cancer. Cancer Chemotherapy and Pharmacology 64:2, 385-390
CrossRef436
Oscar Arrieta, Dolores Gallardo-Rincón, Cynthia Villarreal-Garza, Rosa M. Michel, Alma M. Astorga-Ramos, Luis Martínez-Barrera, Jaime de la Garza. (2009) High Frequency of Radiation Pneumonitis in Patients with Locally Advanced Non-small Cell Lung Cancer Treated with Concurrent Radiotherapy and Gemcitabine after Induction with Gemcitabine and Carboplatin. Journal of Thoracic Oncology 4:7, 845-852
CrossRef437
E. H. Tan, J. Rolski, T. Grodzki, C. P. Schneider, U. Gatzemeier, P. Zatloukal, E. Aitini, G. Carteni, H. Riska, Y. H. Tsai, R. Abratt. (2009) Global Lung Oncology Branch trial 3 (GLOB3): final results of a randomised multinational phase III study alternating oral and i.v. vinorelbine plus cisplatin versus docetaxel plus cisplatin as first-line treatment of advanced non-small-cell lung cancer. Annals of Oncology 20:7, 1249-1256
CrossRef438
Songwen ZHOU, Shengxiang REN, Lianghua YAN, Ling ZHANG, Liang TANG, Jie ZHANG, Caicun ZHOU. (2009) Clinical efficacy of erlotinib in patients previously treated for advanced non-small cell lung cancer. Respirology 14:5, 709-715
CrossRef439
Eric J. Avery, Anne Kessinger, Apar Kishor Ganti. (2009) Therapeutic options for elderly patients with advanced non-small cell lung cancer. Cancer Treatment Reviews 35:4, 340-344
CrossRef440
Jianfang Xu, Caicun Zhou, Aiwu Li. (2009) Gefitinib in the treatment of 41 cases with refractory non-small cell lung cancer. The Chinese-German Journal of Clinical Oncology 8:6, 314-316
CrossRef441
Makoto Sonobe, Fengshi Chen, Takuji Fujinaga, Kiyoshi Sato, Tsuyoshi Shoji, Hiroaki Sakai, Ryo Miyahara, Toru Bando, Kenichi Okubo, Toshiki Hirata, Hiroshi Date. (2009) Use of totally implantable central venous access port via the basilic vein in patients with thoracic malignancies. International Journal of Clinical Oncology 14:3, 208-212
CrossRef442
Jian Ming Xu, Yu Han, Hai Qing Duan, E. Mei Gao, Yang Zhang, Xiao Qing Liu, Jing Sheng Zhang, Luca Toschi, Domenico Galetta, Amalia Azzariti, Angelo Paradiso. (2009) EGFR mutations and HER2/3 protein expression and clinical outcome in Chinese advanced non-small cell lung cancer patients treated with gefitinib. Journal of Cancer Research and Clinical Oncology 135:6, 771-782
CrossRef443
Serap Hasturk, Nilgun Hatabay, Ferah Ece, Meltem Karatasli, Ismail Hanta. (2009) Gemcitabine, Vinorelbine, and Cisplatin in the Treatment of Advanced Nonsmall Cell Lung Cancer. American Journal of Clinical Oncology 32:3, 280-285
CrossRef444
Kiyoshi Mori, Hiroyuki Kobayashi, Yukari Kamiyama, Yasuhiko Kano, Tetsuro Kodama. (2009) A phase II trial of weekly chemotherapy with paclitaxel plus gemcitabine as a first-line treatment in advanced non-small-cell lung cancer. Cancer Chemotherapy and Pharmacology 64:1, 73-78
CrossRef445
Emilio Esteban, Marta Casillas, Alejo Cassinello. (2009) Pemetrexed in first-line treatment of non-small cell lung cancer. Cancer Treatment Reviews 35:4, 364-373
CrossRef446
M. A. Socinski, M. N. Saleh, D. F. Trent, T. W. Dobbs, L. M. Zehngebot, M. A. Levine, R. Bordoni, P. J. Stella. (2009) A randomized, phase II trial of two dose schedules of carboplatin/paclitaxel/cetuximab in stage IIIB/IV non-small-cell lung cancer (NSCLC). Annals of Oncology 20:6, 1068-1073
CrossRef447
Ulrich Gatzemeier, Tudor Ciuleanu, Mircea Dediu, Elena Ganea-Motan, Heinz Lubenau, Auro Del Giglio. (2009) XM02, the First Biosimilar G-CSF, is Safe and Effective in Reducing the Duration of Severe Neutropenia and Incidence of Febrile Neutropenia in Patients with Small Cell or Non-small Cell Lung Cancer Receiving Platinum-Based Chemotherapy. Journal of Thoracic Oncology 4:6, 736-740
CrossRef448
Volker Steger, Thorsten Walles, Bora Kosan, Tobias Walker, Thomas Kyriss, Stefanie Veit, Jürgen Dippon, Godehard Friedel. (2009) Trimodal Therapy for Histologically Proven N2/3 Non–Small Cell Lung Cancer: Mid-Term Results and Indicators for Survival. The Annals of Thoracic Surgery 87:6, 1676-1683
CrossRef449
Kathleen Lang, Martin D. Marciniak, Douglas Faries, Michael Stokes, Don Buesching, Craig Earle, Joseph Treat, Steve Babineaux, Nathalie Morissette, David Thompson. (2009) Costs of First-Line Doublet Chemotherapy and Lifetime Medical Care in Advanced Non–small-Cell Lung Cancer in the United States. Value in Health 12:4, 481-488
CrossRef450
Koichi Azuma, Tetsuro Sasada, Akihiko Kawahara, Sinzo Takamori, Satoshi Hattori, Jiro Ikeda, Kyogo Itoh, Akira Yamada, Masayoshi Kage, Michihiko Kuwano, Hisamichi Aizawa. (2009) Expression of ERCC1 and class III β-tubulin in non-small cell lung cancer patients treated with carboplatin and paclitaxel. Lung Cancer 64:3, 326-333
CrossRef451
N.J. Dickgreber. (2009) Pemetrexed mit Cisplatin in der Erstlinientherapie des NSCLC. Der Pneumologe 6:3, 176-178
CrossRef452
H. L. West, H. A. Wakelee, M. C. Perry, R. J. Belt, R. Chen, C. Obasaju. (2009) Gemcitabine and pemetrexed administered in rapid sequence as front-line chemotherapy for advanced non-small-cell lung cancer: a phase II clinical trial. Annals of Oncology 20:5, 850-856
CrossRef453
Hatem A. Azim Jr, Inas Elattar, Fausto R. Loberiza Jr, Hamdy Azim, Tony Mok, Apar Kishor Ganti. (2009) Third generation triplet cytotoxic chemotherapy in advanced non-small cell lung cancer: A systematic overview. Lung Cancer 64:2, 194-198
CrossRef454
Wei Wang, Masaaki Adachi, Rong Zhang, Jin Zhou, Daling Zhu. (2009) A Novel Combination Therapy With Arsenic Trioxide and Parthenolide Against Pancreatic Cancer Cells. Pancreas 38:4, e114-e123
CrossRef455
George Pentheroudakis, F.A. Greco, Nicholas Pavlidis. (2009) Molecular assignment of tissue of origin in cancer of unknown primary may not predict response to therapy or outcome: A systematic literature review. Cancer Treatment Reviews 35:3, 221-227
CrossRef456
J. Feng, X. Sun, N. Sun, S. Qin, F. Li, H. Cheng, B. Chen, Y. Cao, J. Ma, L. Cheng, Z. Lu, J. Ji, Y. Zhou. (2009) XPA A23G polymorphism is associated with the elevated response to platinum-based chemotherapy in advanced non-small cell lung cancer. Acta Biochimica et Biophysica Sinica 41:5, 429-435
CrossRef457
Giulio Metro, Federico Cappuzzo. (2009) New targeted therapies for non-small-cell lung cancer. Therapy 6:3, 335-350
CrossRef458
Sai-Hong Ignatius Ou, Coty Ho. (2009) Treatment of Advanced Lung Cancer. Clinical Pulmonary Medicine 16:3, 157-171
CrossRef459
Masaru Nakamura, Tomonobu Koizumi, Munehara Hayasaka, Masanori Yasuo, Kenji Tsushima, Keishi Kubo, Kotaro Gomi, Naoto Shikama. (2009) Cisplatin and weekly docetaxel with concurrent thoracic radiotherapy for locally advanced stage III non-small-cell lung cancer. Cancer Chemotherapy and Pharmacology 63:6, 1091-1096
CrossRef460
Nagahiro Saijo, Masahiro Takeuchi, Hideo Kunitoh. (2009) Reasons for response differences seen in the V15-32, INTEREST and IPASS trials. Nature Reviews Clinical Oncology 6:5, 287-294
CrossRef461
M. Scheffler, J. Wolf. (2009) Aktuelle Entwicklungen in der Bildgebung beim nichtkleinzelligen Bronchialkarzinom. Der Onkologe 15:5, 496-501
CrossRef462
Edward S. Kim, Ann M. Mauer, William N. William, Hai T. Tran, Diane Liu, Jack J. Lee, Paul Windt, Waun K. Hong, Everett E. Vokes, Roy S. Herbst. (2009) A phase 2 study of cetuximab in combination with docetaxel in chemotherapy-refractory/resistant patients with advanced nonsmall cell lung cancer. Cancer 115:8, 1713-1722
CrossRef463
C Tanai, H Nokihara, S Yamamoto, H Kunitoh, N Yamamoto, I Sekine, Y Ohe, T Tamura. (2009) Characteristics and outcomes of patients with advanced non-small-cell lung cancer who declined to participate in randomised clinical chemotherapy trials. British Journal of Cancer 100:7, 1037-1042
CrossRef464
, Satoshi Oizumi, Koichi Yamazaki, Hiroshi Yokouchi, Jun Konishi, Fumihiro Hommura, Tetsuya Kojima, Hiroshi Isobe, Masaharu Nishimura. (2009) Phase I study of amrubicin and vinorelbine in non-small cell lung cancer previously treated with platinum-based chemotherapy. International Journal of Clinical Oncology 14:2, 125-129
CrossRef465
Chih-Ming Lin, Chih-Hung Chen, John WC Chang, Thomas CY Tsao. (2009) Phase II Study of Epirubicin in Combination With Weekly Docetaxel for Patients With Advanced NSCLC Who Have Failed or Relapsed After the Frontline Platinum-Based Chemotherapy. American Journal of Clinical Oncology 32:2, 169-173
CrossRef466
Keqi Han, Weiguo Cao, Jinfeng Che, Shenxu Bo, Xiaodong Guo, Guang Huang, Lijun Ma, Liangqi Sun, Chunfang Gao, Baoliang Zhong, Zhigang Cao, Steven Jay Tucker, Daoyuan Wang. (2009) First Line Chemotherapy with Weekly Docetaxel and Cisplatin in Elderly Patients with Advanced Non-small Cell Lung Cancer. Journal of Thoracic Oncology 4:4, 512-517
CrossRef467
Min Jae Park, Jeeyun Lee, Jung Yong Hong, Moon Ki Choi, Joon Ho Yi, Su Jin Lee, Suk Joong Oh, Jin Seok Ahn, Keunchil Park, Myung Ju Ahn. (2009) Prognostic model to predict outcomes in nonsmall cell lung cancer patients treated with gefitinib as a salvage treatment. Cancer 115:7, 1518-1530
CrossRef468
Martin Reck. (2009) Gefitinib in the treatment of advanced non-small-cell lung cancer. Expert Review of Anticancer Therapy 9:4, 401-412
CrossRef469
Anne M. Traynor, Joan H. Schiller, Laura P. Stabile, Jill M. Kolesar, Jens C. Eickhoff, Sanja Dacic, Tien Hoang, Sarita Dubey, Sarah M. Marcotte, Jill M. Siegfried. (2009) Pilot study of gefitinib and fulvestrant in the treatment of post-menopausal women with advanced non-small cell lung cancer. Lung Cancer 64:1, 51-59
CrossRef470
Marcello Tiseo, Marco Bartolotti, Francesco Gelsomino, Andrea Ardizzoni. (2009) First-line treatment in advanced non-small-cell lung cancer: the emerging role of the histologic subtype. Expert Review of Anticancer Therapy 9:4, 425-435
CrossRef471
D. S. Hsu, C. R. Acharya, B. S. Balakumaran, R. F. Riedel, M. K. Kim, M. Stevenson, S. Tuchman, S. Mukherjee, W. Barry, H. K. Dressman, J. R. Nevins, S. Powers, D. Mu, A. Potti. (2009) Characterizing the developmental pathways TTF-1, NKX2-8, and PAX9 in lung cancer. Proceedings of the National Academy of Sciences 106:13, 5312-5317
CrossRef472
JY Wang. (2009) Effects of Feiyanning Decoction on gene expression of nuclear factor-κB activated by tumor necrosis factor-α in lung adenocarcinoma cell line. Journal of Chinese Integrative Medicine 7:3, 249-254
CrossRef473
Shadia I Jalal, Foluso O Ademuyiwa, Nasser H Hanna. (2009) The role of maintenance chemotherapy in advanced nonsmall cell lung cancer. Current Opinion in Oncology 21:2, 110-115
CrossRef474
Chia-Chi Lin, Chih-Hsin Yang. (2009) Epidermal growth factor receptor tyrosine kinase inhibitors in elderly or poor performance status patients with advanced non-small cell lung cancer. Targeted Oncology 4:1, 37-44
CrossRef475
Alain Vergnenègre, Julie Tillon, Romain Corre, Fabrice Barlési, Henri Berard, Jean-Marc Vernejoux, Hervé Le Caer, Pierre Fournel, Benoit Marin, Christos Chouaïd. (2009) A Randomized Phase II Trial Assessing in Advanced Non-small Cell Lung Cancer Patients with Stable Disease after Two Courses of Cisplatin-Gemcitabine an Early Modification of Chemotherapy Doublet with Paclitaxel-Gemcitabine Versus Continuation of Cisplatin-Gemcitabine Chemotherapy (GFPC 03-01 Study). Journal of Thoracic Oncology 4:3, 364-370
CrossRef476
Devalingam Mahalingam, Alain Mita, Monica M. Mita, Steffan T. Nawrocki, Francis J. Giles. (2009) Targeted Therapy for Advanced Non-small Cell Lung Cancers: Historical Perspective, Current Practices, and Future Development. Current Problems in Cancer 33:2, 73-111
CrossRef477
Rossana Berardi, Lorena Verdecchia, Marzia Di Pietro Paolo, Riccardo Giampieri, Mario Scartozzi, Chiara Pierantoni, Maristella Bianconi, Paola Mazzanti, Stefano Cascinu. (2009) Women and lung cancer: Clinical and molecular profiling as a determinate for treatment decisions. Critical Reviews in Oncology/Hematology 69:3, 223-236
CrossRef478
Hiromasa Yamamoto, Shinichi Toyooka, Tetsuya Mitsudomi. (2009) Impact of EGFR mutation analysis in non-small cell lung cancer. Lung Cancer 63:3, 315-321
CrossRef479
Jun Zhao, Zhi-jie Wang, Jian-chun Duan, Qing-zhi Guo, Hua Bai, Lu Yang, Tong-tong An, Xin Wang, Yu-yan Wang, Mei-na Wu, Xu-yi Liu, Jie Wang. (2009) A phase II clinical trial of celecoxib combined with platinum-based regimen as first-line chemotherapy for advanced non-small cell lung cancer patients with cyclooxygenase-2 positive expression. Chinese Journal of Cancer Research 21:1, 1-12
CrossRef480
Ruta Gupta, Aditi M. Dastane, Robert McKenna, Alberto M. Marchevsky. (2009) The predictive value of epidermal growth factor receptor tests in patients with pulmonary adenocarcinoma: review of current “best evidence” with meta-analysis. Human Pathology 40:3, 356-365
CrossRef481
Glenwood Goss, Frances A. Shepherd, Scott Laurie, Isabelle Gauthier, N. Leighl, Eric Chen, Ronald Feld, Jean Powers, Lesley Seymour. (2009) A phase I and pharmacokinetic study of daily oral cediranib, an inhibitor of vascular endothelial growth factor tyrosine kinases, in combination with cisplatin and gemcitabine in patients with advanced non-small cell lung cancer: A study of the National Cancer Institute of Canada Clinical Trials Group. European Journal of Cancer 45:5, 782-788
CrossRef482
Tadashi Igishi, Yasushi Shigeoka, Kazuhito Yasuda, Hisashi Suyama, Satoru Katayama, Akinori Sugitani, Shingo Matsumoto, Mitsunobu Yamamoto, Yasuto Ueda, Kenichi Takeda, Takashi Sumikawa, Takanori Sako, Masahiro Kodani, Yutaka Hitsuda, Eiji Shimizu. (2009) UFT Plus Vinorelbine in Advanced Non-small Cell Lung Cancer. Journal of Thoracic Oncology 4:3, 376-382
CrossRef483
Naruo Yoshimura, Shinzoh Kudoh, Tatsuo Kimura, Shigeki Mitsuoka, Shigenori Kyoh, Yoshihiro Tochino, Kazuhisa Asai, Toyoki Kodama, Yukikazu Ichimaru, Takashi Yana, Kazuto Hirata. (2009) Phase II Study of Docetaxel and Carboplatin in Elderly Patients with Advanced Non-small Cell Lung Cancer. Journal of Thoracic Oncology 4:3, 371-375
CrossRef484
Frank Schaarschmidt, Egbert Biesheuvel, Ludwig A. Hothorn. (2009) Asymptotic Simultaneous Confidence Intervals for Many-to-One Comparisons of Binary Proportions in Randomized Clinical Trials. Journal of Biopharmaceutical Statistics 19:2, 292-310
CrossRef485
Jason H. Smouse, Edmund S. Cibas, Pasi A. Jänne, Victoria A. Joshi, Kelly H. Zou, Neal I. Lindeman. (2009) EGFR mutations are detected comparably in cytologic and surgical pathology specimens of nonsmall cell lung cancer. Cancer Cytopathology 117:1, 67-72
CrossRef486
Q. Sun, C. Liu, H. Zhong, B. Zhong, H. Xu, W. Shen, D. Wang. (2009) Multi-center Phase II Trial of Weekly Paclitaxel Plus Cisplatin Combination Chemotherapy in Patients with Advanced Gastric and Gastro-esophageal Cancer. Japanese Journal of Clinical Oncology 39:4, 237-243
CrossRef487
Wallace Akerley, Kenneth M. Boucher, Joel S. Bentz, Kylee Arbogast, Theodore Walters. (2009) A Phase II Study of Erlotinib as Initial Treatment for Patients with Stage IIIB-IV Non-small Cell Lung Cancer. Journal of Thoracic Oncology 4:2, 214-219
CrossRef488
Jaime Feliu, Jose Luis Firvida, Javier Castro, Catherina Madroñal, Angeles Rodríguez-Jaráiz, Mercedes Salgado, Cristóbal Belda-Iniesta, Enrique Casado, Jesús García-Mata, Manuel González-Barón, . (2009) Combination therapy with docetaxel and low dose of cisplatin in elderly patients with advanced non-small cell lung cancer: multicenter phase II study. Cancer Chemotherapy and Pharmacology 63:3, 403-409
CrossRef489
Diana C. Márquez-Garbán, Hsiao-Wang Chen, Lee Goodglick, Michael C. Fishbein, Richard J. Pietras. (2009) Targeting Aromatase and Estrogen Signaling in Human Non-Small Cell Lung Cancer. Annals of the New York Academy of Sciences 1155:1, 194-205
CrossRef490
Kathleen Lang, Martin D. Marciniak, Doug Faries, Michael Stokes, Don Buesching, Craig Earle, Joseph Treat, Nathalie Morissette, David Thompson. (2009) Trends and predictors of first-line chemotherapy use among elderly patients with advanced non-small cell lung cancer in the United States. Lung Cancer 63:2, 264-270
CrossRef491
Makoto Kawaishi, Yutaka Fujiwara, Tomoya Fukui, Terufumi Kato, Kazuhiko Yamada, Yuichiro Ohe, Hideo Kunitoh, Ikuo Sekine, Noboru Yamamoto, Hiroshi Nokihara, Takeshi Watabe, Yuji Shimoda, Tokuzo Arao, Kazuto Nishio, Tomohide Tamura, Fumiaki Koizumi. (2009) Circulating Endothelial Cells in Non-small Cell Lung Cancer Patients Treated with Carboplatin and Paclitaxel. Journal of Thoracic Oncology 4:2, 208-213
CrossRef492
Xishan Xiong, Lili Fu, Li Wang, Houan Cai, Lin Li, Hualiang Jiang, Wenhu Duan, Changlin Mei. (2009) Antitumor activity of a novel EGFR tyrosine kinase inhibitor against human lung carcinoma in vitro and in vivo. Investigational New Drugs 27:1, 1-11
CrossRef493
Thomas E. Stinchcombe, Mark A. Socinski. (2009) Treatment Paradigms for Advanced Stage Non-small Cell Lung Cancer in the Era of Multiple Lines of Therapy. Journal of Thoracic Oncology 4:2, 243-250
CrossRef494
Gordana Cvetkovic, Goran Plavec, Ilija Tomic, Vesna Ilic, Zvonko Magic, Zeljka Tatomirovic, Dobrivoje Novkovic, Rade Milic, Vukojica Karlicic. (2009) K-ras mutation predictive significance in platinum based chemotherapeutic protocols in patients with advanced non-small cell lung cancer. Vojnosanitetski pregled 66:2, 149-155
CrossRef495
Antonio Rossi. (2009) Non-small-cell lung cancer: targeted therapies. Therapy 6:1, 95-98
CrossRef496
Martin Reck, Lucio Crinò. (2009) Advances in anti-VEGF and anti-EGFR therapy for advanced non-small cell lung cancer. Lung Cancer 63:1, 1-9
CrossRef497
V. Surmont, J. G. J. V. Aerts, K. Y. Tan, F. Schramel, R. Vernhout, H. C. Hoogsteden, R. J. van Klaveren. (2009) Non-Cross Resistant Sequential Single Agent Chemotherapy in First-Line Advanced Non-Small Cell Lung Cancer Patients: Results of a Phase II Study. Journal of Oncology 2009, 1-6
CrossRef498
Maki Nemoto, Gou Takahashi, Takahito Sugisaki, Kazuyoshi Kawakami, Shutaro Higuchi, Hajime Sugiyama, Nao Tunoda, Yasuo Nakamura, Masami Hanade, Naoko Kuroda, Toshihiro Hama. (2009) Preparation of Brochure for Patients Undergoing R-CHOP Chemotherapy Based on Adverse Reactions Survey. Iryo Yakugaku (Japanese Journal of Pharmaceutical Health Care and Sciences) 35:2, 129-135
CrossRef499
Yoshiki Hayashi, Hideyuki Kuriyama, Hajime Umezu, Junta Tanaka, Tatsuya Yoshimasu, Tomoko Furukawa, Hiroshi Tanaka, Hiroshi Kagamu, Fumitake Gejyo, Hirohisa Yoshizawa. (2009) Class III β-Tubulin Expression in Tumor Cells is Correlated with Resistance to Docetaxel in Patients with Completely Resected Non-Small-Cell Lung Cancer. Internal Medicine 48:4, 203-208
CrossRef500
Romano Danesi, Giuseppe Altavilla, Elisa Giovannetti, Raffael Rosell. (2009) Pharmacogenomics of gemcitabine in non-small-cell lung cancer and other solid tumors. Pharmacogenomics 10:1, 69-80
CrossRef501
Zheng Yun Cui, Min Jae Park, Jeeyun Lee, Jin Seok Ahn, Myung Ju Ahn, Soo Won Seo, Jin Woo Park, Youngro Byun, Keunchil Park. (2009) Modest Anti-Cancer Activity of a Bile Acid Acylated Heparin Derivative in a PC14PE6 Induced Orthotopic Lung Cancer Model. Cancer Research and Treatment 41:2, 80
CrossRef502
Toyoaki Hida, Shizu Ogawa, Jang Chul Park, Ji Young Park, Junichi Shimizu, Yoshitsugu Horio, Kimihide Yoshida. (2009) Gefitinib for the treatment of non-small-cell lung cancer. Expert Review of Anticancer Therapy 9:1, 17-35
CrossRef503
Ioannis Boukovinas, Paris Kosmidis. (2009) Treatment of non-small cell lung cancer patients with performance status2 (PS2). Lung Cancer 63:1, 10-15
CrossRef504
Elia Neninger, Beatriz García Verdecia, Tania Crombet, Carmen Viada, Susana Pereda, Idrissa Leonard, Zaima Mazorra, Gladys Fleites, Marta González, Bárbara Wilkinson, Gisela González, Agustín Lage. (2009) Combining an EGF-based Cancer Vaccine With Chemotherapy in Advanced Nonsmall Cell Lung Cancer. Journal of Immunotherapy 32:1, 92-99
CrossRef505
Choel-Kyu Park, Kyu-Sik Kim, In-Jae Oh, Manaljav Tseden-Ish, Yoo-Duk Choi, Yong-Soo Kwon, Yoo-Il Kim, Sung-Chul Lim, Young-Chul Kim. (2009) Efficacy of Pemetrexed in Relapsed Non-Small Cell Lung Cancer and Thymidylate Synthase Expression. Tuberculosis and Respiratory Diseases 67:3, 191
CrossRef506
Masaki Okamoto, Koichi Azuma, Tomoaki Hoshino, Haruki Imaoka, Jiro Ikeda, Takashi Kinoshita, Shinzo Takamori, Koichi Ohshima, Nobutaka Edakuni, Seiya Kato, Tomoaki Iwanaga, Hisamichi Aizawa. (2009) Correlation of Decreased Survival and IL-18 in Bone Metastasis. Internal Medicine 48:10, 763-773
CrossRef507
Shunsuke Okumura, Takaaki Sasaki, Noriaki Sukou, Masao Harada, Satoshi Ohizumi, Fumihiro Motomura, Takushi Saito, Youichi Nishiura, Hiroshi Isobe, Yoshinobu Ohsaki. (2009) Phase I Study of Paclitaxel and Carboplatin Combination Chemotherapy for Elderly Patients Aged 75 Years and Over with Advanced Non-small Cell Lung Cancer. Haigan 49:2, 146-150
CrossRef508
Yuichi Ozawa, Naoki Inui, Tateaki Naitoh, Kazumasa Yasuda, Masaharu Nagayama, Toshihiro Shirai, Hideki Suganuma, Masato Fujii, Hirotoshi Nakamura, Takafumi Suda, Kingo Chida. (2009) Phase II study of combination chemotherapy with S-1 and weekly cisplatin in patients with previously untreated advanced non-small cell lung cancer. Lung Cancer 63:1, 68-71
CrossRef509
Angela M. Davies, Kari Chansky, Primo N. Lara, Paul H. Gumerlock, John Crowley, Kathy S. Albain, Stanley J. Vogel, David R. Gandara. (2009) Bortezomib Plus Gemcitabine/Carboplatin as First-Line Treatment of Advanced Non-small Cell Lung Cancer. Journal of Thoracic Oncology 4:1, 87-92
CrossRef510
R ZINNER, R KOMAKI, J COX, B GLISSON, K PISTERS, R HERBST, M KIES, Z LIAO, W HONG, F FOSSELLA. (2009) Dose Escalation of Gemcitabine Is Possible With Concurrent Chest Three-Dimensional Rather Than Two-Dimensional Radiotherapy: A Phase I Trial in Patients With Stage III Non–Small-Cell Lung Cancer. International Journal of Radiation OncologyBiologyPhysics 73:1, 119-127
CrossRef511
Ryujiro Suzuki, Masashi Yamamoto, Hideo Saka, Hiroyuki Taniguchi, Joe Shindoh, Yoshimasa Tanikawa, Fumio Nomura, Hideo Gonda, Kazuyoshi Imaizumi, Yoshinori Hasegawa, Kaoru Shimokata. (2009) A phase II study of carboplatin and paclitacel with meloxicam. Lung Cancer 63:1, 72-76
CrossRef512
M J McKeage, J Von Pawel, M Reck, M B Jameson, M A Rosenthal, R Sullivan, D Gibbs, P N Mainwaring, M Serke, J-J Lafitte, C Chouaid, L Freitag, E Quoix. (2008) Randomised phase II study of ASA404 combined with carboplatin and paclitaxel in previously untreated advanced non-small cell lung cancer. British Journal of Cancer 99:12, 2006-2012
CrossRef513
M. Soda, S. Takada, K. Takeuchi, Y. L. Choi, M. Enomoto, T. Ueno, H. Haruta, T. Hamada, Y. Yamashita, Y. Ishikawa, Y. Sugiyama, H. Mano. (2008) A mouse model for EML4-ALK-positive lung cancer. Proceedings of the National Academy of Sciences 105:50, 19893-19897
CrossRef514
I Sekine, N Yamamoto, K Nishio, N Saijo. (2008) Emerging ethnic differences in lung cancer therapy. British Journal of Cancer 99:11, 1757-1762
CrossRef515
Hiroyuki Mano. (2008) Non-solid oncogenes in solid tumors: EML4-ALK fusion genes in lung cancer. Cancer Science 99:12, 2349-2355
CrossRef516
Kaoru Kubota, Masaaki Kawahara, Mitsumasa Ogawara, Yutaka Nishiwaki, Kiyoshi Komuta, Koichi Minato, Yuka Fujita, Satoshi Teramukai, Masanori Fukushima, Kiyoyuki Furuse. (2008) Vinorelbine plus gemcitabine followed by docetaxel versus carboplatin plus paclitaxel in patients with advanced non-small-cell lung cancer: a randomised, open-label, phase III study. The Lancet Oncology 9:12, 1135-1142
CrossRef517
A.G. Pallis, S. Agelaki, S. Kakolyris, A. Kotsakis, A. Kalykaki, N. Vardakis, P. Papakotoulas, A. Agelidou, A. Geroyianni, M. Agelidou, D. Hatzidaki, D. Mavroudis, V. Georgoulias. (2008) Chemotherapy-induced neutropenia as a prognostic factor in patients with advanced non-small cell lung cancer treated with front-line docetaxel–gemcitabine chemotherapy. Lung Cancer 62:3, 356-363
CrossRef518
Kaoru Kubota, Yutaka Nishiwaki, Tomohide Tamura, Kazuhiko Nakagawa, Kaoru Matsui, Koshiro Watanabe, Toyoaki Hida, Masaaki Kawahara, Nobuyuki Katakami, Koji Takeda, Akira Yokoyama, Kazumasa Noda, Masahiro Fukuoka, Nagahiro Saijo. (2008) Efficacy and Safety of Erlotinib Monotherapy for Japanese Patients with Advanced Non-small Cell Lung Cancer. Journal of Thoracic Oncology 3:12, 1439-1445
CrossRef519
Bryan J. Schneider, Gregory P. Kalemkerian, Michael J. Kraut, Antoinette J. Wozniak, Francis P. Worden, Daryn W. Smith, Wei Chen, Shirish M. Gadgeel. (2008) Phase II Study of Celecoxib and Docetaxel in Non-small Cell Lung Cancer (NSCLC) Patients with Progression after Platinum-Based Therapy. Journal of Thoracic Oncology 3:12, 1454-1459
CrossRef520
Rachel E. Sanborn. (2008) Cisplatin Versus Carboplatin in NSCLC: Is There One “Best” Answer?. Current Treatment Options in Oncology 9:4-6, 326-342
CrossRef521
Marianna Aita, Gianpiero Fasola, Carlotta Defferrari, Annalisa Brianti, Maria Giovanna Dal Bello, Alessandro Follador, Graziella Sinaccio, Paolo Pronzato, Francesco Grossi. (2008) Targeting the VEGF pathway: Antiangiogenic strategies in the treatment of non-small cell lung cancer. Critical Reviews in Oncology/Hematology 68:3, 183-196
CrossRef522
Taofeek K. Owonikoko, Suresh Ramalingam. (2008) The Role of Targeted Agents in the Treatment of Elderly Patients with Non-Small Cell Lung Cancer (NSCLC). Current Treatment Options in Oncology 9:4-6, 313-325
CrossRef523
Edgardo S Santos, Aurelio Castrellon, Marcelo Blaya, Luis E Raez. (2008) Controversies in the management of stage IIIA non-small-cell lung cancer. Expert Review of Anticancer Therapy 8:12, 1913-1929
CrossRef524
Dimitri Moreau, Catherine Jacquot, Polyxeni Tsita, Ioanna Chinou, Cristophe Tomasoni, Marcel Juge, Ekaterini Antoniadou-Vyza, Lionel Martignat, Alain Pineau, Christos Roussakis. (2008) Original triazine inductor of new specific molecular targets, with antitumor activity against nonsmall cell lung cancer. International Journal of Cancer 123:11, 2676-2683
CrossRef525
M. Früh, S. Gillessen, T. Cerny, R. Demmer, G. D’Addario. (2008) Two-weekly gemcitabine fixed dose rate and oxaliplatin combination chemotherapy for advanced non-small-cell lung cancer. Lung Cancer 62:3, 344-350
CrossRef526
Nilesh Vora, Karen L. Reckamp. (2008) Non-Small Cell Lung Cancer in the Elderly: Defining Treatment Options. Seminars in Oncology 35:6, 590-596
CrossRef527
Jeong-Ok Lee, Dae-Young Kim, Joo Han Lim, Myung-Deock Seo, Hyeon Gyu Yi, Yu Jung Kim, Se-Hoon Lee, Dong-Wan Kim, Seok-Chul Yang, Young Whan Kim, Dae Seog Heo. (2008) Risk factors for bacterial pneumonia after cytotoxic chemotherapy in advanced lung cancer patients. Lung Cancer 62:3, 381-384
CrossRef528
Michiko Harao, Shinya Hirata, Atsushi Irie, Satoru Senju, Tetsuya Nakatsura, Hiroyuki Komori, Yoshiaki Ikuta, Kazunori Yokomine, Katsunori Imai, Mitsuhiro Inoue, Kumiko Harada, Takeshi Mori, Takuya Tsunoda, Shuichi Nakatsuru, Yataro Daigo, Hiroaki Nomori, Yusuke Nakamura, Hideo Baba, Yasuharu Nishimura. (2008) HLA-A2-restricted CTL epitopes of a novel lung cancer-associated cancer testis antigen, cell division cycle associated 1, can induce tumor-reactive CTL. International Journal of Cancer 123:11, 2616-2625
CrossRef529
W.-C. Hsieh, Y.-W. Cheng, C.-J. Lin, M.-C. Chou, C.-Y. Chen, H. Lee. (2008) Prognostic Significance of X-ray Cross-complementing Group 1 T-77C Polymorphism in Resected Non-small Cell Lung Cancer. Japanese Journal of Clinical Oncology 39:2, 81-85
CrossRef530
Marios E. Froudarakis, Athanasia Pataka, Periklis Pappas, Stavros Anevlavis, Evangelia Argiana, Martha Nikolaidou, George Kouliatis, Sofia Pozova, Marios Marselos, Demosthenes Bouros. (2008) Phase 1 trial of lipoplatin and gemcitabine as a second-line chemotherapy in patients with nonsmall cell lung carcinoma. Cancer 113:10, 2752-2760
CrossRef531
Xifeng Wu, Charles Lu, Yuanqing Ye, Joe Chang, Hushan Yang, Jie Lin, Jian Gu, Waun Ki Hong, David Stewart, Margaret R. Spitz. (2008) Germline genetic variations in drug action pathways predict clinical outcomes in advanced lung cancer treated with platinum-based chemotherapy. Pharmacogenetics and Genomics 18:11, 955-965
CrossRef532
Chandra P. Belani, Marshall T. Schreeder, Ronald G. Steis, Richard A. Guidice, Thomas A. Marsland, Elizabeth H. Butler, Suresh S. Ramalingam. (2008) Cetuximab in combination with carboplatin and docetaxel for patients with metastatic or advanced-stage nonsmall cell lung cancer. Cancer 113:9, 2512-2517
CrossRef533
Chia-Hsuin Chang, Kuan-Yu Chen, Yinong Young-Xu, Tobias Kurth, E. John Orav, Pan-Chyr Yang, K. Arnold Chan. (2008) The safety and efficacy of gefitinib versus platinum-based doublets chemotherapy as the first-line treatment for advanced non-small-cell lung cancer patients in East Asia: A meta-analysis. Lung Cancer 62:2, 242-252
CrossRef534
Nina Helbekkmo, Ulf Aasebø, Stein H. Sundstrøm, Christian von Plessen, Paal Fr. Brunsvig, Roy M. Bremnes. (2008) Treatment outcome in performance status 2 advanced NSCLC patients administered platinum-based combination chemotherapy. Lung Cancer 62:2, 253-260
CrossRef535
Todd M. Erickson, John R. Koeppe, York E. Miller, Rodney W. Stuart, D Ross Camidge. (2008) Bronchioloalveolar Carcinoma Presenting as Chronic Progressive Pulmonary Infiltrates in a Woman with HIV. Journal of Thoracic Oncology 3:11, 1353-1355
CrossRef536
Hossein Borghaei, Corey J. Langer, Michael Millenson, Karen J. Ruth, Samuel Litwin, Holly Tuttle, Judie Sylvester Seldomridge, Marc Rovito, David Mintzer, Roger Cohen, Joseph Treat. (2008) Phase II Study of Paclitaxel, Carboplatin, and Cetuximab as First Line Treatment, for Patients with Advanced Non-small Cell Lung Cancer (NSCLC). Journal of Thoracic Oncology 3:11, 1286-1292
CrossRef537
Shirish M. Gadgeel, Antoinette Wozniak, John C. Ruckdeschel, Lance K. Heilbrun, Raghu Venkatramanamoorthy, Ruth A. Chaplen, Michael J. Kraut, Gregory P. Kalemkerian. (2008) Phase II Study of Docetaxel and Celecoxib, a Cyclooxygenase-2 Inhibitor, in Elderly or Poor Performance Status (PS2) Patients with Advanced Non-small Cell Lung Cancer. Journal of Thoracic Oncology 3:11, 1293-1300
CrossRef538
Rogerio C. Lilenbaum, Roy S. Herbst. (2008) Advances in the Treatment of Metastatic Non–Small-Cell Lung Cancer With Chemotherapy and Targeted Agents. Clinical Pulmonary Medicine 15:6, 352-358
CrossRef539
Se Hoon Park, Junshik Hong, Young Saing Kim, Yujin Kim, Sun Young Kyung, Chang Hyeok An, Sang Pyo Lee, Jeong Woong Park, Sung Hwan Jeong, Jinny Park, Eun Kyung Cho, Dong Bok Shin, Jae Hoon Lee. (2008) Phase II trial of weekly docetaxel and gemcitabine for previously untreated, advanced non-small cell lung cancer. Lung Cancer 62:1, 72-77
CrossRef540
Rebecca Suk Heist, Panos Fidias, Mark Huberman, Blair Ardman, Lecia V. Sequist, Jennifer S. Temel, Thomas J. Lynch. (2008) A Phase II Study of Oxaliplatin, Pemetrexed, and Bevacizumab in Previously Treated Advanced Non-small Cell Lung Cancer. Journal of Thoracic Oncology 3:10, 1153-1158
CrossRef541
Bruce J. Giantonio, Arlene A. Forastiere, Robert L. Comis. (2008) The Role of the Eastern Cooperative Oncology Group in Establishing Standards of Cancer Care: Over 50 Years of Progress Through Clinical Research. Seminars in Oncology 35:5, 494-506
CrossRef542
Reury-Perng Perng, Chih-Hsin Yang, Yuh-Min Chen, Gee-Chen Chang, Meng-Chih Lin, Ruey-Kuen Hsieh, Nei-Min Chu, Ruay-Sheng Lai, Wu-Chou Su, Chao-Jung Tsao, Te-Chun Hsia, Hao-Cheng Chen, Chih-Hung Chen, Ming-Shyan Huang, Jui-Long Wang, Ming-Lin Ho, Chih-Yuan Chung, Chong-Jen Yu, Wen-Cheng Chang, Han-Pin Kuo, Chih-Teng Yu, Zhong-Zhe Lin, Woei-Yau Kao. (2008) High efficacy of erlotinib in Taiwanese NSCLC patients in an expanded access program study previously treated with chemotherapy. Lung Cancer 62:1, 78-84
CrossRef543
Anthe S. Zandvliet, Jan H. M. Schellens, Christian Dittrich, Jantien Wanders, Jos H. Beijnen, Alwin D. R. Huitema. (2008) Population pharmacokinetic and pharmacodynamic analysis to support treatment optimization of combination chemotherapy with indisulam and carboplatin. British Journal of Clinical Pharmacology 66:4, 485-497
CrossRef544
Nagahiro Saijo. (2008) Advances in the treatment of non-small cell lung cancer. Cancer Treatment Reviews 34:6, 521-526
CrossRef545
Paul Wheatley-Price, Frances A. Shepherd. (2008) Targeting Angiogenesis in the Treatment of Lung Cancer. Journal of Thoracic Oncology 3:10, 1173-1184
CrossRef546
Antonius A. Miller, Xiaofei F. Wang, Lin Gu, Philip Hoffman, Jamil Khatri, Frank Dunphy, Martin J. Edelman, Michael Bolger, Everett E. Vokes, Mark R. Green. (2008) Phase II Randomized Study of Dose-Dense Docetaxel and Cisplatin Every 2 Weeks With Pegfilgrastim and Darbepoetin Alfa With and Without the Chemoprotector BNP7787 in Patients With Advanced Non-small Cell Lung Cancer (CALGB 30303). Journal of Thoracic Oncology 3:10, 1159-1165
CrossRef547
Frank Griesinger. (2008) Das fortgeschrittene nichtkleinzellige Lungenkarzinom. best practice onkologie 3:5, 26-36
CrossRef548
Noriyuki Ebi, Hiroshi Semba, Sho j i Tokunaga, Koichi Takayama, Hiroshi Wataya, Takashige Kuraki, Hidehiko Yamamoto, Shin j i Akamine, Isamu Okamoto, Yoichi Nakanishi. (2008) A Phase II Trial of Gefitinib Monotherapy in Chemotherapy-Naïve Patients of 75 Years or Older with Advanced Non-small Cell Lung Cancer. Journal of Thoracic Oncology 3:10, 1166-1171
CrossRef549
Osamu Kawai, Genichiro Ishii, Kaoru Kubota, Yukinori Murata, Yoichi Naito, Tetsuya Mizuno, Keiju Aokage, Nagahiro Saijo, Yutaka Nishiwaki, Akihiko Gemma, Syoji Kudoh, Atsushi Ochiai. (2008) Predominant infiltration of macrophages and CD8 + T Cells in cancer nests is a significant predictor of survival in stage IV nonsmall cell lung cancer. Cancer 113:6, 1387-1395
CrossRef550
Seema Harichand-Herdt, Suresh S. Ramalingam. (2008) Targeted Therapy for the Treatment of Non-Small Cell Lung Cancer: Focus on Inhibition of Epidermal Growth Factor Receptor. Seminars in Thoracic and Cardiovascular Surgery 20:3, 217-223
CrossRef551
Katerina Vrzalikova, Joseph Skarda, Jiri Ehrmann, Paul G. Murray, Eduard Fridman, Jury Kopolovic, Petra Knizetova, Marian Hajduch, Jiri Klein, Vitezslav Kolek, Lenka Radova, Zdenek Kolar. (2008) Prognostic value of Bmi-1 oncoprotein expression in NSCLC patients: a tissue microarray study. Journal of Cancer Research and Clinical Oncology 134:9, 1037-1042
CrossRef552
Chao Hui Huang, Michael M. Millenson, Eric J. Sherman, Hossein Borghaei, David M. Mintzer, Roger B. Cohen, Arthur P. Staddon, Judi Seldomridge, Ocn Joseph Treat, Holly Tuttle, Karen J. Ruth, Corey J. Langer. (2008) Promising Survival in Patients with Recurrent Non-small Cell Lung Cancer Treated with Docetaxel and Gemcitabine in Combination as Second-Line Therapy. Journal of Thoracic Oncology 3:9, 1032-1038
CrossRef553
Eleni M. Karapanagiotou, Adrianni Charpidou, Ifigenia Tzannou, Kalliopi Dilana, Elias Kotteas, Ioannis Tourkantonis, Epaminondas Kosmas, Aspasia Provata, Kostas Syrigos. (2008) A phase II study of sequential docetaxel and gemcitabine followed by docetaxel and carboplatin as first-line therapy for non-small cell lung cancer. Medical Oncology 25:3, 303-308
CrossRef554
Balázs Döme, Melinda Magyar. (2008) A daganatos érhálózat mint terápiás célpont nem kissejtes tüdőrákban. Magyar Onkológia 52:3, 247-259
CrossRef555
C. Hennequin, F. Mornex, J. Trédaniel. (2008) Chimioradiothérapie concomitante pour le traitement des cancers bronchiques non à petites cellules, localisés au thorax, inopérables ou non résécables. Oncologie 10:9, 531-535
CrossRef556
A. Kretzschmar. (2008) Prognoseadaptierte Therapie beim fortgeschrittenen CUP-Syndrom. Der Onkologe 14:9, 920-930
CrossRef557
David E. Gerber. (2008) EGFR inhibition in the treatment of non-small cell lung cancer. Drug Development Research 69:6, 359-372
CrossRef558
Shinji Atagi, Masaaki Kawahara, Yoko Kusunoki, Minoru Takada, Tomoya Kawaguchi, Kyoiti Okishio, Akihito Kubo, Kazutaka Uehira, Katsuyuki Yumine, Yoshio Tomizawa, Ryusei Saito, Shimao Fukai, Hikotaro Komatsu. (2008) Phase I/II Study of Docetaxel and S-1 in Patients with Previously Treated Non-small Cell Lung Cancer. Journal of Thoracic Oncology 3:9, 1012-1017
CrossRef559
Suresh Ramalingam, Michael C. Perry, Renato V. La Rocca, David Rinaldi, Preston S. Gable, William J. Tester, Chandra P. Belani. (2008) Comparison of outcomes for elderly patients treated with weekly paclitaxel in combination with carboplatin versus the standard 3-weekly paclitaxel and carboplatin for advanced nonsmall cell lung cancer. Cancer 113:3, 542-546
CrossRef560
Nithya Ramnath, Jihnhee Yu, Nikhil I. Khushalani, Ronald H. Gottlieb, James K. Schwarz, Renuka V. Iyer, Youcef M. Rustum, Patrick J. Creaven. (2008) Scheduled administration of low dose irinotecan before gemcitabine in the second line therapy of non-small cell lung cancer: a phase II study. Anti-Cancer Drugs 19:7, 749-752
CrossRef561
Fumihiro Oshita, Kouzo Yamada, Haruhiro Saito, Kazumasa Noda. (2008) Phase II study of nedaplatin and irinotecan followed by gefitinib for elderly patients with unresectable non-small cell lung cancer. Cancer Chemotherapy and Pharmacology 62:3, 465-470
CrossRef562
Petr Zatloukal, Radj Gervais, Johan Vansteenkiste, Léon Bosquee, Christiana Sessa, Etienne Brain, Eric Dansin, Thierry Urban, Nadine Dohollou, Michèle Besenval, Elisabeth Quoix. (2008) Randomized Multicenter Phase II Study of Larotaxel (XRP9881) in Combination with Cisplatin or Gemcitabine as First-Line Chemotherapy in Nonirradiable Stage IIIB or Stage IV Non-small Cell Lung Cancer. Journal of Thoracic Oncology 3:8, 894-901
CrossRef563
Raymond Ng, Michael Loreto, Roy Lee, Natasha B. Leighl. (2008) Brief report: Retrospective review of efficacy of erlotinib or gefitinib compared to docetaxel as subsequent line therapy in advanced non-small cell lung cancer (NSCLC) following failure of platinum-based chemotherapy. Lung Cancer 61:2, 262-265
CrossRef564
Emmanouel Saloustros, Vassilis Georgoulias. (2008) Docetaxel in the treatment of advanced non-small-cell lung cancer. Expert Review of Anticancer Therapy 8:8, 1207-1222
CrossRef565
Oscar Arrieta, Luis Martinez-Barrera, Sergio Treviño, Enrique Guzman, Patricia Castillo-Gonzalez, Miguel Angel Rios-Trejo, Diana Flores-Estrada, Eduardo Téllez, Cesar Gonzalez, Johny de la Cruz Vargas, Claudia Haydee Gonzalez-De la Rosa, Norma Hernandez-Pedro, Rafael Morales-Barrera, Jaime De la Garza. (2008) Wood-Smoke Exposure as a Response and Survival Predictor in Erlotinib-treated Non-small Cell Lung Cancer Patients. Journal of Thoracic Oncology 3:8, 887-893
CrossRef566
Schiller, Joan H., . (2008) Noninvasive Monitoring of Tumors. New England Journal of Medicine 359:4, 418-420
Full Text567
E. Giovannetti, A. C. Laan, E. Vasile, C. Tibaldi, S. Nannizzi, S. Ricciardi, A. Falcone, R. Danesi, G. J. Peters. (2008) Correlation Between Cytidine Deaminase Genotype and Gemcitabine Deamination in Blood Samples. Nucleosides, Nucleotides and Nucleic Acids 27:6-7, 720-725
CrossRef568
F. Anthony Greco, Philip Bonomi, Jeffrey Crawford, Karen Kelly, Yun Oh, Wendy Halpern, Larry Lo, Gilles Gallant, Jerry Klein. (2008) Phase 2 study of mapatumumab, a fully human agonistic monoclonal antibody which targets and activates the TRAIL receptor-1, in patients with advanced non-small cell lung cancer. Lung Cancer 61:1, 82-90
CrossRef569
Diego Dongiovanni, Lorenzo Daniele, Carla Barone, Vincenzo Dongiovanni, Camilla Fissore, Anna Sapino, Luigia Macrì, Giovanni Bussolati, Lucio Buffoni, Fabio Gaspari, Raffaella Grillo, Nadia Birocco, Alfredo Addeo, Libero Ciuffreda, Marina Schena. (2008) Gefitinib (ZD1839): Therapy in selected patients with non-small cell lung cancer (NSCLC)?. Lung Cancer 61:1, 73-81
CrossRef570
Christian Manegold. (2008) Antiangiogenic treatments of advanced non-small cell lung cancer. Targeted Oncology 3:3, 187-196
CrossRef571
R.M. Huber. (2008) Therapie des Lungenkarzinoms. Der Pneumologe 5:4, 259-266
CrossRef572
Francesco Grossi, Cesare Gridelli, Marianna Aita, Filippo De Marinis. (2008) Identifying an optimum treatment strategy for patients with advanced non-small cell lung cancer. Critical Reviews in Oncology/Hematology 67:1, 16-26
CrossRef573
Pandurang M. Kulkarni, Ruqin Chen, Taruna Anand, Matthew J. Monberg, Coleman K. Obasaju. (2008) Efficacy and safety of pemetrexed in elderly cancer patients: Results of an integrated analysis. Critical Reviews in Oncology/Hematology 67:1, 64-70
CrossRef574
Rafael Sirera, Mireia Gil, Ana Blasco, Andrea Cabrera, María José Safont, Vega Iranzo, Diego Cayuela, Rafael Rosell, Carlos Camps. (2008) Retrospective analysis of the prognostic role of p16 protein inactivation in plasma in patients with locally advanced non-small cell lung cancer. Lung Cancer 61:1, 104-108
CrossRef575
Dae Ho Lee, Ji‐Youn Han, Heung Tae Kim, Sung Jin Yoon, Hong Ryull Pyo, Kwan Ho Cho, Sang‐Hoon Shin, Heon Yoo, Seung‐Hoon Lee, Jin Soo Lee. (2008) Primary chemotherapy for newly diagnosed nonsmall cell lung cancer patients with synchronous brain metastases compared with whole‐brain radiotherapy administered first. Cancer 113:1, 143-149
CrossRef576
Benjamin B. Bridges, Leno Thomas, Petr F. Hausner, L. Austin Doyle, Michelle Bedor, Ruth Smith, Julie Brahmer, Martin J. Edelman. (2008) Phase II trial of gemcitabine/carboplatin followed by paclitaxel in patients with performance status=2,3 or other significant co-morbidity (HIV infection or s/p organ transplantation) in advanced non-small cell lung cancer. Lung Cancer 61:1, 61-66
CrossRef577
Raffaele Califano, Fiona H. Blackhall, Giovanna Finocchiaro, Luca Toschi, Nicholas Thatcher, Federico Cappuzzo, Lucio Crinò. (2008) EGFR tyrosine kinase inhibitors in non-small cell lung cancer patients: how do we interpret the clinical and biomarker data?. Targeted Oncology 3:3, 173-186
CrossRef578
Giorgio Vittorio Scagliotti, Giovanni Selvaggi. (2008) Targeted therapies in bronchioloalveolar carcinoma. Targeted Oncology 3:3, 197-204
CrossRef579
M. Reck, U. Gatzemeier. (2008) Advanced non-small cell lung cancer therapy: historical and future perspectives. Targeted Oncology 3:3, 135-147
CrossRef580
Robert Matthew Strother, Christopher Sweeney. (2008) Lessons learned from development of docetaxel. Expert Opinion on Drug Metabolism & Toxicology 4:7, 1007-1019
CrossRef581
David R. Spigel, Ming Lin, Vincent O'Neill, John D. Hainsworth. (2008) Final survival and safety results from a multicenter, open-label, phase 3b trial of erlotinib in patients with advanced nonsmall cell lung cancer. Cancer 112:12, 2749-2755
CrossRef582
N B Leighl, F A Shepherd, D Zawisza, R L Burkes, R Feld, J Waldron, A Sun, D Payne, A Bezjak, M H N Tattersall. (2008) Enhancing treatment decision-making: pilot study of a treatment decision aid in stage IV non-small cell lung cancer. British Journal of Cancer 98:11, 1769-1773
CrossRef583
Takashi Seto, Takeharu Yamanaka, Makiko Nakano, Mayuko Ota, Riichiroh Maruyama, Tatsuro Okamoto, Hiroshi Wataya, Kazutsugu Uematsu, Nobuhiko Seki, Kenji Eguchi, Hiroshi Semba, Yukito Ichinose. (2008) Tegafur-Uracil Plus Gemcitabine Combination Chemotherapy in Patients with Advanced Non-small Cell Lung Cancer Previously Treated with Platinum. Journal of Thoracic Oncology 3:6, 637-642
CrossRef584
Rogerio C. Lilenbaum. (2008) New Horizons in Chemotherapy: Platforms for Combinations in First-Line Advanced Non-small Cell Lung Cancer. Journal of Thoracic Oncology 3:Supplement 2, S171-S174
CrossRef585
George Blumenschein. (2008) Sorafenib in Lung Cancer: Clinical Developments and Future Directions. Journal of Thoracic Oncology 3:Supplement 2, S124-S127
CrossRef586
Yuhchyau Chen, Kishan J. Pandya, Richard Feins, David W. Johnstone, Thomas Watson, Therese Smudzin, Peter C. Keng. (2008) Toxicity Profile and Pharmacokinetic Study of A Phase I Low-Dose Schedule–Dependent Radiosensitizing Paclitaxel Chemoradiation Regimen for Inoperable Non–Small-Cell Lung Cancer. International Journal of Radiation Oncology*Biology*Physics 71:2, 407-413
CrossRef587
Jorge García-González, Juan Cueva, María Jesús Lamas, Teresa Curiel, Begoña Graña, Rafael López-López. (2008) Paclitaxel and cisplatin in the treatment of metastatic non-small-cell lung cancer during pregnancy. Clinical and Translational Oncology 10:6, 375-376
CrossRef588
Yoichi Naito, Kaoru Kubota, Keiji Nihei, Tomonori Fujii, Kiyotaka Yoh, Seiji Niho, Koichi Goto, Hironobu Ohmatsu, Nagahiro Saijo, Yutaka Nishiwaki. (2008) Concurrent Chemoradiotherapy with Cisplatin and Vinorelbine for Stage III Non-small Cell Lung Cancer. Journal of Thoracic Oncology 3:6, 617-622
CrossRef589
Corey J. Langer, Kenneth J. O’Byrne, Mark A. Socinski, Sergei M. Mikhailov, Krzysztof Leśniewski-Kmak, Martin Smakal, Tudor E. Ciuleanu, Sergey V. Orlov, Mircea Dediu, David Heigener, Amy J. Eisenfeld, Larissa Sandalic, Fred B. Oldham, Jack W. Singer, Helen J. Ross. (2008) Phase III Trial Comparing Paclitaxel Poliglumex (CT-2103, PPX) in Combination with Carboplatin Versus Standard Paclitaxel and Carboplatin in the Treatment of PS 2 Patients with Chemotherapy-Naïve Advanced Non-small Cell Lung Cancer. Journal of Thoracic Oncology 3:6, 623-630
CrossRef590
Lecia V. Sequist. (2008) First-Generation Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in EGFR Mutation. Journal of Thoracic Oncology 3:Supplement 2, S143-S145
CrossRef591
Diego Cortinovis, Paolo Bidoli, Nicoletta Zilembo, Alberto Fusi, Emilio Bajetta. (2008) Oxaliplatin doublets in non-small cell lung cancer: A literature review. Lung Cancer 60:3, 325-331
CrossRef592
Vittorio Gebbia. (2008) Does an optimal therapeutic sequence exist in advanced non-small cell lung cancer?. Expert Opinion on Pharmacotherapy 9:8, 1321-1337
CrossRef593
Junichi SHIMIZU, Yoshitsugu HORIO, Hirotaka OSADA, Toyoaki HIDA, Yoshinori HASEGAWA, Kaoru SHIMOKATA, Takashi TAKAHASHI, Yoshitaka SEKIDO, Yasushi YATABE. (2008) mRNA expression of RRM1, ERCC1 and ERCC2 is not associated with chemosensitivity to cisplatin, carboplatin and gemcitabine in human lung cancer cell lines. Respirology 13:4, 510-517
CrossRef594
Petros Nikolinakos, John V. Heymach. (2008) The Tyrosine Kinase Inhibitor Cediranib for Non-small Cell Lung Cancer and Other Thoracic Malignancies. Journal of Thoracic Oncology 3:Supplement 2, S131-S134
CrossRef595
J.-C. Ko, S.-C. Ciou, C.-M. Cheng, L.-H. Wang, J.-H. Hong, M.-Y. Jheng, S.-T. Ling, Y.-W. Lin. (2008) Involvement of Rad51 in cytotoxicity induced by epidermal growth factor receptor inhibitor (gefitinib, IressaR) and chemotherapeutic agents in human lung cancer cells. Carcinogenesis 29:7, 1448-1458
CrossRef596
J Souglakos, I Boukovinas, M Taron, P Mendez, D Mavroudis, M Tripaki, D Hatzidaki, A Koutsopoulos, E Stathopoulos, V Georgoulias, R Rosell. (2008) Ribonucleotide reductase subunits M1 and M2 mRNA expression levels and clinical outcome of lung adenocarcinoma patients treated with docetaxel/gemcitabine. British Journal of Cancer 98:10, 1710-1715
CrossRef597
Jialei Wang, Jin Li, Xiaonan Hong, Weiyu Tang, Xichun Hu, Biyun Wang, Ye Gu. (2008) Retrospective case series of gemcitabine plus cisplatin in the treatment of recurrent and metastatic nasopharyngeal carcinoma. Oral Oncology 44:5, 464-470
CrossRef598
Christian Manegold. (2008) Bevacizumab for the treatment of advanced non-small-cell lung cancer. Expert Review of Anticancer Therapy 8:5, 689-699
CrossRef599
Rogerio Lilenbaum, Luis Raez, Jennifer Tseng, Leonard Seigel, Enrique Davila. (2008) Efficacy and Safety of Oxaliplatin and Gemcitabine with Bevacizumab in Advanced Non-small Cell Lung Cancer. Journal of Thoracic Oncology 3:5, 511-515
CrossRef600
Nicholas J Vogelzang. (2008) Chemotherapy for malignant pleural mesothelioma. The Lancet 371:9625, 1640-1642
CrossRef601
Jen-Chung Ko, Jhao-Hao Hong, Lyu-Han Wang, Yun-Wei Lin. (2008) The role of repair protein Rad51 in synergistic cytotoxicity and mutagenicity induced by epidermal growth factor receptor inhibitor (Gefitinib, IressaR) and benzo[a]pyrene in human lung cancer. Experimental Cell Research 314:8, 1881-1891
CrossRef602
Ping K. Ruan, Robert J. Gray. (2008) Sensitivity analysis of progression-free survival with dependent withdrawal. Statistics in Medicine 27:8, 1180-1198
CrossRef603
Jun Guo, Weiping Li, Degang Song, Zhehai Wang, Jie Liu, Changzheng Li, Zhen Chen, Huan Shi. (2008) Clinical study of docetaxel-vinorelbine as second-line chemotherapy in advanced non-small cell lung cancer. The Chinese-German Journal of Clinical Oncology 7:4, 200-202
CrossRef604
Kentaro Okuda, Takashi Hirose, Hiroo Ishida, Sojiro Kusumoto, Tomohide Sugiyama, Kohichi Ando, Takao Shirai, Tsukasa Ohnishi, Naoya Horichi, Tohru Ohmori, Mitsuru Adachi. (2008) Phase I study of the combination of nedaplatin and weekly paclitaxel in patients with advanced non-small cell lung cancer. Cancer Chemotherapy and Pharmacology 61:5, 829-835
CrossRef605
Supriya Gupta Mohile, Farid Berenji, Deepak Sahasrabudhe, Gary Morrow, Daniel P Petrylak. (2008) Efficacy and safety of docetaxel in the elderly. Aging Health 4:2, 113-127
CrossRef606
Meiqi Shi, Bo Shen, Guochun Cao, Yun Zeng, Guohao Xia, Jifeng Feng, Lin Xu. (2008) Comparison of efficacy and toxicity between gemcitabine plus cisplatin and plus carboplatin in first-line treatment of advanced non-small cell lung cancer. The Chinese-German Journal of Clinical Oncology 7:4, 196-199
CrossRef607
Anuj Agarwala, William Fisher, Daniel Bruetman, John McClean, David Taber, Michael Titzer, Beth Juliar, Menggang Yu, Tim Breen, Lawrence H. Einhorn, Nasser Hanna. (2008) Gefitinib Plus Celecoxib in Chemotherapy-Na??ve Patients with Stage IIIB/IV Non-small Cell Lung Cancer. Journal of Thoracic Oncology 3:4, 374-379
CrossRef608
Arkadiusz Z. Dudek, Timothy Larson, Michael J. McCleod, Daniel J. Schneider, Jonathan E. Dowell, Tarit K. Banerjee, Kishan J. Pandya, Jane L. Bromund, Ruqin Chen, Matthew J. Monberg, Coleman K. Obasaju. (2008) Phase 1/2 Dose Escalating Study of Twice-Monthly Pemetrexed and Gemcitabine in Patients with Advanced Cancer and Non-small Cell Lung Cancer. Journal of Thoracic Oncology 3:4, 394-399
CrossRef609
Clorinda Schettino, Maria Anna Bareschino, Vincenzo Ricci, Fortunato Ciardiello. (2008) Erlotinib: an EGF receptor tyrosine kinase inhibitor in non-small-cell lung cancer treatment. Expert Review of Respiratory Medicine 2:2, 167-178
CrossRef610
Y Kaida, N Inui, T Suda, H Nakamura, H Watanabe, K Chida. (2008) The CYP2A6*4 Allele Is Determinant of S-1 Pharmacokinetics in Japanese Patients With Non-small-cell Lung Cancer. Clinical Pharmacology & Therapeutics 83:4, 589-594
CrossRef611
K Tamura, I Okamoto, T Kashii, S Negoro, T Hirashima, S Kudoh, Y Ichinose, N Ebi, K Shibata, T Nishimura, N Katakami, T Sawa, E Shimizu, J Fukuoka, T Satoh, M Fukuoka. (2008) Multicentre prospective phase II trial of gefitinib for advanced non-small cell lung cancer with epidermal growth factor receptor mutations: results of the West Japan Thoracic Oncology Group trial (WJTOG0403). British Journal of Cancer 98:5, 907-914
CrossRef612
Martin Gutierrez, Giuseppe Giaccone. (2008) Antiangiogenic therapy in nonsmall cell lung cancer. Current Opinion in Oncology 20:2, 176-182
CrossRef613
Thomas Fong, Daniel Morgensztern, Ramaswamy Govindan. (2008) EGFR Inhibitors as First-Line Therapy in Advanced Non-small Cell Lung Cancer. Journal of Thoracic Oncology 3:3, 303-310
CrossRef614
Frederic Gagnadoux, Jose Hureaux, Laurent Vecellio, Thierry Urban, Alain Le Pape, Isabelle Valo, Jerome Montharu, Valerie Leblond, Michele Boisdron-Celle, Stephanie Lerondel, Caroline Majoral, Patrice Diot, Jean L. Racineux, Etienne Lemarie. (2008) Aerosolized Chemotherapy. Journal of Aerosol Medicine and Pulmonary Drug Delivery 21:1, 61-70
CrossRef615
H. TADA, S. MATSUI, M. KAWAHARA, S. HOSOE, C. HAMADA, M. FUKUSHIMA. (2008) Efficacy, toxicity and cost analysis for non-platinum triplet (gemcitabine and vinorelbine, followed by docetaxel) vs. platinum-based chemotherapy in IIIB/IV non-small-cell lung cancer: single-institution experience. European Journal of Cancer Care 17:2, 120-126
CrossRef616
Takayuki Fukui, Tetsuya Mitsudomi. (2008) Mutations in the epidermal growth factor receptor gene and effects of EGFR-tyrosine kinase inhibitors on lung cancers. General Thoracic and Cardiovascular Surgery 56:3, 97-103
CrossRef617
Kyoichi Kaira, Noriaki Sunaga, Noriko Yanagitani, Haruka Aoki, Tadayoshi Kawata, Mitsuyoshi Utsugi, Yasuo Shimizu, Kimihiro Shimizu, Takeshi Hisada, Tamotsu Ishizuka, Masatomo Mori. (2008) Phase I trial of oral S-1 plus gemcitabine in elderly patients with nonsmall cell lung cancer. Anti-Cancer Drugs 19:3, 289-294
CrossRef618
Frederic Gagnadoux, Jose Hureaux, Laurent Vecellio, Thierry Urban, Alain Le Pape, Isabelle Valo, Jerome Montharu, Valerie Leblond, Michele Boisdron-Celle, Stephanie Lerondel, Caroline Majoral, Patrice Diot, Jean L. Racineux, Etienne Lemarie. (2008) Aerosolized Chemotherapy. Journal of Aerosol Medicine 0:0, 080207080519480-9
CrossRef619
George R Simon, Mubeena Begum, Gerold Bepler. (2008) Setting the stage for tailored chemotherapy in the management of non-small cell lung cancer. Future Oncology 4:1, 51-59
CrossRef620
Lecia V. Sequist, Thomas J. Lynch. (2008) EGFR Tyrosine Kinase Inhibitors in Lung Cancer: An Evolving Story. Annual Review of Medicine 59:1, 429-442
CrossRef621
Yataro Daigo, Yusuke Nakamura. (2008) From cancer genomics to thoracic oncology: discovery of new biomarkers and therapeutic targets for lung and esophageal carcinoma. General Thoracic and Cardiovascular Surgery 56:2, 43-53
CrossRef622
Emilio Esteban, Noemi Villanueva, Isabel Muñiz, Yolanda Fernández, Joaquin Fra, Maria Luque, Paula Jiménez, Beatriz Llorente, Marta Capelan, José M. Vieitez, Enrique Estrada, José M. Buesa, Angel Jiménez-Lacave. (2008) Pulmonary toxicity in patients treated with gemcitabine plus vinorelbine or docetaxel for advanced non-small cell lung cancer: outcome data on a randomized phase II study. Investigational New Drugs 26:1, 67-74
CrossRef623
Riichiroh Maruyama, Ichiro Yoshino, Shoji Tokunaga, Morio Ohta, Masato Kato, Hiroyuki Yoshimine, Koji Yamazaki, Yoichi Nakanishi, Yukito Ichinose. (2008) Feasibility trial of adjuvant chemotherapy with paclitaxel and carboplatin after surgical resection in Japanese patients with non-small cell lung cancer: report of the Lung Oncology Group in Kyushu (LOGIK) protocol 0501. General Thoracic and Cardiovascular Surgery 56:2, 68-73
CrossRef624
Jue Wang, Yong Fang Kuo, Jean Freeman, Avi B. Markowitz, James S. Goodwin. (2008) Temporal trends and predictors of perioperative chemotherapy use in elderly patients with resected nonsmall cell lung cancer. Cancer 112:2, 382-390
CrossRef625
Koichi TAKAYAMA, Masayuki KAWASAKI, Kiyoshi NINOMIYA, Akira MOTOHIRO, Masaki FUJITA, Kentaro WATANABE, Akira KAJIKI, Fumiyuki IWAMI, Naoki MIYAZAKI, Miiru IZUMI, Nobuyuki HARA, Yoichi NAKANISHI, . (2008) Phase II study of uracil-tegafur plus cisplatin in patients with previously untreated advanced non-small cell lung cancer. Respirology 13:1, 103-107
CrossRef626
N.H. Hanna. (2008) Paclitaxel–Carboplatin Alone or with Bevacizumab for Non–Small-Cell Lung Cancer. Yearbook of Medicine 2008, 209-211
CrossRef627
Frank C. Detterbeck, Mark A. Socinski, Richard J. Gralla, Martin J. Edelman, Thierry M. Jahan, David M. Loesch, Steven A. Limentani, Ramaswamy Govindan, M B. Zaman, Zhishen Ye, Matthew J. Monberg, Coleman K. Obasaju. (2008) Neoadjuvant Chemotherapy with Gemcitabine-Containing Regimens in Patients with Early-Stage Non-small Cell Lung Cancer. Journal of Thoracic Oncology 3:1, 37-45
CrossRef628
Francesco Di Costanzo, Francesca Mazzoni, Marinella Micol Mela, Lorenzo Antonuzzo, Daniele Checcacci, Matilde Saggese, Federica Di Costanzo. (2008) Bevacizumab in Non-Small Cell Lung Cancer. Drugs 68:6, 737-746
CrossRef629
Katsumi Tanizawa, Yoshiko Kiriyama, Toshikazu Shintani, Kunio Hayase, Ochimi Kato, Hitomi Teramachi, Teruo Tsuchiya, Yoshinori Itoh. (2008) A Retrospective Study on the Use of G-CSF in Paclitaxel plus Carboplatin Combination Chemotherapy for the Treatment of Advanced Lung Cancer. Iryo Yakugaku (Japanese Journal of Pharmaceutical Health Care and Sciences) 34:4, 361-365
CrossRef630
S N Metodieva. (2008) Angiogenesis and Non Small Cell Lung Cancer. Balkan Journal of Medical Genetics 11:2, 3-10
CrossRef631
Young Jin Yuh, Hyo Rak Lee, Sung Rok Kim. (2008) Gemcitabine and Carboplatin Combination Chemotherapy for Elderly Patients with Advanced Non-small Cell Lung Cancer: A Feasibility Study. Cancer Research and Treatment 40:3, 116
CrossRef632
Jiang Zhu, Yongshu Diao, Ming Jiang, Yu Yang. (2008) A pilot study of weekly docetaxel chemotherapy combined with regional hyperthermia for pretreated stage III non-small cell lung cancer. The Chinese-German Journal of Clinical Oncology 7:1, 35-39
CrossRef633
Foluso O Ademuyiwa, Nasser Hanna. (2008) Cetuximab in non-small cell lung cancer. Expert Opinion on Biological Therapy 8:1, 107-113
CrossRef634
Angela M. Davies, Christopher Ruel, Primo N. Lara, Derick H. Lau, Paul H. Gumerlock, Richard Bold, Stephen Shibata, Heinz-Josef Lenz, David P. Schenkein, David R. Gandara. (2008) The Proteasome Inhibitor Bortezomib in Combination with Gemcitabine and Carboplatin in Advanced Non-small Cell Lung Cancer: A California Cancer Consortium Phase I Study. Journal of Thoracic Oncology 3:1, 68-74
CrossRef635
Jonathan K Reynolds, Terri L Levien. (2008) Quality-of-Life Assessment in Phase III Clinical Trials of Gemcitabine in Non-Small-Cell Lung Cancer. Drugs & Aging 25:11, 893-911
CrossRef636
V GEORGOULIAS, N ANDROULAKIS, A KOTSAKIS, D HATZIDAKI, K SYRIGOS, A POLYZOS, A AGELIDOU, I VARTHALITIS, N ZIRAS, M AGELIDOU. (2008) Docetaxel versus docetaxel plus gemcitabine as front-line treatment of patients with advanced non-small cell lung cancer: A randomized, multicenter phase III trial. Lung Cancer 59:1, 57-63
CrossRef637
Anand Rajeswaran, Andreas Trojan, Bernard Burnand, Massimo Giannelli. (2008) Efficacy and side effects of cisplatin- and carboplatin-based doublet chemotherapeutic regimens versus non-platinum-based doublet chemotherapeutic regimens as first line treatment of metastatic non-small cell lung carcinoma: A systematic review of randomized controlled trials. Lung Cancer 59:1, 1-11
CrossRef638
Tiejun Yin, Qingqing Liu, Changyao Hu, Mengtao Liu. (2007) Determination of carboplatin dose by area under the curve in combination chemotherapy for senile non-small cell lung cancer. Journal of Huazhong University of Science and Technology [Medical Sciences] 27:6, 710-712
CrossRef639
Tetsuya Mitsudomi, Yasushi Yatabe. (2007) Mutations of the epidermal growth factor receptor gene and related genes as determinants of epidermal growth factor receptor tyrosine kinase inhibitors sensitivity in lung cancer. Cancer Science 98:12, 1817-1824
CrossRef640
Marcello Tiseo, Andrea Ardizzoni. (2007) Cisplatin or carboplatin in the treatment of non-small cell lung cancer: a comprehensive review. Oncology Reviews 1:3, 162-169
CrossRef641
Hui Li, Hong-Jing Jiang, Ming-Quan Ma, Feng Wei, Xiu-Mei An, Xiu-Bao Ren. (2007) Vaccination with Allogeneic GM-CSF Gene-Modified Lung Cancer Cells: Antitumor Activity Comparing with that Induced by Autologous Vaccine. Cancer Biotherapy & Radiopharmaceuticals 22:6, 790-798
CrossRef642
Keiko Shibuya, Ritsuko Komaki, Tomoaki Shintani, Satoshi Itasaka, Anderson Ryan, Juliane M. Jürgensmeier, Luka Milas, Kian Ang, Roy S. Herbst, Michael S. O'Reilly. (2007) Targeted Therapy Against VEGFR and EGFR With ZD6474 Enhances the Therapeutic Efficacy of Irradiation in an Orthotopic Model of Human Non–Small-Cell Lung Cancer. International Journal of Radiation Oncology*Biology*Physics 69:5, 1534-1543
CrossRef643
Matthias Felber, Jürgen Sonnemann, James F Beck. (2007) Inhibition of novel protein kinase Cɛ augments TRAIL-induced cell death in A549 lung cancer cells. Pathology & Oncology Research 13:4, 295-301
CrossRef644
Yuria Mano, Koji Takahashi, Nobuhisa Ishikawa, Atsushi Takano, Wataru Yasui, Kouki Inai, Hitoshi Nishimura, Eiju Tsuchiya, Yusuke Nakamura, Yataro Daigo. (2007) Fibroblast growth factor receptor 1 oncogene partner as a novel prognostic biomarker and therapeutic target for lung cancer. Cancer Science 98:12, 1902-1913
CrossRef645
Vicki L. Keedy, Alan B. Sandler. (2007) Inhibition of angiogenesis in the treatment of non-small cell lung cancer. Cancer Science 98:12, 1825-1830
CrossRef646
Lynn T. Tanoue, Scott Gettinger. (2007) Treatment of Lung Cancer in Older Patients. Clinics in Chest Medicine 28:4, 735-749
CrossRef647
Emmanuelle Wesarg, Sandra Hoffarth, Rainer Wiewrodt, Monika Kröll, Stefan Biesterfeld, Christoph Huber, Martin Schuler. (2007) Targeting BCL-2 family proteins to overcome drug resistance in non-small cell lung cancer. International Journal of Cancer 121:11, 2387-2394
CrossRef648
F. Hohla, A. V. Schally, C. A. Kanashiro, S. Buchholz, B. Baker, C. Kannadka, A. Moder, E. Aigner, C. Datz, G. Halmos. (2007) Growth inhibition of non-small-cell lung carcinoma by BN/GRP antagonist is linked with suppression of K-Ras, COX-2, and pAkt. Proceedings of the National Academy of Sciences 104:47, 18671-18676
CrossRef649
Reid C. Vegeler, Michele T. Yip-Schneider, Matthew Ralstin, Huangbing Wu, Peter A. Crooks, Sundar Neelakantan, Harikrishna Nakshatri, Christopher J. Sweeney, C. Max Schmidt. (2007) Effect of Celecoxib and Novel Agent LC-1 in a Hamster Model of Lung Cancer. Journal of Surgical Research 143:1, 169-176
CrossRef650
Ferdinand Ploner. (2007) NSCLC: Update der 2nd line Therapie nach ASCO 2007. Wiener Medizinische Wochenschrift 157:21-22, 540-544
CrossRef651
Norbert Hasenöhrl. (2007) Bevacizumab in der First-Line-Therapie des fortgeschrittenen NSCLC. Wiener Medizinische Wochenschrift 157:21-22, 576-578
CrossRef652
John D. Hainsworth, David R. Spigel, Cindy Farley, Dianna L. Shipley, James D. Bearden, Jitendra Gandhi, Gerry Ann Houston, F. Anthony Greco. (2007) Weekly docetaxel versus docetaxel/gemcitabine in the treatment of elderly or poor performance status patients with advanced nonsmall cell lung cancer. Cancer 110:9, 2027-2034
CrossRef653
Jean-Yves Blay, Serge Koscielny, Jean Trédaniel, Bernard Asselain, François Goldwasser, Jean-Louis Misset, Cécile de Labareyre, Charles Hagège, Hervé Bismut, Michel Marty. (2007) Rationale and delineation of a composite index of relative antitumoural efficacy (In-RATE). Critical Reviews in Oncology/Hematology 64:2, 106-114
CrossRef654
Giuseppe Giaccone, Egbert Smit, Suresh Senan, Rick Paul. 2007. Multidisciplinary Team Management of Lung Cancer. .
CrossRef655
Craig P CARDEN, Mark A ROSENTHAL. (2007) Immediate versus delayed chemotherapy in patients with asymptomatic incurable metastatic cancer. Asia-Pacific Journal of Clinical Oncology 0:0, 071011204603001-???
CrossRef656
Sophie Sun, Joan H. Schiller, Monica Spinola, John D. Minna. (2007) New molecularly targeted therapies for lung cancer. Journal of Clinical Investigation 117:10, 2740-2750
CrossRef657
Manrique Alvarez, Eloy Roman, Edgardo S Santos, Luis E Raez. (2007) New targets for non-small-cell lung cancer therapy. Expert Review of Anticancer Therapy 7:10, 1423-1437
CrossRef658
M. Pérol, D. Arpin. (2007) Les inhibiteurs de tyrosine kinase de l’EGFR dans le traitement du CBNPC. Revue des Maladies Respiratoires 24:8, 188-197
CrossRef659
B. Mennecier. (2007) Place actuelle des anti-angiogéniques dans le traitement des cancers bronchiques primitifs. Revue des Maladies Respiratoires 24:8, 198-205
CrossRef660
É. Lemarié. (2007) Cancer bronchique non à petites cellules de stade IV : la première ligne en 2007. Revue des Maladies Respiratoires 24:8, 101-107
CrossRef661
Cesare Gridelli, Antonio Rossi, Paolo Maione, Giuseppe Colantuoni, Filomena Del Gaizo, Carmine Ferrara, Dario Nicolella, Ciro Guerriero. (2007) Erlotinib in non-small-cell lung cancer. Expert Opinion on Pharmacotherapy 8:15, 2579-2592
CrossRef662
Minggui Pan, Monica Santamaria, David B Wollman. (2007) CNS response after erlotinib therapy in a patient with metastatic NSCLC with an EGFR mutation. Nature Clinical Practice Oncology 4:10, 603-607
CrossRef663
Toshiyuki Kozuki, Akiko Hisamoto, Masahiro Tabata, Nagio Takigawa, Katsuyuki Kiura, Yoshihiko Segawa, Masao Nakata, Koichi Mandai, Kenji Eguchi, Hiroshi Ueoka, Mitsune Tanimoto. (2007) Mutation of the epidermal growth factor receptor gene in the development of adenocarcinoma of the lung. Lung Cancer 58:1, 30-35
CrossRef664
Noriko Yanagitani, Satoshi Tsuchiya, Kyoichi Kaira, Noriaki Sunaga, Yukiko Tsuchiya, Koji Sato, Satoru Watanabe, Shiro Nomura, Shuzo Sakai, Ryusei Saito, Masatomo Mori. (2007) Phase I Study of Biweekly Paclitaxel and Carboplatin for Frail Patients With Advanced Non-Small Cell Lung Cancer. American Journal of Clinical Oncology 30:5, 487-491
CrossRef665
D. Moro-Sibilot, E. Pluquet, G. Zalcman, J.-M. Bréchot, P.-J. Souquet, D. Debieuvre, F. Morin, J.-F. Morère. (2007) Quel traitement pour un patient de PS-2/3 ayant un cancer bronchique non à petites cellules (CBNPC). Revue des Maladies Respiratoires 24:8, 120-124
CrossRef666
Kiyotaka Yoh, Kaoru Kubota, Ryutaro Kakinuma, Hironobu Ohmatsu, Koichi Goto, Seiji Niho, Nagahiro Saijo, Yutaka Nishiwaki. (2007) Phase II trial of carboplatin and paclitaxel in non-small cell lung cancer patients previously treated with chemotherapy. Lung Cancer 58:1, 73-79
CrossRef667
Jean-Yves Douillard, Silvy Laporte, Frank Fossella, Vassilis Georgoulias, Jean-Louis Pujol, Kaoru Kubota, Alain Monnier, Shinzoh Kudoh, Jaime Ernesto Rubio, Michel Cucherat. (2007) Comparison of Docetaxel- and Vinca Alkaloid???Based Chemotherapy in the First-line Treatment of Advanced Non-small Cell Lung Cancer: A Meta-analysis of Seven Randomized Clinical Trials. Journal of Thoracic Oncology 2:10, 939-946
CrossRef668
Yoshio Tomizawa, Shin-ichi Ishihara, Hironobu Iijima, Hisao Imai, Koji Sato, Masakiyo Yatomi, Yasuki Iwasaki, Hidenori Yamada, Go Kobayashi, Emi Ishida, Teruki Inoue, Haruka Aoki, Satoru Watanabe, Osamu Kawashima, Masatomo Mori, Ryusei Saito. (2007) A Phase I Dose Escalation Study of Biweekly Gemcitabine and Carboplatin in Completely Resected Stage IB-IIIA Nonsmall Cell Lung Cancer. American Journal of Clinical Oncology 30:5, 498-502
CrossRef669
Daniel B. Costa, Susumu Kobayashi, Daniel G. Tenen, Mark S. Huberman. (2007) Pooled analysis of the prospective trials of gefitinib monotherapy for EGFR-mutant non-small cell lung cancers. Lung Cancer 58:1, 95-103
CrossRef670
Jose R. Pereira, Luis Fein, Auro del Giglio, César R. Blajman, Eduardo Richardet, Gilberto Schwartsmann, Mauro Orlando, Belinda J. Hall, Teena M. West, Maximiliano van Kooten. (2007) Gemcitabine administered as a short infusion versus a fixed dose rate in combination with cisplatin for the treatment of patients with advanced non-small cell lung cancer. Lung Cancer 58:1, 80-87
CrossRef671
Richard Booton, Tim Ward, Linda Ashcroft, Julie Morris, Jim Heighway, Nick Thatcher. (2007) ERCC1 mRNA Expression Is Not Associated with Response and Survival after Platinum-Based Chemotherapy Regimens in Advanced Non-Small Cell Lung Cancer. Journal of Thoracic Oncology 2:10, 902-906
CrossRef672
Tetsuya Oguri, Hiroyuki Achiwa, Hideki Muramatsu, Hiroaki Ozasa, Shigeki Sato, Shigeki Shimizu, Hideko Yamazaki, Tadaaki Eimoto, Ryuzo Ueda. (2007) The absence of human equilibrative nucleoside transporter 1 expression predicts nonresponse to gemcitabine-containing chemotherapy in non-small cell lung cancer. Cancer Letters 256:1, 112-119
CrossRef673
Elisabetta Campagnoli, Isabella Garassino, Armando Santoro, Fabio De Vincenzo, Paolo Andrea Zucali, Giovanni Luca Ceresoli, Fabio Romano Lutman, Marco Alloisio, Hector Josè Soto Parra, Raffaele Cavina. (2007) Phase II trial of alternating intravenous and oral vinorelbine in combination with cisplatin in advanced non-small cell lung cancer. Investigational New Drugs 25:6, 559-564
CrossRef674
Yasushi Ono, Mitsunori Hino, Yuka Ueda, Ryoko Kamizuru, Masatoshi Omata, Takashi Uehara, Yosuke Tanaka, Tomoyuki Soma, Shoji Kudoh. (2007) Phase I study of paclitaxel, carboplatin and UFT in chemo-naive patients with advanced non-small cell lung cancer (NSCLC). Medical Oncology 24:4, 402-406
CrossRef675
H Kimura, M Suminoe, K Kasahara, T Sone, T Araya, S Tamori, F Koizumi, K Nishio, K Miyamoto, M Fujimura, S Nakao. (2007) Evaluation of epidermal growth factor receptor mutation status in serum DNA as a predictor of response to gefitinib (IRESSA). British Journal of Cancer 97:6, 778-784
CrossRef676
G Vlahovic, A M Ponce, Z Rabbani, F K Salahuddin, L Zgonjanin, I Spasojevic, Z Vujaskovic, M W Dewhirst. (2007) Treatment with imatinib improves drug delivery and efficacy in NSCLC xenografts. British Journal of Cancer 97:6, 735-740
CrossRef677
Jong Gwang Kim, Sang Kyun Sohn, Hong Suk Song, Ki-Young Kwon, Young Rok Do, Kyung Hee Lee, Myung Soo Hyun, Hun Mo Ryoo, Sung Hwa Bae, Keon Uk Park, Jin Ho Baek, Won Sik Lee, Joo Seop Chung, Goon Jae Cho, Chang-Hak Sohn, Jung Soon Jang, Ho Young Chung, Wansik Yu. (2007) Multicenter phase II study of weekly paclitaxel plus cisplatin combination chemotherapy in patients with advanced gastric cancer. Cancer Chemotherapy and Pharmacology 60:6, 863-869
CrossRef678
Maria Q. Baggstrom, Thomas E. Stinchcombe, Daniel B. Fried, Charles Poole, Thomas A. Hensing, Mark A. Socinski. (2007) Third-Generation Chemotherapy Agents in the Treatment of Advanced Non-small Cell Lung Cancer: A Meta-Analysis. Journal of Thoracic Oncology 2:9, 845-853
CrossRef679
Koichi Azuma, Yoshihiro Komohara, Tetsuro Sasada, Yasuhiro Terazaki, Jiro Ikeda, Tomoaki Hoshino, Kyogo Itoh, Akira Yamada, Hisamichi Aizawa. (2007) Excision repair cross-complementation group 1 predicts progression-free and overall survival in non-small cell lung cancer patients treated with platinum-based chemotherapy. Cancer Science 98:9, 1336-1343
CrossRef680
Enriqueta Felip, Mariacarmela Santarpia, Rafael Rosell. (2007) Emerging drugs for non-small-cell lung cancer. Expert Opinion on Emerging Drugs 12:3, 449-460
CrossRef681
Victoria A Joshi, Raju Kucherlapati. (2007) Pharmacogenomics of lung cancer: with a view to address EGFR-targeted therapies. Pharmacogenomics 8:9, 1211-1220
CrossRef682
Marco Rosetti, Wainer Zoli, Anna Tesei, Paola Ulivi, Francesco Fabbri, Ivan Vannini, Giovanni Brigliadori, Anna Maria Granato, Dino Amadori, Rosella Silvestrini. (2007) Iressa strengthens the cytotoxic effect of docetaxel in NSCLC models that harbor specific molecular characteristics. Journal of Cellular Physiology 212:3, 710-716
CrossRef683
F. Honecker, I. Thoem, D. Branscheid, T.G. Wendt. (2007) Bronchialkarzinom. Der Onkologe 13:9, 823-830
CrossRef684
Jingwei Jiang, Xiaohua Liang, Xinli Zhou, Ruofan Huang, Zhaohui Chu. (2007) A meta-analysis of randomized controlled trials comparing carboplatin-based to cisplatin-based chemotherapy in advanced non-small cell lung cancer. Lung Cancer 57:3, 348-358
CrossRef685
Tony S.K. Mok, Simon Ho, Gong Chan, Wing-Ming Ho, Herman Wong, Anthony T.C. Chan, Winnie Yeo, Anthony P.C. Yim, Karen Chak, Yolanda Lee, Kwok-Chi Lam. (2007) Sequential Chemotherapy with Combination Irinotecan and Cisplatin Followed by Docetaxel for Treatment-Na??ve Patients with Advanced Non-small Cell Lung Cancer. Journal of Thoracic Oncology 2:9, 838-844
CrossRef686
Thomas E. Stinchcombe, Mark A. Socinski, Christine M. Walko, Bert H. O’Neil, Frances A. Collichio, Anastasia Ivanova, Hua Mu, Michael J. Hawkins, Richard M. Goldberg, Celeste Lindley, E. Claire Dees. (2007) Phase I and pharmacokinetic trial of carboplatin and albumin-bound paclitaxel, ABI-007 (Abraxane®) on three treatment schedules in patients with solid tumors. Cancer Chemotherapy and Pharmacology 60:5, 759-766
CrossRef687
Manabu Soda, Young Lim Choi, Munehiro Enomoto, Shuji Takada, Yoshihiro Yamashita, Shunpei Ishikawa, Shin-ichiro Fujiwara, Hideki Watanabe, Kentaro Kurashina, Hisashi Hatanaka, Masashi Bando, Shoji Ohno, Yuichi Ishikawa, Hiroyuki Aburatani, Toshiro Niki, Yasunori Sohara, Yukihiko Sugiyama, Hiroyuki Mano. (2007) Identification of the transforming EML4–ALK fusion gene in non-small-cell lung cancer. Nature 448:7153, 561-566
CrossRef688
Thomas E Stinchcombe. (2007) Nanoparticle albumin-bound paclitaxel: a novel Cremphor-EL ® -free formulation of paclitaxel. Nanomedicine 2:4, 415-423
CrossRef689
O. S. Zhukova, G. K. Gerasimova, I. Zh. Shubina, M. V. Kiselevskii. (2007) Combined effect of cisplatin and lymphokine-activated killer cells on A549 cells of non-small cell lung cancer. Bulletin of Experimental Biology and Medicine 144:2, 231-234
CrossRef690
Suresh S. Ramalingam. (2007) Targeted therapy for non-small cell lung cancer: beyond EGFR and VEGF. Journal of Thoracic Oncology 2:Supplement 4, S220-S221
CrossRef691
Fumihiro Oshita, Haruhiro Saito, Kouzo Yamada, Kazumasa Noda. (2007) Phase II Study of Paclitaxel and Irinotecan Chemotherapy in Patients With Advanced Nonsmall Cell Lung Cancer. American Journal of Clinical Oncology 30:4, 358-360
CrossRef692
Tony S. Mok. (2007) Salvage therapy for NSCLC. Journal of Thoracic Oncology 2:Supplement 4, S289-290
CrossRef693
Rafael Rosell. (2007) The predictive and prognostic roles of ERCC1 Expression and Akin DNA repair genes in non-small-cell lung cancer. Journal of Thoracic Oncology 2:Supplement 4, S166-S167
CrossRef694
Alexandru Grigorescu, Tudor Ciuleanu, Elena Firoiu, Delia Ruta Muresan, Gabriela Teodorescu, Bruce R. Basson. (2007) A randomized phase II trial of sequential gemcitabine plus vinorelbine followed by gemcitabine plus ifosfamide versus gemcitabine plus cisplatin in the treatment of chemo-naive patients with stages III and IV non-small cell lung cancer (NSCLC). Lung Cancer 57:2, 168-174
CrossRef695
Bilal Piperdi, Yi-He Ling, Roman Perez-Soler. (2007) Schedule-Dependent Interaction between the Proteosome Inhibitor Bortezomib and the EGFR-TK Inhibitor Erlotinib in Human Non-small Cell Lung Cancer Cell Lines. Journal of Thoracic Oncology 2:8, 715-721
CrossRef696
David H. Johnson. (2007) Advances in Management of NSCLC - Advances in Chemotherapy. Journal of Thoracic Oncology 2:Supplement 4, S145-S146
CrossRef697
Timothy R. Wassenaar, Jens C. Eickhoff, Daniel R. Jarzemsky, Stevens S. Smith, Marilyn L. Larson, Joan H. Schiller. (2007) Differences in Primary Care Clinicians?? Approach to Non-small Cell Lung Cancer Patients Compared with Breast Cancer. Journal of Thoracic Oncology 2:8, 722-728
CrossRef698
Bhawna Sirohi, Sue Ashley, Alison Norton, Sanjay Popat, Sarah Hughes, Panagiotous Papadopoulos, Kathryn Priest, Mary OʼBrien. (2007) Early Response to Platinum-Based First-Line Chemotherapy in Non-small Cell Lung Cancer May Predict Survival. Journal of Thoracic Oncology 2:8, 735-740
CrossRef699
N Helbekkmo, S H Sundstrøm, U Aasebø, P Fr Brunsvig, C von Plessen, H H Hjelde, O K Garpestad, A Bailey, R M Bremnes. (2007) Vinorelbine/carboplatin vs gemcitabine/carboplatin in advanced NSCLC shows similar efficacy, but different impact of toxicity. British Journal of Cancer 97:3, 283-289
CrossRef700
Christopher G. Azzoli, Lee M. Krug, Vincent A. Miller, Naiyer A. Rizvi, Mark G. Kris, Megan Dunne, Amy Farmer, Barbara Pizzo, Leslie Tyson, Teresa Seeger, Barbara Coleman, Erin Moore, Lauren Lastinger, Ennapadam Venkatraman, Charles M. Rudin. (2007) A Phase II Tolerability Study of Cisplatin Plus Docetaxel as Adjuvant Chemotherapy for Resected Non-small Cell Lung Cancer. Journal of Thoracic Oncology 2:7, 638-644
CrossRef701
Francesco Grossi, Marianna Aita. (2007) Bevacizumab and non-small-cell lung cancer. Expert Opinion on Biological Therapy 7:7, 1107-1119
CrossRef702
Helen Steed, Michael B Sawyer. (2007) Pharmacology, pharmacokinetics and pharmacogenomics of paclitaxel. Pharmacogenomics 8:7, 803-815
CrossRef703
George R. Simon, Roohi Ismail-Khan, Gerold Bepler. (2007) Nuclear excision repair-based personalized therapy for non-small cell lung cancer: From hypothesis to reality. The International Journal of Biochemistry & Cell Biology 39:7-8, 1318-1328
CrossRef704
C. G. Azzoli, M. G. Kris, D. G. Pfister. (2007) Cisplatin Versus Carboplatin for Patients With Metastatic Non-Small-Cell Lung Cancer--An Old Rivalry Renewed. JNCI Journal of the National Cancer Institute 99:11, 828-829
CrossRef705
A. Ardizzoni, L. Boni, M. Tiseo, F. V. Fossella, J. H. Schiller, M. Paesmans, D. Radosavljevic, A. Paccagnella, P. Zatloukal, P. Mazzanti, D. Bisset, R. Rosell. (2007) Cisplatin- Versus Carboplatin-Based Chemotherapy in First-Line Treatment of Advanced Non-Small-Cell Lung Cancer: An Individual Patient Data Meta-analysis. JNCI Journal of the National Cancer Institute 99:11, 847-857
CrossRef706
Paul J. Hesketh, Rogerio C. Lilenbaum, Kari Chansky, Afshin Dowlati, Patricia Graham, Robert A. Chapman, John J. Crowley, David R. Gandara. (2007) Chemotherapy in Patients ???80 with Advanced Non-small Cell Lung Cancer: Combined Results from SWOG 0027 and LUN 6. Journal of Thoracic Oncology 2:6, 494-498
CrossRef707
Cesare Gridelli, Ciro Gallo, Anna Ceribelli, Vittorio Gebbia, Teresa Gamucci, Fortunato Ciardiello, Francesco Carozza, Adolfo Favaretto, Bruno Daniele, Domenico Galetta, Santi Barbera, Francesco Rosetti, Antonio Rossi, Paolo Maione, Francesco Cognetti, Antonio Testa, Massimo Di Maio, Alessandro Morabito, Francesco Perrone. (2007) Factorial phase III randomised trial of rofecoxib and prolonged constant infusion of gemcitabine in advanced non-small-cell lung cancer: the GEmcitabine-COxib in NSCLC (GECO) study. The Lancet Oncology 8:6, 500-512
CrossRef708
Yuh-Min Chen, Reury-Perng Perng, Jen-Fu Shih, Chun-Ming Tsai, Jacqueline Whang-Peng. (2007) A randomized phase II study of docetaxel or vinorelbine in combination with cisplatin against inoperable, chemo-naïve non-small-cell lung cancer in Taiwan. Lung Cancer 56:3, 363-369
CrossRef709
Luca Toschi, Giovanna Finocchiaro, Giovanni Luca Ceresoli, Paolo Andrea Zucali, Raffaele Cavina, Isabella Garassino, Fabio De Vincenzo, Armando Santoro, Federico Cappuzzo. (2007) Is gemcitabine cost effective in cancer treatment?. Expert Review of Pharmacoeconomics & Outcomes Research 7:3, 239-249
CrossRef710
Giorgio Scagliotti. (2007) Optimizing Chemotherapy for Patients with Advanced Non-small Cell Lung Cancer. Journal of Thoracic Oncology 2:Suppl 2, S86-S91
CrossRef711
Jacek Jassem. (2007) Chemotherapy for advanced NSCLC: any light at the end of the tunnel?. The Lancet Oncology 8:6, 461-463
CrossRef712
Yoshiko Urata, Shunichi Negoro, Miyako Satouchi, Takayasu Kurata, Sho Yoshimura, Temiko Shimada, Yoshiki Takada. (2007) Prolonged survival of a patient with lung cancer after treatment with S-1, a new oral fluoropyrimidine anticancer drug. Medical Oncology 24:1, 103-107
CrossRef713
Da-Tong Chu, Sang-We Kim, Han-Pin Kuo, Rifat Ozacar, Frantisek Salajka, S. Krishnamurthy, Danail Damyanov, Sedat Altug, William H.H. Reece, Li Wang. (2007) Patient attitudes towards chemotherapy as assessed by patient versus physician: A prospective observational study in advanced non-small cell lung cancer. Lung Cancer 56:3, 433-443
CrossRef714
T E Stinchcombe, M A Socinski. (2007) Bevacizumab in the treatment of non-small-cell lung cancer. Oncogene 26:25, 3691-3698
CrossRef715
Linrun Wang, Xiuhua Wu, Mingzhu Huang, Jie Cai, Nong Xu, Jian Liu. (2007) The efficacy and relationship between peak concentration and toxicity profile of fixed-dose-rate gemcitabine plus carboplatin in patients with advanced non-small-cell lung cancer. Cancer Chemotherapy and Pharmacology 60:2, 211-218
CrossRef716
Anthony W. Tolcher, Anthony W. Tolcher. 2007. Other Novel Targeted Therapies in Lung Cancer. , 123-148.
CrossRef717
Emilio Bria, Federica Cuppone, Fabiana Letizia Cecere, Michele Milella, Cecilia Nisticò, Francesco Cognetti, Edmondo Terzoli. (2007) Adjuvant Chemotherapy for Non-small Cell Lung Cancer. Journal of Thoracic Oncology 2:Supplement 1, S7-S11
CrossRef718
James Spicer, Simon Chowdhury, Peter Harper. (2007) Targeting novel and established therapies for non-small cell lung cancer. Cancer Letters 250:1, 9-16
CrossRef719
Thomas A. d'Amato. (2007) Adjuvant Chemotherapy and the Role of Chemotherapy Resistance Testing for Stage I Non–Small Cell Lung Cancer. Thoracic Surgery Clinics 17:2, 287-299
CrossRef720
Lucio Crinò, Jennifer Foglietta, Alketa Hamzaj. (2007) Lung Cancer. Journal of Thoracic Oncology 2:Supplement 1, S24-S26
CrossRef721
Sophie Sun, Joan H. Schiller. (2007) Angiogenesis inhibitors in the treatment of lung cancer. Critical Reviews in Oncology/Hematology 62:2, 93-104
CrossRef722
Maria Anna Bareschino, Floriana Morgillo, Fortunato Ciardiello. (2007) Combination of Standard Chemotherapy and Targeted Agents. Journal of Thoracic Oncology 2:Supplement 1, S19-S23
CrossRef723
Federico Cappuzzo. (2007) Predictive Factors for Response and for Resistance to Tyrosine Kinase Inhibitor Therapy in Lung Cancer. Journal of Thoracic Oncology 2:Supplement 1, S12-S14
CrossRef724
Federico Cappuzzo, Claudio Ligorio, Luca Toschi, Elisa Rossi, Rocco Trisolini, Daniela Paioli, Elisabetta Magrini, Giovanna Finocchiaro, Stefania Bartolini, Alessandra Cancellieri, Fred R. Hirsch, Lucio Crino, Marileila Varella-Garcia. (2007) EGFR and HER2 Gene Copy Number and Response to First-Line Chemotherapy in Patients with Advanced Non-small Cell Lung Cancer (NSCLC). Journal of Thoracic Oncology 2:5, 423-429
CrossRef725
Michael T. Milano, Yuhchyau Chen. 2007. Advances in Chemoradiation Treatment of Locoregionally Advanced Non–Small Cell Lung Cancer. , 175-206.
CrossRef726
Hao-Wei Wang, Chin-Ping Lin, Jen-Hwey Chiu, Kuan-Chih Chow, Kuang-Tai Kuo, Chen-Sung Lin, Liang-Shun Wang. (2007) Reversal of inflammation-associated dihydrodiol dehydrogenases (AKR1C1 and AKR1C2) overexpression and drug resistance in nonsmall cell lung cancer cells by wogonin and chrysin. International Journal of Cancer 120:9, 2019-2027
CrossRef727
Yong Wha Moon, Sung Ho Choi, Yong Tai Kim, Joo Hyuk Sohn, Joon Chang, Se Kyu Kim, Moo Suk Park, Kyung Young Chung, Hyoun Ju Lee, Joo-Hang Kim. (2007) Adenosine triphosphate-based chemotherapy response assay (ATP-CRA)-guided platinum-based 2-drug chemotherapy for unresectable nonsmall-cell lung cancer. Cancer 109:9, 1829-1835
CrossRef728
Enriqueta Felip, Rafael Rosell. (2007) Testing for excision repair cross-complementing 1 in patients with non-small-cell lung cancer for chemotherapy response. Expert Review of Molecular Diagnostics 7:3, 261-268
CrossRef729
Yi-Long Wu, Wen-Zhao Zhong, Long-Yun Li, Xiao-Tong Zhang, Li Zhang, Cai-Cun Zhou, Wei Liu, Bin Jiang, Xin-Lin Mu, Jia-Ying Lin, Qing Zhou, Chong-Rui Xu, Zhen Wang, Guo-Chun Zhang, Tony Mok. (2007) Epidermal Growth Factor Receptor Mutations and Their Correlation with Gefitinib Therapy in Patients with Non-small Cell Lung Cancer: A Meta-Analysis Based on Updated Individual Patient Data from Six Medical Centers in Mainland China. Journal of Thoracic Oncology 2:5, 430-439
CrossRef730
D SCHALLIER, B NEYNS, C FONTAINE, J STEENE, J DEMEY, M MEYSMAN, J DEGREVE. (2007) A novel triplet regimen with paclitaxel, carboplatin and gemcitabine (PACCAGE) as induction chemotherapy for locally advanced unresectable non small cell lung cancer (NSCLC). Lung Cancer 56:2, 247-254
CrossRef731
S A Belinsky, M J Grimes, E Casas, C A Stidley, W A Franklin, T J Bocklage, D H Johnson, J H Schiller. (2007) Predicting gene promoter methylation in non-small-cell lung cancer by evaluating sputum and serum. British Journal of Cancer 96:8, 1278-1283
CrossRef732
Roger B. Cohen, Corey J. Langer, George Rajan Simon, Peter David Eisenberg, John Daniel Hainsworth, Stefan Madajewicz, Thomas Michael Cosgriff, Kristen Pierce, Huiping Xu, Katherine Liau, Diane Healey. (2007) A phase I/randomized phase II, non-comparative, multicenter, open label trial of CP-547,632 in combination with paclitaxel and carboplatin or paclitaxel and carboplatin alone as first-line treatment for advanced non-small cell lung cancer (NSCLC). Cancer Chemotherapy and Pharmacology 60:1, 81-89
CrossRef733
Masahiro Tabata, Toshiyuki Kozuki, Hiroshi Ueoka, Katsuyuki Kiura, Shingo Harita, Atsuhiko Tada, Takuo Shibayama, Nagio Takigawa, Toshiro Yonei, Kenichi Gemba, Yoshihiko Segawa, Daizo Kishino, Shinya Tada, Shunkichi Hiraki, Mitsune Tanimoto, . (2007) A triplet chemotherapy with cisplatin, docetaxel and gemcitabine in patients with advanced non-small-cell lung cancer: a phase I/II study. Cancer Chemotherapy and Pharmacology 60:1, 53-59
CrossRef734
D. Binder, H. Schweisfurth, C. Grah, C. Schäper, B. Temmesfeld-Wollbrück, G. Siebert, N. Suttorp, T. Beinert. (2007) Docetaxel/gemcitabine or cisplatin/gemcitabine followed by docetaxel in the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC): results of a multicentre randomized phase II trial. Cancer Chemotherapy and Pharmacology 60:1, 143-150
CrossRef735
Jhanelle Gray, George Simon, Gerold Bepler. (2007) Molecular predictors of chemotherapy response in non-small-cell lung cancer. Expert Review of Anticancer Therapy 7:4, 545-549
CrossRef736
Shirish M. Gadgeel, John C. Ruckdeschel, Elisabeth I. Heath, Lance K. Heilbrun, Raghu Venkatramanamoorthy, Antoinette Wozniak. (2007) Phase II Study of Gefitinib, an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR-TKI), and Celecoxib, a Cyclooxygenase-2 (COX-2) Inhibitor, in Patients with Platinum Refractory Non-small Cell Lung Cancer (NSCLC). Journal of Thoracic Oncology 2:4, 299-305
CrossRef737
Suresh Ramalingam, Chandra P Belani. (2007) Role of bevacizumab for the treatment of non-small-cell lung cancer. Future Oncology 3:2, 131-139
CrossRef738
Jean-Gabriel Judde, Magali Rebucci, Nicolas Vogt, Patricia de Cremoux, Alain Livartowski, Alain Chapelier, Carine Tran-Perennou, Karine Boye, Rémy Defrance, Marie-France Poupon, Rui-Alberto Bras-Gonçalves. (2007) Gefitinib and chemotherapy combination studies in five novel human non small cell lung cancer xenografts. Evidence linking EGFR signaling to gefitinib antitumor response. International Journal of Cancer 120:7, 1579-1590
CrossRef739
Philip Bonomi. (2007) Paclitaxel poliglumex (PPX, CT-2103): macromolecular medicine for advanced non-small-cell lung cancer. Expert Review of Anticancer Therapy 7:4, 415-422
CrossRef740
David J. Stewart, Gabriela Chiritescu, Simone Dahrouge, Srabani Banerjee, Eva M. Tomiak. (2007) Chemotherapy dose–response relationships in non-small cell lung cancer and implied resistance mechanisms. Cancer Treatment Reviews 33:2, 101-137
CrossRef741
Kyoichi Kaira, Noriaki Sunaga, Noriko Yanagitani, Hisao Imai, Mitsuyoshi Utsugi, Yasuo Shimizu, Hironobu Iijima, Yoshio Tomizawa, Takeshi Hisada, Tamotsu Ishizuka, Ryusei Saito, Masatomo Mori. (2007) A phase I dose-escalation study of S-1 plus carboplatin in patients with advanced non-small-cell lung cancer. Anti-Cancer Drugs 18:4, 471-476
CrossRef742
J Neukirchen, A Meier, A Rohrbeck, G Garcia-Pardillos, U Steidl, R Fenk, R Haas, R Kronenwett, U-P Rohr. (2007) The proteasome inhibitor bortezomib acts differently in combination with p53 gene transfer or cytotoxic chemotherapy on NSCLC cells. Cancer Gene Therapy 14:4, 431-439
CrossRef743
(2007) Bevacizumab for Non–Small-Cell Lung Cancer. New England Journal of Medicine 356:13, 1373-1375
Full Text744
W Jeffrey Petty, Sommer N. Knight, Libyadda Mosley, James Lovato, James Capellari, Robert Tucker, A William Blackstock, Mark Steven Miller, Antonius A. Miller. (2007) A Pharmacogenomic Study of Docetaxel and Gemcitabine for the Initial Treatment of Advanced Non-Small Cell Lung Cancer. Journal of Thoracic Oncology 2:3, 197-202
CrossRef745
Jennifer Spratlin, Michael B. Sawyer. (2007) Pharmacogenetics of paclitaxel metabolism. Critical Reviews in Oncology/Hematology 61:3, 222-229
CrossRef746
Yoshiro Fujiwara, Katsuyuki Kiura, Katsuyuki Hotta, Masahiro Tabata, Nagio Takigawa, Mitsune Tanimoto. (2007) Being overweight influences the development of hepatic dysfunction in Japanese patients with non-small-cell lung cancer undergoing cytotoxic chemotherapy. Lung Cancer 55:3, 343-348
CrossRef747
Swan Swan Leong, Chee Keong Toh, Wan Teck Lim, Xu Lin, Say Beng Tan, Donald Poon, Miah Hiang Tay, Kian Fong Foo, Juliana Ho, Eng Huat Tan. (2007) A Randomized Phase II Trial of Single-Agent Gemcitabine, Vinorelbine, or Docetaxel in Patients with Advanced Non-small Cell Lung Cancer Who Have Poor Performance Status and/or Are Elderly. Journal of Thoracic Oncology 2:3, 230-236
CrossRef748
Mitsuharu Hanada, Toshihiro Noguchi, Takashi Yamaoka. (2007) Amrubicin, a novel 9-aminoanthracycline, enhances the antitumor activity of chemotherapeutic agents against human cancer cells in vitro and in vivo. Cancer Science 98:3, 447-454
CrossRef749
C Dittrich, A S Zandvliet, M Gneist, A D R Huitema, A A J King, J Wanders. (2007) A phase I and pharmacokinetic study of indisulam in combination with carboplatin. British Journal of Cancer 96:4, 559-566
CrossRef750
Zheng, Zhong, Chen, Tingan, Li, Xueli, Haura, Eric, Sharma, Anupama, Bepler, Gerold, . (2007) DNA Synthesis and Repair Genes RRM1 and ERCC1 in Lung Cancer. New England Journal of Medicine 356:8, 800-808
Full Text751
Anna Ceribelli, Maria S. Pino, Alain J. Gelibter, Michele Milella, Fabiana L. Cecere, Mauro Caterino, Francesco Facciolo, Alessandra Mirri, Francesco Cognetti. (2007) Sequential chemotherapy in nonsmall-cell lung cancer. Cancer 109:4, 727-731
CrossRef752
Se Hoon Park, Soo Jin Choi, Sun Young Kyung, Chang Hyeok An, Sang Pyo Lee, Jeong Woong Park, Sung Hwan Jeong, Eun Kyung Cho, Dong Bok Shin, Jae Hoon Lee. (2007) Randomized phase II trial of two different schedules of docetaxel plus cisplatin as first-line therapy in advanced nonsmall cell lung cancer. Cancer 109:4, 732-740
CrossRef753
Toru Itaya, Nobuyuki Yamaoto, Masahiko Ando, Masako Ebisawa, Yukiko Nakamura, Haruyasu Murakami, Gyo Asai, Masahiro Endo, Toshiaki Takahashi. (2007) Influence of histological type, smoking history and chemotherapy on survival after first-line therapy in patients with advanced non-small cell lung cancer. Cancer Science 98:2, 226-230
CrossRef754
Thomas A. d‘Amato, Rodney J. Landreneau, William Ricketts, Weidong Huang, Ricardo Parker, Eugene Mechetner, Ing-Ru Yu, James D. Luketich. (2007) Chemotherapy resistance and oncogene expression in non–small cell lung cancer. The Journal of Thoracic and Cardiovascular Surgery 133:2, 352-363
CrossRef755
Suresh Ramalingam, Chandra P Belani. (2007) Recent advances in targeted therapy for non-small cell lung cancer. Expert Opinion on Therapeutic Targets 11:2, 245-257
CrossRef756
Henry Wang, Janice Ryu, David Gandara, Richard J. Bold, Shiro Urayama, Michael Tanaka, Zelanna Goldberg, David Follette, Samir Narayan, Derick Lau. (2007) A Phase II Study of Paclitaxel, Carboplatin, and Radiation with or without Surgery for Esophageal Cancer. Journal of Thoracic Oncology153-157
CrossRef757
Kyoichi Kaira, Satoshi Tsuchiya, Noriaki Sunaga, Noriko Yanagitani, Satoru Watanabe, Hisao Imai, Takeshi Hisada, Tamotsu Ishizuka, Ryusei Saito, Masatomo Mori. (2007) A Phase I Dose Escalation Study of Weekly Docetaxel and Carboplatin in Elderly Patients With Nonsmall Cell Lung Cancer. American Journal of Clinical Oncology 30:1, 51-56
CrossRef758
Achille Norsa, Vincenzo Martino. (2007) Somatostatin, Retinoids, Melatonin, Vitamin D, Bromocriptine, and Cyclophosphamide in Chemotherapy-Pretreated Patients with Advanced Lung Adenocarcinoma and Low Performance Status. Cancer Biotherapy & Radiopharmaceuticals 22:1, 50-55
CrossRef759
Zhenye Xu. (2007) An optimized 3-step strategy for preventing and treating post-operation relapse and metastasis of malignant tumors with traditional Chinese medicine. Journal of Chinese Integrative Medicine5-10
CrossRef760
Chandra P. Belani, Sherry Marts, Joan Schiller, Mark A. Socinski. (2007) Women and lung cancer: Epidemiology, tumor biology, and emerging trends in clinical research. Lung Cancer 55:1, 15-23
CrossRef761
Ilija Tomic, Marina Petrovic, Goran Plavec, Srbislav Ilic. (2007) Influence of chemiotherapeutic protocol and neuroendocrine differentiation on metastatic non-small cell lung cancer treatment results. Vojnosanitetski pregled 64:9, 591-596
CrossRef762
W. Michael ALBERTS. (2007) Follow up and surveillance of the patient with lung cancer: What do you do after surgery?. Respirology 12:1, 16-21
CrossRef763
N HANNA. (2007) Adding Gemcitabine to Paclitaxel/Carboplatin Combination Increases Survival in Advanced Non–Small-Cell Lung Cancer: Results of a Phase II-III StudyPaccagnella A, Oniga F, Bearz A, et al (Med Oncology Department, Venezia, Italy; Centro Riferimento Oncologico, Aviano, Italy; Azienda Ospedaliera, Padova, Italy; et al) J Clin Oncol 24:681–687, 2006§. Yearbook of Oncology 2007, 201-203
CrossRef764
Aminah Jatoi, Dawn Aranguren. (2007) A Critical Look at the Role of Chemotherapy in Older Patients with Non-small Cell Lung Cancer. Journal of Thoracic Oncology 2:1, 83-90
CrossRef765
2007. L. , 116-124.
CrossRef766
Cai Li, Akihiko Gemma, Yuji Minegishi, Kuniko Matsuda, Yoko Seike, Rintaro Noro, Aki Shionoya, Akiko Kawakami, Naoki Ogawa, Shoji Kudoh. (2007) In vitro Simulation Study of Individualized Chemotherapy in Lung Cancer. Journal of Nippon Medical School 74:3, 217-222
CrossRef767
J Nemunaitis, J Nemunaitis. (2007) A review of vaccine clinical trials for non-small cell lung cancer. Expert Opinion on Biological Therapy 7:1, 89-102
CrossRef768
Bong-Gun Seo, Sung Yong Oh, Dong Mee Lee, Hyun Seung Yoo, Suee Lee, Seong-Geun Kim, Sung-Hyun Kim, Hyuk-Chan Kwon, Hyo-Jin Kim. (2007) A Phase II Study of Paclitaxel and Cisplatin as Salvage Therapy for Patients with Advanced or Metastatic Gastric Cancer. Cancer Research and Treatment 39:1, 6
CrossRef769
Katsuyuki Kiura, Nagio Takigawa, Yoshihiko Segawa, Masahiro Tabata, Takuo Shibayama, Kenichi Gemba, Akihiro Bessho, Nobukazu Fujimoto, Ichiro Takata, Katsuyuki Hotta, Keiichi Fujiwara, Yoshiyuki Tokuda, Shoichi Kuyama, Tetsu Shinkai, Hiroshi Ueoka, Mitsune Tanimoto. (2007) Triple Combination Chemotherapy with Cisplatin, Docetaxel, and Irinotecan for Advanced Non-small Cell Lung Cancer: A Phase I/II Trial. Journal of Thoracic Oncology 2:1, 44-50
CrossRef770
Kazuhisa Takahashi. (2007) Nippon Ronen Igakkai Zasshi. Japanese Journal of Geriatrics 44:2, 158-161
CrossRef771
Peter J. Hoskin. 2007. Dolor oncológico. , 1171-1187.
CrossRef772
Leora Horn, Antonio Visbal, Natasha B Leighl. (2007) Docetaxel in Non-Small Cell Lung Cancer. Drugs & Aging 24:5, 411-428
CrossRef773
Adrian Cassidy, Stephen W. Duffy, Jonathan P. Myles, Triantafillos Liloglou, John K. Field. (2007) Lung cancer risk prediction: A tool for early detection. International Journal of Cancer 120:1, 1-6
CrossRef774
Kimihide Yoshida, Yasushi Yatabe, Ji Young Park, Junichi Shimizu, Yoshitsugu Horio, Keitaro Matsuo, Takayuki Kosaka, Tetsuya Mitsudomi, Toyoaki Hida. (2007) Prospective Validation for Prediction of Gefitinib Sensitivity by Epidermal Growth Factor Receptor Gene Mutation in Patients with Non-Small Cell Lung Cancer. Journal of Thoracic Oncology 2:1, 22-28
CrossRef775
Sandler, Alan, Gray, Robert, Perry, Michael C., Brahmer, Julie, Schiller, Joan H., Dowlati, Afshin, Lilenbaum, Rogerio, Johnson, David H., . (2006) Paclitaxel–Carboplatin Alone or with Bevacizumab for Non–Small-Cell Lung Cancer. New England Journal of Medicine 355:24, 2542-2550
Full Text776
Yoon Kyung Jeon, Sook-Whan Sung, Jin-Haeng Chung, Weon-Seo Park, Jeong-Wook Seo, Chul Woo Kim, Doo Hyun Chung. (2006) Clinicopathologic features and prognostic implications of epidermal growth factor receptor (EGFR) gene copy number and protein expression in non-small cell lung cancer. Lung Cancer 54:3, 387-398
CrossRef777
Hatem A. Azim, Apar Kishor Ganti. (2006) Targeted therapy in advanced non-small cell lung cancer (NSCLC): Where do we stand?. Cancer Treatment Reviews 32:8, 630-636
CrossRef778
H Kimura, Y Fujiwara, T Sone, H Kunitoh, T Tamura, K Kasahara, K Nishio. (2006) EGFR mutation status in tumour-derived DNA from pleural effusion fluid is a practical basis for predicting the response to gefitinib. British Journal of Cancer 95:10, 1390-1395
CrossRef779
Eloá Pereira Brabo, Marcos Eduardo Machado Paschoal, Irene Biasoli, Fernanda Esteves Nogueira, Magda Conceição B. Gomes, Isabelle Pimentel Gomes, Leila Cristina Andrade Martins, Nelson Spector. (2006) Brazilian version of the QLQ-LC13 lung cancer module of the European Organization for Research and Treatment of Cancer: preliminary reliability and validity report. Quality of Life Research 15:9, 1519-1524
CrossRef780
N. Xu, P. Shen, X. C. Zhang, L. F. Yu, H. Y. Bao, G. M. Shi, S. Huang, J. Chen, H. B. Mou, W. J. Fang. (2006) Phase II trial of a 2-h infusion of gemcitabine plus carboplatin as first-line chemotherapy for advanced non-small-cell lung cancer. Cancer Chemotherapy and Pharmacology 59:1, 1-7
CrossRef781
Tefurumi KATO, Kazuto NISHIO. (2006) Clinical aspects of epidermal growth factor receptor inhibitors: Benefit and risk. Respirology 11:6, 693-698
CrossRef782
K. A. CHEONG, K. CHRYSTAL, P. G. HARPER. (2006) The management of PS2 patients with advanced non-small cell lung cancer. International Journal of Clinical Practice 60:11, 1493-1496
CrossRef783
Miranda Payne, Paul Ellis, David Dunlop, Malcolm Ranson, Sarah Danson, Lee Schacter, Denis Talbot. (2006) DHA-Paclitaxel (Taxoprexin) as First-Line Treatment in Patients with Stage IIIB or IV Non-small Cell Lung Cancer: Report of a Phase II Open-Label Multicenter Trial. Journal of Thoracic Oncology 1:9, 984-990
CrossRef784
Takamoto Saijo, Genichiro Ishii, Atsushi Ochiai, Kiyotaka Yoh, Koichi Goto, Kanji Nagai, Harubumi Kato, Yutaka Nishiwaki, Nagahiro Saijo. (2006) Eg5 expression is closely correlated with the response of advanced non-small cell lung cancer to antimitotic agents combined with platinum chemotherapy. Lung Cancer 54:2, 217-225
CrossRef785
J. de Castro Carpeño, C. Belda-Iniesta, J. Feliu Batlle, M. González Barón. (2006) Cáncer de pulmón (II). Tratamiento médico. Medicine - Programa de Formación Médica Continuada Acreditado 9:66, 4265-4269
CrossRef786
Dae Ho Lee, Ji-Youn Han, Sun Young Yu, Hyae Young Kim, Byung-Ho Nam, Eun Kyung Hong, Heung Tae Kim, Jin Soo Lee. (2006) The Role of Gefitinib Treatment for Korean Never-Smokers with Advanced or Metastatic Adenocarcinoma of the Lung: A Prospective Study. Journal of Thoracic Oncology 1:9, 965-971
CrossRef787
Giancarlo A. Pillot, William L. Read, Kristin L. Hennenfent, Sharon Marsh, Feng Gao, Avinash Viswanathan, Kristopher Cummings, Howard L. McLeod, Ramaswamy Govindan. (2006) A Phase II Study of Irinotecan and Carboplatin in Advanced Non-small Cell Lung Cancer with Pharmacogenomic Analysis: Final Report. Journal of Thoracic Oncology 1:9, 972-978
CrossRef788
Osamu Ishimoto, Shunichi Sugawara, Akira Inoue, Takashi Ishida, Mitsuru Munakata, Sadahiro Koinumaru, Yukihiro Hasegawa, Toshiro Suzuki, Hiroshi Miki, Yasuo Saijo, Toshihiro Nukiwa. (2006) Phase II Study of Carboplatin Combined with Biweekly Docetaxel for Advanced Non-small Cell Lung Cancer. Journal of Thoracic Oncology 1:9, 979-983
CrossRef789
Eduard Vrdoljak, Tomislav Omrčen, Žana Saratlija Novaković, Tihana Boraska Jelavić, Tomislav Prskalo, Dario Hrepić, Wolfgang Hamm. (2006) Concomitant chemobrachyradiotherapy with ifosfamide and cisplatin followed by consolidation chemotherapy for women with locally advanced carcinoma of the uterine cervix—Final results of a prospective phase II-study. Gynecologic Oncology 103:2, 494-499
CrossRef790
Mark G. Kris, Giuseppe Giaccone, Angela Davies, Masahiro Fukuoka, David H. Garfield, Jacek Jassem, Elisabeth A. Quoix, Alan B. Sandler, Giorgio V. Scagliotti, Jan P. Van Meerbeeck, Howard West. (2006) Systemic Therapy of Bronchioloalveolar Carcinoma: Results of the First IASLC/ASCO Consensus Conference on Bronchioloalveolar Carcinoma. Journal of Thoracic Oncology 1:Supplement, S32-S36
CrossRef791
Eva Szabo. (2006) Selecting targets for cancer prevention: where do we go from here?. Nature Reviews Cancer 6:11, 867-874
CrossRef792
G. Goss, L. L. Siu, I. Gauthier, E. X. Chen, A. M. Oza, R. Goel, J. Maroun, J. Powers, W. Walsh, M. Maclean, D. W. Drolet, J. Rusk, L. K. Seymour. (2006) A phase I, first in man study of OSI-7836 in patients with advanced refractory solid tumors: IND.147, a study of the Investigational New Drug Program of the National Cancer Institute of Canada Clinical Trials Group. Cancer Chemotherapy and Pharmacology 58:5, 703-710
CrossRef793
Hector Soto Parra, Raffaele Cavina, Fiorenza Latteri, Elisabetta Campagnoli, Emanuela Morenghi, Walter Torri, Giorgio Brambilla, Marco Alloisio, Armando Santoro. (2006) Cisplatin plus gemcitabine on days 1 and 4 every 21 days for solid tumors: Result of a dose-intensity study. Investigational New Drugs 25:1, 57-62
CrossRef794
H Asahina, K Yamazaki, I Kinoshita, N Sukoh, M Harada, H Yokouchi, T Ishida, S Ogura, T Kojima, Y Okamoto, Y Fujita, H Dosaka–akita, H Isobe, M Nishimura. (2006) A phase II trial of gefitinib as first-line therapy for advanced non-small cell lung cancer with epidermal growth factor receptor mutations. British Journal of Cancer 95:8, 998-1004
CrossRef795
C von Plessen, B Bergman, O Andresen, R M Bremnes, S Sundstrom, M Gilleryd, R Stephens, J Vilsvik, U Aasebo, S Sorenson. (2006) Palliative chemotherapy beyond three courses conveys no survival or consistent quality-of-life benefits in advanced non-small-cell lung cancer. British Journal of Cancer 95:8, 966-973
CrossRef796
G Vlahovic, Z N Rabbani, J E Herndon, M W Dewhirst, Z Vujaskovic. (2006) Treatment with Imatinib in NSCLC is associated with decrease of phosphorylated PDGFR-β and VEGF expression, decrease in interstitial fluid pressure and improvement of oxygenation. British Journal of Cancer 95:8, 1013-1019
CrossRef797
J. F. Morère, J. M. Brechot, R. Etessami. (2006) Angiogenesis and antiangiogenic treatment in lung cancer. Targeted Oncology 1:4, 215-219
CrossRef798
Yoshihiko Segawa, Katsuyuki Hotta, Shigeki Umemura, Yoshiro Fujiwara, Tetsu Shinkai, Hiroshi Ueoka, Nagio Takigawa, Masahiro Tabata, Katsuyuki Kiura, Mitsune Tanimoto. (2006) Clinical factors affecting acquired resistance to gefitinib in previously treated Japanese patients with advanced nonsmall cell lung cancer. Cancer 107:8, 1866-1872
CrossRef799
Manuel Cobo Dols, Esther Villar Chamorro, Inmaculada Alés Díaz, Silvia Gil Calle, Julia Alcalde García, Vanesa Gutiérrez Calderón, Francisco Carabantes Ocón, Álvaro Montesa Pino, Juan J. Bretón García, Manuel Benavides Orgaz. (2006) Gemcitabine and vinorelbine followed by weekly docetaxel in patients with advanced non-small-cell lung cancer: a phase II trial of sequential chemotherapy. Clinical and Translational Oncology 8:10, 742-749
CrossRef800
J. R. Kroep, E. F. Smit, G. Giaccone, K. Born, J. H. Beijnen, C. J. Groeningen, W. J. F. Vijgh, P. E. Postmus, H. M. Pinedo, G. J. Peters. (2006) Pharmacology of the paclitaxel–cisplatin, gemcitabine–cisplatin, and paclitaxel–gemcitabine combinations in patients with advanced non-small cell lung cancer. Cancer Chemotherapy and Pharmacology 58:4, 509-516
CrossRef801
Helen J. Ross, Lowell L. Hart, Paul M. Swanson, Mark U. Rarick, Robert A. Figlin, Andrew D. Jacobs, David E. McCune, Arthur H. Rosenberg, Ari D. Baron, Laurie E. Grove, Michael D. Thorn, Dennis M. Miller, Jonathan G. Drachman, Charles M. Rudin. (2006) A randomized, multicenter study to determine the safety and efficacy of the immunoconjugate SGN-15 plus docetaxel for the treatment of non-small cell lung carcinoma. Lung Cancer 54:1, 69-77
CrossRef802
Antonius A. Miller, Doug Case, James N. Atkins, Jeffrey K. Giguere, James D. Bearden. (2006) Phase II Study of Carboplatin, Irinotecan, and Thalidomide in Patients with Advanced Non-small Cell Lung Cancer. Journal of Thoracic Oncology 1:8, 832-836
CrossRef803
Hiroshi Saito, Shinzoh Kudoh, Kazuhiko Nakagawa, Shunichi Negoro, Kaoru Matsui, Hiroshi Semba, Minoru Takada. (2006) Phase II Study of 3-Week Scheduling of Irinotecan in Combination With Cisplatin in Patients With Advanced Nonsmall-Cell Lung Cancer. American Journal of Clinical Oncology 29:5, 503-507
CrossRef804
Kouki Ohtsuka, Hiroaki Ohnishi, Go Furuyashiki, Hiroshi Nogami, Yoshihiko Koshiishi, Akiko Ooide, Satsuki Matsushima, Takashi Watanabe, Tomoyuki Goya. (2006) Clinico-Pathological and Biological Significance of Tyrosine Kinase Domain Gene Mutations and Overexpression of Epidermal Growth Factor Receptor for Lung Adenocarcinoma. Journal of Thoracic Oncology 1:8, 787-795
CrossRef805
(2006) Mycelial Extract of Phellinus linteus Induces Cell Death in A549 Lung Cancer Cells and Elevation of Nitric Oxide in Raw 264.7 Macrophage Cells. Mycobiology 34:3, 143-147
CrossRef806
Cabot, Richard C.Harris, Nancy Lee, Shepard, Jo-Anne O., Rosenberg, Eric S., Cort, Alice M., Ebeling, Sally H.Peters, Christine C., Costenbader, Karen H., Fidias, Panos, Gilman, Matthew D., Qureshi, Anwer, Tambouret, Rosemary H., . (2006) Case 29-2006. New England Journal of Medicine 355:12, 1263-1272
Full Text807
Luis E. Raez, Edgardo S. Santos, Gilberto Lopes, Manuel F. Rosado, Lawrence M. Negret, Caio Rocha-Lima, Kalhed Tolba, Nancy Farfan, Kara Hamilton-Nelson, Orlando Silva, Eloy Roman. (2006) Efficacy and safety of oxaliplatin and docetaxel in patients with locally advanced and metastatic non-small-cell lung cancer (NSCLC). Lung Cancer 53:3, 347-353
CrossRef808
Richard Booten, Tim Ward, Jim Heighway, Linda Ashcroft, Julie Morris, Nicholas Thatcher. (2006) Glutathione-S-Transferase P1 Isoenzyme Polymorphisms, Platinum-Based Chemotherapy, and Non-small Cell Lung Cancer. Journal of Thoracic Oncology 1:7, 679-683
CrossRef809
Gregory A. Masters, Sigui Li, Afshin Dowlati, Stefan Madajewicz, Corey Langer, Joan Schiller, David Johnson. (2006) A Phase II Trial of Carboplatin and Gemcitabine with Exisulind (IND #65,056) in Patients with Advanced Non-small Cell Lung Cancer: An Eastern Cooperative Oncology Group Study (E1501). Journal of Thoracic Oncology 1:7, 673-678
CrossRef810
Pierre-Jean Souquet, Laurence Geriniere. (2006) Docetaxel in non-small cell lung cancer. Therapy 3:5, 579-590
CrossRef811
Luis E Raez, Joseph D Rosenblatt, Eckhard R Podack. (2006) Present and future of lung cancer vaccines. Expert Opinion on Emerging Drugs 11:3, 445-459
CrossRef812
Balaji Agoram, Anne C. Heatherington, Marc R. Gastonguay. (2006) Development and evaluation of a population pharmacokinetic-pharmacodynamic model of darbepoetin alfa in patients with nonmyeloid malignancies undergoing multicycle chemotherapy. The AAPS Journal 8:3, E552-E563
CrossRef813
Masao Ichiki, Masayuki Kawasaki, Koichi Takayama, Kiyoshi Ninomiya, Mutsuo Kuba, Fumiyuki Iwami, Naoki Miyazaki, Kazunori Oishi, Sadanori Takeo, Hisamichi Aizawa, Yoichi Nakanishi. (2006) A multicenter phase II study of carboplatin and paclitaxel with a biweekly schedule in patients with advanced non-small-cell lung cancer: Kyushu thoracic oncology group trial. Cancer Chemotherapy and Pharmacology 58:3, 368-373
CrossRef814
Ramaswamy Govindan, Ronald Natale, James Wade, Roy Herbst, Annetta Krebs, Richard Reiling, Thomas Hensing, Antoinette Wozniak, Chandra P. Belani, Karen Kelly, Judith Ochs. (2006) Efficacy and safety of gefitinib in chemonaive patients with advanced non-small cell lung cancer treated in an Expanded Access Program. Lung Cancer 53:3, 331-337
CrossRef815
Takayasu Kurata, Keitaro Matsuo, Minoru Takada, Masaaki Kawahara, Masahiro Tsuji, Yuka Matsubara, Nagahiro Otani, Shigeki Matsuyama, Kenya Muraishi, Tetsuya Fujita, Masato Ishikawa, Keita Koyano, Isamu Okamoto, Taroh Satoh, Kenji Tamura, Kazuhiko Nakagawa, Masahiro Fukuoka. (2006) Is the Importance of Achieving Stable Disease Different between Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors and Cytotoxic Agents in the Second-Line Setting for Advanced Non-small Cell Lung Cancer?. Journal of Thoracic Oncology 1:7, 684-691
CrossRef816
Javier Castro Carpeño, M. González Barón, J. Aguiar, J. I. Chacón, J. Feliu, M. J. García, C. Madroñal, A. Colmenarejo, J. J. Sánchez, A. Ordóñez, . (2006) Biweekly regimen of cisplatin, gemcitabine and vinorelbine for advanced non-small-cell lung cancer. Cancer Chemotherapy and Pharmacology 58:2, 266-271
CrossRef817
Antonio Rossi, Paolo Maione, Cesare Gridelli. (2006) Cetuximab in advanced non-small cell lung cancer. Critical Reviews in Oncology/Hematology 59:2, 139-149
CrossRef818
Mika A. Sovak, Stuart Lutzker, Ling Zheng, Lisa Guensch, Margaret Joyce, Susan Schwartz, Yujun Wu, Joseph Aisner. (2006) Rational drug sequencing of paclitaxel, gemcitabine and carboplatin in patients with untreated stage IV and select stage IIIB non-small cell lung cancer. Lung Cancer 53:2, 177-181
CrossRef819
Ikuo Sekine, Hiroshi Nokihara, Noboru Yamamoto, Hideo Kunitoh, Yuichiro Ohe, Nagahiro Saijo, Tomohide Tamura. (2006) Common arm analysis: One approach to develop the basis for global standardization in clinical trials of non-small cell lung cancer. Lung Cancer 53:2, 157-164
CrossRef820
Nobuhisa Ishikawa, Yataro Daigo, Atsushi Takano, Masaya Taniwaki, Tatsuya Kato, Sonosuke Tanaka, Wataru Yasui, Yukio Takeshima, Kouki Inai, Hitoshi Nishimura, Eiju Tsuchiya, Nobuoki Kohno, Yusuke Nakamura. (2006) Characterization of SEZ6L2 cell-surface protein as a novel prognostic marker for lung cancer. Cancer Science 97:8, 737-745
CrossRef821
Toshihiko Yokoyama, Masashi Kondo, Yasuhiro Goto, Takayuki Fukui, Hiromu Yoshioka, Kohei Yokoi, Hirotaka Osada, Kazuyoshi Imaizumi, Yoshinori Hasegawa, Kaoru Shimokata, Yoshitaka Sekido. (2006) EGFR point mutation in non-small cell lung cancer is occasionally accompanied by a second mutation or amplification. Cancer Science 97:8, 753-759
CrossRef822
David Planchard, Hugues Bourgeois, Mich??le Adoun, Jean-Fran??ois Paitel, Pierre Blanc, Dominique Genet, Aur??lie Ferru, Jean-Chaude Meurice, C??line Deletage, Jean-Marc Tourani. (2006) Gemcitabine, Ifosfamide, and Cisplatin Combination (GIP) in Treatment of Patients With Locally Advanced or Metastatic Nonsmall Cell Lung Cancer. American Journal of Clinical Oncology 29:4, 345-351
CrossRef823
M. Reck, K.M. Deppermann, U. Gatzemeier, N. Niederle. (2006) Nichtkleinzelliges Lungenkarzinom. Der Onkologe 12:8, 761-768
CrossRef824
Tetsuya Mitsudomi, Takayuki Kosaka, Yasushi Yatabe. (2006) Biological and clinical implications of EGFR mutations in lung cancer. International Journal of Clinical Oncology 11:3, 190-198
CrossRef825
Mario Scartozzi, Vittorio Franciosi, Nicoletta Campanini, Giovanni Benedetti, Fausto Barbieri, Giulio Rossi, Rossana Berardi, Roberta Camisa, Rosa Rita Silva, Alfredo Santinelli, Andrea Ardizzoni, Lucio Crinò, Guido Rindi, Stefano Cascinu. (2006) Mismatch repair system (MMR) status correlates with response and survival in non-small cell lung cancer (NSCLC) patients. Lung Cancer 53:1, 103-109
CrossRef826
Paul J. Hesketh, Kari Chansky, Derick H. M. Lau, James H. Doroshow, Carol M. Moinpour, Robert A. Chapman, J Wendall Goodwin, Howard M. Gross, John J. Crowley, David R. Gandara. (2006) Sequential Vinorelbine and Docetaxel in Advanced Non-small Cell Lung Cancer Patients Age 70 and Older and/or with a Performance Status of 2: A Phase II Trial of the Southwest Oncology Group (S0027). Journal of Thoracic Oncology 1:6, 537-544
CrossRef827
Wolfgang A. Weber, Hinrich Wieder. (2006) Monitoring chemotherapy and radiotherapy of solid tumors. European Journal of Nuclear Medicine and Molecular Imaging 33:S1, 27-37
CrossRef828
Yiwei Chu, Li-Xin Wang, Guojun Yang, Helen J. Ross, Walter J. Urba, Rodney Prell, Karin Jooss, Sidong Xiong, Hong-Ming Hu. (2006) Efficacy of GM-CSF-producing Tumor Vaccine after Docetaxel Chemotherapy in Mice Bearing Established Lewis Lung Carcinoma. Journal of Immunotherapy 29:4, 367-380
CrossRef829
Goulnar Kasymjanova, Harvey Kreisman, José A. Correa, Esther Dajczman, David Small. (2006) Does Granulocyte Colony–Stimulating Factor Affect Survival in Patients with Advanced Non-small Cell Lung Cancer?. Journal of Thoracic Oncology 1:6, 564-570
CrossRef830
Joseph Treat, Philip Bonomi, Michael McCleod, Neal P. Christiansen, David M. Mintzer, Matthew J. Monberg, Zhishen Ye, Ruqin Chen, Coleman K. Obasaju. (2006) Administration of pemetrexed immediately following gemcitabine as front-line therapy in advanced non-small cell lung cancer: A phase II trial. Lung Cancer 53:1, 77-83
CrossRef831
Markus Schwaiger, Christian Peschel. (2006) Biological imaging for selecting and monitoring cancer therapy; a pathway to individualised therapy. European Journal of Nuclear Medicine and Molecular Imaging 33:S1, 1-5
CrossRef832
Atsushi Osoegawa, Ichiro Yoshino, Takuro Kometani, Masafumi Yamaguchi, Toshifumi Kameyama, Tomofumi Yohena, Yoshihiko Maehara. (2006) Overexpression of jun activation domain-binding protein 1 in nonsmall cell lung cancer and its significance in p27 expression and clinical features. Cancer 107:1, 154-161
CrossRef833
F.L. Pimentel, S. Bhalla, L. Laranjeira, M. Guerreiro. (2006) Cost-minimization analysis for Portugal of five doublet chemotherapy regimens from two phase III trials in the treatment of advanced non-small cell lung cancer. Lung Cancer 52:3, 365-371
CrossRef834
Giorgio Scagliotti. (2006) Proteasome inhibitors in lung cancer. Critical Reviews in Oncology/Hematology 58:3, 177-189
CrossRef835
A. Yaren, I. Oztop, A. Kargi, C. Ulukus, A. Onen, A. Sanli, O. Binicier, U. Yilmaz, M. Alakavuklar. (2006) Bax, bcl-2 and c-kit expression in non-small-cell lung cancer and their effects on prognosis. International Journal of Clinical Practice 60:6, 675-682
CrossRef836
Jeffrey A. Jones, Elenir B. C. Avritscher, Catherine D. Cooksley, Marisol Michelet, B. Nebiyou Bekele, Linda S. Elting. (2006) Epidemiology of treatment-associated mucosal injury after treatment with newer regimens for lymphoma, breast, lung, or colorectal cancer. Supportive Care in Cancer 14:6, 505-515
CrossRef837
F. Cappuzzo, S. Novello, F. De Marinis, G. Selvaggi, G.V. Scagliotti, F. Barbieri, M. Maur, M. Papi, E. Pasquini, S. Bartolini, L. Marini, L. Crinò. (2006) A randomized phase II trial evaluating standard (50mg/min) versus low (10mg/min) infusion duration of gemcitabine as first-line treatment in advanced non-small-cell lung cancer patients who are not eligible for platinum-based chemotherapy. Lung Cancer 52:3, 319-325
CrossRef838
Heather A. Wakelee, Wei Wang, Joan H. Schiller, Corey J. Langer, Alan B. Sandler, Chandra P. Belani, David H. Johnson. (2006) Survival Differences by Sex for Patients with Advanced Non-small Cell Lung Cancer on Eastern Cooperative Oncology Group Trial 1594. Journal of Thoracic Oncology 1:5, 441-446
CrossRef839
Ranee Mehra. (2006) The second annual symposium on the future of lung cancer: a translational focus. Expert Opinion on Therapeutic Targets 10:3, 475-480
CrossRef840
Richard Booton, Tim Ward, Jim Heighway, Pat Taylor, Fiona Power, Linda Ashcroft, Julie Morris, Nicholas Thatcher. (2006) Xeroderma pigmentosum group D haplotype predicts for response, survival, and toxicity after platinum-based chemotherapy in advanced nonsmall cell lung cancer. Cancer 106:11, 2421-2427
CrossRef841
Nobuyuki Katakami, Yuichi Takiguchi, Kozo Yoshimori, Hiroshi Isobe, Akihiro Bessho, Akinobu Yoshimura, Hisanobu Niitani. (2006) Docetaxel in Combination with Either Cisplatin or Gemcitabine in Unresectable Non-small Cell Lung Carcinoma: A Randomized Phase II Study by the Japan Lung Cancer Cooperative Clinical Study Group. Journal of Thoracic Oncology 1:5, 447-453
CrossRef842
Vamsidhar Velcheti, Avinash Viswanathan, Ramaswamy Govindan. (2006) The Proportion of Patients with Metastatic Non-small Cell Lung Cancer Potentially Eligible for Treatment with Bevacizumab: A Single Institutional Survey. Journal of Thoracic Oncology 1:5, 501
CrossRef843
R. M. Huber. (2006) Lungenkarzinom. Der Internist 47:6, 611-622
CrossRef844
Nagahiro Saijo. (2006) Recent trends in the treatment of advanced lung cancer. Cancer Science 97:6, 448-452
CrossRef845
Hiroaki Ohnishi, Kouki Ohtsuka, Akiko Ooide, Satsuki Matsushima, Tomoyuki Goya, Takashi Watanabe. (2006) A Simple and Sensitive Method for Detecting Major Mutations Within the Tyrosine Kinase Domain of the Epidermal Growth Factor Receptor Gene in Non???small-cell Lung Carcinoma. Diagnostic Molecular Pathology 15:2, 101-108
CrossRef846
Francesco Grossi, Marcello Tiseo. (2006) Granulocyte growth factors in the treatment of non-small cell lung cancer (NSCLC). Critical Reviews in Oncology/Hematology 58:3, 221-230
CrossRef847
Steven C. Rose, Patricia A. Thistlethwaite, Patrick E. Sewell, Ralph B. Vance. (2006) Lung Cancer and Radiofrequency Ablation. Journal of Vascular and Interventional Radiology 17:6, 927-951
CrossRef848
J Bennouna, J-L Breton, J-M Tourani, C Ottensmeier, M O'Brien, P Kosmidis, T E Huat, M-C Pinel, C Colin, J-Y Douillard. (2006) Vinflunine – an active chemotherapy for treatment of advanced non-small-cell lung cancer previously treated with a platinum-based regimen: results of a phase II study. British Journal of Cancer 94:10, 1383-1388
CrossRef849
Heather A. Wakelee, Patricia Bernardo, David H. Johnson, Joan H. Schiller. (2006) Changes in the natural history of nonsmall cell lung cancer (NSCLC)—Comparison of outcomes and characteristics in patients with advanced NSCLC entered in Eastern Cooperative Oncology Group trials before and after 1990. Cancer 106:10, 2208-2217
CrossRef850
R Suzuki, Y Hasegawa, K Baba, H Saka, H Saito, H Taniguchi, M Yamamoto, S Matsumoto, K Kato, T Oishi, K Imaizumi, K Shimokata. (2006) A phase II study of single-agent gefitinib as first-line therapy in patients with stage IV non-small-cell lung cancer. British Journal of Cancer
CrossRef851
Emilio Esteban, Joaquin Fra, Yolanda Fernández, Norberto Corral, José M. Vieitez, Isabel Palacio, José L. Sande, José L. Fernández, Isabel Muñiz, Noemi Villanueva, Enrique Estrada, Beatriz Mareque, Esther Uña, José M. Buesa, Angel J. Lacave, . (2006) Gemcitabine and vinorelbine (GV) versus cisplatin, gemcitabine and vinorelbine (CGV) as first-line treatment in advanced non small cell lung cancer: Results of a prospective randomized phase II study. Investigational New Drugs 24:3, 241-248
CrossRef852
Estelle Marrer, Florent Baty, Jeanne Kehren, Salah-Dine Chibout, Martin Brutsche. (2006) Past, present and future of gene expression-tailored therapy for lung cancer. Personalized Medicine 3:2, 165-175
CrossRef853
Luis E Raez, Rogerio Lilenbaum. (2006) New developments in chemotherapy for advanced non-small cell lung cancer. Current Opinion in Internal Medicine 5:3, 305-310
CrossRef854
Leticia R Villela, Brad L Stanford, Sachin R Shah. (2006) Pemetrexed, a Novel Antifolate Therapeutic Alternative for Cancer Chemotherapy. Pharmacotherapy 26:5, 641-654
CrossRef855
Sarita Dubey, Jill M Siegfried, Anne M Traynor. (2006) Non-small-cell lung cancer and breast carcinoma: chemotherapy and beyond. The Lancet Oncology 7:5, 416-424
CrossRef856
Aarati Ranganathan, Alfredo Budillon, Primo Lara. (2006) Highlights From: 97th Annual Meeting of the American Association for Cancer Research; Washington, DC, April 2006. Clinical Lung Cancer 7:6, 373-377
CrossRef857
Takao Shirai, Takashi Hirose, Munehide Noda, Kouichi Ando, Hiroo Ishida, Takamichi Hosaka, Tetsuzi Ozawa, Kentarou Okuda, Tsukasa Ohnishi, Tohru Ohmori, Naoya Horichi, Mitsuru Adachi. (2006) Phase II study of the combination of gemcitabine and nedaplatin for advanced non-small-cell lung cancer. Lung Cancer 52:2, 181-187
CrossRef858
Daniel Morgensztern, Ramaswamy Govindan. (2006) Clinical trials of antiangiogenic therapy in non-small cell lung cancer: focus on bevacizumab and ZD6474. Expert Review of Anticancer Therapy 6:4, 545-551
CrossRef859
Zhimin Tong, Xuli Wu, Ching-Shih Chen, James P. Kehrer. (2006) Cytotoxicity of a non-cyclooxygenase-2 inhibitory derivative of celecoxib in non-small-cell lung cancer A549 cells. Lung Cancer 52:1, 117-124
CrossRef860
Dae Ho Lee, Ji-Youn Han, Seong Min Yoon, Jae Jin Lee, Hong Gi Lee, Hyae Young Kim, Sung Jin Yoon, Eun Kyung Hong, Jin Soo Lee. (2006) A Pilot Trial of Gemcitabine and Vinorelbine Plus Capecitabine in Locally Advanced or Metastatic Nonsmall Cell Lung Cancer. American Journal of Clinical Oncology 29:2, 143-147
CrossRef861
Akira Inoue, Kazuhiro Usui, Osamu Ishimoto, Nobuyuki Matsubara, Masashi Tanaka, Mariko Kanbe, Kazunori Gomi, Sadahiro Koinumaru, Yasuo Saijo, Toshihiro Nukiwa. (2006) A phase II study of weekly paclitaxel combined with carboplatin for elderly patients with advanced non-small cell lung cancer. Lung Cancer 52:1, 83-87
CrossRef862
Jee Hyun Kim, Si Young Kim, Kyung Hae Jung, Keunchil Park, Cheol Won Suh, Ho Young Lim, Yeul Hong Kim, Baek Yeol Ryoo, Eun Kyung Cho, Byung Joo Park, Dae Seog Heo. (2006) Randomized phase II study of gemcitabine plus cisplatin versus etoposide plus cisplatin for the treatment of locally advanced or metastatic non-small cell lung cancer: Korean Cancer Study Group experience. Lung Cancer 52:1, 75-81
CrossRef863
Dennis A. Revicki, David Feeny, Timothy L. Hunt, Bernard F. Cole. (2006) Analyzing Oncology Clinical Trial Data Using the Q-TWiST Method: Clinical Importance and Sources for Health State Preference Data*. Quality of Life Research 15:3, 411-423
CrossRef864
Jean-Louis Pujol, Fabrice Barlesi, Jean-Pierre Daurès. (2006) Should chemotherapy combinations for advanced non-small cell lung cancer be platinum-based? A meta-analysis of phase III randomized trials. Lung Cancer 51:3, 335-345
CrossRef865
K. A. Cheong, K. Chrystal, P. G. Harper. (2006) Management of the elderly patient with advanced
non-small cell lung cancer. International Journal of Clinical Practice 60:3, 340-343
CrossRef866
Eric D. Bernstein, Scott M. Herbert, Nasser H. Hanna. (2006) Chemotherapy and Radiotherapy in the Treatment of Resectable Non–Small-Cell Lung Cancer. Annals of Surgical Oncology 13:3, 291-301
CrossRef867
Yuji Bessho, Tetsuya Oguri, Hiroyuki Achiwa, Hideki Muramatsu, Hiroyoshi Maeda, Takashi Niimi, Shigeki Sato, Ryuzo Ueda. (2006) Role of ABCG2 as a biomarker for predicting resistance to CPT-11/SN-38 in lung cancer. Cancer Science 97:3, 192-198
CrossRef868
Jonathan E. Dowell. (2006) Epidermal Growth Factor Receptor Mutations in Non-Small Cell Lung Cancer: A Basic Science Discovery with Immediate Clinical Impact. The American Journal of the Medical Sciences 331:3, 139-149
CrossRef869
Martin Reck. (2006) Beyond the TRIBUTE trial: integrating HER1/EGFR tyrosine kinase inhibitors with chemotherapy in advanced NSCLC. Future Oncology 2:1, 47-51
CrossRef870
Frederick H. Hausheer, Richard L. Schilsky, Stacey Bain, Elmer J. Berghorn, Frank Lieberman. (2006) Diagnosis, Management, and Evaluation of Chemotherapy-Induced Peripheral Neuropathy. Seminars in Oncology 33:1, 15-49
CrossRef871
Rafael Rosell, Fabiana Cecere, Francesco Cognetti, Mauricio Cuello, Jose Miguel Sanchez, Miquel Taron, Noemi Reguart, David Jablons. (2006) Future Directions in the Second-Line Treatment of Non–Small Cell Lung Cancer. Seminars in Oncology 33, 45-51
CrossRef872
Michael Cullen. (2006) Second-Line Treatment Options in Advanced Non–Small Cell Lung Cancer: Current Status. Seminars in Oncology 33, 3-8
CrossRef873
Achille Norsa, Vincenzo Martino. (2006) Somatostatin, Retinoids, Melatonin, Vitamin D, Bromocriptine, and Cyclophosphamide in Advanced Non–Small-Cell Lung Cancer Patients with Low Performance Status. Cancer Biotherapy & Radiopharmaceuticals 21:1, 68-73
CrossRef874
Antonio Saha, Robin Rudd. (2006) Gemcitabine and carboplatin: is this the best combination for non-small cell lung cancer?. Expert Review of Anticancer Therapy 6:2, 165-173
CrossRef875
Thomas E. Stinchcombe, Jaeun Choi, Michael J. Schell, Andrea Mears, Paul E. Jones, Robert V. Nachtsheim, Mark A. Socinski. (2006) Carboplatin-based chemotherapy in patients with advanced non-small cell lung cancer and a poor performance status. Lung Cancer 51:2, 237-243
CrossRef876
Yuh-Min Chen, Reury-Perng Perng, Chun-Ming Tsai, Jacqueline Whang-Peng. (2006) A Phase II Randomized Study of Paclitaxel Plus Carboplatin or Cisplatin against Chemo-Naive Inoperable Non-small Cell Lung Cancer in the Elderly. Journal of Thoracic Oncology 1:2, 141-145
CrossRef877
Manuel Cobo Dols, Silvia Gil Calle, Inmaculada Alés Díaz, Ester Villar Chamorro, Julia Alcaide García, Vanesa Gutiérrez Calderón, Manuel Benavides Orgaz. (2006) Bronchiolitis obliterans organizing pneumonia simulating progression in bronquioloalveolar carcinoma. Clinical and Translational Oncology 8:2, 133-135
CrossRef878
Thomas A. d’Amato, Rodney J. Landreneau, Robert J. McKenna, Ricardo S. Santos, Ricardo J. Parker. (2006) Prevalence of In Vitro Extreme Chemotherapy Resistance in Resected Nonsmall-Cell Lung Cancer. The Annals of Thoracic Surgery 81:2, 440-447
CrossRef879
Atul Kumar, Heather Wakelee. (2006) Second- and third-line treatments in non-small cell lung cancer. Current Treatment Options in Oncology 7:1, 37-49
CrossRef880
Charles Lu, Margaret R. Spitz, Hua Zhao, Qiong Dong, Mylene Truong, Joe Y. Chang, George R. Blumenschein, Waun K. Hong, Xifeng Wu. (2006) Association between glutathione S-transferase π polymorphisms and survival in patients with advanced nonsmall cell lung carcinoma. Cancer 106:2, 441-447
CrossRef881
Sung Woo Yang, Pyoung Rak Choi, Hong Jun You, Jin Gu Kim, Chul Ho Oak, Tae Won Jang, Maan Hong Jung. (2006) Relation between ERCC1 Expression in Sputum and Survival after Cisplatin-Based Chemotherapy in Patients with Non-Small Cell Lung Cancer. Tuberculosis and Respiratory Diseases 60:2, 151
CrossRef882
M. Reck. (2006) Erlotinib beim Bronchialkarzinom. Der Pneumologe 3:1, 53-58
CrossRef883
Satoshi Hirano, Yuichiro Takeda, Shinyu Izumi, Nobuyuki Kobayashi, Koichiro Kudo. (2006) Efficacy of Chemotherapy in Patients With Asymptomatic Brain Metastases From Non-small Cell Lung Cancer. Haigan 46:2, 111-116
CrossRef884
Jong-Hoon Jung, Hak-Ryul Kim, Eun-Jung Kim, Ki-Eun Hwang, So-Young Kim, Jung-Hyun Park, Hwi-Jung Kim, Sei-Hoon Yang, Eun-Taik Jeong. (2006) The Role of Heme Oxygenase-1 in Lung Cancer Cells. Tuberculosis and Respiratory Diseases 60:3, 304
CrossRef885
Gregory A. Masters, Athanassios E. Argiris, Elizabeth A. Hahn, J Thaddeus Beck, P Gregory Rausch, Zhishen Ye, Matthew J. Monberg, Leslie P. Bloss, Rafael E. Curiel, Coleman K. Obasaju. (2006) A Randomized Phase II Trial Using Two Different Treatment Schedules of Gemcitabine and Carboplatin in Patients with Advanced Non???Small-Cell Lung Cancer. Journal of Thoracic Oncology 1:1, 19-24
CrossRef886
Michael Fanucchi, Fadlo R Khuri. (2006) Taxanes in the Treatment of Non-Small Cell Lung Cancer. Treatments in Respiratory Medicine 5:3, 181-191
CrossRef887
ICHIRO KAWASE. (2006) Nihon Naika Gakkai Zasshi 95:3, 529-533
CrossRef888
Mauro Gacci, Riccardo Bartoletti, Tommaso Cai, Stefano Nerozzi, Novello Pinzi, Fabrizio Repetti, Fabrizio Viggiani, Paolo Ghezzi, Gabriella Nesi, Marco Carini. (2006) Intravesical Gemcitabine in BCG-Refractory T1G3 Transitional Cell Carcinoma of the Bladder: A Pilot Study. Urologia Internationalis 76:2, 106-111
CrossRef889
Paolo Andrea Zucali, Hector Jose Soto Parra, Raffaele Cavina, Elisabetta Campagnoli, Fiorenza Latteri, Fabio De Vincenzo, Giovanni Luca Ceresoli, Maria Fazio, Marco Alloisio, Armando Santoro. (2006) Short Schedule of Cisplatin and Vinorelbine: A Dose-Finding Study in Non-Small-Cell Lung Cancer. Oncology 71:3-4, 229-236
CrossRef890
Young-Chul Kim, Kyu-Sik Kim. (2006) Drugs for Lung Cancer Treatment. Tuberculosis and Respiratory Diseases 60:2, 123
CrossRef891
Caicun Zhou, Jian Ni, Yinmin Zhao. (2006) Rapid Detection of Epidermal Growth Factor Receptor Mutations in Non-Small Cell Lung Cancer Using Real-Time Polymerase Chain Reaction with TaqMan-MGB Probes. The Cancer Journal 12:1, 33-39
CrossRef892
Louise Bordeleau. (2006) Pharmacoeconomics of Systemic Therapies for Lung Cancer. Treatments in Respiratory Medicine 5:2, 129-141
CrossRef893
Hoon-Kyo Kim, Jun Suk Kim, Hun Mo Ryoo, Dong Gun Shin, Byoung Young Shim, Kyong Hwa Park, Sung Hwa Bae, Chi Hong Kim. (2006) The Efficacy and Safety of Padexol® (Paclitaxel) and Cisplatin for Treating Advanced Non-small Cell Lung Cancer. Cancer Research and Treatment 38:2, 66
CrossRef894
Michael Bergqvist, Sverre S??renson, Daniel Brattstr??m, Tony Mok, Roger Henriksson. (2006) Role of Non-Taxane-Containing Chemotherapy in Advanced Non-Small Cell Lung Cancer. American Journal of Cancer 5:4, 223-244
CrossRef895
Yoshimasa Tanikawa, Hiroyuki Taniguchi, Osamu Nishiyama, Masahiro Aoyama, Yoshitaka Hibino, Takeshi Mizutani, Yasuhiro Kondoh, Tomoki Kimura, Keisuke Kato, Ryujirou Suzuki. (2006) Evaluation of Efficacy and Safety of Carboplatin+Weekly Paclitaxel+a Selective Cyclooxygenase-2 (COX-2) Inhibitor (Meloxicam) Combination Therapy for Advanced Non-small Cell Lung Cancer. Haigan 46:6, 705-710
CrossRef896
Mohan K Tummala, Martin J Edelman. (2006) Role of Non-Platinum-Based Chemotherapy in Advanced Non-Small Cell Lung Cancer. American Journal of Cancer 5:4, 245-257
CrossRef897
Ji-Youn Han, Dae Ho Lee, Sung Young Lee, Chun Gun Park, Hyae Young Kim, Hong Gi Lee, Jae Jin Lee, Heung Tae Kim, Jin Soo Lee. (2005) Phase II study of weekly irinotecan plus capecitabine for chemotherapy-naive patients with advanced nonsmall cell lung carcinoma. Cancer 104:12, 2759-2765
CrossRef898
Y Takeda, E Tsuduki, S Izumi, M Hojo, M Kamimura, G Naka, K Kobayashi, K Kudo. (2005) A phase I/II trial of irinotecan–cisplatin combined with an anti-late-diarrhoeal programme to evaluate the safety and antitumour response of this combination therapy in patients with advanced non-small-cell lung cancer. British Journal of Cancer 93:12, 1341-1349
CrossRef899
F Cappuzzo, L Toschi, I Domenichini, S Bartolini, G L Ceresoli, E Rossi, V Ludovini, A Cancellieri, E Magrini, L Bemis, W A Franklin, L Crino, P A Bunn, F R Hirsch, M Varella-Garcia. (2005) HER3 genomic gain and sensitivity to gefitinib in advanced non-small-cell lung cancer patients. British Journal of Cancer 93:12, 1334-1340
CrossRef900
Emilio Esteban-Gonzalez, Yolanda Fernández, Noemí Villanueva, Joaquin Fra, Isabel Muñiz, Isabel Palacio, Jose M. Vieitez, Esther Uña, Beatriz Mareque, Angel J. Lacave. (2005) Activity of carboplatin in patients with advanced non-small cell lung cancer pre-treated with a non-platinum combination. Investigational New Drugs 23:6, 597-601
CrossRef901
Rafael Rosella, Manuel Cobo, Dolores Isla, Jose Miguel Sanchez, Miquel Taron, Giuseppe Altavilla, Mariacarmela Santarpia, Teresa Moran, Silvia Catot, Olatz Etxaniza. (2005) Applications of genomics in NSCLC. Lung Cancer 50, S33-S40
CrossRef902
Giovanni Selvaggi, Giorgio V. Scagliotti. (2005) Management of bone metastases in cancer: A review. Critical Reviews in Oncology/Hematology 56:3, 365-378
CrossRef903
Chandra P. Belani. (2005) Optimizing chemotherapy for advanced non-small cell lung cancer: focus on docetaxel. Lung Cancer 50, S3-S8
CrossRef904
Alan B. Sandler. (2005) Targeting Angiogenesis in Lung Cancer. Seminars in Oncology 32, 16-22
CrossRef905
Giorgio Scagliotti. (2005) An evaluation of pemetrexed in second-line treatment of non-small cell lung cancer. Expert Opinion on Pharmacotherapy 6:16, 2855-2866
CrossRef906
Suresh Ramalingam, Chandra P Belani. (2005) Molecularly-targeted therapies for non-small cell lung cancer. Expert Opinion on Pharmacotherapy 6:15, 2667-2679
CrossRef907
Corey J. Langer, Ronald B. Natale. (2005) The Emerging Role of Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitors. Seminars in Oncology 32, 23-29
CrossRef908
Quincy Chu, Mark Vincent, Diane Logan, Jean A. Mackay, William K. Evans. (2005) Taxanes as first-line therapy for advanced non-small cell lung cancer: A systematic review and practice guideline. Lung Cancer 50:3, 355-374
CrossRef909
Athanasios Athanasiadis, George Roussos, Thomas Papakostoulis, Daniela-Carmen Athanasiadou, George P. Stathopoulos. (2005) Paclitaxel and gemcitabine combination in a biweekly schedule in patients with advanced non small-cell lung cancer: a phase i study. Cancer Chemotherapy and Pharmacology 56:6, 653-658
CrossRef910
Yuichiro Ohe. (2005) Chemoradiotherapy for lung cancer. Expert Opinion on Pharmacotherapy 6:16, 2793-2804
CrossRef911
Ralph G. Zinner, Frank V. Fossella, Gregory W. Gladish, Bonnie S. Glisson, George R. Blumenschein, Vassiliki A. Papadimitrakopoulou, Katherine M.W. Pisters, Edward S. Kim, Yun W. Oh, Beverly O. Peeples, Zhishen Ye, Rafael E. Curiel, Coleman K. Obasaju, Waun K. Hong, Roy S. Herbst. (2005) Phase II study of pemetrexed in combination with carboplatin in the first-line treatment of advanced nonsmall cell lung cancer. Cancer 104:11, 2449-2456
CrossRef912
Marissa DANIELS, Genni M NEWNHAM, Gavin M WRIGHT. (2005) From evidence to practice: Audit of adjuvant chemotherapy after complete resection of non-small cell lung cancer in an Australian lung cancer center. Asia-Pacific Journal of Clinical Oncology 1:4, 138-144
CrossRef913
Thomas Lynch, Edward Kim. (2005) Optimizing chemotherapy and targeted agent combinations in NSCLC. Lung Cancer 50, S25-S32
CrossRef914
Massimo Di Maio, Cesare Gridelli, Nicola Normanno, Francesco Perrone, Fortunato Ciardiello. (2005) Trying to compose the puzzle with all the pieces: Epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer. Journal of Cellular Physiology 205:3, 355-363
CrossRef915
Lee M. Krug, Vincent A. Miller, Jyoti Patel, John Crapanzano, Christopher G. Azzoli, Jorge Gomez, Mark G. Kris, Robert T. Heelan, Barbara Pizzo, Leslie Tyson, Christine Sheehan, Jeffrey S. Ross, Ennapadam Venkatraman. (2005) Randomized phase II study of weekly docetaxel plus trastuzumab versus weekly paclitaxel plus trastuzumab in patients with previously untreated advanced nonsmall cell lung carcinoma. Cancer 104:10, 2149-2155
CrossRef916
Benjamin Solomon, Paul A. Bunn. (2005) Gemcitabine plus docetaxel for advanced or metastatic non-small cell lung cancer: Similar survival to cisplatin plus vinorelbine and less toxicity. Cancer Treatment Reviews 31:7, 571-576
CrossRef917
Ray D. Page, Frederick P. Smith, George F. Geils, Charles L. Beall, Moshe Fridman, Barbara J. Allen. (2005) Dose-dense vinorelbine and docetaxel with Filgrastim support in patients with advanced nonsmall cell lung carcinoma. Cancer 104:9, 1956-1961
CrossRef918
Tawee Tanvetyanon. (2005) Consideration before administering cytotoxic chemotherapy to the critically ill*. Critical Care Medicine 33:11, 2689-2691
CrossRef919
Chadrick E. Denlinger, Brian K. Rundall, David R. Jones. (2005) Inhibition of phosphatidylinositol 3-kinase/Akt and histone deacetylase activity induces apoptosis in non–small cell lung cancer in vitro and in vivo. The Journal of Thoracic and Cardiovascular Surgery 130:5, 1422-1429
CrossRef920
Lucie Kutikova, Lee Bowman, Stella Chang, Stacey R. Long, Coleman Obasaju, William H. Crown. (2005) The economic burden of lung cancer and the associated costs of treatment failure in the United States. Lung Cancer 50:2, 143-154
CrossRef921
Antonio Rossi, Paolo Maione, Cesare Gridelli. (2005)
S afety profile of platinum-based chemotherapy in the treatment of advanced non-small cell lung cancer in elderly patients. Expert Opinion on Drug Safety 4:6, 1051-1067
CrossRef922
Chai-Hooi LEOW, Chong-Kin LIAM. (2005) Gemcitabine and carboplatin in the treatment of locally advanced and metastatic non-small cell lung cancer. Respirology 10:5, 629-635
CrossRef923
Takehiko Segawa, Toshiyuki Kamoto, Hidefumi Kinoshita, Yasuharu Kunishima, Koji Yoshimura, Akihiro Ito, Takeshi Takahashi, Shin Higashi, Eijiro Nakamura, Hirofumi Nishiyama, Noriyuki Ito, Shingo Yamamoto, Tomonori Habuchi, Osamu Ogawa. (2005) Monthly paclitaxel and carboplatin with oral estramustine phosphate in patients with hormone-refractory prostate cancer. International Journal of Clinical Oncology 10:5, 333-337
CrossRef924
Rosario García-Campelo, Guillermo Alonso-Curbera, LM Antón Aparicio, Rafael Rosell. (2005) Pharmacogenomics in lung cancer: an analysis of DNA repair gene expression in patients treated with platinum-based chemotherapy. Expert Opinion on Pharmacotherapy 6:12, 2015-2026
CrossRef925
Riccardo Bartoletti, Tommaso Cai, Mauro Gacci, Gianluca Giubilei, Fabrizio Viggiani, Giorgio Santelli, Fabio Repetti, Stefano Nerozzi, Paolo Ghezzi, Michele Sisani. (2005) Intravesical gemcitabine therapy for superficial transitional cell carcinoma: Results of a Phase II prospective multicenter study. Urology 66:4, 726-731
CrossRef926
C.C. Zielinski, T. Beinert, J. Crawford, J.R. Fischer, V. Georgoulias, C. Gridelli, F. Hirsch, J. Jassem, Ch. Herold, P. Kosmidis, M. Krainer, M. Krzakowski, Ch. Manegold, R. Pirker, J.L. Pujol, N. Thatcher, S. Tomek, N. van Zandwijk, S. Zöchbauer-Müller, M. Zwitter. (2005) Consensus on medical treatment of non-small-cell lung cancer—update 2004. Lung Cancer 50:1, 129-137
CrossRef927
Guillermo L??pez-Vivanco, Ainhoa Viteri, Ram??n Barcel??, Alberto Mu??oz, Itziar Rubio, Joan Manel Ma????, Natalia Fuente. (2005) Biweekly Administration of Cisplatin/Gemcitabine in Advanced Nonsmall Cell Lung Cancer. American Journal of Clinical Oncology 28:5, 501-507
CrossRef928
Ewan R Brown, Frances A Shepherd. (2005) Erlotinib in the treatment of non-small cell lung cancer. Expert Review of Anticancer Therapy 5:5, 767-775
CrossRef929
Gang Cheng. (2005) Clinical review of Iressa for the treatment of NSCLC. Chinese Journal of Clinical Oncology 2:5, 829-833
CrossRef930
Chih-Hung Chen, John W. C. Chang, Cheng-Huei Lee, Thomas C. Y. Tsao. (2005) Dose-Finding and Phase 2 Study of Weekly Paclitaxel (Taxol) and Cisplatin Combination in Treating Chinese Patients With Advanced Nonsmall Cell Lung Cancer. American Journal of Clinical Oncology 28:5, 508-512
CrossRef931
M Michael, A Wirth, D L Ball, M MacManus, D Rischin, L Mileshkin, B Solomon, J McKendrick, A D Milner. (2005) A phase I trial of high-dose palliative radiotherapy plus concurrent weekly Vinorelbine and Cisplatin in patients with locally advanced and metastatic NSCLC. British Journal of Cancer 93:6, 652-661
CrossRef932
Kristan D. Rollins, Celeste Lindley. (2005) Pemetrexed: A multitargeted antifolate. Clinical Therapeutics 27:9, 1343-1382
CrossRef933
Tetsuya Oguri, Hiroyuki Achiwa, Yuji Bessho, Hideki Muramatsu, Hiroyoshi Maeda, Takashi Niimi, Shigeki Sato, Ryuzo Ueda. (2005) The role of thymidylate synthase and dihydropyrimidine dehydrogenase in resistance to 5-fluorouracil in human lung cancer cells. Lung Cancer 49:3, 345-351
CrossRef934
Makoto Nishio, Masanori Matsuda, Fumiyoshi Ohyanagi, Yukitohi Sato, Sakae Okumura, Daisuke Tabata, Akinobu Morikawa, Ken Nakagawa, Takeshi Horai. (2005) Antipyrine test predicts pharmacodynamics in docetaxel and cisplatin combination chemotherapy. Lung Cancer 49:2, 245-251
CrossRef935
Luis E Raez, Edgardo S Santos, Raja Mudad, Eckhard R Podack. (2005) Clinical trials targeting lung cancer with active immunotherapy: the scope of vaccines. Expert Review of Anticancer Therapy 5:4, 635-644
CrossRef936
Kerry Cheong, James Spicer, Simon Chowdhury, Peter Harper. (2005) Combination therapy versus single agent chemotherapy in non-small cell lung cancer. Expert Opinion on Pharmacotherapy 6:10, 1693-1700
CrossRef937
Brian J. Byrne, Jennifer Garst. (2005) Epidermal growth factor receptor inhibitors and their role in non-small-cell lung cancer. Current Oncology Reports 7:4, 241-247
CrossRef938
Giuseppe Giaccone. (2005) Targeting HER1/EGFR in cancer therapy: experience with erlotinib. Future Oncology 1:4, 449-460
CrossRef939
Richard F Riedel, Phillip G Febbo. (2005) Epidermal growth factor receptor mutations predict sensitivity to gefitinib in patients with non-small-cell lung cancer. Future Oncology 1:4, 461-466
CrossRef940
George Dranitsaris, William K. Evans, Debbie Milliken, Brent Zanke. (2005) The impact of practice guidelines and funding policies on the use of new drugs in advanced non-small cell lung cancer*. Journal of Evaluation in Clinical Practice 11:4, 350-356
CrossRef941
Kun-Huei Yeh, Shiou-Hwei Yeh, Joeu-Pei Wan, Ying-Chun Shen, Ann-Lii Cheng. (2005) Somatic mutations in epidermal growth factor receptor underlying complete responsiveness to gefitinib in a Taiwanese female patient with metastatic adenocarcinoma of lung. Anti-Cancer Drugs 16:7, 739-742
CrossRef942
Brian K. Rundall, Chadrick E. Denlinger, David R. Jones. (2005) Suberoylanilide hydroxamic acid combined with gemcitabine enhances apoptosis in non–small cell lung cancer. Surgery 138:2, 360-367
CrossRef943
F Cappuzzo, S Novello, F De Marinis, V Franciosi, M Maur, A Ceribelli, V Lorusso, F Barbieri, L Castaldini, E Crucitta, L Marini, S Bartolini, G V Scagliotti, L Crinò. (2005) Phase II study of gemcitabine plus oxaliplatin as first-line chemotherapy for advanced non-small-cell lung cancer. British Journal of Cancer 93:1, 29-34
CrossRef944
Preeta Tyagi, Chandra P. Belani, Vinay K. Jain. (2005) Bexarotene in Combination with Chemotherapy Fails to Prolong Survival in Patients with Advanced Non–Small- Cell Lung Cancer: Results from the SPIRIT I and II Trials. Clinical Lung Cancer 7:1, 17-19
CrossRef945
C. Manegold. (2005) Therapie des nichtkleinzelligen Lungenkarzinoms: Standards und Grenzen. Der Onkologe 11:S01, 3-6
CrossRef946
Vera Hirsh, Jean Latreille, Harvey Kreisman, Pierre Desjardins, Linda Ofiara, Renaud Whittom, Susan Fox, Mark David Palayew, Javier Pintos. (2005) Sequential therapy with Vinorelbine followed by Gemcitabine in patients with metastatic non small cell lung cancer (NSCLC), performance status (PS) 2, or elderly with comorbidities—a multicenter phase II trial. Lung Cancer 49:1, 117-123
CrossRef947
Alan S. Lader, Justin J. Lee, Gregor Cicchetti, David J. Kwiatkowski. (2005) Mechanisms of gelsolin-dependent and -independent EGF-stimulated cell motility in a human lung epithelial cell line. Experimental Cell Research 307:1, 153-163
CrossRef948
K.-M. Deppermann. (2005) Perspektiven der „targeted therapy“. Der Pneumologe 2:4, 268-275
CrossRef949
W. Schütte. (2005) Palliative Chemotherapie des fortgeschrittenen NSCLC. Der Pneumologe 2:4, 260-267
CrossRef950
Stephen G Spiro, Gerard A Silvestri. (2005) The treatment of advanced non-small cell lung cancer. Current Opinion in Pulmonary Medicine 11:4, 287-291
CrossRef951
W. Eberhardt, S. Korfee. (2005) Einsatz von Erlotinib: prognostische und prädiktive Faktoren beim nichtkleinzelligen Lungenkarzinom. Der Onkologe 11:S01, 36-39
CrossRef952
Ze Lu, Trini S.-S. Wientjes, Jessie L.-S. Au. (2005) Nontoxic Suramin Treatments Enhance Docetaxel Activity in Chemotherapy-Pretreated Non-Small Cell Lung Xenograft Tumors. Pharmaceutical Research 22:7, 1069-1078
CrossRef953
Nicholas W Choong, Patrick C Ma, Ravi Salgia. (2005) Therapeutic targeting of receptor tyrosine kinases in lung cancer. Expert Opinion on Therapeutic Targets 9:3, 533-559
CrossRef954
Daniel T. Milton, Vincent A. Miller. (2005) Advances in Cytotoxic Chemotherapy for the Treatment of Metastatic or Recurrent Non-Small Cell Lung Cancer. Seminars in Oncology 32:3, 299-314
CrossRef955
Janessa J. Laskin, Alan B. Sandler, David H. Johnson. (2005) Redefining Bronchioloalveolar Carcinoma. Seminars in Oncology 32:3, 329-335
CrossRef956
S. Novello, A. Kielhorn, G. Stynes, G. Selvaggi, F. De Marinis, A. Maestri, P. Foggi, D. Tilden, M. Tonato, L. Crinò, M. Rinaldi, A.M. Migliorino, G.V. Scagliotti. (2005) Cost-minimisation analysis comparing gemcitabine/cisplatin, paclitaxel/carboplatin and vinorelbine/cisplatin in the treatment of advanced non-small cell lung cancer in Italy. Lung Cancer 48:3, 379-387
CrossRef957
Kenji Tamura, Masahiro Fukuoka. (2005) Gefitinib in non-small cell lung cancer. Expert Opinion on Pharmacotherapy 6:6, 985-993
CrossRef958
Johan Vansteenkiste, Jean-Luc Canon, Henrik Riska, Robert Pirker, Patrick Peterson, William John, Pekka Mali, Michael Lahn. (2005) Randomized phase II evaluation of aprinocarsen in combination with gemcitabine and cisplatin for patients with advanced/metastatic non-small cell lung cancer. Investigational New Drugs 23:3, 263-269
CrossRef959
J V Heymach. (2005) ZD6474 – clinical experience to date. British Journal of Cancer 92, S14-S20
CrossRef960
M Nishio, F Ohyanagi, A Horiike, Y Ishikawa, Y Satoh, S Okumura, K Nakagawa, K Nishio, T Horai. (2005) Gefitinib treatment affects androgen levels in non-small-cell lung cancer patients. British Journal of Cancer 92:10, 1877-1880
CrossRef961
F. Cappuzzo, F. R. Hirsch, E. Rossi, S. Bartolini, G. L. Ceresoli, L. Bemis, J. Haney, S. Witta, K. Danenberg, I. Domenichini, V. Ludovini, E. Magrini, V. Gregorc, C. Doglioni, A. Sidoni, M. Tonato, W. A. Franklin, L. Crino, P. A. Bunn, M. Varella-Garcia. (2005) Epidermal Growth Factor Receptor Gene and Protein and Gefitinib Sensitivity in Non-Small-Cell Lung Cancer. JNCI Journal of the National Cancer Institute 97:9, 643-655
CrossRef962
Sung-Hsin Kuo, Chih-Hsin Yang, Chong-Jen Yu, Chiun Hsu, Ann-Lii Cheng, Pan-Chyr Yang. (2005) Survival of stage IIIB/IV non-small cell lung cancer patients who received chemotherapy but did not participate in clinical trials. Lung Cancer 48:2, 275-280
CrossRef963
F. Lohr, A. Dietz, A. Hoos. (2005) Moderne immuntherapeutische Ansätze für die Behandlung von Lungen- und Kopf-Hals-Tumoren. Der Onkologe 11:5, 554-570
CrossRef964
Ramaswamy Govindan. (2005) Chemotherapy for metastatic NSCLC: current status and future direction. Nature Clinical Practice Oncology 2:5, 238-239
CrossRef965
Peilin Zhang. (2005) Lung cancer drug resistance and DNA damage signaling. Therapy 2:3, 381-386
CrossRef966
Giorgio V. Scagliotti. (2005) Pemetrexed plus carboplatin or oxaliplatin in advanced non-small cell lung cancer. Seminars in Oncology 32, S5-S8
CrossRef967
Kyoichi Kaira, Atsushi Takise, Koichi Minato, Yasuki Iwasaki, Shinichi Ishihara, Yoshikazu Takei, Satoshi Tsuchiya, Ryusei Saito, Koji Sato, Masatomo Mori. (2005) Phase II study of weekly docetaxel and cisplatin in patients with non-small cell lung cancer. Anti-Cancer Drugs 16:4, 455-460
CrossRef968
David S. Ettinger. (2005) Non-Small Cell Lung Cancer Treatment-Related Bone Marrow Toxicities. Seminars in Oncology 32, 81-85
CrossRef969
Corey J. Langer, Jennifer Moughan, Benjamin Movsas, Ritsuko Komaki, David Ettinger, Jean Owen, J. Frank Wilson. (2005) Patterns of care survey (PCS) in lung cancer: how well does current U.S. practice with chemotherapy in the non-metastatic setting follow the literature?. Lung Cancer 48:1, 93-102
CrossRef970
H. Shigematsu, L. Lin, T. Takahashi, M. Nomura, M. Suzuki, I. I. Wistuba, K. M. Fong, H. Lee, S. Toyooka, N. Shimizu, T. Fujisawa, Z. Feng, J. A. Roth, J. Herz, J. D. Minna, A. F. Gazdar. (2005) Clinical and Biological Features Associated With Epidermal Growth Factor Receptor Gene Mutations in Lung Cancers. JNCI Journal of the National Cancer Institute 97:5, 339-346
CrossRef971
Gianmauro Numico, Ornella Garrone, Vincenzo Dongiovanni, Nicola Silvestris, Ida Colantonio, Gianna Di Costanzo, Cristina Granetto, Marcella Occelli, Elena Fea, Abdelamid Heouaine, Milena Gasco, Marco Merlano. (2005) Prospective evaluation of major vascular events in patients with nonsmall cell lung carcinoma treated with cisplatin and gemcitabine. Cancer 103:5, 994-999
CrossRef972
Nikos Androulakis, Vassilis Georgoulias. (2005) NSCLC—platinum or not. Lung Cancer 47:3, 381-383
CrossRef973
Fred R Hirsch, Samir Witta. (2005) Biomarkers for prediction of sensitivity to EGFR inhibitors in non-small cell lung cancer. Current Opinion in Oncology 17:2, 118-122
CrossRef974
Yuh-Min Chen, Reury-Perng Perng, Jen-Fu Shih, Chun-Ming Tsai, Jacqueline Whang-Peng. (2005) A randomized phase II study of vinorelbine plus gemcitabine with/without cisplatin against inoperable non-small-cell lung cancer previously untreated. Lung Cancer 47:3, 373-380
CrossRef975
Fiona H Blackhall, Jaishree Bhosle, Nicholas Thatcher. (2005) Chemotherapy for advanced non-small cell lung cancer patients with performance status 2. Current Opinion in Oncology 17:2, 135-139
CrossRef976
Kobayashi, Susumu, Boggon, Titus J., Dayaram, Tajhal, Jänne, Pasi A., Kocher, Olivier, Meyerson, Matthew, Johnson, Bruce E., Eck, Michael J., Tenen, Daniel G., Halmos, Balázs, . (2005) EGFR Mutation and Resistance of Non–Small-Cell Lung Cancer to Gefitinib. New England Journal of Medicine 352:8, 786-792
Full Text977
David Aguiar, Jos
Aguiar, Uriel Bohn. (2005) Alternating weekly administration of paclitaxel and gemcitabine: a phase II study in patients with advanced non-small-cell lung cancer. Cancer Chemotherapy and Pharmacology 55:2, 152-158
CrossRef978
J. Castro, A. Lorenzo, S. Morales, J. Bel
CrossRef979
L Toschi, G Finocchiaro, S Bartolini, V Gioia, F Cappuzzo. (2005) Role of gemcitabine in cancer therapy. Future Oncology 1:1, 7-17
CrossRef980
Toni Ibrahim, Wainer Zoli, Giovanni Luca Frassineti, Anna Tesei, Ida Colantonio, Manuela Monti, Dino Amadori. (2005) Innovative sequence of docetaxel–gemcitabine based on preclinical data in the treatment of advanced non small cell lung cancer: a phase I study. Lung Cancer 47:2, 261-267
CrossRef981
Diego Dongiovanni, Camilla Fissore, Alfredo Berruti, Lucio Buffoni, Alfredo Addeo, Carla Barone, Maria Antonia Polimeni, Davide Ottaviani, Oscar Bertetto, Vincenzo Dongiovanni. (2005) Sequential chemotherapy of cisplatin and vinorelbine followed by paclitaxel and gemcitabine in advanced non-small-cell lung cancer. Lung Cancer 47:2, 269-275
CrossRef982
J Foeglé, G Hédelin, M P Lebitasy, A Purohit, M Velten, E Quoix. (2005) Non-small-cell lung cancer in a French department, (1982–1997): management and outcome. British Journal of Cancer
CrossRef983
F M Wachters, H J M Groen, B Biesma, F M N H Schramel, P E Postmus, J A Stigt, E F Smit. (2005) A randomised phase II trial of docetaxel vs docetaxel and irinotecan in patients with stage IIIb–IV non-small-cell lung cancer who failed first-line treatment. British Journal of Cancer 92:1, 15-20
CrossRef984
R. Natale. (2005) A ten-year review of progress in the treatment of non-small-cell lung cancer with gemcitabine. Lung Cancer 50, S2-S4
CrossRef985
Peilin Zhang, John Rogers. (2005) Targeted lung cancer therapy: what have we learned from gefitinib?. Therapy 2:1, 1-2
CrossRef986
T. Le Chevalier, G. Scagliotti, R. Natale, S. Danson, R. Rosell, R. Stahel, P. Thomas, R.M. Rudd, J. Vansteenkiste, N. Thatcher, C. Manegold, J.-L. Pujol, N. van Zandwijk, C. Gridelli, J.P. van Meerbeeck, L. Crino, A. Brown, P. FitzGerald, M. Aristides, J.H. Schiller. (2005) Efficacy of gemcitabine plus platinum chemotherapy compared with other platinum containing regimens in advanced non-small-cell lung cancer: a meta-analysis of survival outcomes. Lung Cancer 47:1, 69-80
CrossRef987
Christian Manegold. (2005) Current Advancements in Hard-To-Treat Cancers. American Journal of Cancer 4:2, 105-113
CrossRef988
Michael Boyer. (2005) The Importance of Balancing Toxicity and Efficacy in Chemotherapy. American Journal of Cancer 4:2, 127-136
CrossRef989
Sarah Danson, Fiona Blackhall, Paul Hulse, Malcolm Ranson. (2005) Interstitial Lung Disease in Lung Cancer. Drug Safety 28:2, 103-113
CrossRef990
Tony S.K. Mok, Kwok Chi Lam, Conrad Lee, Li Zhang, Herman Wong, Anthony T.C. Chan, Winnie Yeo, Anthony P.C. Yim, Karen Chak, Benny Zee. (2005) Phase II Randomized Study Comparing the Toxicity Profile of Gemcitabine plus Cisplatin with Gemcitabine plus Oral Etoposide in the Treatment of Advanced Non-Small Cell Lung Cancer. Oncology 68:4-6, 485-492
CrossRef991
Takashi HIROSE, Naoya HORICHI, Tohru OHMORI, Sohjiroh KUSUMOTO, Tomohide SUGIYAMA, Takao SHIRAI, Tetsuji OZAWA, Tsukasa OHNISHI, Mitsuru ADACHI. (2005) Patients Preferences in Chemotherapy for Advanced Non-small-cell Lung Cancer. Internal Medicine 44:2, 107-113
CrossRef992
Robert Pirker, Katrin Wiesenberger, Wilma Minar. (2005) Cancer-Related Anemia. American Journal of Cancer 4:4, 233-245
CrossRef993
Heather Wakelee, Sakkaraiappan Ramalingam, Chandra P Belani. (2005) Docetaxel in advanced non-small cell lung cancer. Expert Review of Anticancer Therapy 5:1, 13-24
CrossRef994
Niels Neymark, Pilar Lianes, Egbert F Smit, Jan P van Meerbeeck. (2005) Economic Evaluation of Three Two-Drug Chemotherapy Regimens in Advanced Non-Small-Cell Lung Cancer. PharmacoEconomics 23:11, 1155-1166
CrossRef995
Sanjay Goel, Kavita Desai, Manuel Macapinlac, Scott Wadler, Gary Goldberg, Abbie Fields, Mark Einstein, Fabio Volterra, Benny Wong, Russell Martin, Sridhar Mani. (2005) A phase I safety and dose escalation trial of docetaxel combined with GEM®231, a second generation antisense oligonucleotide targeting protein kinase A R1α in patients with advanced solid cancers. Investigational New Drugs 24:2, 125
CrossRef996
Marcus A. Neubauer, David H. Garfield, Paul R. Kuerfler, Robert N. Raju, Deborah L. Lindquist, Edward W. Soo, Myrna Khan, Kristi A. Boehm, Lina Asmar. (2005) Results of a phase II multicenter trial of weekly docetaxel and gemcitabine as first-line therapy for patients with advanced non-small cell lung cancer. Lung Cancer 47:1, 121-127
CrossRef997
Nam-Su Lee, Hee-Sook Park, Jong-Ho Won, Dae-Sik Hong, Su-Taek Uh, Sang-Jae Lee, Joo-Hang Kim, Se-Kyu Kim, Myung-Ju Ahn, Jung-Hye Choi, Suk-Chul Yang, Jung-Ae Lee, Keun-Seok Lee, Chang-Yeol Yim, Yong-Chul Lee, Chul-Soo Kim, Moon-Hee Lee, Kab-Do Jung, Hanlim Moon, Yl-Sub Lee. (2005) Randomized, Multi-center Phase II Trial of Docetaxel Plus Cisplatin Versus Etoposide Plus Cisplatin as the First-line Therapy for Patients with Advanced Non-Small Cell Lung Cancer. Cancer Research and Treatment 37:6, 332
CrossRef998
Leanne S. Budde, Nasser H. Hanna. (2005) Antimetabolites in the management of non-small cell lung cancer. Current Treatment Options in Oncology 6:1, 83-93
CrossRef999
M. Noguer Mediavilla, A. Fernández Freire, A. Sabino Álvarez. (2005) Cáncer de pulmón no microcítico. Medicine - Programa de Formación Médica Continuada Acreditado 9:24, 1550-1562
CrossRef1000
Alberto Chiappori, George Simon, Charles Williams, Eric Haura, Caio Rocha-Lima, Henry Wagner, Gerold Bepler, Scott Antonia. (2005) Phase II Study of First-Line Sequential Chemotherapy with Gemcitabine-Carboplatin Followed by Docetaxel in Patients with Advanced Non-Small Cell Lung Cancer. Oncology 68:4-6, 382-390
CrossRef1001
Makoto FURONAKA, Mitsuru MIYAZAKI, Masamistu NAKAJIMA, Shintaro HIRATA, Kazunori FUJITAKA, Keiichi KONDO, Akihito YOKOYAMA, Hiroyuki MAEDA, Nobuoki KOHNO. (2005) Neutropenic Enterocolitis in Lung Cancer: A Report of Two Cases and a Review of the Literature. Internal Medicine 44:5, 467-470
CrossRef1002
Minoru Fukuda, Mikio Oka, Hiroshi Soda, Akitoshi Kinoshita, Masaaki Fukuda, Seiji Nagashima, Mutsuo Kuba, Hiroshi Takatani, Junji Tsurutani, Yoichi Nakamura, Takashi Kasai, Yuichi Inoue, Yoshifumi Soejima, Shigeru Kohno, . (2004) Phase II study of irinotecan combined with carboplatin in previously untreated non-small-cell lung cancer. Cancer Chemotherapy and Pharmacology 54:6, 573-577
CrossRef1003
Aminah Jatoi, James R. Jett, Jeff Sloan, Paul Novotny, Joyce Ford, Uma Prabhakar, Charles L. Loprinzi. (2004) A pilot study on safety and pharmacokinetics of infliximab for the cancer anorexia/weight loss syndrome in non-small-cell lung cancer patients. Supportive Care in Cancer 12:12, 859-863
CrossRef1004
Corey Langer, Rogerio Lilenbaum. (2004) Role of chemotherapy in patients with poor performance status and advanced non-small cell lung cancer. Seminars in Oncology 31, 8-15
CrossRef1005
Chandra P. Belani. (2004) Recent updates in the clinical use of platinum compounds for the treatment of lung, breast, and genitourinary tumors and myeloma. Seminars in Oncology 31, 25-33
CrossRef1006
David P Carbone. (2004) Biomarkers of response to gefitinib in non-small-cell lung cancer. Nature Clinical Practice Oncology 1:2, 66-67
CrossRef1007
Katsuyuki Hotta, Katsuyuki Kiura, Hiroshi Ueoka, Masahiro Tabata, Keiichi Fujiwara, Toshiyuki Kozuki, Toshiaki Okada, Akiko Hisamoto, Mitsune Tanimoto. (2004) Effect of gefitinib (‘Iressa’, ZD1839) on brain metastases in patients with advanced non-small-cell lung cancer. Lung Cancer 46:2, 255-261
CrossRef1008
Chadrick E. Denlinger, Brian K. Rundall, David R. Jones. (2004) Proteasome inhibition sensitizes non–small cell lung cancer to histone deacetylase inhibitor–induced apoptosis through the generation of reactive oxygen species. The Journal of Thoracic and Cardiovascular Surgery 128:5, 740-748
CrossRef1009
Chadrick E. Denlinger, Brian K. Rundall, Michael D. Keller, David R. Jones. (2004) Proteasome Inhibition Sensitizes Non–Small-Cell Lung Cancer to Gemcitabine-Induced Apoptosis. The Annals of Thoracic Surgery 78:4, 1207-1214
CrossRef1010
Vera Hirsh, R. Whittom, P. Desjardins, F. Laberge, J. Latreille, B. Samson, A. Langleben. (2004) Docetaxel and Gemcitabine administered on days 1 and 8 for metastatic non-small cell lung carcinoma (NSCLC): a phase II multicenter trial. Lung Cancer 46:1, 113-118
CrossRef1011
Francesco Grossi, Ornella Belvedere, Gianpiero Fasola, Fabio Barbone, Simona Rizzato, Angela Sibau, Leonardo Recchia, Enrico Vigevani, Tino Ceschia, Angelo Morelli, Alessandra Guglielmi, Fabio Puglisi, Alessandro Follador, Giovanni Talmassons, Alberto F. Sobrero. (2004) Sequential chemotherapy with paclitaxel plus cisplatin, followed by vinorelbine, followed by gemcitabine in advanced non-small cell lung cancer: an Alpe-Adria Thoracic Oncology Multidisciplinary group study (ATOM 001). Lung Cancer 46:1, 99-106
CrossRef1012
(2004) EGFR Mutations and Sensitivity to Gefitinib. New England Journal of Medicine 351:12, 1260-1261
Full Text1013
Steven A. Belinsky. (2004) Gene-promoter hypermethylation as a biomarker in lung cancer. Nature Reviews Cancer 4:9, 707-717
CrossRef1014
Hiroyuki Achiwa, Tetsuya Oguri, Shigeki Sato, Hiroyoshi Maeda, Takashi Niimi, Ryuzo Ueda. (2004) Determinants of sensitivity and resistance to gemcitabine: The roles of human equilibrative nucleoside transporter 1 and deoxycytidine kinase in non-small cell lung cancer. Cancer Science 95:9, 753-757
CrossRef1015
Artyom Sedrakyan, Jan van Der Meulen, Ken O'Byrne, Joseph Prendiville, Jennifer Hill, Tom Treasure. (2004) Postoperative chemotherapy for non–small cell lung cancer: A systematic review and meta-analysis. The Journal of Thoracic and Cardiovascular Surgery 128:3, 414-419
CrossRef1016
P Comella, G Frasci, P Carnicelli, B Massidda, F Buzzi, G Filippelli, L Maiorino, M Guida, N Panza, S Mancarella, R Cioffi. (2004) Gemcitabine with either paclitaxel or vinorelbine vs paclitaxel or gemcitabine alone for elderly or unfit advanced non-small-cell lung cancer patients. British Journal of Cancer 91:3, 489-497
CrossRef1017
Gianfranco Buccheri, Domenico Ferrigno. (2004) Second-line weekly paclitaxel in patients with inoperable non-small cell lung cancer who fail combination chemotherapy with cisplatin. Lung Cancer 45:2, 227-236
CrossRef1018
Robert Pirker. (2004) Therapy of advanced non-small-cell lung cancer (take home message). Lung Cancer 45, S259-S262
CrossRef1019
Sakkaraiappan Ramalingam, Chandra P Belani. (2004) Paclitaxel for non-small cell lung cancer. Expert Opinion on Pharmacotherapy 5:8, 1771-1780
CrossRef1020
Aruna Kommareddy, Margaret A Coplin, Feng Gao, Danelle Behnken, Edie Romvari, William Read, Ramaswamy Govindan. (2004) Single agent gefitinib as first line therapy in patients with advanced non-small cell lung cancer: Washington University Experience. Lung Cancer 45:2, 221-225
CrossRef1021
S. Wong, M. A. Rosenthal, R. deBoer, M. D. Green, R. M. Fox. (2004) Five years managing metastatic non-small cell lung cancer: experience at a teaching hospital. Internal Medicine Journal 34:8, 458-463
CrossRef1022
Branislav Jeremic, Biljana Milicic, Aleksandar Dagovic, Jasna Aleksandrovic, Slobodan Milisavljevic. (2004) Stage III Non–Small-Cell Lung Cancer Treated With High-Dose Hyperfractionated Radiation Therapy and Concurrent Low-Dose Daily Chemotherapy With or Without Weekend Chemotherapy. American Journal of Clinical Oncology 27:4, 350-360
CrossRef1023
A Onn, M Tsuboi, N Thatcher. (2004) Treatment of non-small-cell lung cancer: a perspective on the recent advances and the experience with gefitinib. British Journal of Cancer 91, S11-S17
CrossRef1024
Brian K. Rundall, Chadrick E. Denlinger, David R. Jones. (2004) Combined histone deacetylase and NF-κB inhibition sensitizes non-small cell lung cancer to cell death. Surgery 136:2, 416-425
CrossRef1025
S. Korfee, T. Gauler, R. Hepp, C. Pöttgen, W. Eberhardt. (2004) New targeted treatments in lung cancer — overview of clinical trials. Lung Cancer 45, S199-S208
CrossRef1026
P Camus, S Kudoh, M Ebina. (2004) Interstitial lung disease associated with drug therapy. British Journal of Cancer 91, S18-S23
CrossRef1027
Martin Reck, Ulrich Gatzemeier. (2004) Chemotherapy in stage-IV NSCLC. Lung Cancer 45, S217-S222
CrossRef1028
Floris M Wachters, John W.G van Putten, H.Marike Boezen, Harry J.M Groen. (2004) Phase II study of docetaxel and carboplatin as second-line treatment in NSCLC. Lung Cancer 45:2, 255-262
CrossRef1029
George Farmer. (2004) From the analyst's couch: Targeted lung cancer therapies. Nature Reviews Drug Discovery 3:7, 547-548
CrossRef1030
Jyoti D. Patel, Boris Pasche, Athanassios Argiris. (2004) Targeting non-small cell lung cancer with epidermal growth factor tyrosine kinase inhibitors: where do we stand, where do we go. Critical Reviews in Oncology/Hematology 50:3, 175-186
CrossRef1031
Robert S. Kerbel, Barton A. Kamen. (2004) The anti-angiogenic basis of metronomic chemotherapy. Nature Reviews Cancer 4:6, 423-436
CrossRef1032
Jeong-Seon Ryu, Yun-Chul Hong, Hye-Seung Han, Jong-Eun Lee, Sook Kim, Young-Mee Park, Young-Chul Kim, Tae-Sook Hwang. (2004) Association between polymorphisms of ERCC1 and XPD and survival in non-small-cell lung cancer patients treated with cisplatin combination chemotherapy. Lung Cancer 44:3, 311-316
CrossRef1033
Christian Manegold. (2004) Gemcitabine (Gemzar®) in non-small cell lung cancer. Expert Review of Anticancer Therapy 4:3, 345-360
CrossRef1034
Gina D’Amato, Caio Rocha Lima, J.J Mahany, Carlos Muro-Cacho, Eric B Haura. (2004) Neutropenic enterocolitis (typhilitis) associated with docetaxel therapy in a patient with non-small-cell lung cancer: case report and review of literature. Lung Cancer 44:3, 381-390
CrossRef1035
Masataka Hirabayashi, Kazuo Endoh, Masayoshi Teramachi, Masato Okuda, Kazuyuki Yamaguchi, Kohji Fukuda, Hidetoshi Tokuhisa, Hitoshi Kagioka, Naoharu Nakai, Masaharu Nakade. (2004) Phase II study of carboplatin and weekly paclitaxel combination chemotherapy in advanced non-small cell lung cancer: a Kansai Clinical Oncology Group study. Lung Cancer 44:3, 355-362
CrossRef1036
Lynch, Thomas J., Bell, Daphne W., Sordella, Raffaella, Gurubhagavatula, Sarada, Okimoto, Ross A., Brannigan, Brian W., Harris, Patricia L., Haserlat, Sara M., Supko, Jeffrey G., Haluska, Frank G., Louis, David N., Christiani, David C., Settleman, Jeff, Haber, Daniel A., . (2004) Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to Gefitinib. New England Journal of Medicine 350:21, 2129-2139
Full Text1037
J-L Pujol, O Molinier, W Ebert, J-P Daurès, F Barlesi, G Buccheri, M Paesmans, E Quoix, D Moro-Sibilot, M Szturmowicz, J-M Bréchot, T Muley, J Grenier. (2004) CYFRA 21-1 is a prognostic determinant in non-small-cell lung cancer: results of a meta-analysis in 2063 patients. British Journal of Cancer
CrossRef1038
David J Stewart, Eva Tomiak, Farid M Shamji, Donna E Maziak, Peter MacLeod. (2004) Phase II study of alternating chemotherapy regimens for advanced non-small cell lung cancer. Lung Cancer 44:2, 241-249
CrossRef1039
Pasi A. Jänne, Sarada Gurubhagavatula, Beow Y. Yeap, Joan Lucca, Patricia Ostler, Arthur T. Skarin, Panos Fidias, Thomas J. Lynch, Bruce E. Johnson. (2004) Outcomes of patients with advanced non-small cell lung cancer treated with gefitinib (ZD1839, ‘Iressa’) on an expanded access study. Lung Cancer 44:2, 221-230
CrossRef1040
Giovanni Luca Ceresoli, Vanesa Gregorc, Stefano Cordio, Katia Bruna Bencardino, Stefano Schipani, Cesare Cozzarini, Roberto Bordonaro, Eugenio Villa. (2004) Phase II study of weekly paclitaxel as second-line therapy in patients with advanced non-small cell lung cancer. Lung Cancer 44:2, 231-239
CrossRef1041
Sarah Danson. (2004) Paclitaxel plus cisplatin is as effective as regimens containing gemcitabine in people with advanced non-small cell lung cancer. Cancer Treatment Reviews 30:3, 309-314
CrossRef1042
Keith T. Flaherty, James P. Stevenson, Maryann Redlinger, Kenneth M. Algazy, Bruce Giantonio, Peter J. O’Dwyer. (2004) A phase I, dose escalation trial of ZD0473, a novel platinum analogue, in combination with gemcitabine. Cancer Chemotherapy and Pharmacology 53:5, 404-408
CrossRef1043
Tracy E. Kim, John R. Murren. (2004) Therapy for Stage IIIA, IIIB and IV Non???Small Cell Lung Cancer. Clinical Pulmonary Medicine 11:3, 161-174
CrossRef1044
Kato, Harubumi, Ichinose, Yukito, Ohta, Morio, Hata, Enjo, Tsubota, Noriaki, Tada, Hirohito, Watanabe, Yoh, Wada, Hiromi, Tsuboi, Masahiro, Hamajima, Nobuyuki, Ohta, Mitsuo, . (2004) A Randomized Trial of Adjuvant Chemotherapy with Uracil–Tegafur for Adenocarcinoma of the Lung. New England Journal of Medicine 350:17, 1713-1721
Full Text1045
T Kurata, K Tamura, N Yamamoto, T Nogami, T Satoh, H Kaneda, K Nakagawa, M Fukuoka. (2004) Combination phase I study of nedaplatin and gemcitabine for advanced non-small-cell lung cancer. British Journal of Cancer
CrossRef1046
Shoichi Mori, Genshi Ito, Noriyasu Usami, Hiromu Yoshioka, Yuichi Ueda, Yoshinori Kodama, Masahide Takahashi, Kwun M. Fong, Kaoru Shimokata, Yoshitaka Sekido. (2004) p53 apoptotic pathway molecules are frequently and simultaneously altered in nonsmall cell lung carcinoma. Cancer 100:8, 1673-1682
CrossRef1047
Chadrick E Denlinger, Michael D Keller, Marty W Mayo, R.Michael Broad, David R Jones. (2004) Combined proteasome and histone deacetylase inhibition in non–small cell lung cancer. The Journal of Thoracic and Cardiovascular Surgery 127:4, 1078-1086
CrossRef1048
Wade Smith, Fadlo R Khuri. (2004) The care of the lung cancer patient in the 21st century: A new age. Seminars in Oncology 31, 11-15
CrossRef1049
M. Ranson, S. Wardell. (2004) Gefitinib, a novel, orally administered agent for the treatment of cancer. Journal of Clinical Pharmacy and Therapeutics 29:2, 95-103
CrossRef1050
B JEREMIC, M MACHTAY. (2004) Concurrent radiochemotherapy in the treatment of locally advanced non–small cell lung cancer. Hematology/Oncology Clinics of North America 18:1, 91-100
CrossRef1051
B MOVSAS, C SCOTT. (2004) Quality-of-life trials in lung cancer: past achievements and future challenges. Hematology/Oncology Clinics of North America 18:1, 161-186
CrossRef1052
S RAMALINGAM, C BELANI. (2004) Basic treatment considerations: chemotherapy. Hematology/Oncology Clinics of North America 18:1, 13-28
CrossRef1053
Rafael Rosell, Miquel Taron, Aurelio Ariza, Agusti Barnadas, Jose Luis Mate, Noemı́ Reguart, Mireia Margelı́, Enriqueta Felip, Pedro Méndez, Rosario Garcı́a-Campelo. (2004) Molecular predictors of response to chemotherapy in lung cancer. Seminars in Oncology 31, 20-27
CrossRef1054
Edward S Kim, Everett E Vokes, Merrill S Kies. (2004) Cetuximab in cancers of the lung and head & neck. Seminars in Oncology 31, 61-67
CrossRef1055
S DUBEY, J SCHILLER. (2004) Chemotherapy for advanced non–small cell lung cancer. Hematology/Oncology Clinics of North America 18:1, 101-114
CrossRef1056
Fabrice Barlesi, Patrick Villani, Christophe Doddoli, Celine Gimenez, Jean-Pierre Kleisbauer. (2004) Gemcitabine-induced severe pulmonary toxicity. Fundamental and Clinical Pharmacology 18:1, 85-91
CrossRef1057
W LESLIE, P BONOMI. (2004) Novel treatments in non–small cell lung cancer. Hematology/Oncology Clinics of North America 18:1, 245-267
CrossRef1058
F MACBETH, R STEPHENS. (2004) Palliative treatment for advanced non–small cell lung cancer. Hematology/Oncology Clinics of North America 18:1, 115-130
CrossRef1059
Hugues Bourgeois, Isabelle Billiart, Virginie Chabrun, St??phanie Chieze, David Lemerre, Thierry Germain, V??ronique Ferrand, Jean-Claude Meurice, Alain Daban, Jean-Marc Tourani. (2004) Phase I Study With Dose Escalation of Gemcitabine and Cisplatin in Combination With Ifosfamide (GIP) in Patients With Non???Small-Cell Lung Carcinoma. American Journal of Clinical Oncology 27:1, 89-95
CrossRef1060
Sakkaraiappan Ramalingam, Chandra P Belani. (2004) State-of-the-art chemotherapy for advanced non-small cell lung cancer. Seminars in Oncology 31, 68-74
CrossRef1061
Wood, Alastair J.J., , Spira, Alexander, Ettinger, David S., . (2004) Multidisciplinary Management of Lung Cancer. New England Journal of Medicine 350:4, 379-392
Full Text1062
Joan Schiller, Dominic Tilden, Michael Aristides, Michael Lees, Adrian Kielhorn, Nikos Maniadakis, Shkun Bhalla. (2004) Retrospective cost analysis of gemcitabine in combination with cisplatin in non-small cell lung cancer compared to other combination therapies in Europe. Lung Cancer 43:1, 101-112
CrossRef1063
Beverley Forsythe, Karen Faulkner. (2004) Overview of the Tolerability of Gefitinib (IRESSA???) Monotherapy. Drug Safety 27:14, 1081-1092
CrossRef1064
Pierre Fournel. (2004) Actualit??s sur la Gemcitabine (Gemzar??) dans le Cancer Bronchique non ?? Petites Cellules. American Journal of Cancer 3:Special Issue 1, 9-12
CrossRef1065
Mitchell Machtay, Jason H Lee, James P Stevenson, Joseph B Shrager, Kenneth M Algazy, Joseph Treat, Larry R Kaiser. (2004) Two commonly used neoadjuvant chemoradiotherapy regimens for locally advanced stage III non–small cell lung carcinoma: long-term results and associations with pathologic response. The Journal of Thoracic and Cardiovascular Surgery 127:1, 108-113
CrossRef1066
Adriano Paccagnella, A. Favaretto, F. Oniga, F. Barbieri, G. Ceresoli, W. Torri, E. Villa, C. Verusio, G.L. Cetto, A. Santo, V. De Pangher, F. Artioli, G.C. Cacciani, G. Parodi, F. Soresi, M.G. Ghi, A. Morabito, R. Biason, M. Giusto, P. Mosconi, V. Chiarion Sileni. (2004) Cisplatin versus carboplatin in combination with mitomycin and vinblastine in advanced non small cell lung cancer. A multicenter, randomized phase III trial. Lung Cancer 43:1, 83-91
CrossRef1067
Jong-Sung Park, Chang-Min Lee, Shin-Ae Lee, Chang-kil Jung, Sung-Hyun Kim, Hyuk-Chan Kwon, Jae-Seok Kim, Hyo-Jin Kim. (2004) A 21-day Schedule of Gemcitabine and Cisplatin Administration in the Treatment of Advanced Non-Small Cell Lung Carcinoma: a Phase II Study. Cancer Research and Treatment 36:1, 62
CrossRef1068
Thomas Delea, Corey Langer, James McKiernan, Martin Liss, John Edelsberg, Jane Brandman, Jennifer Sung, Monika Raut, Gerry Oster. (2004) The Cost of Treatment of Skeletal-Related Events in Patients with Bone Metastases from Lung Cancer. Oncology 67:5-6, 390-396
CrossRef1069
Nobuyuki Katakami, Takahiko Sugiura, Toshiji Nogami, Hidehiko Yamamoto, Shunichi Negoro, Takashi Nakano, Naoki Okamoto, Yoshiki Takada, Keiji Kodama, Yutaka Ariyoshi. (2004) Combination chemotherapy of gemcitabine and vinorelbine for patients in stage IIIB–IV non-small cell lung cancer: a phase II study of the West Japan Thoracic Oncology Group (WJTOG) 9908. Lung Cancer 43:1, 93-100
CrossRef1070
Paul M Harari, Mark A Ritter, Daniel G Petereit, Minesh P Mehta. (2004) Chemoradiation for upper aerodigestive tract cancer: balancing evidence from clinical trials with individual patient recommendations. Current Problems in Cancer 28:1, 7-40
CrossRef1071
Jean-Louis Pujol. (2004) Introduction. American Journal of Cancer 3:Special Issue 1, 1-4
CrossRef1072
Hitoshi Ueda, Takashi Sakada, Motohisa Kuwahara, Akira Motohiro. (2004) A small randomized phase III single-center trial on postoperative UFT administration in patients with completely resected non-small cell lung cancer. Anti-Cancer Drugs 15:1, 29-33
CrossRef1073
Jean-Philippe Spano, David Khayat. (2004) Changes in the therapeutic strategies of metastatic non-small cell lung cancer. American Journal of Cancer 3:Supplement 2, 9-10
CrossRef1074
Nam-Su Lee, Jae-Ho Byun, Sang-Byung Bae, Chan-Kyu Kim, Kyu-Taeg Lee, Sung-Kyu Park, Jong-Ho Won, Dae-Sik Hong, Hee-Sook Park. (2004) Combination of Gemcitabine and Cisplatin as First-Line Therapy in Advanced Non-Small-Cell Lung Cancer. Cancer Research and Treatment 36:3, 173
CrossRef1075
Jean-Louis Pujol. (2004) Foreword. American Journal of Cancer 3:Special Issue 1, 5-8
CrossRef1076
N van Zandwijk. (2003) Tolerability of gefitinib in patients receiving treatment in everyday clinical practice. British Journal of Cancer 89, S9-S14
CrossRef1077
Dong Wook Kim, Hak Choy. (2003) Combined modality therapy for non-small cell lung cancer, past, present, and future. Lung Cancer 42, S35-S40
CrossRef1078
Melodie Thomas. (2003) Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors. Cancer Nursing 26:Supplement 6S, 21S???25S
CrossRef1079
Francisco Robert, Elizabeth Busby, Marisa B Marques, Robert E Reynolds, Delicia E Carey. (2003) Phase II study of docetaxel plus enoxaparin in chemotherapy-naive patients with metastatic non-small cell lung cancer: preliminary results. Lung Cancer 42:2, 237-245
CrossRef1080
Hiroyuki Achiwa, Shigeki Sato, Shigeki Shimizu, Hiroyoshi Maeda, Takashi Niimi, Takashi Takahashi, Ryuzo Ueda, Tetsuya Mitsudomi. (2003) Analysis of β-tubulin gene alteration in human lung cancer cell lines. Cancer Letters 201:2, 211-216
CrossRef1081
Tien Hoang, KyungMann Kim, Anthony Jaslowski, Paul Koch, Peter Beatty, James McGovern, Maria Quisumbing, Gary Shapiro, Robert Witte, Joan H. Schiller. (2003) Phase II study of second-line gemcitabine in sensitive or refractory small cell lung cancer. Lung Cancer 42:1, 97-102
CrossRef1082
E. B. Lamont. (2003) Is Patient Travel Distance Associated With Survival on Phase II Clinical Trials in Oncology?. CancerSpectrum Knowledge Environment 95:18, 1370-1375
CrossRef1083
Petr Zatloukal, Luboš Petruželka, Milada Zemanová, Vı́tězslav Kolek, Jana Skřičková, Miloš Pešek, Hana Fojtů, Ivona Grygárková, Dimka Sixtová, Jaromı́r Roubec, Eva Hořenková, Libor Havel, Petr Průša, Leona Nováková, Tomáš Skácel, Milan Kůta. (2003) Gemcitabine plus cisplatin vs. gemcitabine plus carboplatin in stage IIIb and IV non-small cell lung cancer: a phase III randomized trial. Lung Cancer 41:3, 321-331
CrossRef1084
Yuhchyau Chen, Paul Okunieff, Steven A. Ahrendt. (2003) Translational research in lung cancer. Seminars in Surgical Oncology 21:3, 205-219
CrossRef1085
Mitchell Machtay, Branislav Jeremic. (2003) Complex and controversial issues in locally advanced non-small cell lung carcinoma. Seminars in Surgical Oncology 21:2, 128-137
CrossRef1086
David R. Spigel, F. Anthony Greco. (2003) Chemotherapy in metastatic and locally advanced non-small cell lung cancer. Seminars in Surgical Oncology 21:2, 98-110
CrossRef1087
Thomas A. Hensing, Amy H. Peterman, Michael J. Schell, Ji-Hyun Lee, Mark A. Socinski. (2003) The impact of age on toxicity, response rate, quality of life, and survival in patients with advanced, Stage IIIB or IV nonsmall cell lung carcinoma treated with carboplatin and paclitaxel. Cancer 98:4, 779-788
CrossRef1088
Phillip Bonomi. (2003) New approaches to symptom improvements in lung cancer patients. Lung Cancer 41, S32-S36
CrossRef1089
Philip Bonomi. (2003) Erlotinib: a new therapeutic approach for non-small cell lung cancer. Expert Opinion on Investigational Drugs 12:8, 1395-1401
CrossRef1090
J.P Braybrooke, M Ranson, C Manegold, K Mattson, N Thatcher, P Cheverton, M Sekiguchi, M Suzuki, R Oyama, D.C Talbot. (2003) Phase II study of exatecan mesylate (DX-8951f) as first line therapy for advanced non-small cell lung cancer. Lung Cancer 41:2, 215-219
CrossRef1091
Philip Bonomi. (2003) Clinical studies with non-iressa EGFR tyrosine kinase inhibitors. Lung Cancer 41, 43-48
CrossRef1092
Afshin Dowlati, Nathan Levitan. (2003) Combination chemotherapy with topotecan for non-small cell lung cancer. Lung Cancer 41, S23-S26
CrossRef1093
David H. Johnson. (2003) Targeted therapy in non-small cell lung cancer: myth or reality. Lung Cancer 41, 3-8
CrossRef1094
Corey J. Langer, Fred R. Hirsch, Hernan Cortés-Funes, Stephen T. Sawyer, Nick Thatcher. (2003) Targeted molecular mechanisms of epoetin alfa. Lung Cancer 41, 133-145
CrossRef1095
Sarah Danson, Mark R. Middleton, Kenneth J. O'Byrne, Mark Clemons, Malcolm Ranson, Jurjees Hassan, Heather Anderson, Paul A. Burt, Corrine Fairve-Finn, Ronald Stout, Isabel Dowd, Linda Ashcroft, Cheryl Beresford, Nicholas Thatcher. (2003) Phase III trial of gemcitabine and carboplatin versus mitomycin, ifosfamide, and cisplatin or mitomycin, vinblastine, and cisplatin in patients with advanced nonsmall cell lung carcinoma. Cancer 98:3, 542-553
CrossRef1096
Rafael Rosell, Miquel Taron, Vicente Alberola, Bartomeu Massuti, Enriqueta Felip. (2003) Genetic testing for chemotherapy in non-small cell lung cancer. Lung Cancer 41, 97-102
CrossRef1097
Anna Ceribelli, Cesare Gridelli, Filippo De Marinis, Alessandra Fabi, Teresa Gamucci, Enrico Cortesi, Maria Barduagni, Mauro Antimi, Paolo Maione, Maria R. Migliorino, Diana Giannarelli, Francesco Cognetti. (2003) Prolonged gemcitabine infusion in advanced non-small cell lung carcinoma. Cancer 98:2, 337-343
CrossRef1098
C. Harris Spiridonidis. (2003) Special Patients, Special Treatments. Clinical Lung Cancer 5:1, 39
CrossRef1099
Paola Mazzanti, Cristian Massacesi, Marco B.L. Rocchi, Rodolfo Mattioli, Paolo Lippe, Raffaele Trivisonne, Franco Buzzi, Giorgio De Signoribus, Guido Tuveri, Giorgio Rossi, Liberato Di Lullo, Fabio Sturba, Donatella Morale, Sergio Catanzani, Alberta Pilone, Maurizio Bonsignori, Tullio Battelli. (2003) Randomized, multicenter, phase II study of gemcitabine plus cisplatin versus gemcitabine plus carboplatin in patients with advanced non-small cell lung cancer. Lung Cancer 41:1, 81-89
CrossRef1100
Andrew W. Millar, Kevin P. Lynch. (2003) Rethinking clinical trials for cytostatic drugs. Nature Reviews Cancer 3:7, 540-545
CrossRef1101
J. de Castro, C. Belda-Iniesta, P. Cejas, E. Casado, J.A. Fresno Vara, D. Hardisson, J.J. Sánchez, J. Feliu, A. Ordóñez, M. Nistal, M. González-Barón. (2003) New insights in β-tubulin sequence analysis in non-small cell lung cancer. Lung Cancer 41:1, 41-48
CrossRef1102
Martin J Edelman. (2003) Neoadjuvant chemotherapy and chemoradiotherapy for non-small cell lung cancer: current status and future prospects. Expert Opinion on Pharmacotherapy 4:6, 843-852
CrossRef1103
K TSANG. (2003) Coriolus versicolor polysaccharide peptide slows progression of advanced non-small cell lung cancer. Respiratory Medicine 97:6, 618-624
CrossRef1104
Francisco Robert, Elizabeth M. Busby, Albert F. LoBuglio. (2003) Chemotherapy Tolerance After Radioimmunotherapy with 90 Y-CC49 Monoclonal Antibody in Patients with Advanced Non-Small Cell Lung Cancer: Clinical Effects and Hematologic Toxicity. Cancer Biotherapy & Radiopharmaceuticals 18:3, 317-325
CrossRef1105
Wallace Akerley, James E. Herndon, Merrill J. Egorin, Alan P. Lyss, Hedy L. Kindler, Dianne M. Savarese, Carol A. Sherman, D. Marc Rosen, Donna Hollis, Mark J. Ratain, Mark R. Green. (2003) Weekly, high-dose paclitaxel in advanced lung carcinoma. Cancer 97:10, 2480-2486
CrossRef1106
Federico Cappuzzo, Stefania Bartolini, Lucio Crinò. (2003) Emerging drugs for non-small cell lung cancer. Expert Opinion on Emerging Drugs 8:1, 179-192
CrossRef1107
Tony S. K. Mok, Anthony T. C. Chan. (2003) Nonplatinum-Based Chemotherapy for Advanced Non-Small Cell Lung Cancer. Clinical Pulmonary Medicine 10:3, 143-153
CrossRef1108
Giorgio V Scagliotti, Silvia Novello. (2003) Pemetrexed and its emerging role in the treatment of thoracic malignancies. Expert Opinion on Investigational Drugs 12:5, 853-863
CrossRef1109
Angela M Davies, Primo N Lara Jr, Philip C Mack, David R Gandara. (2003) Docetaxel in non-small cell lung cancer: a review. Expert Opinion on Pharmacotherapy 4:4, 553-565
CrossRef1110
Ian Chau, Mark Harries, David Cunningham, Mark Hill, Paul J. Ross, Caroline D. Archer, Andrew R. Norman, Andrew Wotherspoon, Dow Mu Koh, Kairen Gill, Maggie Uzzell, Yvonne Prior, Daniel Catovsky. (2003) Gemcitabine, cisplatin and methylprednisolone chemotherapy (GEM-P) is an effective regimen in patients with poor prognostic primary progressive or multiply relapsed Hodgkin's and non-Hodgkin's lymphoma. British Journal of Haematology 120:6, 970-977
CrossRef1111
Akihiko Yamamoto, Seiji Yano, Minoru Shiraga, Hirohisa Ogawa, Hisatsugu Goto, Toyokazu Miki, Helong Zhang, Saburo Sone. (2003) A third-generation matrix metalloproteinase (MMP) inhibitor (ONO-4817) combined with docetaxel suppresses progression of lung micrometastasis of MMP-expressing tumor cells in nude mice. International Journal of Cancer 103:6, 822-828
CrossRef1112
Angel Artal-Cortés, Javier Martínez-Trufero, Ana Herrero, Teresa Puértolas, Vicente Alonso, Mónica Corral, Concepción Ceballos, Joan Maurel, Antonio Antón. (2003) Increasing-dose gemcitabine plus low-dose cisplatin in metastatic non-small cell lung cancer. Anti-Cancer Drugs 14:2, 111-118
CrossRef1113
Yoshitaka Sekido, Kwun M. Fong, John D. Minna. (2003) Molecular Genetics of Lung Cancer. Annual Review of Medicine 54:1, 73-87
CrossRef1114
Roy S Herbst. (2003) Dose-comparative monotherapy trials of ZD1839 in previously treated non–small cell lung cancer patients. Seminars in Oncology 30:1, 30-38
CrossRef1115
Davide Tassinari, Francesca Fochessati, Valentina Arcangeli, Ilaria Panzini, Alberto Ravaioli, Sergio Sartori. (2003) Carboplatin and gemcitabine in stage IV non small cell lung cancer: beyond cisplatin in palliative chemotherapy. Lung Cancer 39:1, 107-108
CrossRef1116
Veena John, Sandeep Mashru, Stuart M Lichtman. (2003) Pharmacological Factors Influencing Anticancer Drug Selection in the Elderly. Drugs & Aging 20:10, 737-759
CrossRef1117
Matthew J. Schuchert, James D. Luketich. (2003) Solitary sites of metastatic disease in non-small cell lung cancer. Current Treatment Options in Oncology 4:1, 65-79
CrossRef1118
In Sil Choi, Byung Su Kim, Sook Ryun Park, Sang Yoon Lee, Do Yeun Kim, Jee Hyun Kim, Se Hoon Lee, Tae-You Kim, Dae Seog Heo, Yung-Jue Bang, Noe Kyeong Kim. (2003) Efficacy of modified regimen with attenuated doses of paclitaxel plus carboplatin combination chemotherapy in elderly and/or weak patients with advanced non-small cell lung cancer. Lung Cancer 39:1, 99-101
CrossRef1119
Ramaswamy Govindan. (2003) Management of patients with non-small cell lung cancer and poor performance status. Current Treatment Options in Oncology 4:1, 55-59
CrossRef1120
E Massarelli, F Andre, D.D Liu, J.J Lee, M Wolf, A Fandi, J Ochs, T Le Chevalier, F Fossella, R.S Herbst. (2003) A retrospective analysis of the outcome of patients who have received two prior chemotherapy regimens including platinum and docetaxel for recurrent non-small-cell lung cancer. Lung Cancer 39:1, 55-61
CrossRef1121
Brigette B. Y. Ma, Ian F. Tannock, Gregory R. Pond, Matthew R. Edmonds, Lillian L. Siu. (2002) Chemotherapy with gemcitabine-containing regimens for locally recurrent or metastatic nasopharyngeal carcinoma. Cancer 95:12, 2516-2523
CrossRef1122
José Miguel Sánchez, Carme Balañá, Albert Font, José Javier Sánchez, José Luis Manzano, Mónica Guillot, Mireia Margelı́, Martin Richardet, Rafael Rosell. (2002) Phase II non-randomized study of three different sequences of docetaxel and vinorelbine in patients with advanced non-small cell lung cancer. Lung Cancer 38:3, 309-315
CrossRef1123
Sakkaraiappan Ramalingam, Chandra P Belani. (2002) Taxanes for advanced non-small cell lung cancer. Expert Opinion on Pharmacotherapy 3:12, 1693-1709
CrossRef1124
Mark G. Kris, Maurizio Tonato. (2002) New approaches in the treatment of non-small cell lung cancer. Lung Cancer 38, 1-3
CrossRef1125
Rafael Rosell, Reginald V.N Lord, Miquel Taron, Noemi Reguart. (2002) DNA repair and cisplatin resistance in non-small-cell lung cancer. Lung Cancer 38:3, 217-227
CrossRef1126
T Hoang. (2002) Novel therapies for lung cancer. Surgical Oncology 11:4, 229-241
CrossRef1127
David Lee, Lori Johnson, Heather DeGrendele, Chandra P. Belani, Michael Perry, Harvey Pass. (2002) 2002 Highlights From: 27th Congress of the European Society for Medical Oncology; Nice, France October 18–22, 2002. Clinical Lung Cancer 4:3, 140-145
CrossRef1128
Ala Szczepura. (2002) Healthcare outcomes: gemcitabine cost-effectiveness in the treatment of non-small cell lung cancer. Lung Cancer 38, 21-28
CrossRef1129
Pieter E Postmus. (2002) Activity of pemetrexed (alimta), a new antifolate, against non-small cell lung cancer. Lung Cancer 38, 3-7
CrossRef1130
Panagiotis Ginopoulos, Emanuel Kontomanolis, Dimitrios Kardamakis, Maria Sougleri, Spiros Rathosis, Afroditi Karana, Helias Christias, George Mandellos. (2002) A phase II study of non-platinum based chemotherapy with paclitaxel and vinorelbine in non-small cell lung cancer. Lung Cancer 38:2, 199-203
CrossRef1131
Giuseppe Giaccone. (2002) Targeted therapy in non-small cell lung cancer. Lung Cancer 38, 29-32
CrossRef1132
Irina E. Popa, Kathleen Stewart, Frederick P. Smith, Naiyer A. Rizvi. (2002) A Phase II trial of gemcitabine and docetaxel in patients with chemotherapy-naive, advanced nonsmall cell lung carcinoma. Cancer 95:8, 1714-1719
CrossRef1133
J Cosaert, E Quoix. (2002) Platinum drugs in the treatment of non-small-cell lung cancer. British Journal of Cancer 87:8, 825-833
CrossRef1134
Andy Millar. (2002) Limitations of combination anti-angiogenesis and chemotherapy. Nature Reviews Cancer 2:10,
CrossRef1135
Domenico Galetta, Vittorio Gebbia, Francesco Giotta, Ernesto Durini, Sante Romito, Nicola Borsellino, Carlo Cazzato, Giuseppe Pezzella, Giuseppe Colucci. (2002) Gemcitabine and docetaxel every 2 weeks in advanced non-small cell lung cancer: a phase II study of the Gruppo Oncologico Italia Meridionale. Lung Cancer 38:1, 79-84
CrossRef1136
Sumeet Bhatia, Nasser Hanna, Rafat Ansari, William Pletcher, Lawrence Einhorn, Elizabeth Ng, Alan Sandler. (2002) A phase II study of weekly gemcitabine and paclitaxel in patients with previously untreated stage IIIb and IV non-small cell lung cancer. Lung Cancer 38:1, 73-77
CrossRef1137
J.-C. Soria. (2002) Is cisplatin still the best platinum compound in non-small-cell lung cancer?. Annals of Oncology 13:10, 1515-1517
CrossRef1138
R. Rosell. (2002) Phase III randomised trial comparing paclitaxel/carboplatin with paclitaxel/cisplatin in patients with advanced non-small-cell lung cancer: a cooperative multinational trial. Annals of Oncology 13:10, 1539-1549
CrossRef1139
. (2002) Chemotherapie van longkanker, veel narigheid en weinig vooruitgang. Medisch-Farmaceutische Mededelingen 40:9, 260-261
CrossRef1140
J S Waters, M E R O'Brien. (2002) The case for the introduction of new chemotherapy agents in the treatment of advanced non small cell lung cancer in the wake of the findings of The National Institute of Clinical Excellence (NICE). British Journal of Cancer 87:5, 481-490
CrossRef1141
Tien Hoang, Joan H Schiller. (2002) Advanced NSCLC: from cytotoxic systemic chemotherapy to molecularly targeted therapy. Expert Review of Anticancer Therapy 2:4, 393-401
CrossRef1142
Jean-Philippe Durand, François Goldwasser. (2002) Dramatic recovery of paclitaxel-disabling neurosensory toxicity following treatment with venlafaxine. Anti-Cancer Drugs 13:7, 777-780
CrossRef1143
Roy S. Herbst, Fadlo R. Khuri, Charles Lu, Diane D. Liu, Frank V. Fossella, Bonnie S. Glisson, Katherine M. W. Pisters, Dong M. Shin, Vassiliki A. Papadimitrakopoulou, Jonathan M. Kurie, George Blumenschein, Merrill S. Kies, Ralph Zinner, Maria S. Jung, Robert Lu, J. Jack Lee, Reginald F. Munden, Waun Ki Hong, Jin Soo Lee. (2002) The novel and effective nonplatinum, nontaxane combination of gemcitabine and vinorelbine in advanced nonsmall cell lung carcinoma. Cancer 95:2, 340-353
CrossRef1144
Maurizio Tonato. (2002) Chemotherapy of advanced non-small cell lung cancer: any standard treatment?. Lung Cancer 37:1, 15-16
CrossRef1145
Federico Cappuzzo, Lucio Crinò. (2002) Gemcitabine in non-small cell lung cancer. Expert Opinion on Pharmacotherapy 3:6, 745-753
CrossRef1146
Thierry Le Chevalier. (2002) Gemcitabine and pemetrexed (Alimta) in thoracic cancers: Present and future perspectives. Introduction and current controversies. Seminars in Oncology 29:3, 43-46
CrossRef1147
Lucio Crinò, Federico Cappuzzo. (2002) Present and future treatment of advanced non–small cell lung cancer. Seminars in Oncology 29:3, 9-16
CrossRef1148
Maurie Markman, Tarek M Mekhail. (2002) Paclitaxel in cancer therapy. Expert Opinion on Pharmacotherapy 3:6, 755-766
CrossRef1149
(2002) Chemotherapy for Lung Cancer. New England Journal of Medicine 346:19, 1498-1498
Full Text1150
Carney, Desmond N., . (2002) Lung Cancer — Time to Move on from Chemotherapy. New England Journal of Medicine 346:2, 126-128
Full Text1151
&NA;. (2002) New treatment combinations for lung cancer advantageous?. Inpharma Weekly &NA;:1321, 12
CrossRef
